PROGRESS IN
Nucleic A c i d Research a n d M o l e c u l a r Biology Volume 47
This Page Intentionally Left Blank
...
19 downloads
1105 Views
22MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
PROGRESS IN
Nucleic A c i d Research a n d M o l e c u l a r Biology Volume 47
This Page Intentionally Left Blank
PROGRESS IN
Nucleic Acid Research and Molecular Biology edited by
WALDO E. COHN
KlVlE MOLDAVE
Biology Dicision Oak Ridge National I A o r u t o n j Oak Ridge. Tennessee
Departtnent of Molecular Biology and Biochemistry C'nioersity of Ca1if)rnia. Iroine Ircine, California
Volume 47
ACAD EMlC PRESS A Division of Harcourt Brace 6 Company Son Diego New York Boston London Sydney Tokyo Toronto
This book is printed on acid-free paper. @
Copyright 0 1994 by ACADEMIC PRESS, INC. All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.
Academic Press, Inc. 525 B Street, Suite 1900, San Diego, California 92101-4495 United Kingdom Edition published by
Academic Press Limited 24-28 Oval Road, London NWl 7DX InternationalStandard Serial Number: 0079-6603 International Standard Book Number: 0-12-540047-0 PRINTED IN THE UNITED STATES OF AMERICA 94 9 5 9 6 97 98 99
BB
9 8 7 6 5 4 3 2
1
Contents
ABBREVIATIONS AND SYMBOLS. . . , . . . . . . . . . . . . . . . . . . . . . SOME ARTICLESPLANNED FOR FUTUREVOLUMES . . . . . . . .
. . .. .. . . .. ...
ix xi
Prestalk Cell-differentiation and Movement during the Morphogenesis of Dictyosteliurn discoideum Jeffrey Williams and Alastair Morrison I. Extracellular CAMP-signaling in Dictyosteliurn . . . . . . . . . . . . . . . . . . . . 11. Cellular Differentiation and the Role of Differentiation-inducing Factor . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111. Prestalk Cell Heterogeneity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I\'. Slug Format ion . . . . . . . . . lJ.Culmination . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VI. Intracellular Signaling and the Multiple Roles of CAMP-dependent Protein Kinase VII. Other Extracell ........................................ differentiation . \'HI. Concliisions . . . . . . . . . . . . . . . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 3 10
13 16
19
21 22 23
Collagen Genes: Mutations Affecting Collagen Structure and Expression William G. Cole I. 'The Collagens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111. I\? V. VI. VII. VIII.
Type-I1 Collagen Gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Type-I11 Collagen Gene ................................ Type-IV Collagen Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Type-VII Collagen Gene Type-IX Collagen Genes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Tyt3e-X Collagen Gene . . . . . . . . . . . . . . . . . . . . . . .
.......................... References . . . . . . . . . . . . . .
29 30 47 57 62 65 66 68 70 70
vi
CONTENTS
Signal-Transducing G Proteins: Basic and Clinical implications C. W. Emala, W. F. Schwindinger, G. S. Wand and
M. A. Levine .................... I. Guanine Nucleotide Binding Proteins 11. Structure of a Subunits of G Proteins ........................... 111. Function of a Subunits of G Proteins . . .................... IV. Structure of p Subunits of G Proteins ........................... V. Function of Py Dimers of G Proteins ...................... VI. The P3 Subunit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VII. Clinical Implications of Altered G-Protein Function . . . . . . . . . . . . VIII. Summary ....................... ....................... IX. Glossary .................................... ......... References ... . . . . . . . . . . . . . . . . . . . ....................
81 82 86 88 90 92 93 105 106 107
The tis Genes, Primary Response Genes Induced by Growth Factors and Tumor Promoters in 3T3 Cells Harvey R. Herschman, Dean A. Kujubu, Bradley S. Fletcher, Qiufu Ma, Brian C. Varnum, Rebecca S. Gilbert and Srinivasa T.Reddy I. Phorbol-induced Primary Response Genes Can Be Cloned from Swiss 3T3 Cells . . . . . . . . . . . 11. The tisZl Gene Encodes a Pr Anti-oncogene . . . . . . . . . . . . 111. The tisll Gene Is a Member of a Multigene Family . . . . . . . . . . . . . . . IV. The tislO Gene Encodes a Functional Prostaglandin Synthase/Cyclooxygenase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Both Prostaglandin Synthesis and TISlO/PGS-Z Synthesis Are Induced in Swiss 3T3 Cells .................................... VI. The Structures of the tislO/pgs-Z and pgs-1 Genes Are Similar . . . . . VII. tislO/pgs-2 Satisfies the Criteria for the “Second Pool” of Prostaglandin Synthase ........................................ VIII. tislO/pgs-2 Is Induced in Macrophages . IX. Can the Proteins Encoded by the tislO/p Functional Heterodimers? What Would Be the Consequences of This Interaction for Pharmacologic Intervention? ...................... X. Similarities in the Expression and Regulation of Inducible Forms of Prostaglandin Synthase and Nitric-Oxide Synthase . . . . . . . . . . . . . . . . XI. Conclusions and Future Directions . . . . . . . . . ....... References . . . . .............. ....................
115 119 121 124 126 137 139 139
142 142 143 144
CONTENTS
vii
Nuclear Pre-mRNA Processing in Higher Plants Kenneth R. Luehrsen, Sharif Taha and Virginia Walbot I. 11. 111. IV. V. \‘I.
Biochemistry of Splicing and Intron Recognition . . . . . . . . . . . . . . . . . . Plant Splicing . . . . . . . . . . . . . . . . . . . . . . . . Transposable-clement-induced Mutants of Examples of Alternative Splicing . . . . . . . . . . . . . . . . Biological Phenomena Associated with Splicing . . . . . . . . . . . . . . . . . . . Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . .............................
lS0 158 174 183 185 188 190
New Concepts in Protein-DNA Recognition: Sequence-directed DNA Bending and Flexibility Rodney E. Harrington and Ilga Winicov I. DNA Sequence Dependence in Protein-Nuclcic Acid Binding Specificity . . . . . . . . . . . . . . . . . . . . . . 11. .4 Short Taxonomy of DNA-bending Proteins and Their Recognition
196
213
111. Models of Seq
I\’. Past Challenges and Future Prospects . . . . . . . . . . . . . V. Glossary of Ahbreviations and Polynucleotide Notation . . . . . . . . . . . . Refcrenccs . . . . . . . . ........
253 259 26 1 263
Nonsense-mediated mRNA Decay in Yeast Stuart W. Peltz, Feng He, Ellen Welch and Allan Jacobson I. Identification of cis-Acting Sequences Involved in Nonsensemediated mRNA Decay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11. trans-Acting Factors Involved in the Nonsense-mediated mRNA Decay Pathway . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111. Possible Functions of the Nonsense-mediated mRNA Decay Pathway IV. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
272 283 290 293 296
Molecular Biology and Regulatory Aspects of Glycogen Biosynthesis in Bacteria Jack Preiss and Tony Romeo I. Genetic Regulation of the Glycogen Synthesis Pathway in Esclierichia coli . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
301
viii
CONTENTS
I1. Site-directed Mutagenesis of the ADPglucose Pyrophosphorylase Genes to Study Structure-Function Relationships of Enzyme Action and Regulatory Control ........................................ I11. Glossary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
315 326 327
Diverse Mechanisms for Regulating Ribosomal Protein Synthesis in Escherichia coli Janice M . Zengel and Lasse Lindahl I . Organization of Ribosomal Protein Genes in Escherichia coli I1. Overview of the Control of Ribosomal Protein Synthesis in Escherichia coli
.......
..............................................
I11. Review of Individual Operons .................................. IV. Epilogue .................................................... References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
332 336 341 363 365
Enzymologic Mechanism of Replicative DNA Polymerases in Higher Eukaryotes Paul A . Fisher I . Catalytic Core of DNA Polymerase ci ............................ I1. Holoenzyme of DNA Polymerase a ............................. I11. Interaction of DNA Polymerase ci with Template-Primers Containing Chemically Damaged Nucleotides .............................. IV. DNA Polymerase 6 ........................................... V. Conclusions and Prospects for Future Research . . . . . . . . . . . . . . . . . . . References ..................................................
ADDENDUMTO New Concepts in Protein-DNA Recognition: Sequence-directed DNA Bending and Flexibility . . . . . . . . . . . . . . . . INDEX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
372 380 386 390 394 396
399 401
Abbreviations and Symbols All contributors to this Series are asked to use the terminology (abbreviations and symbols) recommended by the IIJPAC-IUB Commission on Biochemical Nomenclature (CBN) and approved by IUP.4C and IUB, and the Editors endeavor to assure conformity. These Hecoinmendations have been published in many journals (I, 2) and compendia (3);they are therefore considered to he generally known. Those used in nucleic acid work, originally set out in section 5 of the first Recommendations (1)and subsequently revised and expanded (2, 3), are given in condensed form in the frontmatter ofVolumes 9-33 of this series. A recent expansion of the oneletter system ( 5 )follows. SINGLE-LEI-I-ER C o u e RECOMMENDATIONSO(5) Symbol
Meaning
Origin of symbol
G A T(U) C
Guanosine Adenosine (riho)Thymidine (Uridine) Cytidine
G or A T(U) or C -4or C G or T(U)
G or C A o r T(U)
puRine pyrimidine aMino Keto Strong interaction (3 H-bonds) Weak interaction (2 H-bonds)
A or C or T(U) G or T(U) or C G or C or A G or A or T(U)
not not not not
G o r A or T(U) or C
aNy nucleoside (i.e.. unspecified)
Q
Queuosine (nucleoside of queuine)
G; H follows G in the alphabet A; B follows A T (not U); V follows U C; D follows C
aModified from Proc. &‘at/. Acad. Sci. U.S.A. 83,4 (1986). hW has been used for wyosine, the nucleoside of “base Y” (wye). “D has been used for dihvdrouridine (hU or H, Urd).
Enzymes
In naming enzymes, the 1984 recommendations of the IUB Commission on Biochemical Nomenclature ( 4 ) are followed as far as possible. At first mention, each enzyme is described either by its systematic name or by the equation for the reaction catalyzed o r by the recommended trivial name, followed by its EC number in parentheses. Thereafter, a trivial name may be used. Enzynir names are not to be abbreviated except when the substrate has an approved abbreviation (e.g., ATPase, hut not LDH, is acceptable).
ix
ABBREVIATIONS AND SYMBOLS
X
REFERENCES
1. ]BC 241,527(1966);Bchern 5,1445 (1966);BJ 101,1(1966);ABB 115,1(1966),129,1(1969); and elsewhere. General. 2. EJB 15, 203 (1970);]BC 245, 5171 (1970);] M B 55, 299 (1971);and elsewhere. 3. “Handbook of Biochemistry” (G. Fasman, ed.), 3rd ed. Chemical Rubber Co., Cleveland, Ohio, 1970,1975,Nucleic Acids, Vols. I and 11, pp. 3-59. Nucleic acids. 4. “Enzyme Nomenclature” [Recommendations (1984)of the Nomenclature Committee of the IUB]. Academic Press, New York, 1984. 5. EJB 150, 1 (1985).Nucleic Acids (One-letter system). Abbreviations of Journal Titles JOUt-tta2.S
Abbreviations used
Annu. Rev. Biochem. Annu. Rev. Genet. Arch. Biochem. Biophys. Biochem. Biophys. Res. Commun. Biochemistry Biochem. J. Biochim. Biophys. Acta Cold Spring Harbor Cold Spring Harbor Lab Cold Spring Harbor Symp. Quant. Biol. Eur. J. Biochem. Fed. Proc. Hoppe-Seyler‘s Z. Physiol. Chem. J. Amer. Chem. SOC. J. Bacteriol. J. Biol. Chem. J. Chem. SOC. J. Mol. Biol. J. Nat. Cancer Inst. Mol. Cell. Biol. Mol. Cell. Biochem. Mol. Gen. Genet. Nature, New Biology Nucleic Acid Research Proc. Natl. Acad. Sci. U. S.A. Proc. SOC.Exp. Biol. Med. Progr. Nucl. Acid. Res. Mol. Biol.
ARB ARGen ABB BBRC Bchem BJ BBA CSH CSHLab CSHSQB EJB FP ZpChem JACS J. Bact. JBC JCS JMB JNCI MCBiol MCBchem MGG Nature NB NARes PNAS PSEBM This Series
Some Articles Planned for Future Volumes
The Poly ADP-ribosylation System of Higher Eukaryotes
FELIXH. ALTHAUS Role of Multisite Phosphorylation in the Regulation of RNA Polymerase II Activity M . E. DAHMUS Adenylyl Cyclases. A Heterogenous Class of ATP-utilizing Enzymes
OCTAV~AN BARZU AND ANTOINE DANCHIN Genetic Dissection of the Synthesis and Function of Modified Nucleotides in Bacterial tRNA
GLENNBJORK mRNA Binding Proteins in Eukaryotic Cells
TOMDONAHUE AND K . GULYAS Processing of Eukaryotic Ribosomal RNA
DUANEC. EICHLERAND NESSLYCRAIG Mechanism of Transcription Fidelity GUNTHER
EICHHORN AND JIMBUTZOW
Regulution of Replication of an Iteron-containing DNA Molecule M. FILUTOWICZ, S. DELLIS,I. LEVCHENKO, M. URH, F. wu AND D. YORK Molecular Properties and Regulation of G Protein-coupled Receptors CLAIREM. FRASER,NORMANH . LEE, SUSANM. PELLECRINO AND ANTHONY
R. KERLAVAGE The Human Immunodeficiency Virus Type-1 Long Terminal Repeat and Its Role in Gene Expression JOSEPH A. GARCIAAND RICILARD B . GAYNOR The Mechanics and Specificity of Signal Transduction to the Nucleus: Lessons from c-fos
MICHAEL GILMAN RNA Polymerase as a Molecular Machine: The Coupling between Catalytic Function and Propagation along DNA ALEX GOLDFARB
xi
xii
SOME ARTICLES PLANNED FOR FUTURE VOLUMES
Polynucleotide Recognition and Degradation by Bleomycin STEFANIEA. KANE AND SIDNEYM. HECHT Aminoacyl-tRNA Synthetases from Higher Eukaryotes L. KISSELEVAND A. D. WOLFSON
START Control in Cycling S. cerevisiae Cells , ROTTJAKOB,A. SCHWEDAND W. ZWERSCHKE H. K ~ N T Z E L H.-W. Adeno-associated Virus Type 2: A Latent Life Cycle C. J. LEONARDAND K. I. BERNS Uracil-excision DNA Repair D. W. MOSBAUGH AND S. E. BENNETT The Regulation of Ribosomal Transcription TOMMoss Analysis of EGF-Receptor Interaction by Protein Engineering SALILK. NIYOGIAND STEVECAMPION The Role .of the 5' Untranslated Region of Eukaryotic mRNAs in Translation and Its Investigation Using Anti-sense Technologies H. E. JOHANSSON AND M. W. HENTZE K. PANTOFOULOS, New Members of the Collagen Gene Family TMNAPIHLAJANIEMI AND MARKREHN DNA Methylation from Embryo to Adult A. RAZIN AND T. KAFRI The Prosomes (Multicatalytic Proteinases-Proteasomes) and Their Relation to the Untranslated Messenger Ribonucleoproteins, the Cytoskeleton, and Cell Differentiation KLAUSSCHERRER AND FAYCALBEY Biological Implications of the Mechanism of Action of Human DNA(Cytosine-5)Methyltransferase STEVENS. SMITH Human Mutational Spectrometry: Means and Ends WILLIAMG. THILLY AND KONSTANTIN KHRAPKO The Balbiani Ring Multigene Family: Coding Repetitive Sequences and Evolution of a Tissue-specific Cell Function L. WIESLANDER
Prestalk Cell-differentiation and Movement during the Morphogenesis of Dictyosteliurn discoideum W I L L I AAND ~ ALASTAIRMORRISON JEFFREY
Imperial Cancer Research Fund Clare Hall Laboratories South Mimms, Herts EN6 3LD United Kingdom I. Extracellular CAMP-signaling in Dictyosteliuin .................... 11. Cellular Differentiation and the Role of Differentiation-inducing
3
......................................
3 10 13 16
IV. Slug Formation.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . V. Culmination . . . . . . . ............
......................
Protein Kinase
19
alk and Stalk Cell-
VII. Other Extracel
........ ........................................... References .....................
differentiation . . .
VIII. Conclusions
21 22 23
The cellular slime mold Dictyostelium discoideum displays almost all the characteristic features of development found in higher eukaryotes, so that insights gained by studying Dictyostelium are likely to be of general relevance. First, there is true cellular dqferentiation. Growing amoebae entering development have two totally distinct choices: 80%form spores and 20% form stalk cells (Fig. 1).The spores are elliptical cells that are highly resistant to environmental insult. The stalk is composed of dead, vacuolated cells surrounded by a wall composed of protein and cellulose (1-3). The fruiting bodies, or culminants, have a distinctform. The stalk tapers from bottom to top and is widely expanded at the base, to create the supporting basal disc from which D. discoideum derives its name. There is regulation at a level that is unsurpassed in other developing systems, with an approximate 4-to-1 stalk-to-spore cell-ratio being maintained at widely varying aggregate sizes (4, 5). Finally, Dictyostelium shows morphogenetic cell movement, initially to
Progress in Nucleic Acid Research and Molecuhr Biology, Vol. 47
1
Copyright 0 1994 by Academic Press. Inc. All rights of reproduction in any form reserved.
2
JEFFREY WILLIAMS AND ALASTAIR MORRISON Earty
wengate
Tight aggregate
First Finger Prestalk
Cells
-
M i culminant
Late culminant
A
Slug
FIG. 1. The Dictyosteliurn asexual life cycle. This is a highly schematic representation of the development of Dictyosteliurn. Cellular aggregation yields mounds containing up to 105 cells, wherein about 20% of cells differentiate into prestalk cells and the remaining cells differentiate as prespore cells. The environmental conditions that exist below the surface of the forest floor (high humidity, darkness, and high ionic strength) promote formation of a migratory slug. If the aggregate forms under the conditions that exist at the surface, it enters culmination immediately, the migratory slug phase being entirely omitted. Typically, the slug is 1-2 mm in length. When the slug encounters conditions favorable for fruiting body formation, it enters culmination. If the slug phase is eschewed, the entire developmental process is completed within about 24 hours.
bring cells together during aggregation and then later to build the fruiting body. In this review we concentrate on multicellular development, the period after the cells have aggregated together. Furthermore, we lay special emphasis on prestalk and stalk cells, because it is their movement and differentiation that are ultimately responsible for building the fruiting body. The genes encoding the extracellular matrix' proteins, EcmA and EcmB, are markers of prestalk and stalk cell-differentiation (6) and analysis of their expression reveals an unexpectedly complex pattern of prestalk celldifferentiation and movement, both during slug formation and at culmination (7, 8). Three extracellular signaling molecules, CAMP, DIF, and ammonia, combine to regulate expression of the two genes. We review what is known about the cognate intracellular signal-transduction systems.
* Abbreviations: Ecm, extracellular matrix; DIF, differentiation-inducing factor, 1-[(3,5dichloro-2,6dihydroxy-4-methoxy~phenyl]hexan-l-one; ALC, anterior-like cell; PSV, prespore vesicle: PKA, CAMP-dependent protein kinase; pst, prestalk; psp, prespore.
Dictyostelium
MOFWHOGENESIS
3
1. Extracellular CAMP-signaling in Dictyostelium
A. Multiple Developmental Roles of Extracellular cAMP Signals The movement of cells toward each other at aggregation occurs as the result of the chemotaxis of individual amoebae up a concentration gradient of cAMP (reviewed in 9). Signaling is initiated by cells at the center of the aggregation territory. On receipt of a cAMP signal, cells farther out in the territory synthesize and secrete CAMP, so relaying the signal. In addition to its function as a chemoattractant, cAMP regulates gene expression at several stages of development. Genes expressed early in development are transcriptionally repressible by CAMP, genes expressed somewhat later during aggregation are inducible by cAMP pulses, and gene expression in prespore cells is inducible by a high constant level of cAMP (reviewed in 10-13).
B. The cAMP Signal-transduction System The complex pattern of responses to cAMP is probably achieved by utilizing multiple receptors that differ in their precise responses to extracellular CAMP. The cAMP receptors are proteins with seven trunsmembrane domains and they exhibit a high degree of homology to mammalian G-protein-linked receptors, such as the P-adrenergic receptor (14). There are at least four different cAMP receptors (15-17) and at least eight Ga proteins (18-20). The genes encoding the receptors and the Ga proteins are developmentally regulated, both temporally and in their cell-type specificity, and this provides a mechanism whereby cells can change their responsiveness to cAMP as they differentiate. In response to receipt of a cAMP signal, adenylate cyclase, guanylate cyclase, and phospholipase C are activated, but the precise coupling of receptors to G proteins is not well understood (reviewed in 11,21-25). The intracellular signal-transduction pathways responsible for regulating prespore cell-specific gene expression are as yet undefined.
II. Cellular Differentiation and the Role of Differentiation-inducing Factor
A. Markers of Cellular Differentiation At the end of aggregation the cells group into a cylindrical structure known as the first finger (Fig. 1). If the first finger is formed under the environmental conditions that exist below the surface of the soil or leaf litter,
4
JEFFREY WILLIAMS AND ALASTAIH MOHHISON
it topples onto its side and undertakes a period of migration as a slug. The slug is both phototactic and thermotactic, and these sensitivities direct it to the surface, where terminal differentiation, to form a fruiting body, takes place (26-28). The slug is patterned. Cells within the front one-fifth differentiate to form stalk cells, whereas most of the cells in the rear four-fifths differentiate to form spore cells (1).There are, however, scattered cells in the back of the slug, known as anterior-like cells (ALCs), that share most of the properties of prestalk cells (29-31). Cells are not irreversibly committed to these fates, so that if the slug is cut between the prestalk and prespore cells, there is regulation, i.e., some of the prestalk and prespore cells change their fate to give a normally proportioned fruit (1, 32, 33). Regulation implies communication, and two extracellular signaling molecules that control initial prespore and prestalk cell-differentiation are, perhaps, involved in regulation. As mentioned, extracellular CAMP induces prespore differentiation, whereas DIF, a chlorinated hexaphenone (Fig. 2), induces prestalk and stalk cell-differentiation (34-38). The DIF signaling pathway has been investigated using two genes that depend on DIF for their expression, the ecmA and ecmB genes (6).These genes also provided the first definitive markers of prestalk- and stalk-specific differentiation. Because there is some confusion as to the reliability of various prestalk-specific markers, and of the nature of the extracellular signals that induce prestalk celldifferentiation, it is worthwhile considering these questions in some detail. Markers of prespore differentiation are relatively easy to identih. Prespore cells contain vesicles (prespore vesicles, or PSVs) that act as the repository for spore coat-proteins prior to spore maturation, at which time they fuse with the cell membrane (39, 40). The PSVs can be detected immunologically and the genes encoding the major spore coat-proteins, the cotA, OH
0
CI FIG. 2. The clietnical structure of DIF-1. l-[(R,5-dichloro-2,6-dih?.drox).-4-metl~oxy)pheiiyl]hesan- 1-one.
Dictyostelium
MORPHOGENESIS
5
-B, and -C genes (formerly called, respectively, the SP96, -70, and -60 genes), have been cloned (41-45). In another approach to identifying prespore-specific markers, monoclonal antibodies have been raised against slug-stage cells, yielding MUD1, an antibody that detects a protein called PsA, which is expressed only in prespore cells (46, 47). Subsequent analysis showed that the PsA protein is encoded by a gene, termed D19 (48), originally identified by differential screening of a cDNA library prepared &om slug-stage cells (49). The library was screened with labeled cDNA prepared using RNAs isolated from prespore cells and prestalk cells separated by centrifugation through a density gradient (50, 51). A similar approach has been used to identify several other prespore-specific mRNAs encoding proteins of unknown function (41). Prespore markers are, for the most part, highly specific to prespore cells and they share the property of being induced when cells shaken in suspension are exposed to exogenous cAMP (41, 49, 52). Conversely, if CAMPsignaling is disrupted, by disaggregating slug cells and shaking them rapidly in buffer in the absence of CAMP, their transcription is inhibited and their mRNAs are rapidly degraded (52-56). In some cases the mRNAs can be induced to reaccumulate by addition of CAMP (57,58). Thus, prespore gene expression is both inducible by, and dependent on, extracellular CAMP. Together, these results support the idea that extracellular cAMP signals induce and maintain prespore cell-differentiation. This success in identifying markers of the prespore cell-differentiation pathway has led to the application of similar approaches to the prestalkcell pathway. Indeed, the same differential screening experiments that yielded prespore-specific markers also yielded cDNA clones that hybridize to mRNA sequences enriched in prestalk cells (41, 49). These prestalk-enriched mRNAs are inducible by cAMP (52). Hence the conclusion drawn was that cAMP induces both prestalk and prespore cell-differentiation. On this premise cAMP becomes a truly totipotent signal, responsible for chemotaxis, for regulating gene expression at stages up to slug formation, and for the differentiation of both cell types. There is, however, a conceptual problem in using the same signal to induce the differentiation of two cell types within such a unitary structure. The CAMP-signaling system operates on a relay principle, so that all cells within a territory or aggregate should, in theory, perceive the same signal. Although developmental changes in the repertoire of receptors and G proteins can alter the signaling system in the ways described above, prior to the process of cellulur dgferentiation all cells must, by definition, possess the same signaling machinery. Thus it is difficult to see how CAMP-signaling could be used at one time in development to induce the differentiation of two different cell types. This theoretical objection was validated using a different
6
JEFFREY WILLIAMS AND ALASTALR MORRISON
approach to the problem of identifying prestalk-specific markers. This approach relied on che identification of the extracellular signal that actually induces prestalk and stalk cell-differentiation.
6. DIF-inducible Genes as Markers of Prestalk Cell-differentiation A major problem in analyzing the induction of prestalk and stalk celldifferentiation is that of access: the prestalk cells are a minor population in a multicellular, three-dimensional structure. A major advance was the demonstration that isolated cells in a tissue culture dish could be induced to differentiate into stalk cells (59). Subsequent analysis showed a density dependence of stalk cell-differentiation in such an in oitro induction system (34, 35). Cells produce a factor that, when removed from a population of cells incubated at a high cell density, can induce cells incubated at a low density to differentiate into stalk cells (36, 37). This factor, differentiation-inducing factor (DIF), was purified and shown to be a chlorinated hexaphenone (38, 60) (Fig. 2). There is a family of related chlorinated compounds, but DIF-12 i$ by far the most biologically active (60-62). D I F is produced during Dictyostelium development and acts at nanomolar concentrations to divert cells from prespore to stalk cell-differentiation (63-66). A mutant strain called HM44, which accumulates greatly reduced amounts of DIF, becomes arrested in its differentiation just prior to tip formation (67). When analyzed by two-dimensional gel electrophoresis the HM44 mutant was found to synthesize prespore-specific gene products but it did not express stalk-specific proteins (68). HM44 is an excellent strain in which to search for DIF-inducible genes, because stalk cell-differentiation is dependent on the addition of exogenous DIF. A cDNA library prepared from HM44 cells exposed to D I F for 12 hours was screened with probe cDNA prepared from the same mRNA or from mRNA isolated from cells not exposed to DIF. This yielded three different cDNA clones, pDd63, pDd56, and pDd26, that hybridize to mRNAs dependent on D I F for their expression (6). The three mRNA sequences differ in their time course of induction by D I F (6).The pDd63 gene is the most rapidly induced; there is an increase in the level of its transcription within 15 minutes of the addition of DIF. It therefore seems likely to be directly induced by the D I F signal transduction pathway. The pDd56 mRNA accumulates much more slowly but, again, D I F acts at the level of gene transcription to induce its accumulation. The pDd26 mRNA accumulates only at the very end of the induction process and addiLn all
subsequent discussions “DIF” is to be taken to mean the DIF-1 molecule
Dictyostelium
MORPHOGENESIS
7
tion of an inhibitor of protein synthesis prevents its induction by DIF (G. Weeks, personal communication). The relative induction kinetics of the three mRNAs are only partially reflected in their time courses of accumulation during normal development (6, 66). The pDd56 and pDd63 mRNAs are first detectable, approximately contemporaneously, about 2-3 hours prior to tip formation. In one study the pDd56 mRNA was actually detectable slightly before the pDd63 mRNA, but this may simply reflect a difference in relative sensitivity of detection of the two gene products (66, 69). The pDd26 mRNA first appears only much later during development, at culmination (6).The pDd63 and pDd56 mRNAs are expressed within the slug and can therefore be used to analyze gene expression in isolated prestalk and prespore cells. There is always cross-contamination of cell types in such experiments but, as closely as could be judged, both mRNA sequences were found to be expressed only in prestalk cells (6).
C. Two Alternative Types of Prestalk-enriched Markers The fact that the pDd63 gene, which seems to be directly inducible by the DIF signaling pathway, is expressed only in prestalk cells constitutes very strong evidence that DIF is the inducer of prestalk cell-differentiation (70). What then of the CAMP-inducibleprestalk-specific genes? Direct, side by side, comparison showed that the CAMP-inducible mRNAs are all present, to a greater or lesser extent, in prespore cells, i.e., that they are enriched in prestalk cells rather than being specific to prestalk cells (41,49).It was suggested, therefore, that there might be two ways of achieving prestalk enrichment, a primary induction route and a secondary route (6, 10, 52). Genes such as pod56 and pDd63, which are induced by DIF and which are expressed only as a cell becomes a prestalk cell, employ the primary mechanism. The other class of genes was suggested to become prestalk enriched by a secondary mechanism, whereby the genes were first expressed in most or aI1 cells, with their mRNA sequences then being selectively degraded in prespcre cells. There is a precedent for such behavior from analysis of a protein detected by a monoclonal antibody (71)and there is now additional evidence for such a mechanism for one of the best characterized prestalk-enriched gene products, that encoded by the Dictyostelium rusD gene. The rusD gene is inducible by CAMPbut is not inducible by DIF ( 6 , 4 1 , 72). The rusD mRNA accumulates to a very low level during growth, disappears early during development, and then reaccumulates later during aggregation (41, 72). The mRNA is only threefold enriched in prestalk cells compared to prespore cells, purified by gradient centrifugation (6),but when the
8
JEFFREY WILLIAMS AND ALASTAIR MORRISON
msD promoter is coupled to a lmZ reporter gene and introduced into Dictyosteliuni by transformation, it proves to be a very good marker for prestalk cells in the migrating slug (73). The fusion gene is strongly expressed in the prestalk region and in ALCs, but there is very little, if any, P-galactosidase protein in prespore cells. A resolution of this apparent conflict with the conclusions drawn from studying DIF-inducible genes has recently come from an analysis of the expression of the rusD-lmZ fusion gene during slug formation (K. Jerinyn and J. G . Williams, unpublished). The fusion gene is expressed in both prestalk and prespore cells during aggregation, and at the tight-mound stage, but the P-galactosidase protein produced by this fusion gene must be unstable, because, by the slug stage, only the prestalk cells are stained. Thus the rusD-lmZ fusion gene utilizes a secondary enrichment mechanism and s o cannot be used to determine the signals that induce prestalk celldifferentiation. Interestingly, the gradient analysis of slug-stage cells showed there to be only a marginal enrichment of the mRNA in prestalk cells, whereas the ZacZ fusion-gene analysis showed there to be no 6-galactosidase protein in prespore cells (6, 73). Perhaps there is some form of translational control at work, whereby the rusD mRNA is present in prespore cells but in an untranslatable form. There is a precedent for this notion derived from an analysis of the closely related rusG gene (74). In axenically growing cells, the rusG niRNA is present throughout development, but the protein disappears from the cells late during aggregation (S. Robbins and G. Weeks, personal communication). Wtiatever the explanation for the presence of the rusD mRNA in prespore cells, the anomaly is resolved: there are no known CAMP-inducible prestalk-specific inRNA sequences, DIF is the inducer of prestalk celldifferentiation, and the challenge now is to determine how it fulfills this function. The DIF-inducible genes have started to give insights into this question, but before discussing the data, we first discuss briefly their possibk= hiological functions.
D. Functional Analysis of the DIF-induced Prestalk-specific mRNAs The pDd26 inRNA encodes a small protein, of unknown function and cellular localization (75), while the pDd63 and pDd56 mRNA sequences encode large proteins, each composed of a linear array of a 24-amino-acid, cysteine-rich repeat (70, 76) (Fig. 3a). The pDd63 gene contains approximately seventy copies of the repeated sequence whereas the pDdS6 gene contains about 35 copies of a very closely related sequence. The migrating slug is surrounded by an extracellular matrix that f o r m a kind of sausage
Dictyostelium MORPHOGENESIS
9
a
b Protein
Antibody
(ST430)
ecm6
EcmB
(Sr310)
JABl&2
FIG.3. (a) The consensus sequences of the repeats encoded by the ecmA and e m B genes. The residues marked with an asterisk are “invariant” residues, defined as being present in more than 90% of copies of the repeat (76). Cysteine residues are highlighted by the boxes. (b) Tabulation of the nomenclature and antibody recognition patterns of the e d and e m B genes. The JAB2 monoclonal antibody recognizes both the e d - and ecmB-encoded proteins whereas the JABl antibody recognizes only the emB-encoded protein (83).
tube (1, 77).The discarded skin, the slime trail, is left on the substratum as the slug moves forward. Stalk cells are surrounded by a chemically similar matrix called the stalk tube (3, 78, 79). Immunoelectron microscopy shows that the pDd63- and pDd56-encoded proteins are present in both matrices (80, 81). The antibodies used for these analyses were also used to show that the proteins encoded by the pDd63 and pDd56 mRNA sequences were already known (81). They had previously been detected by two-dimensional gel electrophoresis, when they were, respectively, called ST430 and ST310 (82) (Fig. 3b), and they were also identified using two monoclonal antibodies, JABl and JAB2 (83) (Fig. 3b). Because they encode extracellular matrix proteins, the pDd63 gene has been renamed e c d and the pDd56 gene has been renamed ecmB. Despite their presence in both the slime sheath and stalk tube, the EcmA protein probably has a primary role during slug formation and the EcmB protein
10
JEFFREY WILLIAMS AND ALASTAIR MORRISON
probably plays a major role during culmination. Part of the evidence for these conclusions derives from analysis of a mutant in which the ecmA gene is inactivated by gene disruption (A. Morrison, unpublished). The mutant forms highly elongated first fingers that are prone to the effects of desiccation, but these go on to form apparently normal fruiting bodies. Thus the EcmA protein plays a role in shaping the slug but, after this stage, it appears to have no essential function. Disruption of the e m B gene has no apparent efiect upon morphogenesis, perhaps because the EcmA protein can subsume its function (A. Morrison, unpublished). The other evidence for the respective roles assigned to these two proteins comes from a consideration of when, and where, they are made. These studies also produced the surprising observation that the slug is composed not of one type of prestalk cell but of several prestalk cell subtypes.
111. Prestalk Cell Heterogeneity When the promoters of the e c m and ecmB genes were coupled to an immunologically detectable reporter gene and introduced into Dictyostelium cells by transformation, a hitherto unsuspected degree of complexity in prestalk cell-differentiation was revealed (7).The ecmA gene was found to be expressed at a high level in cells in the front part of the prestalk zone, but there was no detectable expression in cells in the rear part of the prestalk zone (Fig. 4). The expressing cells were termed pstA cells and the apparently nonexpressing cells were termed pstO cells. Subsequently, when the ecmA promoter was fused to the ZacZ gene, which provides a much more sensitive assay for gene expression, the pstO cells expressed the ecmA gene but at a lower level than did the pstA cells (8). ALC
PstA
FIG.4. Prestalk cell heterogeneity within the slug. Schematic representation of the slug stage of development illustrating the positions and proposed movement patterns of the prestalk cell types. The pstO cells are found in the posterior portion of the prestalk zone; the arrows indicate possible interchange between the anterior-like cells (ALCs) and pstO cells. The pstA cells are shown moving into the central core, where they differentiate into pstAB cells. The pstA cells replace the pstAB cells, which are occasionally lost into the slime trail as the slug moves forward (W), and the pstA cells are replaced by pstO cells.
Dictyostelium MORPHOGENESIS
11
A recent analysis of the e d promoter gives us an insight into the mechanism responsible for the difference in the level of ecrnA gene expression by pstA and pstO cells. The characteristic staining pattern described above is obtained when a region comprising 1694 nucleotides upstream of the cap site of the ecmA gene is fused to the lac2 reporter gene. Analysis of subfragments of the promoter shows that there are at least two discrete regions that direct expression in pstO cells, and that a region proximal to the cap site is necessary for expression in pstA cells (84) (Fig. 5a). Although a fusion gene that is expressed only in pstO cells has been generated, it has not as yet been possible to create a fusion gene that is expressed only in pstA cells. The pstO region occupies the approximate rear two-thirds of the prestalk zone during slug formation. If the first finger forms a migratory slug, the anterior prestalk zone eventually becomes stained, perhaps as the result of forward movement of pstO cells into the pstA zone.
ecmA -1694
-1212
I
-1048
-531
I
I
IpbtO/ALC]
I
I
I
pstO/ALC
ecmB CAP -1614
Chi
I
-1503 I
-a77 - 8 s -757
I
-208
-486
I
I
On in a n t d a prestalk cdls
Off in sntdor prostalk cdk
FIG.5. Comparison of the promoter elements of the ecmA and ecmB genes. Both genes have their regulatory elements contained within approximately 1.6 kb of upstream sequence (84, 119). Also, both genes contain a proximal element that directs expression in anterior prestalk cells (region -877 to -757 in the ecmB gene and region -120 to +41 in the ecmA gene), and distal elements that drive expression in ALC- and pstO-derived cells. The ecmB gene, however, contains an additional region (-486 to -208) that represses the expression of this gene in all anterior prestalk cells until they enter the stalk tube.
12
JEFFREY WILLIAiMS AND ALASTAIR MORRISON
Interestingly, a pstO-specific construct that contains only 164 nucleotides of the promoter region is also expressed strongly in ALCs. There is known to be a considerable rate of forward movement of these cells into the prestalk zone (85, 86), and it may be that they and the pstO cells are the same celltype located within different parts of the slug (Fig. 4). Further evidence for this notion comes from an analysis of their respective fates at culmination, and this will be discussed below. This idea does not, however, provide an entire explanation for the existence of ALCs, because some ALCs express only the ecinB gene while others express both ecmA and ecmB genes (8, 87). Also, some ALCs, identified by selective staining with vital dyes (the original criterion for this cell type), express neither the ectnA nor the ecmB gene (8). The existence of discrete pstA and pstO regions within the slug tip poses a number of interesting questions. How are they formed and maintained and what is the functional significance of this heterogeneity? In transplantation experiments, in which a coherent mass of pstO cells or pstA cells was introduced into the front or back of the prestalk region, the two different cell types seemed to know their correct address; i.e., they rapidly returned to their places of origin (88).Possibly, therefore, the discrete zones are formed and maintained by cell sorting. The close relationship (and possible identity) between pstO cells and ALCs provides a clue as to their function. The ALCs have been proposed to play a key role in regulation within the slug by acting as a kind of a halfivay house, with the option of trans differentiating, either to become an authentic prestalk cell that moves forward into the anterior zone, or to become a prespore cell that remains in the rear of the slug (89, 90). It may be important for this role as an intermediary that the ALCs spend part of their existence within the prespore zone and part of their existence in the prestalk region. The remaining prestalk cell subtype within the anterior region is found as a cone-shaped mass of cells that express both ecinA and ecmB genes (8, 87) (Fig. 4). These cells were originally identified by their expression of the eonB gene and thus were termed pstB cells. They were subsequently renamed pstAB cells when it was realized that they express both ecnd and ecmB genes (87). The pstAB cells lie in the position where stalk tube formation is initiated at culmination and they can be regarded as a kind of stalk primordium. During culmination, pstA cells differentiate into pstAB cells and then into stalk cells in a steplike manner (Fig. 6). It seems that during slug migration some of the pstA cells make the transition into pstAB cells prematurely and then form the central core (90). These observations show that there is an underlying similarity between D. discoideum and other dictyostelid species, such as Dictyosteliutn mucoroides, which continuously produce a stalk during slug migration by trans differentiation of prespore cells at the slug tip (91).
Dictyosteliurn
13
MORPHOGENESIS Upper Cup/Lower Cup/Basai
Cells in late aggregation pStA
--
(ecm.4 high)
Slug Formation
pstAB
,Stalk
(ecmn & e m s )
Culmination
FIG.6. Proposed model for a stepwise progression along the prestalk cell differentiation pathway. W e propose two separate cell pathways along which a prestalk cell may differentiate. It can become a pstA cell or it can become an ALC/pstO cell. The pstA cells invariably differentiate into pstAB cells and thence into stalk cells. However, an ALClpstO cell can either enter the stalk tube and become a stalk cell or it can remain outside the stalk tube and become part of one of the three ancillary structures-the upper cup, the lower cup, or the basal disc.
PstAB cells are stained selectively by the vital dye methylene blue and have been observed to move back through the slug periodically, eventually to fall behind in the slime trail (90). Because some slugs had multiple pstAB regions scattered along the length of the slug, there must be replacement of pstAB cells by recruitment of pstA cells. One attractive idea is that the pstO cells might replace these pstA cells, so accounting for the gradual loss of the discrete pstO zone during slug migration (Fig. 4). The slug should therefore be viewed as a dynamic structure in which pstAB cells discarded into the slime trail are replaced by trans differentiation. The ultimate source of renewal must be the prespore cells, and their trans differentiation into prestalk cells may account for the apparent erosion of the clear boundaries of the prestalk and prespore zones that occurs during prolonged slug migration (92, 93).
IV. Slug Formation A. The Mechanism of Tip Formation Because it is such an attractive system in which to study pattern formation, the process of slug formation has been one of the central foci of Dictyosteliurn research. There are two obvious mechanisms whereby the slug might be formed. The prestalk and prespore cells could differentiate in situ, in response to positionally localized morphogenetic signals. Alternatively, the prestalk and prespore cells could differentiateat random positions within
14
JEFFREY WILLIAMS AND ALASTAIR MORRISON
the aggregate and then move to their respective final positions in a cellsorting process, The weight of evidence greatly favors a cell-sorting mechanism for pattern formation (reviewed in 12), and analysis of the ecmA and ecmB genes provides strong support for this notion. The hndamental problem is to determine how the tip is formed, because this is the event that breaks the symmetry of the aggregate, and the tip of the aggregate eventually comes to form the prestalk zone in the migratory slug. Where do the first prestalk cells arise? Analysis of gene products such as those encoded by the CP2 and rasD genes, which become enriched by the secondary mechanism described in Section II,A, showed that the cells first expressed appear at scattered positions within the aggregate (73, 94). However, these markers cannot safely be used to determine whether there is cell-type sorting during slug formation, because they are initially expressed in both prestalk and prespore cells. Analysis of cells expressing the ecmA-lacZ fusion gene showed that the first detectable expression occurs in randomly scattered cells at the tightaggregate stage and the expressing cells then accumulate in the tip (95). If prestalk cells differentiate at random positions within the aggregate, presumably by exposure to DIF, how is the ratio of prestalk-to-prespore cells regulated? Analysis of the metabolism of DIF suggests that there may be a homeostasis mechanism that limits the number of cells that differentiate as prestalk cells. DIF induces DIF-1 dechlorinase, the enzyme responsible for DIF degradation, and prestalk cells are enriched in this enzyme (96). This could provide a feedback loop to control the concentration of DIF within the aggregate (96). As they enter development, cells are heterogeneous with respect to variables such as position in the cell cycle and nutritional status, and it may be that these factors affect the relative sensitivity to DIF (89, 97, 98). Indeed, there is a clear correlation between the eventual fate of a cell and the phase in the cell cycle at which a cell finds itself when it receives the starvation signal that triggers development (99-102). However, results from cell-cycle studies should not be over-interpreted. While they may provide an inbuilt heterogeneity that prejudices cells toward one or another pathway, there is not an absolute correlation between cell-cycle position and cell fate. Also, this is a regulative developmental system (100,103), so that cell-to-cell communication, by diffusible morphogens such as DIF, must play the over-riding role in controlling the ratio of prestalk cells to prespore cells. The accumulation of pstA and pstO cells within the tip is, of course, only one part of the process of tip formation. The aggregate must undergo a shape change, to convert the hemispherical mound into a cylindrical first finger. This process is in many ways analogous to gastrulation in higher organisms
Dictyostelium MORPHOGENESIS
15
and it may be that similar mechanisms are employed. This process of cellular intercalation presumably requires specific changes in cell shape and this may explain why strains mutated in cytoskeletal components are defective in tip elongation (104-107).
B. Apical Sorting of Prestalk Cells in Response to CAMP-s ignaIing Analysis of a strain that overexpresses extracellular cAMP phosphodiesterase (108), so that the extracellular cAMP concentration is reduced, showed that the sorting of ecd-expressing cells to the tip was greatly retarded (109).Prestalk cells detected by vital dyes can be caused to migrate to the base, rather than to the tip, if tight mounds are transferred to a substratum containing cAMP (110). This also holds true for ecmA-expressing cells in the phosphodiesterase overexpressing strain (109). These results support the notion of the tip as a source of CAMP-signaling and accord well with the observation that prestalk cells are more chemotactically responsive to cAMP than are prespore cells (30, 111, 112).
C. Basipetal Migration of pstB Cells When e c d and ecmB gene expression during slug formation was analyzed, using immunologically detectable markers, most detectable ecmBexpressing cells were found within the base of the tight mound (95). Now, using the much more sensitive enzymatic staining procedures, we know that ecmB-expressing cells arise at random positions within the aggregate (D. Traynor and J. G. Williams, unpublished results). We term these pstB cells because they do not appear to express the ecmA gene when they first arise. They subsequently seem to migrate to the base, where later, during tip extension, they begin to express the e c d gene (95).This basal population of coexpressing cells is left behind if the slug moves away from its site of formation, but if a culminant is formed in situ, they form part of the basal disc (8, 95). Thus there is a striking asymmetry in slug formation, in that ecmAexpressing cells migrate upward and ecmB-expressing cells migrate downward. A subset of ecd-expressing cells within the slug tip then activates expression of the ecmB gene, and ecmB-expressing cells within the base activate expression of the ecmA gene. How can we explain this behavior? The simplest notion is that there is a second CAMP-signalingcenter in the base, a suggestion that was made (113)to explain the downward movement of stalk cells at culmination. However, we still have no idea why the pstA and pstB cells should move in different directions. The only clues to understanding this process come from analysis of the behavior of the prestalk celh during culmination.
16
JEFFREY WILLIAMS AND ALASTAIR MORRISON
V. Culmination A. Stalk-tube Formation At culmination, the tip of the slug stops moving, and its rear end catches up with, and hence comes to sit underneath, the tip (114).The stalk tube is then constructed by the prestalk cells within the slug tip. As noted above, the EcmA and EcmB proteins are both present within the stalk tube. As they move up the outside of the tube, the pstA cells lay down cellulose fibers and proteins; presumably one of these is the EcmA protein (115-11 7). As the proteins reach the apex and enter the tube, the pstA cells reverse their direction of movement. Because of this change of direction, this process has often been likened to a “reverse-fountain” movement. As they pass the entrance to the stalk tube the pstA cells begin to express the ecmB gene and so become pstAB cells (8) (Figs. 6 and 7). The pstAB cells presumably secrete EcmB protein into the stalk tube and thereafter differentiate into dead, vacuolated stalk cells. It may be that expression of the
Early culminant
Late culminant
FIG, 7. Schematic representation of the distribution and movement of various prestalk cell types during the process of culmination. During culmination some of the ALCs move to the base of the aggregate and others move up to join with the pstO cell population (8, 29). Some of these pstO/ALC cells start to express the ecniB gene at a high level while still within the papilla. and they form the upper cup. Although the other (i.e., non-upper-cup) pstO/ALCs at the prestalkprespore boundary are shown as expressing only the ecmA gene, a very low level of e c d gene expression can be detected if staining is allowed to continue for extended periods. The upper cup cells, in cvntrast, show a very high level ofexpression of the eanB gene. Once all ofthe pstA cells have entered the stalk tube. some of the pstO/ALC cells enter the tube and express the ecmB gene. The cells in the upper cup (i.e., those pstO/ALC cells that express the ecmB gene at a high level) never enter the stalk tube and eventually form a disc of cells at the apex of the culminant. Approximately half of the pstO/ALC cells enter the stalk tube and half form the tipper cup.
Dictyostelium
MORPHOGENESIS
17
ecmB gene occurs synchronously with the commitment step because, in another species of slime mold (D. mucoroides), cells very near the top of the stalk are known to be inviable (118). At first glance the mechanisms of pattern formation during culmination and slug formation seem to differ radically. While slug formation appears to occur by cell sorting, stalk formation occurs by positional differentiation; expression of the ecmB gene being induced, presumably by DIF, precisely at the entrance to the stalk tube. This is, however, an oversimplification because the fruiting body is not simply a ball on a stick. Anterior-like cells within the culminant contribute to the formation of ancillary structures that give the fruiting body its characteristic shape, and they undergo extensive cell sorting.
B. The Movement of Anterior-like Cells at Culmination Over the same period that pstA cells in the tip are differentiating into pstAB cells, the ALCs move to surround the emerging spore head and, as they do so, they activate expression of the ecmB gene (8,29) (Figs. 7 and 8). Those ALCs that move downward are split into two as the spore mass begins to rise. This occurs after the stalk tube has embedded itself into the ALCs at the base, in a manner rather like pushing a finger into plasticine (8, 90). Those cells that remain in the base contribute to the basal disc and those cells that move up with the spore head form a kind of a cup (the lower cup)
I
Elevation of intracellular CAMP and activation of
FIG. 8. A model for the regulation of the e m B gene. This is a simplified representation of the e m B gene showing the sequences proximal to the promoter (downstream of residue -877; see Fig. 5) that direct expression in the stalk tube at culmination. This region of the gene is proposed to be potentially active in all cells that are exposed to DIF because of the presence of a positively acting region that lies at the end of the DIF signal transduction pathway. However, two repressor elements ( 1 2 0 ~keep ) the gene inactive in pstA cells. At culmination, when CAMP levels rise, PKA is activated in cells at the entrance to the stalk tube, the repressor is phosphorylated, and hence inactivated, and the e m B qene is expressed.
18
JEFFREY WILLIAMS AND ALASTAIR MORRISON
underneath it (8). Once again, therefore, just as during slug formation, a population of cells that express the ecmB gene move downward to the base. The ALCs that move upward merge with the band of pstO cells. Approximately half the cells within this region enter the stalk and activate expression of the ecmB gene (8)(Figs. 6 and 7). In a first finger that enters culmination immediately, and where there are discrete pstA and pstO regions, the first cells to activate the ecmB gene are the pstA cells, followed by the pstO/ALCs (8).By this stage of development, it is impossible to distinguish the pstO cells from the ALCs, and the fact that they come together in this way provides supportive evidence for their being the same cell type. The half of the pstO/ALC population that fails to enter forms a structure termed the upper cup. The pstO/ALCs that enter the stalk can be distinguished from the upper cup cells, because members of the former population do not activate ecmB gene expression until they enter the stalk tube, whereas members of the latter population do express the ecmB gene (Figs. 6 and 7). In a double-staining experiment, therefore, the upper cup cells are detected as a band of ecmA- and ecmB-expressing cells within a broader band of cells that express only the ecmA gene (8).The upper and lower cups may play a supportive role, cradling and protecting the spore head, or they may play an active role in lifting the spore mass up the spore head. They do not become vacuolated, and are therefore presumably viable cells; this fact has been held to support the latter idea, i.e., that they help lift the spore head up the stalk (29).
C. insights into Culmination from the Structure of the Promoter of the ecmB Gene The fact that the ecmB gene is induced in two different populations of cells, pstA cells and ALCs, is in part explained by the observation that the promoter of the eclnB gene contains separate regions that direct expression in these different cell types (119). A region proximal to the cap site directs expression in pstA cells as they enter the stalk tube and a distal region directs expression in the subset of ALCs that migrate to the upper cup (Fig. 5b). The location of the region that directs expression in the ALCs that move downward at culmination is as yet unknown. Understanding how pstAB differentiation occurs at the entrance to the stalk tube is one of the keys to understanding dictyostelid morphogenesis. As noted above, D. discoideum is somewhat exceptional among the dictyostelids in forming a freely migrating slug with distinct prestalk and prespore zones. Most other species form a stalk continuously during slug migration (4). In a species such as D. mucoroides, prespore cells trans differentiate, directly and rapidly, into stalk cells at the entrance to the stalk tube (91). There is no regulation. If such an aggregate migrates long enough,
Dictyostelium
MORPHOGENESIS
19
it forms an enormously elongated stalk with virtually no spores. The entrance to the stalk tube is, in all dictyostelids, the decision point. The ecmB gene provides a marker for this commitment step. It is with this process, the conversion of a pstA to a pstAB cell, by activation of ecmB gene expression at the entrance to the stalk tube, that the remainder of this review is concerned. The proximal region of the ecmB promoter, which directs expression to the stalk tube, is composed of two parts: a positively acting region capable of directing transcription in all prestalk cells, and a more proximal, negative control region that keeps the gene inactive until cells enter the stalk tube (119) (Fig. 5b). If this negative control region is deleted, the gene is expressed in apical pstA cells, i.e., the ecmB gene is effectively converted into an e m A gene with regard to its pattern of expression. The positively acting signal region may be the site of action of the DIF signal transduction system. DIF is a lipophilic molecule and there is a Dictyostelium protein with some of the properties expected of a steroid receptor (120). The negative control region contains two, apparently redundant, repressor elements, either of which can act to prevent expression of the ecmB gene in pstA cells until they enter the stalk tube (120~). They therefore act antagonistically to the putative DIF response region. These repressor elements are of central importance because they control the switch to stalk celldifferentiation.
VI. lntracellular Signaling and the Multiple Roles of CAMP-dependent Protein Kinase
A. Regulation of Stalk Cell-differentiation by CAMP-dependent Protein Kinase Recent work suggests that the negative control region, which keeps the ecmB gene off until cells enter the stalk tube at culmination, may contain the binding site for a repressor under the ultimate control of the CAMPdependent protein kinase (PKA). The effects of intracellular CAMPin eukaryotes are mediated by PKA. A rise in intracellular CAMPlevels causes dissociation of the R and C subunits of the CAMP-dependent protein kinase. Once dissociated, the C subunit migrates to the nucleus and activates gene expression (reviewed in 121). We believe that stalk cell-differentiation in Dictyostelium at culmination is induced by elevation of the intracellular CAMP concentration and activation of PKA. In the simplest model (Fig. 8) the catalytic subunit of PKA would phosphorylate a repressor protein, so causing it to dissociate from
20
JEFFREY WILLIAMS AND ALASTAIR MORRISON
the negative elements. The evidence for this model comes from analysis of the effects of expressing a dominant inhibitor of PKA selectively in pstA cells. Rni is a mutant form of the D. discoideutn R subunit of PKA, with point mutations in the two CAMP-binding sites that render it unable to bind CAMP (122).It can, however, bind to and inactivate the C subunit. In stable transformants containing the R?n gene fused to the promoter of the ecmA gene (ecmA-Rtn), development appears relatively normal up to slug stage (123). However, the slugs that are formed migrate almost indefinitely, under conditions in which control slugs enter culmination at a high frequency. They therefore phenocopy a class of mutants termed “sluggers” (124, 125). When ecmA-Rm slugs do eventually attempt to culminate, they stop migrating and rear up on end, but they remain indefinitely arrested in this upright position (123). They become blocked because the pstA cells are unable to initiate stalk-tube formation. As might be expected, they are also unable to activate stalk-specific gene expression so that if a ZucZ reporter construct containing a subfragment of the ecmB gene, which directs expression only within the stalk tube, is introduced into the ecmA-Rm mutant, the 2acZ gene is inactive (123). This effect is specific to the stalk-tube-specific region of the promoter, because the region that directs expression in the upper cup is expressed at normal levels in scattered cells within such structures.
B. A Role for CAMP-dependent Protein Kinase in Regulating Morphogenetic Cell Movement during Culmination When ectnA-Rm cells are mixed with an equal number of wild-type cells and allowed to develop, a fruiting body is formed that contains a bulbous protrusion at the prestalk-prespore boundary (123).This protrusion remains completely excluded from the stalk and comes to form a bolus of cells attached to the spore head of the mature culminant. It contains ecmA-Rrn cells that stay, frozen in situ, while the wild-type cells move through them to form and enter the stalk tube. Thus inactivation of PKA has an effect on cell movement that becomes manifest before cells move to the entrance to the stalk tube. Perhaps, then, culmination is a two-step process in which cells throughout the prestalk zone perceive the inductive signal and change their pattern of cell movement, but with activation of stalk-specific gene expression occurring only at the entrance to the stalk tube. Testing such a hypothesis will require a better understanding of the signals that induce culmination. Such factors have been investigated using various in uitro assays.
Dictyostelium
MORPHOGENESIS
21
VII. Other Extracellular Signals Controlling Prestalk and Stalk Cell-diff erentiation
A. Ammonia Several pieces of evidence suggest that the rise in cAMP that triggers culmination is brought about by a drop in ammonia levels. Ammonia is produced in large amounts, as a result of the extensive catabolism of cellular components that occurs during development (126-128), and exposure to an enzymatic “cocktail” that utilizes ammonia induces migrating slugs to culminate (129). Presumably, under natural conditions, there is an increase in the rate of loss of ammonia as the slug reaches the surface of the soil or leaf litter as it orientates upward, toward the light (130, 131). Ammonia inhibits the cAMP relay response, i.e., the stimulation of cAMP production by extracellular cAMP (132-134). Thus a drop in ammonia levels at culmination would be expected to trigger a rise in the intracellular cAMP concentration. There is supportive evidence of a role for ammonia in regulating stalk cell-differentiation from a number of other studies. When assayed in uitro, ammonia and other weak bases inhibit stalk cell-differentiation (36, 135). Conversery, exposure of slugs to weak acids such as CO, causes prestalk cells to differentiate into stalk cells in situ (136). The fact that treatment with ammonia elevates the p H of intracellular vesicles (137) supports the notion that ammonia functions by regulating vesicular pH (pH,) (135,138).There is as yet no clear link between pH, and intracellular CAMP, but there is the suggestion that changes in pH, may act to alter cytosolic calcium concentration (138). Such changes in calcium concentration could, perhaps, act to modulate the activity of adenylate cyclase.
B. Extracellular cAMP Extracellular CAMP-signaling is required in order that cells progress through development, and, as determined using in vitro assays, expression of both the ecmA and the ecmB genes depends on a period of incubation with cAMP (66,69,139,140). There is a DIF-binding protein that has some of the characteristics of a steroid receptor and that could, perhaps, be responsible for gene activation by D I F (120). Accumulation of this protein is dependent on prior incubation with cAMP and this may explain the cAMP dependency of ecmA and e m B gene expression. To a greater or lesser degree, ecmA gene expression is stimulatable by extracellular cAMP in all studies reported to date (66, 141). Surprisingly, however, at times after tip formation, stalk cell formation is inhibited by the addition of cAMP (66, 69, 139).This is an unexpected result because of the considerable body of evidence, described above, showing that a rise in intra-
22
JEFFREY WILLIAMS AND ALASTAIR MORRISON
cellular CAMP activates stalk cell-differentiation. During early development at least, an increase in extracellular cAMP triggers a rise in intracellular cAMP so that extracellular cAMP should stimulate intracellular CAMP accumulation and hence induce stalk cell formation (9). The effect of extracellular CAMP on ecmB gene expression has varied from study to study. In some studies, expression was markedly inhibited (66, 139), whereas in others ecmB gene expression was stimulated (A. Morrison, unpublished) or was highly variable (142). Differences in timing of the cAMP treatment in the various experimental protocols may explain the variability in results (140). The ecmB gene has a complex pattern of gene expression. It is activated during slug formation in scattered cells within the aggregate and is later activated within the stalk tube. The early- and late-expressing cell populations may differ in their responses to extracellular CAMP, so that analysis of the expression at the level of the mRNA may give misleading results. The pDd26 gene is expressed only during culmination and here the situation is quite clear: extracellular CAMP markedly inhibits expression (J. S. So and G. Weeks, personal communication; A. Morrison, unpublished). This apparent paradox-that stalk cell-differentiation is inhibited by extracellular CAMP but requires elevated intracellular CAMP-may have a straightforward explanation. Recent results suggest that extracellular CAMP acts to inhibit stalk cell-differentiation by affecting an intracellular-signaling component other than adenylate cyclase. The evidence for this derives from the observation that expression of the pDd26 gene remains CAMPrepressible in cells in which the catalytic subunit of the kinase is constitutively active ( 1 4 2 ~ )There . may, therefore, be two parallel pathways controlling stalk cell-differentiation: an ammonia-regulated pathway that operates by controlling intracellular CAMP, and a pathway regulated by extracellular CAMP that fiinctions through an as-yet unknown intracellular-signaling mechanism.
VIII. Conclusions The ecmA and ecmB genes have provided a number of new insights into the mechanisms regulating the morphogenesis of Dictyostelium. Rather than a simple binary decision, between stalk cell-differentiation and spore celldifferentiation, it is now clear that cells are faced with a series of differentiation decision. There are multiple prestalk cell subtypes and analysis of the promoter of a gene expressed selectively in prespore cells suggests that there may also be multiple prespore cell subtypes (143,144). We believe that the most important choice a cell faces on the stalk cell pathway is whether it should differentiate as a pstA cell or as a pstO/ALC (Fig. 6). These two
Dictyosteliurn
23
MORPHOGENESIS
prestalk cell subtypes differ in several important aspects of their behavior and we need to identify the biochemical basis for these differences. We also need to define the signaling conditions that direct cells into one or other of these two pathways. The other pressing need is to understand directed cell movement within the aggregate, both during slug formation and at culmination. The latter process is particularly complex, with at least three modes of cell movement occurring simultaneously: what directs the “reverse-fountain’’ movement of pstA cells, and why do some of the ALCs move upward and some move downward? Here the ecmA and ecmB gene show that there is a link between the state of cellular differentiation and the pattern of directed cell movement. The subpopulation of pstO/ALCs that fail to enter the stalk tube at culmination can express the ecmB gene via a specific subregion of its promoter (119). This gives us the hope that, both by identifying other genes with this pattern of expression and by using the subfragment of the ecmB promoter to direct expression of dominant inhibitors within upper cup cells, we may understand the cellular basis for their specific movement pattern. In summary then, the construction of a Dictyostelium fruiting body is a more complex process than was previously believed, but is infinitely less complex than the construction of a fly or a mouse. There is, therefore, the very real hope of obtaining a detailed cellular and molecular understanding of an entire morphogenetic process.
ACKNOWLEDGMENTS We thank Keith Jermyn and Gerry Weeks for their insightful comments on an earlier version of this review.
REFERENCES 1 . K. B. Raper, J . Elisha Mitchell Sci. Soc. 59, 241 (1940). 2. J. T. Bonner, Am. J . Bot. 31, 175 (1944). 3. K. B. Raper and D . I. Fennell, Bull. Torrey Bot. Club 79, 25 (1952). 4. J. T. Bonner, Q . Rev. Biol. 32, 232 (1957). 5. F. 0. Stenhouse and K. L. Williams, Dew. B i d . 59, 140 (1977). 6. K. A. Jermyn, M. Berks, R. R. Kay and J. G. Williams, Dewlopment 100, 745 (1987). 7. K. A. Jermyn, K. Duffy and J. G. Williams, Nature 340, 144 (1989). 8. K. A. Jermyn and J. G . Williams, Development 111, 779 (1991). 9. P. N. Devreotes, “The Development of Dictyosteliurn discoideum” (W. F. Loomis, ed.), p. 117. Academic Press, New York, 1982. 10. J. G. Williams, C. J. Pears, K. A. Jermyn, D . M. Driscoll, H. Mahhubani and R. R. Kay,
24
11.
12. 13. 14.
JEFFREY ‘WILLIAMS AND ALASTAIR MORRISON in “Symposinm of the Society for General Microbiology).” (I. Booth and C. Higgins, eds.), p. 277. Cambridge University Press, Cambridge, England. 1986. 6. Gerisch, ARB 56, 853 (1987). P. Schraap. Dij&rentiation 33, l(1986). A. R. Kimmel and R. A. Firtel, Curr. Opin. Genet. Dec. 1, 383 (1991). P, Klein, T. Sun, C. Saxe, A. R. Kimmel, R. Johnson and P. Devreotes, Science 241, 1467
(1988). 15. C . L. Saxe. H. L. Jolinson, P. Pi. Devreotes and A. R. Kimmel, Dee. Genet. 12,6 (1991). 16. C. I,. Saxe, 6. T. Ginsburg, J. M. Luuis, R. L. Johnson, P. . Devreotesand A. R. Kimmel, Ccnes Dec. 7, 262 (1993). 17. R. L. Johnson, C. L. Saxe, J. hf. Louis, R. Gollop, A. R. Kimmel and P. N. Devreotes, Genes Dec. 7, 273 (1993). 18. M. Pupillo, A. Kuniagdi, G. Pitt. R. A. Firtel and P. N. Devreotes, PNAS 86, 4892 (1989). 19. J. Hadwiger, T. Wilkie, M. Strathmann and R. A. Firtel, PNAS 88, 8213 (1991). 20. J. A. Hadwiger and R. A. Firtel. Genes Deo. 6, 38 (1992). 21. P. C. Newell, G. N . Europe-Finner and N. V. Small, Microbiol. Sci. 4, 5 (1987). 22. P. Janssens and P. Van Haastert, Microbid. Rea 51, 3’36 (1987). 23. B. Snaar Jagalska, F. Kesbeke and P. \’atan Haastert, Dea Genet. 9, 215 (1988). 24. R. A. Firtel, P. J. hl. van Haastert. A. R. Kimmel and P. N . Devreotes, Cell 58, 253 (1989). 25. R . A. Firtel. Trends Genet. 7, 381 (1991). 26. J. T. Bonner, W. W. Clarke, C. L. Neely and hl. K. Slifkin,]. Cell. Comp. Physiol. 36, 149 (1950).
27. D. LL‘. Francis, J. Cell. Conip. Physiol. 64, 131 (1964). 28. K. L. Poff and M. Skokut, PNAS 74, 2007 (1977). 29. J. Sternfeld and C. N. David, Dec;. Biol. 93, 111 (1982). 30. J. Sternfeld and C. N. David, Dijferentiution 20, 10 (1981). .31. K. Ilevine and W. F. Loomis, Dea Biol. 107, 364 (1985). 32. E Sakai, Dec. Grolcfh Differ, 15, 11 (1973). .3.3. 1. Sampson, J. Etnbryol. Exp. Morphul. 36, 663 (1976). .W.C . 11. Town, J. D. Gross and R. R. Kay, h‘ature 262, 717 11976). .35. K. R. Kay. D. Garrod and R. Tilly, Nature 271, 58 (1978). 36. J. D. Cross, C. D. Town, J. J. Brtmkman. K. A. Jermyn, M . J. Peacy and R. R. Kay. Philos. Trmr. R . Soc. London, B 295, 497 (1981). 37. R. R . Kay and K. A. Jermyn. Nature 303, 242 (1983). 38. H. R. Morris, G . R: Taylor, M. S. Xlasento. K. A. Jermyn and R. R. Kay, Nature 328,811 (1987). .39. H. K . Hohl and S. T. Hamamoto. 1. Ultrustruct. Res. 26, 442 (1969). .10. V. Sluller and H. R . Hohl, Diflerentiation 1, 267 (1973). 41. M. C. hlehdy, D. Ratner and R. A. Firtel, Cell 32, 7&3 (1983). -12. B. C . A. Dowds and W. F. Looinis, BBRC 135, 336 (1986). 4.3. C . B. Hong and Wr.F. Loomis, BBA 950, 61 (1988). 44. K. L. Fosnangh and LV. F. Loomis, MCBiol9, 5215 (1989). 4.5. K. L. Fosnaugh and \V. F. h o m i s , h7ARes17, 9489 (1989). 46. J. H. Gregg, ht. Krefft. A. Haaskraus and K. L. Williams, Exp. Cell Res. 142, 229 (1982). 47. hl. KrefFt, L. Voet. J. H. G r e g and K. L. Williams, 1. End>ryol.Exp. Morphol. 88, 15 ( 1985). 45.. A. E. Early. J. G . Williams, H. E. hleyer, S. B. Pnr, E. Smith, K. L. Williams and A. A. Gooley, MCHiol 8, 3458 (1988). 49. E. Barklis and H. F. Lcxlish, Cell 32, 1139 (1983).
Dictyostelium MORPHOGENESIS
25
50. A. Tsang and J. M. Bradbury, Exp. Cell Res. 132, 433 (1981). 51. D. Fatner and W. Borth, Exp. Cell Res. 143, 1 (1983). 52. R. L. Chisholm, E. Barklis and H. F. Lodish, Nature 310, 67 (1984). 53. G. Mangiarotti, S. Chung, C. Zuker and H. F. Lodish, NARes 9, 947 (1981). 54. M. Oyama and D. D. Blumberg, J. Cell B i d . 99, A241 (1984). 55. S. Chung, S. M. Landfear, D. Blumberg, N. S. Cohen and H. F. Lodish, Cell 24, 785 (1981). 56. G Mangiarotti, S. Bulfone, R. Giorda, P. Morandini, A. Ceccarelli and B. Hames, Deuelopment 106, 473 (1989). 57. M. Oyama and D. D. Blumberg, Deu. B i d . 117, 557 (1986). 58. A. J. Richards, A. J. Corney and B. D. Hames, Mol. Microbiol. 4, 1279 (1990). 59. J. Bonner, PNAS 65, 110 (1970). 60. R. R. Kay, B. Dhokia and K. A. Jermyn, EJB 136, 51 (1983). 61. H. Morris, M. Masento, G. Taylor, K. Jermyn and R. Kay, BJ 249, 903 (1988). 62. M. Masento, H. Morris, G. Taylor, S. Johnson, A. Skapski and R. Kay, BJ 256, 23 (1988). 63. J. J. Brookman, C. D. Town, K. Jermyn and R. R. Kay, Deu. B i d . 91, 191 (1982). 64. M. Masento, H. Morns, G. Taylor and R. Kay, Biomed. Enuiron. Mass Spectrom. 16,353 (1988). 65. A. Sobolewski, N. Neave and G. Weeks, Differentiation 25, 93 (1983). 66. M. Berks and R. R. Kay, Deuelopment 110, 977 (1990). 67. W. Kopachik, A. Oohata, B. Dhokia, J. J. Brookman and R. R. Kay, Cell 33, 397 (1983). 68. W. Kopachik, B. Khokia and R. R. Kay, Differentiation 28, 209 (1985). 69. M. Berks, D. Traynor, I. Carrin, R. H. Insall and R. R. Kay, Deuelopment, Suppl. 1, 131 (1991). 70. J. Williams, A. Ceccarelli, S. McRobbie, H. Mahbubani, R. Kay, A. Early, M. Berks and K. Jermyn, Cell 49, 185 (1987). 71. M. Tasaka, T. Noce and I. Takeuchi, PNAS SO, 5340 (1983). 72. C. D. Reymond, R. H. Gomer, M. C. Mehdy and R. A. Firtel, Cell 39, 141 (1984). 73. R. K. Esch and R. A. Firtel, Genes Deu. 5, 9 (1991). 74. S. Bobbins, J. Williams, K. Jermyn, G,. Spiegelman and G. Weeks, PNAS 86, 938 (1989). 75. S. J. McRobbie and A. Ceccarelli, NARes 16, 4738 (1988). 76. A. Ceccarelli, S. J. McRobbie, K. A. Jermyn, K. Du@, A. Early and J. G. Williams, NARes 15, 7463 (1987). 77. B. M. Shaffer, J. Embryol. Exp. Morphol. 13, 97 (1965). 78. H. Freeze and W. Loomis, JBC 252, 820 (1977). 79. H. Freeze and W. F. Loomis, BBA 539, 529 (1978). 80. S. J. McRobbie, K. A. Jermyn, K. Du@, K. Blight and J. Williams, Deuelopment 104,275 (1988). 81. S. McRobbie, R. Tilly, K. Blight, A. Ceccarelli and J. Williams, Deu. Biol. 125, 59 (1988). 82. J. Morrissey, K. Devine and W. Loomis, Deu. Biol. 103, 414 (1984). 83. J. S. Wallace, J. H. Morrissey and P. C. Newell, Cell Differ. 14, 205 (1984). 84. A. Early, M. Gaskell, D. Traynor and J. Williams, Development 118, 353 (1993). 85. D. Francis and D. O’Day, J . Exp. Zool. 176, 265 (1971). 86. T. Kakutani and I. Takeuchi, Deu. Biol. 115, 439 (1986). 87. M. Gaskell, D. Watts, T. Treffry, K. A. Jermyn and J. G. Williams, Differentiution 51, 171 (1992). 88. B. Buhl and H. K. MacWilliams, Differentiation 45, 147 (1991). 89. A. Blaschke, C . Weijer and H. MacWilliams, Differentiation 32, 1 (1986). 90. J. Sternfeld, Wilhelm Roux’s Arch. Deu. B i d . 201, 354 (1992). 91. J. H. Gregg and R. W. Davis, Differentiation 21, 200 (1982).
26
JEFFREY WILLIAMS AND ALASTAIR MORRISON
92. I. Takeuchi, M. Hayashi and M. Tasaka, in “Development and Differentiation in the Cellular Slime Moulds” (P. Cappuccinelli and J. M. Ashworth, eds.), p. 1. Elsevier, New York, 1977. 93. A. J. Harwood. A. E. Early, K. Jermyn and J. G. Williams, Differentiation 46, 7 (1991). 94. R. H. Gomer. S. Goiner and R. A. Firtel, I. Cell B i d . 103, 1999 (1986). 95. J, 6. Williams, K. T. DUE$, D. P. Lane, S.J. McRobbie, A. J. Harwood, D. Traynor and K. A. Jermyn, Cell 59, 1157 (1989). 96. R . H. Insall, 0. Nayler and R. R. Kay, E M B O J . 11, 2849 (1992). 97. C . K. Leach, 1. M . Ashworth and D. R. Garrod,]. Embryol. Exp. Morphol. 29,647 (1973). 98. R. H. Gomer and R. A. Firtel, Science 237, 758 (1987). 99. S. McDonald and A. Durston, I. Cell Sci. 66, 195 (1984). 100. C. J. Weijer, G. Duschl and C. N . David, J . Cell Sci. 70, 133 (1984). 101. R. Gomer and R. Firtel, Science 237, 758 (1987). 102. T. Ohmori and Y. Maeda, Cell Differ. 22, 11 (1987). 103. Y. Maeda. T. Ohmori, T. Abe, F. Abe and A. Amagai, Differentiation 41, 169 (19x9). IO4. A D e Lozanne and J. A. Spudich, Science 236, 1086 (1987). 10.5. D. Knecht and W. Loomis, Deu. B i d . 128, 178 (1988). 106. D. Knecht and W. Loamis, Science 236, 1081 (1987). 107. W. Witke, M. Schleicher and A. A. Noegel, Cell 68, 53 (1992). 108. M. Faure, G . J. Podgorski, J. Franke and R. H. Kessin, PNAS 85, 8076 (1988). 109. 1).Traynor, R. H. Kessin and J. G. Williams, PNAS 89, 8303 (1992). 110. A. J . Durston and F. Vork, 1. Cell Sci. 35, 261 (1979). I l l . S. Matsukuina and A. Durston, 1. Einbryol. Exp. Morphol. 50, 243 (1979). I12. J. D. Mee. C. Tortolo and M. B. Coukell, Biochem. Cell. Biol. 64, 722 (1986). 1 1 3 . M . Sussinan and J. Schindler, Differentiation 10, 1 (1978). 114. K. D. Rand and M. Sussman, Differentiation 24, 88 (1983). 11.5. K. Grzelius and B. Ranby. Exp. Cell Res. 12, 265 (1957). 116. R, P. George. H. R. Hohl and K. B. Raper, I . Gen. Microbiol. 70, 477 (1972). 117. H. Hohl and J. Jehli. Arch. Microbiol. 92, 179 (1973). 118. U’. F. Whittingliam and K. B. Raper, PNAS 46, 642 (1960). 119. A. Ceccarelli, H. Mahbubani and J. G. Williams, Cell 65, 983 (1991). 120. R. Insall and R. R. Kay, E M B O ] . 9, 3323 (1990). 120a. A. J. Hanvood, A. Early and J. G. Williams, Deoelopment (1993). 121. K. A. W. Lee, Curr. Opin. Cell Bwl. 3, 953 (1991). 122. A. J. Harwood, N . A. Hopper, hl.-N. Simon, S. Bouzid, M . Veron and J. G. Williams, Dec. B i d . 149, 90 (1992). 323. A. J. Harwood, N. A . Hopper, M . N. Simon, D. M. Driscoll, M . Veron and J. 6. \Villianis, Cell 69, 615 (1992). 124. M . Sussman, J. Schindler and H. Kim, E x p . Cell Res. 116, 217 (1978). 725. P. C. Newell and F. M. Ross, J , Gen Microbiol. 128, 1639 (1982). 126. J. Gregg, A. Hackney and J. Krivanek, B i d . Bull. 107, 226 (1954). 127. J. Walsh and 8. Wright, I . Gen. Microbiol. 108, 57 (1978). 128. J. Wilson and C. Rutherford, /. Cell. Physiol. 94, 37 (1978). 129. J. Schindler and M. Sussman, J M B 116, 161 (1977). 1.30. J. Bonner, T. Davidowski, W. Hsu. I>. Lapeyrolerie and H. Suthers, Differentiation 21, 123 (1982). 1.31. J. Bonner, H. Suthers and G. Odell. Nuturc 323, 630 (1986). 132. J. Schindler arid M. Sussman, BBRC 79, 611 (1977). 13.3. J. Schindler and M. Sussman, Del;. Genet. 1, 13 (1979). 134. 6. B. Williams. E. M. Elder and M. Sussman, Dgferentiation 31, 92 (1986).
Dictyostelium
MORPHOGENESIS
135. J. D. Gross, J. Bradbury, R. R. Kay and M. Peacey, Nature 303, 244 (1983). 136. K. Inouye, Development 104, 669 (1988). 137. A. Yamamoto and I. Takeuchi, Differentiation 24, 83 (1983). 138. J. Gross, M. Peacey and R. P. Von Stradmann, Differentiation 38, 91 (1988). 139. M. Berks and R. R. Kay, Dew. Biol. 125, 108 (1988). 140. Y. Yamada and K. Okamoto, Dev. B i d 149, 235 (1992). 141. L. Kwong and G . Weeks, Differentiation 44, 88 (1990). 142. J. S. So and G. Weeks, Differentiation 51, 73 (1992). 142n. N. Hopper, C . Anjard, C. Reymond and J. G . Williams, E M B O ] . (1993). 143. L. Haberstroh and R. A. Firtel, Genes Dev. 4, 596 (1990).
144. L. Haberstroh, J. Galinda and R. A. Firtel, Development 113, 947 (1991).
27
This Page Intentionally Left Blank
Collagen Genes: Mutations Affecting Collagen Structure and Expression WILLIAMG. COLE Division of Orthopaedics The Hospital for Sick Children Toronto, Ontario, Canada M5G 1x8
...................... ........................................ .................... ene ....................................... VII. Type-IX Collagen Genes . . . . . . . . . . . . . . . . . . VIII. Type-X Collagen Gene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . IX. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
29 30 47 57
68 70
1. The Collagens The collagens are the major structural proteins of the extracellular matrix. Their importance is most obvious in the connective tissues such as bone, cartilage, ligament, tendon, dermis, and dentin, where they provide a highly organized fibrous matrix. The collagens also provide structural integrity to the capsules, septa, and laminae of the gastrointestinal, cardiovascular, urogenital, respiratory, and nervous systems. Basement-membrane collagens provide important structural and physiological functions in the kidneys, lungs, and other tissues. The collagens of the eyes and ears also have specialized structural and physiological roles. The collagens are a complex family of secreted molecules that share similar triple-helical motifs and have a structural role in the extracellular matrix. There are at least 26 different collagen polypeptide chains encoded by 26 unique collagen genes (1). Acetylcholine esterase, lung-surfactant protein, complement Clq, and conglutinin also contain collagenous (COL)1 1 Abbreviations: COL, collagen(ous); bp, base pairs; kb, kilobases; 0 1 , osteogenesis imperfecta; EDS, Ehlers-Danlos syndrome; NC, noncollagenous; GAG, glycosaminoglycan; RFLP, restriction-fragment-length polymorphism; IF, inhibitory factor; TGF, transforming growth
Progress in Nucleic Acid Research and Molecular Biology. Vol. 47
29
Copyright 0 1994 by Academic Press. Inc. All rights of reproduction in any form reserved.
30
WILLIAM G . COLE
triple-helical domains, but they are not classified as collagens because they do not contribute to the structure of the extracellular matrix (2). Roman numerals are used to identify each of the collagens, and arabic numerals represent individual polypeptide chains, referred to as a-chains (Table I). The collagens can be grouped into categories according to their a-chain characteristics, molecular assembly, and supramolecular structures (Table I). The most widespread and abundant collagens are the fibrillar collagens, types I, 11, 111, V, and XI (reviewed in 2). Type-IV collagen of basement membranes forms complex sheet structures; type-VIII and probably type-X collagens form complex hexagonal lattices; type-VI collagen forms beaded microfibrils; type-VII collagen forms anchoring fibrils; and collagens types IX, XII, and XIV are fibril-associated collagens with interrupted triple helices (FACIT). In addition to these levels of diversity, the collagens are also distributed differently throughout the extracellular matrices (Table I). Rapid progress continues to be made in characterizing the genes that encode the unique collagen a-chains (Table 11). The gene symbols indicate the type of collagen and a-chain. For example, in the symbol C O L l A l , COLl indicates type-I collagen and A1 indicates the al(1) chain of this collagen. The genes are widely dispersed in the genome but some of them are clustered together, such as COLAAl and COLAA2 on chromosome 13q34 and COLGAI and COL6A2 on chromosome 21q22.3 (Table 11). This review focuses on the collagen genes in which naturally occurring or induced mutations have been characterized. It includes the genes that encode collagens types I, 11, 111, IV, VII, IX, and X. Each of the following sections includes a description of the normal collagen and its gene(s) as well as a description of its naturally occurring and induced mutations. Descriptions of other collagen genes and the genes that encode the posttranslational modifying enzymes are available elsewhere (reviewed in 1, 3).
II. Type-I Collagen Genes A. Normal Type-I Collagen Genes Type-I collagen, the classical fibrous collagen, is the most abundant and widespread collagen. Each molecule contains two al(1)and one aZ(I) chains and forms a 300-nm long and 1.4-nm wide semiflexible rod that spontaneously assembles into microfibrils. The molecules overlap by a quarter of &tor; FACIT, fibril-associated collagen with interrupted triple helices; Mov-13, mouse with integration of Moloney leukemia virus into intron 1 of the COLlAl gene; CBF, CCAAT-binding protein: PCR, polymerase chain reaction; SED, spondyloepiphyseal dysplasia; LC, long-chain collagen.
31
COLLAGEN GENES AND THEIR MUTATIONS
TABLE I THE RPES OF COLLAGENS Collagen type
I trimer
IV
Molecular form
al(I),
al(Iv)2a2(Iv) a3(IV), a4(IV), aS(IV)? aW2aW) al(V)a2(V)u3(V)
V
Tissue distribution Skin, tendon, hone, cornea, and most of the connective tissues Embryonic tissues Hyaline cartilage, intervertebral disc, vitreous humor With type I in skin, visceral, cardiovascular tissues, placenta Basal membranes
Type of aggregate Quarter-staggered fibrils Quarter-staggered fibrils Quarter-staggered fibrils Quarter-staggered fibrils Sheets
Ubiquitous
Quarter-staggered fibrils
Aorta intima, placenta, uterus, skin, cartilage, nucleus pulposus, lung, liver Dermo-epidermal junction Endothelial cell culture, Descemet membrane Cartilage, intervertebral disc, vitreous humor Hypertrophic zone growth plate Cartilage
Beaded filaments
am93
VI
al(VI)aZ(VI)a3(VI)
VII VIII
al(VII), al(VIII),
IX
a 1(IX)a2(IX)a3(IX)
X XI
al(X)3 al(XI)a2(XI)a3(XI)
XI1 XI11
al(XII),
Tendon, ligament, skin Skin fibroblast culture
XIV
al(XIV),
Tendon, skin
Anchoring fibrils Sheets FACIP Sheets Quarter-staggered fibrils FACIT Described from cDNA FACIT
their lengths, SO producing the characteristic 67-nm periodicity of collagen fibrils (4). The characteristic properties of type-I collagen are largely due to the triple-helical conformation of approximately 95% of the molecule (5). The triple helix is formed from the uninterrupted sequence of 338 Gly-X-Y triplets in which X is frequently proline and Y is frequently hydroxyproline. Formation of the triple helix is dependent on glycine, the smallest amino acid, occupying each third position, and stabilization of the helix is achieved by hydroxyproline residues in the Y position. The type-I collagen molecule
32
WILLIAM G . COLE
TABLE I1 CHROMOSOMAL
LOCALIZArION OF COLLAGEN GENES
Collagen gene
Chromosome
Ref.
1Al lA2 2A 1 3.4 1 4A 1 4A2 4113 4A4 4'45 5,41 5d2 6'4 1 6A2 6A3 7.4 1 8'4 1 8'4 2 9A 1 1M1 11'41 11'4.2 1.3'41 15'41 16Al
17q21.3-q22 7q21.3-q22.1 12q12-q13.1 2q31-q32.2 13q3.1 13q3-4 2q36-q37 2q3.5337 xq22 9q34.2-q34.3 2q32-q33 21q22.3 21qq22.3 2q3i 3pZ1.1 3 q l l .1 4 3 . 2 lq34.3-~32.3 6q 12-ql4 r-2 1 -q22 lp21 6~21.3 10q22 9q21q22 1P3.5-N
254 255 2.56 256 25 7 257 194,258 258 198, 203 259 260, 261 262-264 262-26.1 263, 264 213, 265 266 267 268 248, 249 269 270, 271 272-274 2 75 2 76
also contains amino- and carboxy-terminal nonhelical extensions called telopeptides. They form intramolecular and intermolecular covalent crosslinkages that stabilize the polymer. The type-I collagen chains are synthesized as pre-pro-a-chains from which the signal peptitles of 22 residues are rapidly removed to yield the pro-a-chains (Table 111). Each type-I procollagen molecule forms by a process of association, registration, and disulfide bonding of the carboxy propeptides of two pro-al(1) and one pro-a2(I) chains (5).These processes ensure the correct alignment of the amino-acid residues required for the formation and propagation of the triple helix from the carboxy terminus of the helical domain. The pro-a-chains also undergo extensive co- and posttranslational modifications. Approximately 100 proline residues in the Y position of GlyX-Y triplets are hydroxylated to 4-hydroxyproline whereas a few specific lysine residues are hyroxylated to hydroxylysine, which may then be glycosylated to produce galactosyl- or glucosylgalactosyl-hydroxylysine.These
33
COLLAGEN GENES AND THEIR MUTATIONS
TABLE 111 DOMAIN STRUCTURES OF PROCOLLAGENS TYPESI, 11, AND IIIa Domain
Pro-al(1)
Pro-a2(1)
Pro-a1(111)
Pro-al(I1) ~~
Signal peptide N-Propeptide N-Telopeptide Triple helix C-Telopeptide C-Propeptide
22 139 17 1014 26 246
22 57 11 1014 15 247
21, 23, or 25 91, 89, or 87 19 1014 27 246
24 129 14 1029 25 246
.Number of amino-acid residues. Data are from 103, 118,170,and 277.
enzymatic modifications occur while the chains are in a nascent state and cease when the helix forms. An N-linked oligosaccharide is also added to the carboxy propeptides. The extensively modified procollagen is secreted and the amino and carboxy propeptides are then removed by specific proteinases to yield type-I collagen, which self-assembles into fibrils. The final enzymatic modification is the oxidative deamination of specific lysine residues, which are essential for the formation of normal intra- and intermolecular cross-linkages. The COLlAl gene, encoding the al(1)chain, and COLlA2 gene, encoding the a2(I) chain, are single-copy genes located on chromosomes 17q21.3q22 and 7q21.3-q22, respectively (Table 11).They contain 52 exons, of which exons 7 to 48 encode the main triple-helical domain of 1014 amino acids and 338 Gly-X-Y repeats (6, 7). The exon sizes in this domain are identical in the two genes except that exons 33 and 34 are fused in COLlAl and are referred to as exon 33/34 (3).The exons encoding the triple-helical domain are predominantly 54 bp, multiples of 54 bp, or combinations of 45 and 54 bp (Table IV). In each case, the exons begin with a complete glycine codon and encode complete Gly-X-Y triplets. The first six exons encode the pre-propeptides whereas the last four exons encode the carboxy telopeptides and carboxy propeptides. Exon 52 of the COLlAl and COLlA2 genes encodes two and four polyadenylation sites, respectively. These exons, and particularly the junctional exons 6 and 48, have sizes that differ markedly from those encoding the triple-helical domain of the protein. Most of the exons encoding the pre-propeptide and carboxy propeptide of the pre-pro-d(I) chain are larger than the equivalent exons of the COLlA2 gene. Despite these differences, the 38-kb COLlA2 gene is much larger than the 18-kb COLlAl gene, due to the larger introns in COLlA2. The expression of the COLlAl and COLlAZ genes is coordinately regulated in many physiological and pathological circumstances (8).The mecha-
34
WILLIAM G . COLE
TABLE IV
E x o ~ sENCODING THE TRIPLE-HELICALDOMAIN OF a2(I) CHAINS OF
Exon number
Exon size (bp)
7
43 54
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
.54 54 54
.54 45
.54 45
54 99 45 99
54 108 54 99 54 99 54 54
RPE-I PRO COLLAGEN^
Amino acids encoded
Exon number
Exon size (bp)
4-18 19-36 37-54 55-72 73-90 91-108 109-123 124-141 142-156 157- 174 175-207 208-222 223-255 2%-273 274-309 310-327 328-360 361-378 379-41 1 412-429 430-447
28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
54 54 45 99 108 54 54 54 54 108 54
54 162 108 108
54 108 54
108 54 108
Amino acids encoded
448-465 466-483 484-498 499-532 533-567 568-585 586-603 604-621 622-639 640-675 676-693 694-711 712-765 766-801 802-837 838-855 856-891 892-909 910-945 946-963 964-999
'Data are from 6, 7. and 103.
nisnis involved in coordinate regulation are poorly understood but both genes share some similar regulatory motifs, which have been more thoroughly studied in COLlAl (8). Studies of the transcriptional activities of the COLlAl gene have revealed functional promoters in the 5' flanking region and transcriptional activator and suppressor elements within the first intron and within the 3' untranslated region (8-12). The embryonic lethal mutation in the homozygous Mov-13 mouse results from insertion of the Moloney murine leukemia virus into the first intron of COLlAl (13).The viral insertion causes changes in the methylation pattern and chromatin conformation of the mutant gene, inactivating its transcription (14, 15).The first intron of human COLlAl also contains cis-regulatory sequences that appear to interact, in transient transfection systems, with 5'-promoter sequences to regulate the transcription of COLlAl (16-18). In contrast, at least 85%of the intron 1 sequences are not essential for expression of the human gene in stably transfected mouse cells (12).
COLLAGEN GENES AND THEIR MUTATIONS
35
The human, mouse, and rat 5'-promoter regions of COLlAl are similar (19). Of particular note are two CCAAT boxes, of which the proximal one interacts with a heterodimeric CCAAT-binding protein (CBF) to activate COLlAl transcription (8). Using an in uitro transcription system, point mutations in the CCAAT motif that showed either no binding or decreased binding of CBF abolished or reduced transcriptional activation by this transacting factor (20). The transcriptional inhibitory motifs, IF1 and IF2, are also near the CCAAT motif of COLlAl (8).The upstream elements also contain a binding site for nuclear factor 1and a related TGF-P activating element (21). In the rat COLlAl, an additional TGF-P activating element has been located upstream at - 1627, and one or more stimulatory elements, which are preferentially active in osteoblastic cells, have been located between -3521 and -2295 (22, 23). The untranslated 3' region of COLlAl also contains numerous putative gene regulatory motifs, and cell-specific binding of nuclear proteins to two highly conserved domains flanking the two polyadenylation sites has been demonstrated (11). Sequences in the 3' untranslated region of al(1)mRNA that might affect its stability by altering its secondary structure or protein binding have been identified (11). A highly conserved inverted repeat sequence of approximately 50 nucleotides in the 5' nontranslated region of al(1)mRNA was proposed to form a stem-loop structure that might alter the availability of the critical -AUGsequence for translation (24). However, deletion of sequences required for the stem-loop formation did not affect the efficiency of translation of transcripts from a fusion gene in either transiently or stably transfected cells. Also, DNase I protection experiments did not reveal binding of any protein to the sequences found in the inverted repeat (25).
B. Naturally Occurring Mutations of the Type-I Collagen Genes Many workers have characterized mutations of the type-I collagen genes in the heritable connective-tissue diseases, osteogenesis imperfecta (01)and Ehlers-Danlos syndrome (EDS). Fortunately, both diseases are expressed in the dermis so that the abnormal type-I collagen protein and mRNA are available with genomic DNA for the characterization of the mutations. The various categories of mutations and their consequences are described in the following sections. 1. MUTATIONS OF TYPE-I COLLAGEN GENES IN OSTEOGENESIS IMPERFECTA This disorder affects the type-I collagen-containing tissues and produces bone fragility, dentinogenesis imperfecta, blue scleral color, premature deaf-
36
WILLIAM G . COLE
ness, and joint laxity (26,27). It is heterogeneous with a mild form (type I), a lethal form (type II), a progressively deforming severe form (type III), and a moderately severe form (type IV) (28). Autosoma] dominant inheritance or sporadic Occurrence of heterozygous mutations of the type-I collagen genes are observed in most patients. Some patients with the type-111 form have autosomal recessive defects of these genes (26).
Biochemical Clussijication of Osteogenesis lmpegecta. Two broad categories of biochemical defects of type-I collagen have been identified. The first category includes dominant-negative mutations of the COLlAl or COLlA2 genes. Approximately 100 such mutations have been characterized to date and have been tabulated (29). The second category includes null mutations, usually of the COLlAl gene, in which the mutant allele fails to produce a pro-a-chain or produces a functionless pro-a-chain (30, 31). The dominant-negative mutations produce abnormalities in the sequence of the helical domain, carboxy telopeptide, or carboxy propeptide or the pro-a-chains. The most common are inissense mutations that alter Gly codons in Gly-X-Y triplets within the triple helix. Less common are point mutations that produce splicing errors with loss of an exon or insertion of intronic sequences, and least common are deletions and insertions involving single or multiple exons (26). In contrast, little is known about the molecular basis of the null mutations. The dominant-negative and the null mutations are outlined in the following sections. u.
I;. Helical Glycine Substitutions, Point mutations of the first two nucleotides of the GGN codon for glycine would be expected to produce substitutions by eight amino acids, including alanine, arginine, aspartic acid, cysteine, glutainic acid, serine, valine, and tryptophan. Substitutions by cysteine are the most common whereas substitutions by alanine are rare and substitutions by glutaniic acid and tryptophan have yet to be seen (26, 29). There is a strong preference for mutations of the first rather than the second base of the glycine codon. There do not appear to be any obvious “hot spots” for point mutations, as glycine substitutions have been observed along both a-chains. Most of the mutations are unique to the affected individual or family members. There are three examples of different substitutions at the same glycine residue consisting of a substitution of glycine 1009 by serine or valine, of glycine 832 by aspartic acid or serine, and of glycine 415 by cvsteine or serine (32-35). However, two unrelated infants with severe osteogenesis imperfecta had new dominant mutations of glycine 154 to arginine in the al(1) chain (36). Another two unrelated infants with lethal
COLLAGEN GENES AND THEIR MUTATIONS
37
perinatal 01 had new dominant mutations of glycine 1003 to serine in the al(1)chain (36). Both of these recurrent mutations appeared in CpG dinucleotides and are consistent with deamination of a methylcytosine to produce thymidine. There may be a marginal preference for mutations in CpG dinucleotides, which are frequent targets for mutations in other genes (37). Substitution of a glycine residue in a glycine-X-Y triplet does not alter the length of the chain but it does alter the formation and integrity of the triple helix. Numerous reports have provided data consistent with a model in which the carboxy propeptides align and disulfide-bond in the normal manner. Formation of the triple helix then commences at the carboxy terminus of the a-chain and continues at a normal rate until it encounters the glycine substitution (38-40). Further propagation of the helix is delayed, so that the amino-terminal portions of the chains remain in the nascent state for an abnormally long period; consequently, more lysine residues are hydroxylated and more hydroxylysine residues are glycosylated. Type-I collagen molecules that contain one or two mutant a-chains are often unstable and susceptible to intracellular degradation (38).In addition, the mutant molecules are secreted poorly, often to such an extent that the rough endoplasmic reticulum is grossly distended. These findings indicate that a significant proportion of the normal a-chains are destroyed in type-I collagen molecules that contain one or two mutant a-chains. For example, a heterozygous mutation of the COLlAl gene that alters half of the pro-al(1) chains synthesized by 01 fibroblasts inactivates half of the normal pro-al(1) chains and half of the normal pro-a2(I) chains produced by the same cells. The consequence of these events is a 75% reduction in the amount of normal type-I collagen that is available to form the extracellular matrix. This phenomenon, in which normal chains are lost in degraded mutant molecules, typical of dominant-negative mutations, has been called “procollagen suicide” (41). Glycine substitutions often reduce the thermal stability of the triple helix (42). However, some glycine substitutions, such as the substitutions of glycines 844 and 631 by serine in the al(1)chain, do not show this phenomenon (43, 44). These findings indicate that the model that considers the collagen helix as a single functional unit in relation to helix formation and stabilization is too simplistic; a more detailed model must consider the helix as being composed of subdomains of differing stabilities. One such model considers these domains as cooperative folding blocks that result in nonlinear helix formation and stabilization (42,44).The position of glycine mutations within these sequence subdomains would be expected to have a critical role in determining the effect of helix propagation on helix destabilization (42). The possible effects of the local sequences in determining the effect of a mutation on helical structure by providing domains of relatively low or high
38
WILLIAM G . COLE
local helix stability have been explored (45). Mutations in regions of low local stability would be less deleterious to helical stability. Further, according to this model, if sequences amino-terminal to the mutation are of high stability, renucleation of helix formation could occur readily with minimal interruption of helix propagation. Some of these points are illustrated by the differing effects of glycine substitutions by serine in the al(1)chain. The nonlethal substitutions of glycines 832 and 844 are in such a region of low stability with a region of higher stability immediately amino-terminal. Thus, disturbance of the helix folding caused by the mutations may be rescued by relatively easy renucleation of triple-helix folding beyond the mutations. In contrast, the more amino-terminal substitutions of glycines 565, 598, and 631 by serine lack such amino-terminal renucleation sites. Different glycine substitutions may also produce different effects on helix stability (46). Decreased thermal stability is a feature of collagens with glycine substitutions by arginine, cysteine, and aspartic acid (29).In a study of the structural effects associated with a substitution of cysteine for glycine 998 in the a l ( I ) chain, Traub and Steinmann (47)examined space-filling molecular models of the predicted structure of the mutant collagen. They found that a glycine-to-cysteine mutation caused only a limited local disturbance of the helix, possibly due to the introduction of disulfide bonds into the helix. Changes of glycines 391 and 667 to arginine in the a l ( I ) chain are also associated with decreased thermal stability of type-I collagen molecules (48, 49). Computerized molecular modeling studies indicate that these glycineto-arginine substitutions lead to only a minor localized disruption of the triple helix (.% These I) results . are in agreement with the space-filling models of the substitution of cysteine for glycine 988 in the al(1)chain. It is likely, in these instances, that the glycine substitutions have a kinetic effect on the collagen folding that leads to overmodification of the collagen ol-chains, rather than that the substitution leads to a major disruption of collagen folding. In 0 1 fibroblast cultures, some of the mutant molecules escape intracellular degradation and are secreted into the extracellular matrix where additional adverse effects occur (38). Delayed removal of the amino propeptide in the conversion of procollagen to collagen has been observed as a secondary effect of some glycine substitutions, even when the substitution is distant from the enzyme cleavage site (51, 52). Abnormal fibril formation has also been noted in a patient with the substitution of glycine 748 by cysteine in the a l ( I ) chain (53). Rotary-shadowing electron-microscopy shows that some of the procollagen molecules have a flexible kink at the site of the cysteine substitution (S4). Further in oitro studies showed that the mutant and normal type-I collagens synthesized by the proband’s fibroblasts are similar enough in structure to copolymerize into the same fibrils, and that, because of the copolymerization, there is a distortion of normal fibril mor-
COLLAGEN GENES AND THEIR MUTATIONS
39
phology, a delay in fibril formation, and a decrease in the net amount of collagen incorporated into fibrils (53). Glycine substitutions within the triple helix produce mild, moderate, and lethal perinatal forms of 0 1 . The most important factors that determine the severity of the phenotype appear to be the type of substitution, the type of chain involved, its position within the a-chain, and the surrounding sequences (26, 55). These relationships have been best studied in patients with glycine substitutions by cysteine in the al(I)chain (56). With the exception of the substitution at position 244, there is a smooth gradation of severity of phenotype from the carboxy-terminal to the amino-terminal substitutions (26). The reason for the lethal phenotype in the infant with the substitution at position 244 is unclear, but may involve unrecognized influences of surrounding sequences or epigenetic factors. If the latter are excluded, the transition region between the lethal and severe phenotypes occurs between cysteine substitutions of glycines 610 and 691; for the severe and moderate phenotypes, it occurs between glycines 415 and 382, and for the moderate and mild phenotypes, it occurs between glycines 175 and 94. In contrast, the transition points are more amino terminal with substitutions of glycine by aspartic acid, arginine, and valine in the al(1)chain. For arginine substitutions, the transition zone separating lethal and severe phenotypes occurs between glycines 298 and 154, and the zone separating severe and mild occurs between glycines 154 and 85 (57). The transition points for glycine substitutions by valine or aspartic acid are not known, but are probably amino terminal to glycine 256 and glycine 97, respectively (58). The relationship between the sites of glycine substitutions by serine in the al(1)chain and the severity of the clinical phenotype is more variable than with other substitutions. Lethal perinatal phenotypes have been observed with substitutions as far amino terminal as glycine 565. However, the substitutions producing lethal phenotypes are interspersed with substitutions producing mild and moderate phenotypes. The reasons for the variable phenotypes are unknown, but may involve variations in local helix stabilities (45). It has been proposed that glycine substitutions in the a2(I) chain are less deleterious than equivalent mutations of the al(I) chains because type-I collagen molecules contain only one a2(I) chain (59). However, 10 of the 16 glycine substitutions so far reported in the a2(I) chain produce lethal perinatal phenotypes. Indeed, all the glycine substitutions by aspartic acid in the al(1)and a2(I) chains produce lethal perinatal phenotypes. c. Helical Splicing Mutations. Point mutations or deletions of splicedonor or -acceptor sites result in the loss of adjoining exon-encoded sequences in the splicing of pre-mRNA to mRNA. The point mutations most
40
WILLIAM G . COLE
often involve the first two positions of the splice-donor (G-T) and -acceptor (A-T)sites. However, mutations at the + 5 splice-donor position can also lead to splicing out of the upstream exon-encoded sequence (60).The translational reading-frame is maintained following loss of an exon-encoded sequence from mRNA, as the exons encode complete codons. The helical-triplet sequence is also maintained as each exon encodes multiple complete glycineX-Y triplets. However, some point mutations and deletions result in the activation of cryptic splice sites, so that intronic sequences are inserted into the mRNA without loss of exon-encoded sequences. For example, a point mutation of T for C at position + 6 in the splice-donor site of intron 33 of the COLlA2 gene resulted in the activation of a cryptic splice site at positions 19 and +20, so that 18 nucleotides were inserted into the inRNA and six nonhelical amino acids were inserted between residues 585 and 586 of the triple-helical domain of the a2(I) chain (61). In a similar manner, 75 nucleotides from intron 35 were inserted into the mRNA and 25 nonhelical amino acids were inscrted into the helical domain of the al(1) chain of another patient (62).
+
d. Helical Deletions und Insertions. Multiexon deletions are uncommon. Examples include deletions of exons 22 to 24 of the COLlAl gene and exons 34 to 40 in the COLlA2 gene (63-66). Multiexon insertions are also uncommon. The one example is a tandem duplication of exons 15, 16, and part of 17 in the COLlAl gene (67, 68). It is surprising, given the repetitive structure of the type-collagen genes, that large rearrangements within the COLlAl and COLlA2 are so uncommon. Smaller deletions have also been reported. Two patients had deletions of a Cly-Ala-Pro triplet in the d ( I ) chain (69, 70). In another patient, three nucleotides were deleted from the a2(I) cDNA, resulting in the loss of valine 255 from the a@) chain (71).The 3' codon of exon 19 of the COLlA2 gene had been deleted in this patient, but its loss did not appear to alter the splicing of pre-mRNA. I n contrast to glycine substitutions, deletions, insertions, or splicing errors alter the length of the affected pro-a-chain. Deletions usually preserve the mandatory repeating glycine-X-Y triplet structure whereas insertions may not. However, the disparity in length of the normal and mutant chains produces major disturbances in collagen metabolism with poor secretion and increased intracellular degradation and procollagen suicide (41).The type of metabolic abnormalities are similar to, but often more severe than, those observed with glycine substitutions. Deletions or insertions in the al(1)chain, as a result of major gene rearrangements or splicing mutations, usually produce lethal perinatal phenotypes. The few exceptions involve exons 8, 9, 17, and 30. These findings
COLLAGEN GENES AND THEIR MUTATIONS
41
suggest that, like glycine substitutions, loss of the more 5’ exons are more likely to produce milder phenotypes than the loss of more 3’ exons. The unexpected clinical severity of the phenotype in an infant showing a skipping of exon 14 was probably due to the homozygous nature of the molecular defect (60).In contrast, deletions and insertions in the a2(I) chain commonly produce mild or only moderately severe phenotypes.
e. Carboxy-Telopeptide and Carboxy-Propeptide Mutations. Mutations in the carboxy-terminal nonhelical domains of the pro-a-chains have been reported less frequently than helical mutations. Point mutations and inframe deletions, as well as out-of-frame insertions and deletions, have been reported. The sole carboxy-telopeptide mutation occurred in the al(1)chain and resulted in the substitution of glycine 3 by cysteine (72). Mutations in the carboxy telopeptides and propeptides may alter chain association and disulfide bonding and delay the formation of the triple helix with consequent overmodification of the full length of the helical domain of the a-chains. Varying amounts of normal and mutant type-I collagen molecules are produced by these mutations. At one extreme are such mutations as the substitution of glycine 3 by cysteine in the carboxy telopeptide of al(1)chains, which produce a biochemical phenotype similar to that produced by glycine substitutions in the carboxy terminus of the triple helix (72). At the other extreme are such mutations as a 5-bp frameshift-deletion involving the carboxy propeptide of the pro-al(I) chain, which prevent the mutant and normal chains from associating and forming disulfide bonds (73). Only normal type-I collagen molecules are produced, procollagen suicide is avoided, and the mutant allele acts like a null allele. In a similar manner, a frameshift deletion of 4 bp from the carboxy proqeptide of the pro-a2(1) chain prevented these chains from associating with normal pro-al(1) chains (74). The normal pro-al(1) chains were not wasted in the phenomenon of procollagen suicide. In the homozygous patient, the mutant pro-a2(1) chains were degraded and the normal p r o d ( 1 ) chains formed al(1)homotrimers (75, 76). In between these extremes are mutations that allow the mutant chain to associate with normal chains, but all of the mutant molecules are retained within the cell and are degraded. Only normal type-I collagen is secreted from cultured dermal fibroblasts and only normal type-I collagen is found in the dermis and bone of the proband. However, in each circumstance, the concentration of type-I collagen is reduced to about 20% of normal because of procollagen suicide (32, 77). The clinical consequences of these mutations are variable, with mild and lethal phenotypes. The one mutation of the carboxy telopeptide of the al(1) chain produced a mild phenotype (72).The mutations of the carboxy propeptides produced lethal phenotypes ifa mutant protein chain, capable of form-
42
WILLIAM G. COLE
ing type-I procollagen molecules, was produced. Two such infants had relatively well-formed but severely porotic skeletons (57). Mutations of the carboxy propeptide of the d ( 1 ) chain that prevented chain association led to a mild phenotype (73). The excess normal a2(I) chains were destroyed, as molecules containing two or three a2(I) chains are unstable at 37°C. In contrast, an equivalent homozygous mutation of the carboxy propeptide of the pro-a2(1) chain resulted in a moderately severe type-111 phenotype, and the heterozygous parents were clinically normal (78).The milder-than-expected clinical phenotypes appeared to be due to the degradation of the mutant pro-a2(I) chains, absence of procollagen suicide, and formation of d ( I ) trimeric molecules that compensated, to some extent, for the lack of type-I collagen.
f. Null Alblic Mutations. Heterozygous mutations of this type result in the production of about half the normal amounts of type-I collagen (79, 80). The collagen produced by cultured dermal fibroblasts and the collagens found in dermis and bone are otherwise normal. The underlying molecular mechanisms are poorly understood but several studies provide insights into some possible mechanisms. Cultured dermal fibroblasts from such individuals produce reduced amounts of pro-orl(1) mRNA and chains (30, 81). Loss of an allele, through deletion or rearrangement, was not the cause of the diminished COLlAl mRNA levels (81). However, there was marked diminution in steady-state mRNA levels from one COLlAl allele. Primer extension with nucleotidespecific chain termination was used to identify mutant COLlAl alleles in cell strains heterozygous for expressed polymorphisms (81). Rowe et a1. (30)observed reduced levels of cytoplasmic d ( 1 ) mRNA and increased levels of nuclear al(1)mRNA. These findings suggested that mutant al(1) mRNA is retained within the nucleus. In more recent studies, Rowe et al. (82) observed that orl(1) mRNA that retained an out-of-frame intron was only detected in the nuclear and not in the cytoplasmic mKNA. They proposed that if a splicing mutation results in a product that is inframe, the abnormal mRNA is transported to the cytoplasm and an abnormal chain is produced, whereas if the abnormal spliced product is out-of-frame, the abnormal mRNA remains within the nucleus and only the normal allele is expressed. These findings are in keeping with reports of a nuclear scanning apparatus involved in the nuclear export of mRNA (83). Rarely, a mutant type-I collagen chain is translatable in uitro but is not detectable in the intracellular or extracellular collagens produced by dermal fibroblasts (73). In such cases, mutations in the carboxy propeptide prevent pro-a-chain association, registration, and disulfide bonding. Alternative mechanisms that have not as yet been identified as causes of a null COLlAl
COLLAGEN GENES AND THEIR MUTATIONS
43
allele in osteogenesis imperfecta include deletion of an allele, regulatory mutations, and nonsense mutations (1). The typical osteogenesis imperfecta type-IA phenotype, which lacks dentinogenesis imperfecta, is produced by heterozygous mutations of the COLlAl gene that produce a functionally null allele (30, 79). Little is known about the clinical effects of null allelic mutations of the COLlA2 gene, except in one child with osteogenesis imperfecta type 111, described in Section II,B,l, who was homozygous for a carboxy-propeptide mutation that prevented the mutant p r o - 4 1 ) chains from associating with pro-al(I) chains.
g . Somatic and Gonadal Mosaicism. Although the recurrence rate of new dominant mutations in 01has been estimated to be 1in 5000 to 1O,OOO, the observed recurrence rate of lethal perinatal01 is approximately 7% (84). This higher than expected rate of recurrence of lethal perinatal 01 is due to parental gonadal mosaicism. Recurrences of lethal perinatal forms of 01 have been observed in families in which the parents are clinically normal or in which one parent is minimally affected by 01. Such recurrences have been proposed to be due to autosomal recessive inheritance (28). However, this proposal is inconsistent with the heterozygous nature of the mutations found in most of the affected infants. The alternative explanation for the recurrence of heterozygous 01 is that one parent has gonadal mosaicism (70, 85, 86). Direct evidence of mosaicism was found in the sperm and somatic cells of some fathers and in somatic cells of some mothers. In one mosaic father, it was estimated that one in eight of his sperm and 40% of his diploid cells, such as white blood cells and hair root bulbs, carried the mutation, although he was clinically normal (85). 2. MUTATIONS OF ? ~ P E -COLLAGEN I GENES I N EHLERS-DANLOS SYNDROME
a . Amino-Telopeptide and Amino-Propeptide Mutations. Mutations that impair the removal of the amino peptides of the pro-a-chains of type-I procollagen produce the Ehlers-Danlos type-VII phenotype with major joint dislocations and skin laxity (87, 88). As in osteogenesis imperfecta, the abnormal collagen is found in the type-I collagen-containing tissues. There are three forms of EDS type VII. EDS type VIIA is due to mutations that remove the N-proteinase cleavage site of the pro-al(1) chains. EDS type VIIB is due to similar defects involving the pro-a2(1) chains. Joint dislocations of similar severity are a feature of these two subtypes of EDS type VII. EDS type VIIC results from a deficiency of N-proteinase and produces a more severe phenotype with greater fragility of the skin. The two reported cases of the VIIA variant were due to a G-to-A transition at the -1 position of the splice donor site of intron 6 of COLlAl. This
44
WILLIAM G . COLE
mutation results in alternative splicing with products lacking exon-6encoded sequences, which includes the N-proteinase cleavage site, or including exon-6 sequences and a substitution of methionine 159 by isoleucine (88-90). The clinical features of these two cases were similar. Ten cases of the type-VIIB variant have been described; three were due to a G-to-A transition at the -1 position of intron 6, as in the type-VIIA cases, except that they involved the COLlA2 gene (91-93). Six cases had point mutations of the GT-dinucleotide splice-donor site of intron 6, which resulted in the complete loss of exon-6-encoded sequences from the 012(I) mRNh and chain (52, 94-98). The deleted sequence included the N-proteinase cleavage site and the cross-linking lysine site in the N-telopeptide of the a2(I) chain. In another case there was partial loss of exon-6-encoded sequences due to a base substitution at the splice-acceptor site of intron 5 of the COLlA2 gene that activated a cryptic splice site at positions +14 and +15 of exon 6 (87).The N-proteinase cleavage site was lost but the nearby cross-linking lysine site in the N-telopeptide was retained. Dermatosparaxis (EDS type VIIC) was first recognized as a recessively inherited disorder of cattle (99, 100).Two human cases of the type VIIC, due to N-proteinase deficiency with retention of the N-propeptides of pro-oll(1) and pro-a2(1) chains, resemble clinically and histologically the animal equivalent, dermatosparaxis (101, 102). It is not clear why mutations that impair the processing of the amino propeptides produce the Ehlers-Danlos type-VII phenotype while mutations of the helix and carboxy-terminal extensions of type-I procollagen produce an osteogenesis imperfecta phenotype. As expected, however, some usteogenesis imperfecta patients with amino-terminal mutations of the triple-helical domain of type-I collagen have features of the Ehlers-Danlos syndrome (103).Cultured fibroblasts from some 0 1 patients with mutations distant from the amino-proteinase cleavage sites also show impaired removal of the amino propeptides (51, 52, 104).
C. Insertional and Site-directed Mutagenesis of the COL7A7 Gene 1. CELL CULTUREAIVD THAXSGENIC MOUSE MODELS OF LETHALFERINATAL OSTEOCEIVESIS IMPERFECTA
Site-directed mutagenesis of the mouse and human COLlAl genes have been used successfully to investigate the effects of glycine substitutions and deletions on the metabolism and structure of tvpe-I collagen in transfected cells and transgenic mice. Site-directed mutagenesis of the mouse COLlAl gene provided direct evidence that glycine substitutions within the triple-helical domain of the
COLLAGEN GENES AND THEIR MUTATIONS
45
pro-al(1) chain result in the biochemical phenotypes observed in human lethal perinatal osteogenesis imperfecta type I1 (105). Mutagenesis of the gene was carried out to produce the substitution of glycine 859 by cysteine or arginine in the d(1) chain (106).These two mutations were selected as they had been identified in the carboxy-terminal region of the a l ( I ) chain in infants with lethal perinatal 01. Neither of them had involved glycine 859 but this residue was selected for substitution because its codon was suitably placed within the genomic nucleotide sequence known at that time. The mutated mouse COLlAl gene was transfected into Mov-13 cells, which did not express their endogenous COLlAl genes, and into NIH 3T3 cells, which did express their endogenous COLlAl genes. The Mov-13 cells produced stable type-I collagen molecules that contained the mutant d(1) chains and the endogenous normal 012(I) chains. The NIH 3T3 cells reproduced the heterozygous state seen in infants with lethal perinatal osteogenesis imperfecta in that the cells produced normal and mutant type-I collagen molecules. Also, as observed in affected infants, the mutant collagen was poorly secreted, enzymatically overmodified, and had reduced thermal stability. To study the effects of these mutations further, the mouse COLlAl gene encoding the substitution of glycine 859 by cysteine was introduced into fertilized normal mouse ova (106). In this heterozygous mouse model, the introduced mutant gene was expressed against the background expression of the endogenous COLlAl gene. The mutant construct was made in such a way that the mutant and normal COLlAl gene and their mRNAs and &-chains could be distinguished from each other. A lethal phenotype was observed in some of the mice carrying the transgene. The severity of the pathological phenotype correIated directly with the extent of mutant gene expression, in that fetuses most severely affected expressed the mutant gene to the greatest extent. A striking reduction of the total type-I collagen content of the dermis, proportional to the level of mutant gene expression, was seen in all transgenic fetuses. For example, fetuses in which only 10 or 30% of the al(1)mRNA was mutant produced 54 or 80% less type-I collagen than controls, respectively. These results showed that the production of relatively small amounts of mutant type-I procollagen leads to a dramatically reduced type-I collagen content of the skin. These findings are in accordance with those observed in the dermis of infants with the lethal perinatal phenotype (54). Similar results were observed with a human COLlAl minigene when expressed in NIH 3T3 cells and transgenic mice (107, 108). A minigene, lacking the central 41 exons and introns, was constructed to mimic a multiexon deletion as observed in one of the first characterized cases of human lethal perinatal osteogenesis imperfecta (64).The naturally occurring mutation,
46
WILLIAM G . COLE
which consisted of an in-frame deletion of exons 22 to 24 from one allele of the COLlAl gene, resulted in the formation of shortened pro-al(1) chains. The engineered construct consisted of 2.5 kb of the 5'-promoter region, the first 5 exons and introns, the last 6 exon and introns, and about 2 kb of the 3' flanking region. The junction of the 5' and 3' halves of the minigene were made in introns so as to preserve the consensus sequence for RNA splicing. Shortened pro-al(I) chains were produced by stably transfected NIH 3T3 cells. The biochemical phenotype was similar to that observed with the naturally occurring deletion of exons 22 to 24 of one COLlAl allele (108). Similarly, transgenic mice expressing high levels of the minigene developed a genetically transmitted lethal 0 1 phenotype (107). Cultured fibroblasts from these mice showed that the shortened pro-al(1) chains synthesized from the human minigene associated with and became disulfide linked to mouse pro-al(1) chains. The major effect of the minigene products appeared to be the depletion of normal type-I procollagen in the transgenic animals through the phenomenon of procollagen suicide.
2. CELL CULTUREAND TRANSGENIC MOUSEMODELS OF OSTEOGENESIS IMPERFECTA TYPEIA The mouse model of mild osteogenesis imperfecta type IA is based on the Mov-13 mouse, in which integration of a murine retrovirus within the first intron of the COLlAl gene blocked transcription, so producing a functidnally null allele (109). In the homozygous Mov-13 mouse, development is normal until approximately the 13th day of gestation, when the embryos die from bleeding (110). The tissues of these mice lack type-I collagen, and cultured dermal fibroblasts do not produce al(1)mRNA or protein. In contrast, tooth rudiments from homozygous Mov-13 mouse embryos produce a dentin layer containing normal amounts of type-I collagen when grown as transplants either in the anterior chamber of the eye or under the kidney capsule of syngeneic hosts (111).Odontoblasts appear to have the ability to produce al(1) mRNA efficiently despite stable integration of the retrovirus within the first intron of the COLlAl gene. Similarly, about 5% of osteoblasts from long bones were able to produce normal amounts of type-I collagen, indicating that a small subset of osteoblasts also did not express the mutant phenotype (111). The heterozygous Mov-13 mouse is a model of mild human osteogenesis imperfecta type IA (112). In keeping with human 01 type I, the dermis contains about half the normal amounts of type-I collagen, and cultured dermal fibroblasts show a similar reduction in type-I collagen production. The long bones are abnormally brittle on biomechanical testing, but the teeth appear to be normal.
COLLAGEN GENES AND THEIR MUTATIONS
47
111. Type4 Collagen Gene A. The Normal Type-ll Collagen Gene Type-I1 collagen is a typical fibrillar collagen with a helical domain 300 nm long and a fibril periodicity of 67 nm. It is a homotrimer, with a molecular weight of 300,000, containing three identical a l ( I I ) chains. It is found in the cartilages and virteous humor although it is transiently expressed more widely during embryogenesis. Chondrocytes are the predominant cell expressing the C O D A 1 gene. The type-I1 collagen gene, approximately 30 kb in size, is a typical singlecopy fibrillar collagen gene (3). It contains 54 exons and is localized to chromosome band 12q13.11-q13.12 (113).The N-propeptide is encoded by 7 exons (114).The 242-bp exon-1 encodes 157 bp of untranslated 5' sequence, the signal peptide, and the N-terminus of the N-propeptide. The 207-bp exon-2 encodes a cysteine-rich region of the N-propeptide that is alternatively spliced (114).The pro-al(I1) chain lacking exon-2 sequences is the B isoform, whereas the chain containing the exon-2 sequences is the A isoform (115).The type IIB isoform is produced by cells with a mature chrondrocytic appearance. The cells expressing the type IIA isoform have a fibroblastic phenotype and appear during embryogenesis where they surround cartilage. However, type-I1 collagen is also transiently produced by many cells, including epithelial cells, during embryogenesis (116, 117). It is likely that the type-IIA isoform is expressed by these embryonic cells and takes part in determining the shape of the craniofacial and other tissues (115).It appears, however, that chondrogenesis depends on removal of exon-2-encoded sequences to produce type-IIB procollagen. The type-IIA and -1IB isoforms are identical except for the alternative splicing of exon 2. The N-telopeptide contains 19 amino acids and the main triple helix contains 1014 amino acids, including 338 Gly-X-Y triplets that are essential for the formation of the triple helix. The C-telopeptide and C-propeptide contain 27 and 246 amino acid residues, respectively (118).All exons encoding the main triple helix contain 54 bp or multiples thereof; all of them contain complete codons and encode complete Gly-X-Y triplets. The carboxy propeptide is encoded by four exons, 51-54. The 334-bp exon 54 contains 230 bp of 3' untranslated sequence. There is a single polyadenylation ATIAAA signal located 23 nucleotides upstream of the poly(A) tail of pro-al(I1) mRNA (119). Regulatory sequences that provide tissue-specific expression are located within the 4.5-kb sequences upstream of the transcription start site and within the 4105-bp first intron of the human COL2Al gene (120-122). A TATA box is located 28 bp upstream of the transcription start site (121, 122).
48
WILLIAM G. COLE
A search for regulatory sequences in the 1542-bp segment upstream of the transcription site revealed numerous potential regulatory elements and several conserved motifs, including four Spl-recognition sites, two enhancer core elements, and one pyrimidine-rich region (122).There also appear to be two “silencer” elements in the promoter that function to keep COL2AI inactive in nonchondrocytes (121). They modify the activity of a powerful promoter located within 130 nucleotides of the start site of transcription (123).An enhancer element, required for chondrocytic expression, is located in the first intron of the rat and human COL2A1 genes (121, 123). A decamer sequence, CACAATGCAT, in the middle of the enhancer binds a chondrocyte nuclear protein(s) necessary for enhancer activity. The same sequence is present in the human gene, and it has homology to the consensus binding-sequence for helix-loop-helix transcription factors (123).
B. Naturally Occurring Mutations of the Type-ll Collagen Gene Mutations of the COL2Al gene would be expected to result in phenotypes characterized by structural anomalies of the hyaline- and fibrocartilages, the eye and the ear. Spranger (125) grouped the bone dysplasias demonstrating these phenotypic features into the type-I1 collagen family. It includes achondrogenesis type-I1 (hypochondrogenesis), spondyloepiphyseal dysplasia congenita, Stickler syndrome, and Kniest syndrome (Table V).
1. MmuTATrorvs OF TYPE-I1 COLLAGEN IN TYPE-I1 ACHONDROGENESISAND HYPOCHONDROGENESIS Achondrogenesis type-I1 and hypochondrogenesis are the same condition, except the former is more severe than the latter (126). The principal features are severe lethal dwarfism. The extremities are very short and broad. the trunk is short, the head is large, the nasal bridge is flat, the jaw is hypoplastic, and a cleft palate is frequent. Ossification of the cranium is normal whereas the long bones are very short and broad with metaphyseal irregularities. Ossification of the pelvis and vertebrae is severely retarded or absent. The hyaline cartilages of the skeleton have a fetal histological appearance. The chondrocytes are enlarged and the amount of intercellular matrix is reduced and disorganized (127, 128). The growth plates are severely disorganized and vascular channels that extend into the epiphyses are fibrotic (1 26). The epiphyseai cartilages, which have an abnormally gelatinous appearance, lack or contain markedly reduced amounts of type-I1 collagen (127-129). The major collagen is type-I collagen, not normally found in hyaline cartilages, with about 10% of type-XI collagen. Sufficient type-I1 collagen was present in the cartilage from one infant to
49
COLLAGEN GENES AND THEIR MUTATIONS TABLE V MUTATIONSOF THE COL2Al GENEAND THEIRPHENOTYPES~ Disease
Zygosity
Mutation
Amino-acid change
Ref.
Ach-H yp Ach-Hyp Ach-Hyp
Hetero Hetero Hetero
G-to-A, exon 46 G-to-A, exon 43 G-to-A, exon 33
Gly-943 to Ser Gly-853 to Glu Gly-574 to Ser
182 133 132
SEDc SEDc SEDc SEDc SEDc
Hetero Hetero Hetero Hetero Hetero
Deletion, exon 48 45-bp insert, exon 48 G-to-A, exon 48 C-to-T, exon 41 C-to-T, exon 31
Deletion Gly-970-IIe-984 Duplication of Gly-970-IIe-984 Gly-997 to Ser Arg-789 to Cysb Arg-519 to Cysc
143 144 150 153 145
Stickler Stickler Stickler Stickler Stickler
Hetero Hetero Mosaic Hetero Hetero
C-to-T, exon 40 T del, exon 40 Skip exon 12 G-to-A, exon 10 Exon 7
Arg-732 to Ter Premature Ter Deletion of Gly-91-Lys-108d Gly-67 to Asp Arg-9 to Ter
160 162 156 163 161
Kniest
Hetero
Skip exon 12
Deletion of Gly-91-Lys-108d
156
OAhbreviations: Ach-Hyp, type-I1 achondrogenesis-hypohondrogenesis; SEDc, spondyloepiphyseal dysplasia congenita; Ter, premature termination condon. bTwo unrelated families shown to have the same mutation. CThree unrelated families shown to have the same mutation. dMemhers of the same family in which the mosaic mother has typical Stickler syndrome and her heterozygous child has typical Kniest syndrome.
enable the mutation to be localized by protein analysis (130). The al(I1) chains migrated slowly on electrophoresis in the manner typical of enzymatic overmodification of lysine residues. It was proposed that the mutation was probably in the carboxy-terminal region of the triple-helical domain of the al(1I) chain, as all of the cyanogen bromide peptides migrated slowly due to overmodification of lysine residues (130). The corresponding region of the COL2Al gene was studied, using a cosmid library that was prepared from the proband’s fibroblast DNA (131).The infant was heterozygous for a G-toA transition in exon 46, which was within the region predicted to contain the mutation. It resulted in the substitution of Gly-943 of the triple-helical domain of the al(I1) chain by Ser (Table V). It interrupted the normal Gly-X-Y repeating-triplet structure and severely impaired the function of type-11 collagen molecules containing one or more mutant chains (131). The chondrocytes were shown by electron-microscopy to contain grossly distended rough endoplasmic reticulum due to impaired secretion of the mutant type-I1 collagen. The lethal phenotype was due to the dominant negative nature of the mutation that resulted in the production of struc-
50
WILLIAM G . COLE
turally defective a l ( I I ) chains and the degradation of a significant fraction of the normal chains produced from the normal C O U A I allele. Although the chain compositions of the type-I1 collagen molecules were not determined in this infant it is likely that approximately 12.5% of the molecules were normal homotrimers, 12.5% were mutant homotrimers, and 75% were heterotrimers containing both normal and mutant chains. It is also likely that most of the molecules containing one or more mutant chains were destroyed and this process would have also led to the destruction of about half of the normal a l ( I I ) chains. Similar abnormalities were observed in an infant with hypochondrogenesis (Table V) due to the substitution of Gly-574 by Ser (132).The strategy used to characterize this mutation differed from the previous case as it relied on using a chondrocyte culture system and cDNA-PCR scanning analysis. The small amounts of available cartilage were used for electronmicroscopy and for cultures. Light-microscopy showed typical features of the disorder whereas eiectron-microscopy showed that most chondrocytes contained dilated rough endoplasmic reticulum and irregular thickening of collagen fibrils. Because cartilage contains few chondrocytes, their numbers were increased by allowing them to proliferate in the fibroblastic state in monolayer cultures. They reexpressed the chondrocyte phenotype when grown on agarose. Within a few days, the cells expressed the COL2A1 gene and produced overmodified mutant chains and normal chains indicating that the proband was heterozygous for the mutation. The protein findings also suggested impaired processing of type-I1 procollagen to collagen. Microscopy showed, as in uit;o, that the chondrocytes contained dilated rough endoplasmic reticulum and an abnormal extracellular matrix. Although the latter studies provided an insight into the pathogenesis of the disease, there was insufficient protein available for localization of the mutation by peptide mapping. Southern and northern blot analyses were also unhelpful, because they were normal. Rather than scanning the COL2A1 gene of 38 kb, Horton et al. (132)scanned the full-length cDNA of approximately 5 kb, prepared from cultured chondrocyte mRNA. The fulllength cDNA, encoding the translated domain of COL2A1, was synthesized as three overlapping fragments (exons 1-22, 22-38, and 38-50), readily analyzed by PCR-amplification, single-strand conformational polymorphism analysis of 200- to 4 0 0 - b ~subfragments, and direct sequencing of abnormal subfragments. With this approach, the infant was shown to be heterozygous for a C-to-A transition in exon 33 resulting in the substitution of Gly-574 of the triple-helical domain of al(I1) chains by Ser. Type-I1 collagen abnormalities were also observed in another case of hypochondrogenesis and were shown to be due to the substitution of Gly-853
COLLAGEN GENES AND THEIR MUTATIONS
51
by Glu resulting from a GGA-to-GAA transition in one allele of COL2Al
(133, 134). 2. MUTATIONS OF T~PE-IICOLLAGEN IN SPONDYLOEPIPHYSEAL DYSPLASIA CONGENITA Spondyloepiphyseal dysplasia (SED) congenita varies markedly in its severity. In its most severe form it produces a short-trunk form of dwarfism with facial hypoplasia, cleft palate, myopia, retinal detachments, sensorineural deafness, abnormal vertebrae, and short long-bones with markedly retarded epiphyseal ossification (135). In its mildest form, it produces minimal epiphyseal dysplasia and premature osteoarthritis (136, 137). Most of the early protein studies (138, 139) reported overmodified typeI1 collagen in patients with SED congenita and its variants and showed that the distribution of the overmodified cyanogen bromide peptides correlated with the clinical severity of the phenotype. For example, the severest phenotypes were observed in patients with overmodification of all peptides, indicative of a carboxy-terminal mutation, and the milder phenotypes were observed when the overmodification was restricted to the more aminoterminal peptides, indicative of a more amino-terminal mutation. As expected, genetic linkage was established between many of these phenotypes and restriction-fragment-length polymorphisms of COL2Al (140-143). However, Lee et al. (143) were the first to report direct evidence of a type-11 collagen mutation in SED congenita. Coarse screening of COL2Al by Southern blot analysis revealed an abnormal restriction pattern, shown by genomic DNA sequencing to be due to a heterozygous deletion of 390 bp from the middle of intron 47 to the splice-donor site of intron 48. The deletion eliminated exon 48 and the 36 amino acids from residues 964 to 999 of the triple-helical domain of the al(I1) chain. Protein studies were not undertaken, but it was predicted that the mutant allele acted in a dominant-negative manner typical of similar mutations of the type-I collagen genes (26). Other COL2A1 mutations have been characterized by a variety of techniques (Table V). In one of them, protein studies were used to localize the mutation for directed analysis of COL2A1, which showed a heterozygous 45bp duplication within exon 48 (144).The in-frame insertion added 15 amino acids to the helical domain of the al(I1) chains, resulting in the observed amino-terminal overmodification of lysine residues. The DNA sequence homology observed in the region of the duplication suggested that the mutation had arisen by unequal crossover between related sequences. Ala-Kokko et al. (145) used an intragenic COL2Al linkage marker to isolate a mutant cosmid clone, containing most of the mutant COL2Al allele, from a proband with mild SED. Sequencing of over 20 kb, including all of
52
WILLIAM G . COLE
the nucleotides for exons 2 to 52, revealed a transition of C-to-T in exon 31 resulting in the replacement of Arg 519 by Cys. This substitution involved the third position of the triplet Gly-Pro-Arg. Protein studies showed that the mutant a l ( I I ) chains migrated slowly due to enzymatic overmodification, and formed disulfide-bonded dimers (146, 147). The protein features were similar to those observed with Gly replacements by Cys in Gly-X-Y triplets of type-I collagen chains (148). The same Arg-519-to-Cys substitution was also identified in two additional, unrelated families with a similar type of mild SED and premature osteoarthritis (149). A novel method was used to characterize a heterozygous G-to-A transition in exon 48 of COUA1 that substituted Ser for Gly-997 (150).Advantage was taken of the phenomenon of low basal or “illegitimate” transcription of genes for tissue-specific proteins by cultured fibroblasts and lymphoblastoid cells (151).Both of these cell types transcribe the COUAI gene to process it in a normal manner (150). Lymphoblastoid cells also transcribe normal and mutant COLlAl and COLlA2 alleles in 0 1 as well as normal and mutant COL3Al alleles, in EDS type IV (150).The low steady-state levels of specific niRNAs in these cells cannot be detected by northern blot analysis and there is no detectable protein produced. However, the sequences can be detected following cDNA-PCK (151). The only modifications to our standard technique of PCR of abundant collagen cDNAs were as follows: to increase the number of amplification cycles from 30 to 40; to amplify only 500- to 600-bp fragments in order to reduce PCR errors; to use oligonucleotide primers that spanned several exons to ensure that cDNA rather than DNA templates were being used; and to include control reactions to detect DNA contamination (150, 151). To take advantage of this phenomenon, a 621-bp fragment from the 3’ coding region of al(I1) cDNA, prepared from cultured SED fibroblasts and lymphoblastoid cells, was amplified by the PCR and examined for sequence anomalies using the chemical cleavage method (1*52).An anomaly was observed that was shown, following sequencing, to consist of a heterozygous G-to-A transition resulting in the substitution of Ser for Gly-997 in the triplehelical domain (150).The mutation altered a restriction site used to confirm that the proband was heterozygous for the point mutation in exon 48 of COL;?Al and that the parents were normal. A heterozygous substitution of Arg-789 in the triple-helical domain of d(11) chains by Cys, which was characterized by a combination of the techniques described above, illustrates the need to use varying strategies according to the availability of cartilage samples and genetic linkage data (153). Collagen protein from the cartilage was used to localize the mutation, and chondrocyte cultures were used to characterize the metabolic consequences of the mutation. As the number of chondrocytes available for the latter
COLLAGEN GENES AND THEIR MUTATIONS
53
studies was limited, cultured fibroblasts were used as an alternative source of al(I1) mRNA, cDNA, and genomic DNA for characterization of the mutation. The region of the cDNA corresponding to the cyanogen bromide peptide map anomaly was amplified by the PCR and shown by single-strand conformational polymorphism and chemical cleavage analyses to contain a sequence anomaly. Direct sequencing showed a C-to-T transition, confirmed by restriction mapping to be due to a heterozygous mutation in exon 41. The type-I1 collagen chains were overmodified and formed disulfide-bonded dimers in a manner similar to the type-I1 collagen bearing a substitution of Cys for Arg-519 (145). The same Arg-789-to-Cys substitution was also identified in an unrelated child with a similar form of SED congenita.
3. MUTATIONSOF TYPE-I1COLLAGEN I N THE KNIEST SYNDROME This is a short-trunk form of dwarfism with spinal deformities, flat face, cleft palate, hearing loss, myopia, and stiff, deformed joints (154).The cartilage is grossly abnormal with large chondrocytes lying in a loosely woven matrix containing numerous empty spaces (154).Electron-microscopic studies showed that the collagen fibril organization was abnormal in epiphyseal and growth plate cartilages (155).The carboxy-terminalpropeptide of type-I1 procollagen appeared to accumulate within chondrocytes, but the remainder of the al(II) chains appeared to be normally secreted. It was proposed that the reduced amount of the carboxy propeptide is responsible for the observed abnormality of collagen fibrils. However, the molecular basis of these changes was not reported. One mutation, however, was identified in a patient kith typical Kniest syndrome (156).It consisted of a deletion of 28 bp from the 3' region of exon 12 including the highly conserved GT dinucleotide at the 5' end of intron 12. The changes in the protein and mRNA were not reported, but shortened species would be expected. This mutation does not account for the anomalies of the carboxy propeptide reported in four other cases (155). 4. MUTATIONS OF TYPE-I1COLLAGEN IN THE STICKLER
SYNDROME (ARTHRO-OPHTHALMOPATHY) Individuals with the Stickler syndrome and those with SED congenita display anomalies of the same tissues. The face is hypoplastic and eye anomalies, deafness, cleft palate, as well as joint anomalies with premature osteoarthritis, are common. In contrast, however, individuals with the Stickler syndrome are excessively tall and thin and have long thin hands and feet (157). Genetic linkage of COL2Al with the Stickler phenotype was reported in several families (158, 159). A stop codon was identified as the cause of the
54
WILLIAM G . COLE
phenotype in one family (160). Cartilage was not available for study but genetic linkage analysis provided an RFLP marker for the mutant COUAI allele. Cosmid clones were prepared and clones containing the marker were subcloned and sequenced. A sequence of over 7 kb was analyzed, including exons 2 to 44, which included 43 of the 54 exons of COL2Al and 38 of the 43 exons encoding the triple-helical domain of al(I1) chains. Sequencing included approximately 40 bp of flanking regions of each exon. A single-base mutation that altered a CG dinucleotide in exon 40 converted the codon CGA for Arg-732 to TGA, a stop codon. The mutation was confirmed in the affected family members, using allele-specific oligonucleotides to the wildtype and mutant sequences. I n another family, a similar mutation, but involving the codon for Arg-9 in exon 7, also produced a stop codon (161). A premature stop codon was also observed in another family, but it resulted from a different molecular mechanism (162). The heterozygous molecular defect consisted of the deletion of the thymidine nucleotide at position 18 of exon 40 of one COL2Al allele, resulting in a translational frameshift and the formation of a nonsense codon, TGA, in the sequences encoded by exon 42. In these families, the Stickler phenotype appeared to be due to a quantitative deficiency of type-I1 collagen, as the truncated mutant pro-al(I1) chains would lack the carboxy propeptide that is essential for chain association, registration, and disulfide bonding. In contrast, mutations that would be expected to produce abnormal al(I1) chains have been identified in two other families (156, 163). One of them had a heterozygous substitution of Asp for Gly-67 due to a G-to-A transition in exon 10 of COL2Al (163).Again, cartilage was not available for study, so screening of genomic DNA was undertaken. Forty three of the 54 exons of COL2Al were amplified, and the PCR products were analyzed for sequence anomalies by denaturing gradient gel electrophoresis. In the other family, the mother of a child with typical Kniest syndrome, described in Section 111,B,3, had a typical Stickler syndrome, due to a mosaic deletion of 28 bp from exon 12 that probably resulted in loss of exon-12 sequences from mature al(I1) mRNA (156).
5. GENOTYPE-PHENOTYPE RELATIONSHIPS Although only a small number of mutations have been characterized to date, some patterns are already emerging that indicate that the osteogenesis imperfecta model of fibrillar collagen mutations also applies to the family of type-I1 collagen diseases. For example, the phenotypes in this family appear to result either from the effects of dominant-negative mutations, with qualitative and quantitative anomalies of type-11 collagen, or from the effects of autosomal dominant mutations that produce a functionless allele and a quan-
COLLAGEN GENES AND THEIR MUTATIONS
55
titative deficiency of type-I1 collagen (Table V). When considered in this way, type-I1 achondrogenesis and hypochondrogenesis are equivalent to lethal perinatal osteogenesis imperfecta (27). SED congenita is the equivalent of 0 1 of type III/IV. As with the latter types of 01, the severity of the phenotype varies and the mutations are intermingled with those that produce a lethal phenotype. It is likely that the severity of the phenotype is related to the type of mutation, its site, surrounding sequences, and epigenetic factors, although the mechanisms involved are poorly understood (26,27). Unexpectedly, three unrelated families shared Arg-519-to-Cys substitutions and two unrelated families shared Arg-789-to-Cys substitutions. The phenotype was more severe in the families with the more carboxy-terminal Arg-to-Cys substitutions, in accordance with the gradient of severity observed with Gly-toCys mutations in the al(1)chain of type-I collagen in 01 (26). The reported deletion of part of exon 12 in the Kniest syndrome was unexpected, as the severity of the phenotype and the results of previous immunohistochemical studies were more in keeping with mutations in the 3’ region of the COL2Al gene. More mutations must be characterized in order to clarify these apparent inconsistencies. The Stickler syndrome results from a quantitative deficiency of type-11 collagen or from amino-terminal glycine substitutions in the helical domain of the oll(I1) chain. As a result, the molecular pathology of the Stickler syndrome is equivalent to that of 01 of type I (27).
C. Site-directed Mutagenesis of the Type4 Collagen Gene The most obvious difficulties with the study of CODA1 mutations in human diseases are the absence, in many cases, of cartilage and chondrocyte cultures, the inability to predict accurately the type and site of the mutation from the clinical and radiological phenotypes, and the consequent need to scan and sequence large regions of cDNA or DNA to localize the mutation. Site-directed mutagenesis of COL2A1, with expression of mutations in cells and transgenic mice, provides the opportunity to study genotypephenotype relationships systematically. A cosmid containing the human type-I1 collagen gene, including 4.5 kb of 5’ and 2.2 kb of 3’ flanking DNA, was introduced into embryonic stem cells, which were used to produce chimeric mice (120). The normal human COL2Al transgene was correctly transcribed in a stage-, cell-, and tissuespecific manner in the chimeric mice. These results showed that the sequences required for normal expression were included within the construct. These conclusions were confirmed in transgenic mice bearing a construct consisting of the rat COL2Al promoter and enhancer and the gene for the
s6
WILLIAM G . COLE
diphtheria toxin A chain (164).This construct led to cell lineage ablation of chondrocytes and resulted in the abortion of small fetuses with shortened and underdeveloped limbs and a cleft palate-the features of a chondrodysplastic mouse. Histological studies showed a sparse and disorganized extracellular matrix surrounding chondrocytes. Chondrodysplastic transgenic mice have also been produced by the introduction of COL2A1 gene constructs containing in-frame deletions or point mutations into pronuclei of one-cell mouse embryos. A minigene version of human COL2A1, containing only 12 of the normal 54 exons, equivalent to a large in-frame deletion, was used to produce five lines of transgenic mice (165). Most of the mice expressing the minigene developed a chondrodysplasia characterized by dwarfism, short thick limbs, short snout, cranial bulge, cleft palate, and delayed mineralization of bone. These features are shared by the lethal and severe members of the human type-I1 collagen family-SED congenita and achondrogenesis type-II-hypochondrogenesis. The cartilage contained thin, sparse, and abnormally organized collagen fibrils. Cultured chondrocytes produced a mixture of normal and truncated al(1I) chains. Some of the latter chains were disulfide-bonded to normal chains, which were largely retained within the cells. The heterotrimers were degraded within the cell by procollagen suicide, which destroys both normal and mutant chains (166).As a result, the phenotype is due to quantitative and qualitative anomalies of type-I1 collagen, indicating that the mutation acted in a dominant negative manner. A similar phenotype was produced by transgenic mice expressing a Glyto-Cys change at residue 85 of the triple-helical domain of al(I1) chains (167). The 39-kb D N A construct contained the mouse COL2A.Z gene, including 3 kb of 5’ flanking sequences and 7 kb of 3’ flanking sequences. The severity of the chondrodysplastic phenotype appeared to depend on the level of expression of the transgene. For example, one set of offspring heterozygous for the transgene did not show overt signs of abnormal bone growth. They expressed the mutant transgene at about one-third the level of expression of the endogenous gene. In contrast, a set of mice that were homozygous for the transgene died at birth and showed symptoms of severe growth retardation. The cartilage structure was similar to that observed with the human COL2Al minigene, except that the matrix also contained some abnormally thick fibrils. These fibrils may have formed because of defective collagen crosslinking, due to the proximity of the point mutation to the cross-linking Lvs at residue 87 of the triple helix. This proposal was supported by the observation of similar large fibrils in transgenic mice bearing a Lys-to-Arg mutation of the latter cross-linking site or of the Lys cross-linking site of the N-telopeptide.
COLLAGEN GENES AND THEIR MUTATIONS
57
The abnormally large collagen fibrils were not present in transgenic chondrodysplastic mice bearing a deletion of exon 7 and intron 7 (168).This deletion removed amino-acid residues 4 to 18 from the triple-helical domain of al(II) chains. It was considered to be too amino terminal to influence cross-linking of Lys-87 (167).As with the other chondrodystrophictiransgenic mice, the cartilage matrix and endochondral ossification were severely disorganized.
IV. Type-Ill Collagen Gene
A. The Normal Type-Ill Collagen Gene Type-I11 collagen is a widely distributed fibrillar collagen, being most abundant in dermis, blood vessels, and fibrous structures of viscera. It forms fine collagen fibrils in uitro, but in uiuo it is appears in heterotypic fibrils with collagens types I and XI. It is secreted by fibroblasts and smooth muscle cells as a procollagen. The amino and carboxy propeptides are cleaved to yield type-111 collagen, although cleavage of the amino propeptide is often slow in uiuo (169). The nucleotide sequence of the 5' nontranslated region of al(II1) cDNA shows three ATG translation start codons (1 70).The first two, at - 15 to - 17 and at -67 to -69, are followed by in-frame stop codons. The amino-acid sizes of the domains of al(II1)procollagen chains are listed in Table 111. The signal peptide, N-propeptide, and N-telopeptides are similar to those of pro-al(I) procollagen chains (1 70, 171). The triple-helical domain contains 343 Gly-X-Y triplets and 1029 amino acids. It is five triplets longer than the al(1)or 4 1 ) chains of type-I collagen and the al(I1)chain of type-I1 collagen (Table 111). Comparison of hydrophobicity plots of the al(II1) chain with al(1)and a2(I) chains showed that the additional triplets increase the differences between the ends of the type-I11 and -I collagens (170).The codon usage for amino acids in the triple-helical domain showed a preference for U in the third position of codons for glycine, proline, and alanine, as also observed for type-I collagen (172). The nucleotide sequence of the 3' nontranslated region of the cDNA showed that the mRNA contains three polyadenylation signals, AATAAA (170).Two major mRNA transcripts of 4.9 and 5.5 kb have been observed in cultured fibroblasts (173). The COL3A1 gene is located on chromosome 2q31-q32.3 (Table 11). The COL5A2 gene has also been colocalized to this region of chromosome 2 (Table 11). It is likely that the C O D A 1 gene contains 52 exons and that it is
58
WILLIAM G. COLE
larger than the COLlAl and COLlA2 genes (174). Partial characterization of the human COLJAI gene showed complete identity between the sizes of the exons encoding the Gly-X-Y triple helical domain and those of COLlA2 and COL2Al (65).These genes differ from COLlAl in that the 54-bp exons 19 and 20 are replaced by a fusion exon of 108 bp in COLlAl (174). Some inconsistencies are observed in the sizes of the four exons that encode the carboxy propeptides of the type-I, -11, and -111 procollagen chains, but these are mainly due to differences in the length of the 3’ untranslated region (65, 174). The amino pre-propeptide is encoded by five exons rather than six exons as in the COLlAl and COLlA2 genes (175).The promoter region of human COL3Al contains a TATA element but lacks a CCAAT sequence. A putative NF- 1 binding sequence, GGGCTGGAAAG, around nucleotide -60, and a potential AP-1 binding site, TGAGTC, at nucleotide -470, were also observed (175). Detailed analyses of the mouse COL3Al promoter has confirmed that the mouse gene also lacks a functional CCAAT sequence that is, however, found in both human and mouse COLlAl and COLlA2 promoters ( 1 76). The mouse promoter contains cis-regulatory elements that are not found in the COLlAl and COLlA2 promoters. The observed differences in the promoters of these genes may provide a mechanism for the separate regulation of tvpe-I and -III collagens genes and account for the varying proportions of type-I and -111 collagens in different tissues and at different ages.
B. Naturally Occurring Mutations of the Type-Ill Collagen Gene Mutations of type-111 collagen produce a range of phenotypes, from the most severe acrogeric forms of Ehlers-Danlos syndrome type IV to the relatively minor phenotypes that are indistinguishable from EDS type I11 and the benign joint-hypermobility syndrome (177). The acrogeric EDS type-IV phenotype is unique. The patients, even at a young age, appear prematurely aged. The face has a pinched appearance with prominent eyes, thin nose, thin lips, and lobeless ears. The hands are prematurely aged, an appearance referred to as acrogeria (177). The skin is thin and fragile and may show a circumscribed rash due to the extrusion of dermal elastin fibers into the epidermis. Loss of the terminal phalanges, a mild arthropathy, keloid scars, and recurrent penumothoraces, as well as intestinal rupture, torsion, and intramural hematomas, are frequent. However, the most important manifestations involve the cardiovascular system with aneurysms and ruptures of the aorta and medium-sized arteries. Some patients have major vascular anomalies but not the acrogeric features typical of the severe forms of EDS. Others have only thin skin and joint hypermobility.
59
COLLAGEN GENES AND THEIR MUTATIONS
A moderate number of dominant-negative mutations of the COL3Al gene have been identified in patients with different forms of the EDS type IV, as outlined in the following sections. The heterozygous dominantnegative mutations consist of deletions within the gene, point mutations that produce exon skipping, and point mutations that produce substitutions of glycine residues in Gly-X-Y triplets in the triple helix (Table VI). The latter mutations appear to be less common than deletions or splicing mutations compared to the pattern of mutations in the genes of type-I and type-I1 collagens. The reasons for this difference are unclear. It may be due to selection bias because of the easier detection of truncated al(II1) chains in the protein screening of cultured skin fibroblasts from patients suspected of having EDS type IV. Alternatively, glycine substitutions may result in a
TABLE VI DOMINANT-NEGATIVE ’I~PE-IIICOLLAGEN MUTATIONS IN EHLERS-DANLOS SYNDROME R P E Iva Mutation 3.3-kb deletion 2-kb deletion of exons 8-15 7.5-kb deletion of exons 9-24 9-kb deletion of exons 34-48 27-bp in-frame deletion, exon 37 IVS 16, G+1 to A, skip exon 16 IVS 17, G+ l to G, skip exon 17 IVS 20, G+1 to A, skip exon 20 IVS 25, G+5 to T, skip exon 25 IVS 27, G+5 to T, skip exon 27 IVS 37, G+5 to T, skip exon 37 IVS 41, G + l to A, skip exon 41 IVS 42, G+1 to A, skip exon 42 G-to-A, exon 14 Exon 35 G-to-A, exon 40 Exon 41 G-to-A, exon 43 Exon 44 G-to-T, exon 45 Exon 48 Exon 48 G-to-A, exon 48 Exon 49 “Zygosity is all hetero. bPersonal observation.
Protein change Deletion of 220 amino acids Deletion of Gly-46-Pro-387 Deletion of Gly-595-Glu-1008 Deletion of Ala-662-Pro-671 Deletion of Gly-166-Lys-183 Deletion of Gly-184-Pro-216 Deletion of Gly-265-Arg-282 Deletion of Gly-388-Asp-420 Deletion of Gly-439-Thr-456 Deletion of Gly-649-Ala-684 Deletion of Gly-775-Lys-810 Deletion of Gly-811-Asp-846 Gly-136 to Arg Gly-619 to Arg Gly-757 to Asp Gly-790 to Ser Gly-847 to Glu Gly-883 to Asp Gly-910 to Val Gly-1000 to Val Gly-1003 to Asp Gly-1006 to Glu Gly-1018 to Asp
Ref.
178 279 179 182 180 278 ll
280 281 282 283 183 279 284 285
b 286 287 286 288 287 287 289 290
60
WILLIAM G. COLE
greater number of intrauterine deaths because of the inability of the mutant homotrimeric molecules to rescue the severe phenotype partially.
1. HELICALDELETIONS An in-frame 3.3-kb, multiexon deletion was the first COL3A1 mutation to be characterized (178). The proband’s cultured fibroblasts produced equal amounts of normal length al(II1) mRNA and mRNA shortened by approximately 600 bases. The cells also produced approximately equal amounts of normal pro-d(III) and mutant pro-al(II1) chains in which the triple helix was shortened by 220 amino acids. The mutant procollagen molecules showed decreased thermal stability and were poorly secreted. Three other multiexon deletions have been reported with maintenance of the translational reading frame and the repetitive Gly-X-Y triplet structure (Table VI). The 7.5-kb deletion resulted from an exon-to-intron recombination with deletion of 16 exons and 1026 nucleotides (179). The deletion extended from position 13 of exon 9 to a domain with intron 24 that contained a series of polymorphic dinucleotide repeats. An in-frame deletion of 27 bp from within exon 37 resulted in the loss of nine amino acids and maintenance of the Gy-X-Y repeating structure of the triple helix (180). The deletion, which was flanked by two short repeats of CTCC, appeared to have arisen by slipped mispairing of bases. These cases showed similar protein anomalies, with poor secretion and decreased thermal stability of the mutant procollagen. The amount of normal type-111 procollagen secreted into the medium was markedly reduced, in keeping with the very low (approximately 12.5%) amount of normal homotrimeric collagen that would be expected in these heterozygous cases (181). Approximately 75% of the molecules would contain a mixture of normal and mutant chains, and 12.5% would be expected to contain only mutant chains (181). The heterotriineric molecules would be unstable and nonfunctional because of the differing lengths of the normal and truncated, mutant chains. However, the mutant homotrimeric molecules are often stable and may be functional (182). 2. HELICALSPLICING MUTATIONS Point mutations involving splice-donor sites of exons encoding the triplehelical domain of al(II1) chains have been identified in patients with EDS type IV (Table VI). The preceding e x m is lost in the conversion of premRNA to mRNA. Because the exons contain complete codons and encode complete Gly-X-Y triplets, the translational reading frame and Gly-X-Y triplet structure is maintained. Half of the cases involve the substitution of G+1
COLLAGEN GENES AND THEIR MUTATIONS
61
by A in the mandatory GT dinucleotide of the splice-donor site (Table VI). The other half involve the substitution of G+5 by T. In contrast to the G+' substitutions, in which exon skipping is complete, the G+5 substitutions show alternative splicing in accordance with similar mutations in other collagen genes. For example, exov skipping was nearly abolished when fibroblasts from a proband with a G+5-to-T transversion of intron 25 of the C O U A I gene were cultured at a reduced temperature (Table VI). The protein anomalies documented in these cases were similar to those already described in (Section IV,B,l) in patients with deletions within the C O U A l gene.
3. HELICALGLYCINESUBSTITUTIONS Glycine substitutions in Gly-X-Y triplets have been characterized along the triple helix of al(II1) chains in patients with EDS type IV (Table VI). The mutations and their metabolic consequences are similar to those observed in collagens types I and 11. The metabolic donsequences are also similar to those observed in fibroblasts from patients with'deletions or exon-skipping mutations of the COL3Al gene. However, it is unlikely that mutant homotrimeric molecules containing al(II1) chains bearing a glycine substitution would be functional, whereas mutant homotrimers containing truncated chains are likely to be stable and functional (183).
4. NULL ALLELICMUTATIONS Mutations of this type have been proposed to account for the finding of reduced production of apparently normal type-111 collagen by cultured fibroblasts from some patients with EDS type IV and its variants (177).
5. GENOTYPE-PHENOTYPE RELATIONSHIPS The clinical and pathological manifestations of EDS type IV are consistent with the known distribution of type-I11 collagen. As expected, the clinical phenotypes are more severe with dominant-negative mutations than with mutations that produce a functionally null COL3Al allele. Most patients with the acrogeric form of EDS have mutations that alter the structure of the carboxy-terminal domain of the triple helix of al(II1) chains (1 77). In contrast, milder phenotypes of patients with predominantly vascular manifestations have mutations that alter the structure of the more amino-terminal domains of the al(II1) chains or have a quantitative deficiency due to a null COL3A1 allele (184). However, more mutations need to be defined in order to better understand the genotype-phenotype relationships and to identify patients who require more frequent clinical monitoring.
62
WILLIAM G . COLE
V. Type-IV Collagen Genes
A. Normal Type-IV Collagen Genes Type-IV collagen is a major constituent of basement membranes, forming supramolecular network-like structures by self-aggregation (185). It was initially characterized as a heterotrimeric molecule containing two al(1V) and one a2(IV) chains with molecular weights of 185,000 and 170,000, respectively (186). The human al(IV) chain is 1669 residues long, with a 27-residue signal peptide, a 145-residue amino-terminal domain, a 1268-residue central triple-helical domain, and a 229-residue noncollagenous domain, NC1 (187, 188). The human a2(IV) chain contains 1712 residues that include a 36residue signal peptide, a 147-residue amino-terminal domain, a 1302residue triple-helical domain, and a 227-residue noncollagenous domain (189, 190). A characteristic feature of the triple-helical domain is the presence of 21 interruptions, 2-11 residues long, in the al(1V) chain, and 23 interruptions, 1-24 residues long, in the a2(IV) chains. These interruptions result in greater flexibility of the triple helix of type-IV collagen when compared to the fibrillar collagens (185). A striking feature of the NC1 domains of the al(1V) and a2(IV) chains is the presence of two equal-sized internal repeats, each containing six cysteine residues. The NC1 domains have thus been suggested to have evolved by an intra- or intergenic duplication (191). The type-IV collagen molecules form aggregates in which four molecules associate alternatively in parallel and antiparallel fashion through their amino-termini (7s domains) with stabilization of the complex by intramolecular and intermolecular disulfide and lysine-derived crosslinkages (185). Interactions of the NCI domains produce dimers that are responsible for tail-to-tail binding of type-IV collagen molecules. The genes for the al(IV) and a2(IV) chains are located together in chromosome 13q34 (Table 11). They are arranged in opposite directions, head-tohead, and separated by 127 bp (192, 193). The intervening promoter segment contains symmetrical functional efements such as C U T boxes and binding sites for S p l but no TATA box. It is probable that the genes have a common, bidirectional promoter (193). This was the first description of two structural human genes encoding two polypeptide chains of the same protein that have overlapping 5’ flanking regions. The a3(IV) and a4(IV) chains have also been identified in glomerular and lens basement membranes, but there is no evidence that they form heterotrimers with either al(1V) or a2(IV) chains (194-197). The Goodpasture epitope, which is involved in Goodpasture’s syndrome-an autoimmune disorder of the kidney and lung-is located within the NC1 domain of the
COLLAGEN GENES AND THEIR MUTATIONS
63
a3(IV) chain (196). The genes for the a3(IV) and a4(IV) genes are located together in chromosomes 2q35-37 (Table 11). The a5(IV) cDNA predicts a translation product with 1685 amino-acid residues, including a 26-residue signal peptide, a 1430-residue collagenous domain starting with a 14-residue noncollagenous sequence, and a Gly-X-Y repeating sequence interrupted at 22 locations, followed by a 229-residue carboxyl-terminal noncollagenous domain (198, 199). The noncollagenous domain has 12 conserved cysteine residues and 83 and 63% sequence homology to the noncollagenous domain of the al(1V) and a2(IV) chains. The calculated molecular weight of the mature chain is 158,303, and the molecular weight (determined by immunoblot analysis) of the a5(IV) chains produced by cultured dermal fibroblasts is 185,000 (198). In the human kidney, the chain is specifically immunolocalized to the glomerulus. The COL5A4 gene is located in Xq22 (198). It is probably at least 110 kb long, and the 3’ half of the exodintron structure is similar to that observed in the C O U A l gene (200, 201).
B. Naturally Occurring Mutations of the Type-IV Collagen Genes Mutations of the COL4A5 gene have been identified in some families with X-linked hereditary nephritis (Alport syndrome). The major phenotypic features of the Alport syndrome are hereditary glomerulonephritis with disruption of the glomerular basement membrane and progressive loss of kidney function as well as progressive sensorineural deafness (202). However, the disorder is heterogeneous, with no deafness in some families. There are also autosomal forms of the Alport syndrome that may prove to be due to mutations of the COMA1 and C O U A 2 genes on chromosome 13 or of the C O U A 3 or C O U A 4 genes on chromosome 2 (Table 11). The COUAS gene and X-linked Alport syndrome are both on Xq22-q23 (202, 203). The COLAAS gene was shown to be the Alport gene by the demonstration of major gene rearrangements and point mutations of this gene in patients with this syndrome (Table VII). Coarse screening of the COUAS gene by Southern map analysis has yielded many positive results. In addition to identifying major rearrangements, it has also revealed loss or gain of restriction-endonuclease cleavage-sites due to point mutations (Table VII). The mutations have usually been located and sequenced using genomic DNA rather than cDNA, because glomerular cells that functionally express the COLAAS have not been available for study. However, lymphoblast mRNA contains a small number of COLAAS transcripts as a result of low basal or “illegitimate” transcription (204). Direct sequencing of a5(IV) cDNA amplified from lymphoblasts was used to identlfy a point mutation that resulted in the substitution of Gly-325 of the triple helix by Arg (204).
64
WILLIAM G . COLE
TABLE VII MurA'rivNs OF
THE
COMA5 GENE IN ALPORT'S SYNDROME (HEREDITARY NEPHRITIS)
Mutation" Deletion, exons 5-10 Complex deletion Deletion of 450 kb including 12 kb of COMAS Deletion of >38 kl) including 5' end of COIAA5 Duplication of 35 kh Complex insertionideletion of 25 kb Contiguous gene deletion with deletion in 5' part of COWAS G-to-h C-to-T, exon 23 C-to-?\, exon 14 C-to-C, exon 4 C-to-C, exon 3
Protein change
Protein domain
Ref.
202 206 201 291 201 201 292 Gly-325 to Arg Glv-325 to Glu GI?-521 to Cys Glv-I 143 to Asp Tryp-1538 to Ser Cys-1564 to Ser
Collagenous Collagenous Collagenous Collagenous Noncollagenous Noncollagenous
204 293 199 205 206 200
nExons are numbered from the 3' end of COIAA5
Major COLAAS gene rearrangements appear to be more frequent than in the fibrillar type-I, -11, and -111 collagen genes. This finding may reflect the greater tolerance of the a5(IV) chain to point mutations, or it may reflect the greater ease of identifying major rearrangements by Southern map analysis. The protein changes that result from these mutations have not been reported. It is likely, however, that the glycine substitutions within the collagenous domain behave like similar mutations in the fibrillar collagen genes (205). It was also proposed that a substitution of a highly conserved cysteine by serine in the carboxy-noncollagenous domain would significantly impair intermolecular cross-linking and formation of the triple helix (200). More mutations must be defined to clarlfy the genotype-phenotype relationships. It is unclear why there is deafness in some families and not in others; it has been proposed that deafness may be correlated with the severity of the defect in COLAA5 (202). For example, profound deafness is a feature of a family with a deletion of exons 5 to 10, whereas hearing is normal in a family with the substitution of Gly-1143 to Asp in the collagenous domain of the (w5(IV)chain (202,205).Hematuria is a feature of females who are heterozygous for a large deletion (206).
COLLAGEN GENES AND THEIR MUTATIONS
65
VI. Type-VII Collagen Gene
A. The Normal Type-VII Collagen Gene Type-VII collagen was initially isolated from chorioamniotic membranes (207). It consists of three identical al(VI1) chains. Because each chain had a molecular weight of approximately 170,000, the collagen is referred to as long-chain (LC) collagen (207). The triple-helical domain of type-VII collagen is about 1.5 times the length of the helix of type-I collagen. The molecules form disulfide-bonded dimeric aggregates (208). Keratincytes of the skin are the major cells expressing the COL7Al gene (209, 210). Only one mRNA of approximately 9.5 kb is produced (210). Analyses of al(VI1) cDNA show that the al(VI1) chain has a large collagenous domain, which is interrupted in its middle by a noncollagenous segment of 31 amino acids and by several 1- to 3-amino-acid insertions or deletions in the Gly-X-Y repeating units of the triple-helical domains (209, 210). The chain also contains N-terminal and C-terminal globular noncollagenous domains. The large N-terminal domains of type-VII collagen interact with other extracellular macromolecules within the basement membranes at the dermal-epidermal junction at one end, and with basement-membrane-like structures, known as anchoring plaques, at the other end (211, 212). The gene for type-VII collagen, COL7A1, is a single-copy gene that is located in chromosome 3p21.3 (209, 213). Details of the gene structure are not yet available.
B. Naturally Occurring Mutations of the Type-VII Collagen Gene Epidermolysis bullosa is a heterogeneous disorder that consists of a group of approximately 20 hereditary and acquired diseases of the skin that share the common feature of the formation of blisters and erosions in response to minor trauma (214). The genetically determined forms can be either autosomal-dominant or autosomal-recessive (212). One form of epidermolysis bullosa simplex, the herpetiform variety, results from mutations of keratin-14 (215);mutations of other components of the cutaneous-basement-membrane zone have been proposed in other types of epidermolysis bullosa (212).There is increasing evidence that mutations of the COL7Al gene produce some of the recessive and dominant subtypes of dystrophic epidermolysis bullosa (212, 216). Genetic linkage of this gene to the dominant phenotype has been found in several families (217) and structurally abnormal type-VII collagen was observed in the skin of a patient with the recessive form (218, 219).
66
WILLIAM G . COLE
By analogy with mutations in the fibrillar collagen genes, Uitto et al. (212)speculated on the types of anchoring fibril anomalies that might follow mutations in various domains of type-VII collagen. For example, they speculated that mutations in the triple-helical domain could prevent or delay the secretion of this collagen from basal keratinocytes, the primary cell responsible for the synthesis of anchoring fibrils (220). In support of this proposal, type-VII collagen is retained within keratinocytes of some patients with recessive dystrophic epidermolysis bullosa (221). In contrast, mutations in the noncollagenous N-terminal domain, which is thought to interact with other components of the basement-membrane zone, may result in impaired anchoring fibril function.
VII. Type-IX Collagen Genes A. Normal Type-IX Collagen Genes Type-IX collagen, a FACIT collagen, is 190 nm long and is a heterotrimer of disulfide-bonded al(IX), a2(IX), and a3(IX) chains (222).The a2(IX) chain contains a covalently bound glycosaminoglycan (GAG) chain (223). Although unable to form quarter-staggered fibrils by itself, type-IX collagen is distributed in a periodic fashion along the surface of type-I1 collagen fibrils. The human molecule is kinked at about 40 nm from the globular N-terminus (223). The kink site corresponds to the NC3 domain of the molecule whereas the other noncollagenous and collagenous domains, NC1, COL1, NC2, and COL2, are aligned along the surface of the fibril. This arrangement is stabilized by covalent cross-linkages between the COL2 domain of type-IX collagen and the telopeptides of type-I1 collagen (224, 225). In this model, the GAG chain, attached to the NC3 domain of the a2(IX) chain, is likely to occupy the gap regions of the type-I1 collagen fibrils. The COL3 and NC4 domains project from the surface of the fibrils and the NC4 domain, with an estimated pZ of 10.4, probably interacts with the polyanionic proteoglycans of the cartilage matrix. Type-IX collagen of hyaline cartilage exists in proteoglycan (PG-IX) and nonproteoglycan (COL-IX) forms (226, 227). The serine attachment site of the GAG is contained within the extra five residues in the NC3 domain of the substituted and nonsubstituted a2(IX) chains (228, 229). The existence of PG-IX and COL-IX is not due to isoforms of the a2(IX) chain but rather to the low efficiency of xylosylation of the acceptor serine residue. In contrast, all of the type-IX collagen of chick vitreous humor appears to bear an extraordinarily large GAG chain, which produces a gel-like matrix (226).In contrast,
COLLAGEN GENES AND THEIR MUTATIONS
67
the gel-like matrix of the mammalian vitreous humor is due to hyaluronan; the type-IX collagen molecules do not have GAG chains as long as those observed in the chicken vitreous humor. The complete cDNA sequences of the human al(1X) and a2(IX) and chick a3(IX) chains have also been determined (230-232). The human d ( I X ) chain exists in two isoforms for which the complete cDNA sequences have been determined (230).The two forms share a common stretch of 663 aminoacid residues, but differ in their N-terminal regions. The long form contains an N-terminal NC4 domain of 245 residues and a putative signal peptide of 23 residues. The NC4 domain of the long form has a calculated molecular mass of 27,430 Da. It contains four cysteine residues and has a calculated pZ of 10.4. The human NC4 domain contains a potential carbohydrate attachment site that appears to be used. The short human al(IX) isoform contains only 25 residues of non-triple-helical sequence at the N-terminus of the triple-helical domain of COL3. If the signal peptidase cleaves between residues 23 and 24, the secreted short form contains only two residues at the N-terminus of the COL3 domain. The human COLSAI gene, located on chromosome band 6q12-14, gives rise to these two transcripts that differ in their 5' regions through the alternative use of two transcription start sites and RNA splicing patterns (230). The long human al(IX) transcript contains a 5' region encoded by exons 1-7 spliced to exon 8. The short human al(1X) transcript contains a 5' region encoded by an alternative exon 1* located in the intron between exons 6 and 7, spliced to exon 8. A novel FACIT-like collagen locus (D6S228E)is also located in human chromosome 6q12-14 (233). Type-IX collagen occurs in hyaline cartilages and in a variety of nonchondrogenic tissues, such as the primary corneal stroma of the chick embryo, vitreous humor, and sclera and neural retina of the eye (226, 234);inner ear (235);and notochordal sheath (236). It is known that the primary corneal stroma and the vitreous humor contain the short isoform of the al(1X) chain (226, 237). Type-I1 collagen and the long isoform al(1X) transcripts are both located in the chondrogenic elements of the developing avian forelimb (238). In contrast, the short al(IX) transcripts are distributed throughout the nonchondrogenic, nonmyogenic mesenchymal regions of the limb and are not detectable in the limb chondrogenic elements. Similarly, the short isoform al(IX) transcripts are in the developing nonchondrogenic notocord (239). Conversely, the long al(IX) transcripts are not detectable in the notocord or perinotocordal sheath. However, all transcripts appear in the developing chondrogenic vertebrae as well as in the chondrocranium and Meckel's cartilage. The expression of the short form in these regions is more restricted than that of the long form of al(1X).
68
WILLIAM G . COLE
B. Site-directed Mutagenesis of the Type-IX Collagen Genes Disorganization of the articular cartilage and corneal stroma was observed in transgenic mice bearing a COLSAI minigene (240).The minigene construct consisted of hybrid human and rat al(1X) collagen cDNA that lacked part of COL3, the entire NC3, and a part of COL2. In order to obtain a high level of expression of this cDNA transcript in cartilaginous tissues, the promoter/enhancer of the rat type-I1 collagen gene was ligated to the 5’ end of the cDNA construct. In affected mice, the cornea was opaque with surface irregularities and disorganization of its stroma. Although radiographic analysis up to 6 months of age showed no detectable skeletal anomalies, there was histological evidence of osteoarthritis. The articular cartilage was irregular, with loss of matrix staining and deep clefts in the articular surface.
VIII. Type-X Collagen Gene A. The Normal Type-X Collagen Gene Type-X collagen is a short-chain collagen with a triple-helical domain of 132 nm and globular domains at either end (241, 242). It is produced exclusively by hypertrophic chondrocytes of the growth plate, and appears first in the human growth plate during the second trimester (243).Type-X collagen is found in the vicinity of type-I1 collagen fibrils in hypertrophic cartilage (244),in matlike aggregates in the pericellular area (245), and in the pericellular capsule of hypertrophic chondrocytes (246). It has been proposed that the matlike structures may represent a hexagonal lattice similar to that observed for another short-chain collagen, type-VIII collagen (247). Human type-X collagen is a disulfide-linked homotrimer and migrates after reduction as 66,000-kDa al(X) chains (242).It is uncertain whether the chain is processed to shorter forms. The human COLlOAl gene is a single-copy gene located on chromosome 6q21-22.3; the full cDNA and genomic DNA sequences are available (248, 249). The largest exon, 2940 bp, encodes 1054 bp of 3’ untranslated sequence, the complete 161-amino-acid residue C-globular domain, the full 463-amino-acid residue triple-helical domain, and 4%-amino-acid residues of the N-globular domain. The 169-bp exon encodes B1/3-amino-acid residues of the N-globular domain, 18 amino acids of the signal peptide, and 15 bp of untranslated 5‘ sequence. It is a condensed gene with a 3200-bp intron separating the two exons. The triple-helical domain contains eight imperfections in the Gly-X-Y sequence and there are two mammalian collagenase cleavage sites. The C-globular domain also contains a putative N-linked
COLLAGEN GENES AND THEIR MUTATIONS
69
oligosaccharide attachment site. The calculated relative molecular mass of the al(X) chain is 59,000 Da (249). The promoter region of the mouse COLlOAl gene contains two TATA boxes separated by 165 bp (250).Both TATA boxes are active in transcription, generating two sets of transcripts with different 5’ termini. The longer transcript is of low abundance and is detectable by the PCR in newborn mice. The short transcript of 3.6 kb is the major species. The COLlOAl promoter also contains a CCAAT box as well as other consensus sequence elements required for binding of transcription factors. However, these findings have not provided an insight into the specific expression of the COLlOAl gene by hypertrophic chondrocytes.
B. Naturally Occurring Mutations of the Type-X Collagen Gene Using PCR and single-strand conformation polymorphism analysis, seven sequence changes have been identified in the coding region of the human COLlOAl gene (251). Six of these are polymorphic and have been used to demonstrate discordant segregation between the COLlOAl locus and both achondroplasia and pseudoachondroplasia. The seventh sequence change resulted in a Val-to-Met substitution in the carboxy-terminal domain of the molecule and was identified only in two persons with hypochondroplasia from a single family. Segregation analysis in this family was inconclusive. A G-to-C transition that results in a Gly-to-Arg substitution at residue 26 of the carboxy propeptide was also detected using similar techniques (252). Analysis of a family with multiple epiphyseal dysplasia ruled out this sequence change as a cause of this autosomal-dominant disease.
C. Site-directed Mutagenesis of the Type-X Collagen Gene Jacenko et al. (253) investigated the phenotype produced by a sitedirected, dominant-negative mutation in transgenic mice. Chick COLlOAl minigene constructs were designed to produce a truncated triple-helical domain, but with a normal C-terminus that would enable the abnormal chain to combine with normal chains. A severe spondylometaphyseal chondrodysplastic phenotype resulted. There were major changes in the growth plates and metaphyses, confirming the importance of type-X collagen in the structure and function of this region of the developing bone. The histological features of collapse of the hypertrophic zone with absence or reduction in the numbers of hypertrophic cells were similar to those observed in human metaphyseal chondrodysplasias. The autosomal dominant
70
WILLIAM G . COLE
disorders-metaphyseal chondrodysplasia of the Schmid type and spondylometaphyseal chondrodysplasia of the Kozlowski type-have many of the same features. Unexpectedly, the transgenic mice also had abnormalities in the bone marrow and lymphoid system, tissues in which the type-X collagen minigene was not expressed. It is possible that integration of the transgene altered the function of another gene that was responsible for the lymphopoietic anomalies.
IX. Summary It is to be expected that more collagen genes will be identified and that additional heritable connective tissue diseases will be shown to arise from collagen mutations. Further progress will be fostered by the coordinated study of naturally occurring and induced heritable connective tissues diseases. In some instances, human mutations will be studied in more detail using transgenic mice, while in others, transgenic studies will be used to determine the type of human phenotype that is likely to result from mutations of a given collagen gene. Further studies of transcriptional regulation of the collagen genes will provide the prospect for therapeutic control of expression of specific collagen genes in patients with genetically determined collagen disorders as well as in a wide range of common human diseases in which abnormal formation of the connective tissues is a feature.
REFERENCES I . E. Vuorio and B. de Cromhrugghe, ARB 59, &37 (1990). 2. M. van der Rest and H. Garrone, FASEB /. 5, 2814 (1991). 3. L. J. Sandell and C. D. Boyd, in “Extracellular Matrix Genes” (L. D. Sandell and C D. Boyd, eds.), p. 1. Academic Press, San Diego, 1990. 4. A. Miller, in “Biochemistry of Collagen” (G. N. Rramachandran and A. H. Reddi, eds.), p. &5. Plenum, New York, 1976. 5 . D. J. Prockop, R. A. Berg, K. I. Kivirikko and J. Uitto, in “Biochemistry of Collagen” (G. N. Ramachandran and A. H. Reddi, eds.), p. 163. Plenum, New York, 1976. 6. W. de Wet, M. Bernard, V. Benson-Chanda, M.-L. Chu, L. Dickson, D. Weil and F. Ramirez. JBC 262, 16032 (1987). 7. M. D’Alessio, M. Bernard, P. J. Pretorius, W. de Wet and F. Ramierz, Gene 67, 105 (1988). 8 . G. Karsenty and B. de Crombrugghe, JBC 265, 9934 (1990). 3. B. Boast, M.-W. Su, F. Ramirez, M. Sanchez and E. V. Avvedimento, JBC 265, 13351 (1990). 10. D. J. Liska, J. L. Slack and P. Bornstein, Cell Regul. 1, 487 (1990). 11. A. Maatta, P. Bornstein and R. P. K. Penttinen, FEBS Lett. 279, 9 (1991).
COLLAGEN GENES AND THEIR MUTATIONS 12. 13. 14. 15. 16. 17.
18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47.
71
A. S. Olson, A. E. Geddis and D. J. Prockop, JBC 266, 1117 (1991). K. Harbers, M. Kuehn, H. Delius and R. Jaenisch, PNAS 81, 1504 (1984). D. Jahner and R. Jaenisch, Nature 315, 594 (1985). J. P. Thompson, C. P. Simkevich, M. A. Holness, A. H. Kang and R. Raghow, JBC 266, 2549 (1991). P. Bornstein, J. McKay, J. K. Hoishima, S. Devarayalu and R. E. Gelinas, PNAS 84, 8869 (1987). C. M. S. Rossouw, W. P. Vergeer, S. du Plooy, M. Bernard, F. Ramirez and W. de Wet, JBC 262, 15151 (1987). A. L. Sherwood and P. Bornstein, BJ 265, 895 (1990). R. Ravazzolo, G. Karsenty and B. de Crombrugghe, JBC 266, 7382 (1991). S. N. Maity, P. T. Golumbek, G. Karsenty and B. de Crombrugghe, Science 241, 582 (1988). P. Rossi, G. Karsenty, A. B. Roberts, N. S. Roche, M. B. Sporn and B. de Crombrugghe, Cell 52, 405 (1988). J. D. Ritzenthaler, R. H. Goldstein, A. Fine, A. Lichtler, D. W. RoseandB. D. Smith, BJ 280, 157 (1991). D. P. Pavlin, A. C. Lichtler, A. Bedalov, B. E. Kream, J. R. Harrison, J. R. Thomas, G. A. Gronowics, S. H. Clark, C. 0. Woody and D. W. Rowe, J. Cell Biol. 116, 227 (1992). Y. Yamada, M. Mudryi and B. de Crombrugghe, JBC 258, 14914 (1983). P. Bornstein, J. McKay, S. Devarayalu and S. C. Cook, NARes 16, 9721 (1988). P. H. Byers, G. A. Wallis and M. C. Willing, J. Med. Genet. 28, 433 (1991). W. G . Cole, in “Calcium Regulating Hormones and Bone Metabolism” (D. V. Cohn, C. Gennari and A. H. Tashjian, Jr., eds.), p. 315. Elsevier, Amsterdam, 1992. D. 0. Sillence, A. Senn and D. M. Danks, J. Med. Genet. 16, 101 (1979). H. Kuivaniemi, G . Tromp and D. J. Prockop, FASEB J . 5, 2052 (1991). D. W. Rowe, J. R. Shapiro, M. Poirier and S. Schlesinger, J. Clin. Invest. 76, 604 (1985). R. J. Wenstrup, M. C. Willing, B. J. Starman and P. H. Byers, Am. J. Hum. Genet. 46,975 (1gw. J. F. Bateman, M. Hannagan, S. R. Lamande, I. Moeller, D. Chan and W. G . Cole, Int. Conj. Osteogenesis Zmperfecta 4th abstr. 2 (1990). D. H. Cohn, G. Wallis, X. Zhang and P. H. Byers, Matrix 10, 236 (1990). J. C. Marini, D. K. Grange, G. S. Gottesman, M. B. Lewis and D. A. Koeplin, JBC 264, 11893 (1989). A. C. Nicholls, J. Oliver, D. V. Renouf, M. Keston and F. M. Pope,]. Med. Genet. 28,757 (1991). C. J. Pruchno, D. H. Cohn, G. A. Wallis, M. C. Willing, B. J. Starman, X. M. Zhangand P. H. Byers, Hum. Genet. 87, 33 (1991). B. Sykes, Nature 348, 18 (1990). J. F. Bateman, T. Mascara, D. Chan and W. G. Cole, BJ 217, 103 (1984). J. Bonadio and P. H. Byers, Nature 316, 363 (1985). J. Bonadio, K. A. Holbrook, R. E. Gelinas, J. Jacob and P. H. Byers, JBC 260,1734 (1985). D. J. Prockop, Am. J . Hum. Genet. 36, 499 (1984). J. Engel and D. J. Prockop, Annu. Reo. Biophys. Chem. 20, 137 (1991). M. Pack, C. D. Constantinou, K. Kalia, K. B. Nielsen and D. J. Prockop, JBC 264,19694 (1989). A. Westerhausen, J. Kishi and D. J. Prockop, JBC 265, 13995 (1990). H. P. Bachinger and J. M. Davis, Int. J. Biol. Mocromol. 13, 152 (1991). V. H. Rao, B. Steinmann, W. de Wet and D. W. Hollister, JBC 264, 1793 (1989). W. Traub and B. Steinmann, FEBS Lett. 198, 213 (1986).
72
WILLIAM G . COLE
48. J. F. Bateman, D. Chan, I. D. Walker, J. G. Rogers and W. G. Cole, JBC 262,7021 (1987). 49. J . F. Bateman, D. Chan, S. b m a n d e , T. Mascara and W. G. Cole, Ann. N.Y. Acad. Sci. 543, 95 (1988). 50. A. T. Baker, J. A. Ramshaw. D. Chan, W. G . Cole and J. F. Bateman, BJ 261, 253 (1989). 51. K. E. Dombrowski, B. E. Vogel and D. J. Prockop, Bchem 28, 7107 (1989). 52. R. R. Minor, M. Sippola-Thiele, J. McKeon, J. Berger and D. J. Prockop, JBC 261, loo06 (1986).
53.
K. E. Kadler, A. Torre-Blanco, E. Adachi, B. E. Vogel. Y. Hojima and D. J. Prockop, Rchem 30,5081 (1991).
S4. B. E. Vogel, R. R. Minor, M. Freund and D. J. Prockop, JBC 262, 14737 (1987).
55. W. G . Cole, D. Chan, S. Lamande, T.Mascara, J. Rogers and J. Bateman, Connect. Tissue
Res. 21, 91 (1989). 56. B. Steinmann, A. Nicholls and F. M. Pope, JBC 261, 8958 (1986).
57. W, G. Cole, C. W. Chow, J. G. Rogers and J. F. Bateman, J . Med. Genet. 27, 228 (1990). 58. W, 6. Cole. E. Patterson, J. Bonadio, P. E. Campbell and D. W. Fortune,J. Med. Genet. 29, 112 (1992). 59. R. J. Wenstrup, P. Tsipouras and P. H. Byers, J . C h . Invest. 78, 1449 (1986). 60. J. Bonadio, F. Ramierz and M. Barr, JBC 265, 2262 (1990). 61. R . J. Wenstrup, A. Schrago-Howe, L. Lever and C. Phillips, Int. Conf. Osteogenesis Iinperfecta, 4th abstr. 58 (1990). 62. C . Genovese, A. Brufsky, J. Shapiro and D. Rowe, JBC 264, 9632 (1989). 63. G . S. Barsh, C. L. Roush, J. Bonadio, P. H. Byers and R. E. Gelinas, PNAS 82, 2870 (1985). 6 4 . M. L. Chu, C. J. Williams, G. Pepe, J. L. Hirsch, D. J. Prockop and F. Ramirez, Nature 304, 78 (1983). 65. M . L. Chu, V. Gargiulo, C. J. Williams and F. Ramirez, JBC 260, 691 (1985). 66. M. C. Willing, D. H . Cohn, B. Starman, K. A. Holbrook, C. R. Greenberg and P. H. Byers, JBC 263, 8398 (1988). 67. P. H. Byers, B. J. Starman, D. H. Cohn and A. L. Horwitz, JBC 263, 7855 (1988). (58. D. H. Cohn. C. J. Pruchno, X. Zhangand P. H. Byers, A m . ] . Hum. Genet. 47, IlO(1990). 69. J. R. Hawhns, A. Superti-Furga, B. Steinmann and R. Dalgleish, JBC 266,22370 (1991). 70. 6. A. Wallis, B. J. Starman and P. H. Byers, Am. J . Hum. Genet. 45, A228 (1989). 71. K. Molyneux, P. H . Byers and R. Dalgleish, lnt. Conf. Osteogenesis Imperfecta, 4th abstr. 19 (1990). 72. D. H. Cohn. S. Apone, D. R. Eyre, B. J. Starman, P. Andreassen, H. Charbonneau, A. C. Nicholls, F. M. Pope and B. H. Byers, JSC 263, 14605 (1988). 73. M .C. Willing, D. H. Cohn and P. H. Byers, J . Clin. Incest. 85, 282 (1990). 74. T. Pihlajaniemi, L. A. Dickson, F. M. Pope, V. R. Korhonen, A. Nicholls, D. J. Prockop and J. C. Myers, JBC 259, 12941 (1984). 75. S. B. Deak, A. Nicholls, F. M. Pope and D. J. Prockop, JBC 258, 15192 (1983). 76. S . B. Deak, M. van der Rest and D. J. Prockop, Collagen Relat. Res. 5, 305 (1985). 77. J. F. Bateman, S. R. Lamande, H. H. Dahl, D. Chan, T. Mascara and W. G. Cole, JBC 264, 10960 (1989). 78. A. C. Nicholls, G . Osse, H. G. Schloon, S. Deak, J. C. Myers, D. J. Prockop, W. R. F. Weigel. P. Fryer and F. M. Pope, J . Med. Genet. 21, 257 (1984). 79. M. J. Francis, K. J. Williams, B. C. Sykes and R. Smith, Clin. Sci. 60,617 (1981). (30.M . C. Willing, C. Pruchno and P. Byers, Am. J . Hum. Genet. 49, A434 (1991). 81. M. C. Willing, C. J. Pruchno, M. Atkinson and P. H. Byers, Am. J . Hum. Genet. 51, 508 ( 1992).
COLLAGEN GENES AND THEIR MUTATIONS
73
82. D. W. Rowe, M. L. Stover, M. McKinstry, A. Brufsky, B. Kream, S. Chipman and J. Shapiro, lnt. Conf. Osteogenesis lmperfectu, 4th abstr. 57 (1990). 83. D. Goldfarh and N. Michaud, Trends Cell Biol. 1, 20 (1991). 84. P. H. Byers, P. Tsipouras, F. J. Bonadio, B. J. Starman and R. C. Schwartz, Am. J. Hum. Genet. 42, 237 (1988). 85. D. H. Cohn, B. J. Starman, B. Blumherg and P. H. Byers, Am. J . Hum. Genet. 46, 591 (1990). 86. C. D. Constantinou, M. Pack, S. B. Young and D. J. Prockop, Am. J. Hum. Genet. 47,670 (1990). 87. A. A. Chiodo, A. Hockey and W. G. Cole, JBC 267, 6361 (1992). 88. D. Weil, M. D’Alessio, F. Ramirez, W. de Wet, W. G. Cole, D. Chan and J. F. Bateman, EMBO J. 8, 1705 (1989). 89. W. G. Cole, D. Chan, D. W. Chambers, I. D. Walker and J. F. Bateman, ]BC 261, 5496 (1986). 90. M. D’Alessio, M. Bernard, P. H. Pretorius, W. de Wet and F. Ramirez, Gene 67, 105 (1988). 91. D. Weil, M. D’Alessio, F. Ramirez, B. Steinmann, M . K. Wirtz, R. W. Glanville and D. W. Hollister, JBC 264, 16804 (1989). 92. B. Steinmann, L. Tuderman, L. Peltonen, G. R. Martin, V. A. McKusick and D. J. Prockop, JBC 255, 8887 (1980). 93. R. B. Watson, G. A. Wallis, D. F. Holmes, D. Vilijoen, P. H. Byers and K. E. Kadler, JBC 267, 9093 (1992). 94. A. C. Nicholls, J. Oliver, D. V. Renouf, J. McPheat, A. Palan and F. M. Pope, Hum. Gcnet. 87, 193 (1991). 95. N. S. Vasan, H. Kuivaniemi, B. E. Vogel, R. R. Minor, J. A. Wootton, G. Tromp, R. Weksherg and D. J. Prockop, Am. J. Hum. Genet. 48, 305 (1991). 96. D. Weil, M. Bernard, N. Combates, M. K. Wirtz, D. W. Hollister, B. Steinmann and F. Ramirez, JBC 263, 8561 (1988). 97. D. Weil, M. D’Alessio, F. Ramirez and D. R. Eyre, ]BC 265, 16007 (1990). 98. M. K. Wirtz, R. W. Glanville, B. Steinmann, V. Rao and D. W. Hollister, JBC 262, 16376 (1987). 99. A. Lenaers, M. Ansay, B. V. Nusgens and C. M. Lapiere, EJB 23, 533 (1971). 100. J. R. Lichtenstein, G. R. Martin and L. D. Kohn, Science 182, 298 (1973). 101, B V. Nusgens and C. Verellen-Dumoulin, T. Hermanns-Le, A. De Paepe, L. Nuytink, G. E. Pierard and C. M. Lapiere, Nature Genet. 1, 214 (1992). 102. L. T. Smith, W. Wertelecki, L. M. Milstone, E. M. Perry, M. R. Seashore, I. M. Braverman, T. G. Jenkins and P. H. Byers, Am. J. Hum. Genet. 51, 235 (1992). 103. H. Kuivaniemi, G. Tromp. M.-L. Chn and D. J. Prockop, BJ 252, 633 (1988). 104. M. Sippola, S . K&e and D. J. Prockop, JBC 259, 14094 (1984). 105. W. 6. Cole, R. Jaenisch and J. F. Bateman, Q . J. Med. 70, 1 (1989). 106. A. Stacey, J. Bateman, T. Choi, T. Mascara, W. Cole and R. Jaenisch, Nature 332, 131 (1988). 107. J. S. Khillan, A. S. Olsen, S. Kontusaari, B. Sokolov and D. J. Prockup, JBC 266, 23373 (1991). 108. A. S. Olsen, A. E. Geddes and D. J. Prockop, JBC 266, 1117 (1991). 109. S. Hartung, R. Jaenisch and M. Breindl, Nature 320, 365 (1986). 110. A. Schnieke, K. Hahers and R. Jaenisch, Nature 304, 315 (1983). 111. K. Kratochwil, K. von der Mark, E. Kollar, R. Jaenisch, M. Mooslehner, M. Schwarz, K. Haase, I. Gmachl and K. Harbers, Cell 57, 807 (1989).
74
WILLIAM G . COLE
112. J. Bonadio. T. L. Saunders, E. Tsdi, S. A. Goldstein, J. Morris-Wiman, L. Brinkley, D. F. Dolan, R. A. Altschuler, J. E. Hawkins, Jr., and J. F. Bateman, PNAS 87, 7145 (1990). 113. E. Takahashi, T. Hori, P. O’Connell, M. Leppert and R. White. Hum. Genet. 86, 14 (1990). 114. M . C. Ryan and L. J. Sandell, J S C 265, 10334 (1990). 115. L. J. Sandell, N . Morris, J. R. Robbins and M. B. Goldring, J. Cell Biol. 114, 1307 (1991). 116. li. S . Cheah, E. T. Lau, P. K. C. Au and P. P. L. Tam, Detjelopment 111, 945 (1991). 117. .4.Wood, D. E. Aslihurst, A. Corbett and P. Thorogtmd, Deoeloptnent 111, 955 (1991). 118. C. T. Baldwin, A. M. Reginato, C. Smith, S. A. Jirnenez and D. J. Prockop, BJ 262,521 (1989). 119. K, Elima, T Vuorio and E. Vuorio, XARes 15, 9499 (1987). 120. R. H. Lovell-Badge, A. Bygrave, A. Bradley, E. Robertson, R. Tilly and K. S. E. Cheah, PNAS 84, 2803 (1987). 121. W. E. Horton, Jr., L. Wang. D. Bradham, P. Precht and R. Balakir, DNA Cell B i d . 11, 193 (1992). 122. M. \?kkula. M. Metsaranta, A.-C. Syvanen. L. Ala-Kokko, E. Vuorio and L. Peltonen, BJ 285, 287 (1992). 123. J. Wu, J. Sugai, R . Yamin, M. Goldring and I,. J. Sandell, Proc. Orthop. Res. SOC. 39, 118 (1993). 124. L. Wang, R. Balakir and W. E. Horton, Jr., JRC 266, 19878 (1991). 125. J. Spranger, P~thol.Irnmumpathol. Res. 7, 76 (1988). 126. P. Maroteaux, V. Stanescu and R . Stanescu. C h . Orthop. Relat. Res. 114, 31 (1976). 127. I).H. E y e , M. P. Upton, F. D. Shapiro, R. H. Wilkinson and D. F. Vawter, Am. J , Hum. Genet. 39, 52 (1986). 128. S. P. Feshchenko, I. A. Rebrin, V. P. Sokolnik, B. M. Sher, B. P. Sokolov, V. N. Kalinin and G. T. Lazjuk, Hum. Genet. 82, 49 (1989). 129, W. A. Horton, M. A. Machado, J. W.Choii and D. Campbell, Pediatr. Res. 22, 324 (1987). 130. h.1. Godfrey and D. W. Hollister, Am. J . Hum. Genet. 43, 904 (1988). 131. H. Vissing. h l . D’Alessio, B. Lee, F. Ramirez, M. Godfrey and D. W. Hollister, JRC 264, 1 8 B (1989). 1.32. W A. Horton, M. A. Machado, J. Ellard, D. Campbell. J. Bartley, F. Rainirez, E. Vitale and B. Lee, PNAS 89, 4.583 (1992). 133. R. Bogaert. G . E. Tiller, M . A. Weiss, H. E. Gruber, D. L. Rimoin, D. H. Cohn and D. R. E y e , JRC 267, 22522 (1992). 134. R . S. Lachnian, 6. E. Tiller, J. M .Graham, Jr., and D. L. Rimoin, Eur. J. Radiol. 14, 1 11992). 135. J. Spranger and H. R. Wiedemann, Heltj. Paediutr. Actu 21, 598 (1966). 136. R. Stanescu, V. Stanescu, C. Bordet and P. Maroteaux. J. Rheumatol. 14, 1061 (1987). 137. P. L. Katzenstein, C. J. Malemud, M. N. Pathria, J. R. Carter, R. P. Sheon and R. W. Moskowitz, Arthritis Rheum. 33, 674 (1990). 138. L. W. Murray, J. Bautista, P. L. James and D. L. Rimoin, Am. J. Hum. Genet. 45,5 (1989). 139. W. A. Horton, J. W. Chou, M. A. Machado and D. Campbell, Collagen Relat. Res. 5,349 (1985). 140. I. J. Anderson, R. B. Goldberg, R. W.Marion, W. B. Upholt and P. Tsipouras, An.J. Hum. Genet. 46, 896 (1990). 141. H. G. Knowlton, P. L. Katzenstoin, R. W. Moskowitz, E. J. Weaver, C. J. Malemu, M. N . Pathria, S. A. Jimenez and D. J. Prockop, N . Engl. J. Med. 322, 526 (1990). 142. C. Sher, R. Ramesar, R. Martell, I. Learmonth, P. Tsiporous and P. Beighton, Am. J . H u m . Genet. 48, 518 (1991). 143. B. Lee, H. Vissing, F. Ramirez, D. Rogers and D. Rimoin, Science 244, 978 (1989).
COLLAGEN GENES AND THEIR MUTATIONS
75
144. G. E. Tiller, D. L. Rimoin, L. W. Murray and D. H. Cohn, PNAS 87, 3889 (1990). 145. L. Ala-Kokko, C . T. Baldwin, R. W. Moskowitz and D. J. Prockop, PNAS 87,6565 (1990). 146. D. R. Eyre, M. A. Weis and R. W. Moskowitz, J. Clin. Znuest. 87, 357 (1991). 147. S. A. Jimenez, L. Ala-Kokko, N. Ahmad, C. Baldwin, R. Dharmavaram, A. Reginato, R. Knowlton and D. J. Prockop, in “Articular Cartilage and Osteoarthritis” (K. Kuettner, R. Schleyerbach, J. G. Peyron and V. C. Hascall, eds.), p. 167. Raven, New York, 1992. 148. B. Steinmann, A. Nicholls and F. M. Pope, JBC 261, 8958 (1986). 149. R. W. Moskowitz, Y. L. W. Pun, S. LieandT. M. Haggi, Proc. Orthop. Res. SOC.39,669 (1993). 150. D. Chan and W. G. Cole, JBC 266, 12487 (1991). 151. J. Chelly, J. Concordet, J. C. Kaplan and A. Kahn, PNAS 86, 2617 (1989). 152. R. G. H. Cotton, N. R. Rodriguez and R. D. Campbell, PNAS 85, 4397 (1988). 153. D. Chan, T.K. F. Taylor and W. G. Cole, JBC 268, 15238 (1993). 154. D. L. Rimoin, D. C. Siggers, R. S. Lachman and R. Silberberg, Clin. Orthop. Relat. Res. 114, 70 (1976). 155. A. R. Poole, I. Pidoux, A. Reiner,L. Rosenberg, D. Hollister, L. Murray and D. Rimoin, J . Clin. Znuest. 81, 579 (1988). 156. A. Winterpacht, M. Hilbert, U. Schwarze, S. Mundlos, J. Spranger and B. U. Zabel, Nature Genet. 3, 323, (1993). 157. G B. Stickler and D. G. Pugh, Mayo Clin. Proc. 42, 495 (1967). 158. R. G. Knowlton, E. J. Weaver, A. F. Struyk, W. H. Knohloch, R. A. King, K. Norris, A. Shamban, J. Uitto, S. A. Jimenez and D. J. Prockop, Am. J . Hum. Genet. 45, 681 (1989). 159. C. A. Francomano, R. M. Liberfarb, T. Hirose, I. H. Maumenee, E. A. Streeteu, D. A. Meyers and R. E. Pyeritz, Genomics 1, 293 (1987). 160. N. N. Ahmad, L. Ala-Kokko, R. G. Knowlton, S. A. Jimenez, E. J. Weaver, J. I. Maguire, W. Tasman and D. J. Prockop, PNAS 88, 6624 (1991). 161. N. N. Ahmad, D. M.McDonald-McGinn, E. H. Zackai, R. G. Knowlton, D. LaRossa, J. Dimascio and D. J. Prockop, Int. Conf. Mol. B i d . Pathol. Matrix, 4th AIII-10 (1992). 162. D. M. Brown, B. E. Nichols, T. A. Weingeist and V. C. Sheffield, Arch. Ophthalmol. 110, 1589 (1992). 163. P. Ritvaniemi, L. Ala-Kokko, J. Korkko, L. Haataja, H. Kaariainen, K. I. Kivirkko and D. J. Prockop, Znt. Conf. Mol. Biol. Pathol. Matrix 4th AIII-47 (1992). 164. L. A. Bruggeman, X. Hou-Xiang, K. S. Brown and Y. Yamada, Teratology 44, 203 (1991). 165. P. Vandenberg, J. S. Khillan, D. J. Prockop, H. Helminen, S. Knotusaari and L. AlaKokko, PNAS 88, 7640 (1991). 166. D. J. Prockop, JBC 265, 15349 (1990). 167. S. Garofalo, E. Vuorio, M. Metsaranta, R. Rosati, D. Toman, J. Vaughan, G. Lozano, R. Mayne, J. Ellard, W. Horton and B. de Crombrugghe, PNAS 88, 9648 (1991). 168. M. Metsaranta, S. Garofalo, G. Decker, M. Rintala, B. de Crombrugghe and E. Vuorio, J . Cell Biol. 118, 203 (1992). 169. R. Fleischmajer, R. Timpl, L. Tuderman, L. Raisher, M. Wiestner, J. S. Perlish and P. N. Graves, PNAS 78, 7360 (1981). 170. L. Ala-Kokko, S. Kontusaari, C. T. Baldwin, H. Kuivaniemi and D. J. Prockop, BJ 260, 509 (1989). 171. R. A. Janeczko and F. Ramierz, NARes 17, 6742 (1989). 172. M. P. Bernard, J. C. Myers, M.-L. Chu, F. Ramirez, E. F. Eikenberry and D. J. Prockop, Bchem 22, 1139 (1988). 173. H. R. Loidl, J. M. Brinker, M. May, T. Pihlajaniemi, S. Morrow, J. Rosenbloom and J. C. Meyers, NARes 12, 9282 (1984).
76
WILLIAM G. COLE
174. F. Ramirez, M. Bernard, M.-L. Chu, L. Dickson, F. Sangiorgi, D. Weil, W. de Wet, C. Junien and M. Sobel, Ann. N.Y. Acad. Sci. 460, 117 (1985). 175. V. Benson-Chanda, S. Ming-Wan, D. Weil, M.-L. Chu and F. Ramirez, Gene 78, 255 (1989). 176. E. C. Ruteshouser and B. de Crombrugghe, JBC 264, 13740 (1989). 177. F. M. Pope. B. E. Kendall, G. I. Slapak, R. Kapoor, W. I. McDonald, D. A. Compston, R. Mitchell, D. T. Hope, M. W. Millar-Craig, J. C. Dean, A. W. Jonston, P. 6. Lynch, P. Sarathchandra, P. Narcisi, A. C. Nicholls, A. J. Richards and J. L. MacKenzie, Rr. J. Yeurosurg. 5, 551 (1991). 178. A. Superti-Furga, E. Gugler, R. Glitzelmann and B. Steinmann. JBC 263, 6226 (1988). 179. B. Lee. M. D’Alessio, H. Vissing, F. Ramirez, B. Steinmann and A. Superti-Furga, Am. J. Hum. Genet. 48, 511 (1991). 180. A. J. Richards, J. C. Lloyd, P. Narcisi, P. N. Ward, A. C. Nicholls, A. De Paepe and F. M. Pope, Hum. Genet. 88, 325 (1992). 181. P. H. Byers, K. A. Holbrook, G. S. Barsh, L. T. Smith and P. Bornstein, h b . Invest. 44, 336 (1981). 182. H . \Tissing, M . D’Alessio, B. Lee, F. Ramirez, P. H. Byers, B. Steinmann and A. SupertiFurga, JBC 266, 5244 (1991). 183. W. 6. Cole. A. A. Chiodo, S. R. Lamande, R. Janeczko, F. Ramirez, H.-H. Dahl, D. Chan and J. F. Bateinan, JBC 265, 17070 (1990). 184. F. M. Pope, A. C. Nicholls, P. Narcisi, A. Temple, Y. Chia, P. Fryer, A. De Paepe, W. P. De Groote, J. R. McEwan, D. A. Compston, H. Oorthuys, J. Davies and D. L. Dinwoodie, Clin. Exp. Dermutol. 13, 285 (1988). 185. H. Timpl, H. Wiedemann, V. van Delden, H. Furthmayr and K. Kuhn, Eur. J. Biochem. 120, 203 (1981). 186. K. Tryggvason, P. Gehron Robey and G. R. Martin, Bchem 19, 1284 (1980). 187. D. Brazel, I. Oberbaumer, H. Dieringer, W. Babel, R. W. Glanville, R. W. Deutzrnann and K. Kuhn, EJB 168, 529 (1987). 188. R. Soininen, T. Haka-Risku, D. J. Prockop and K. Trywason, FEBS Lett, 225,188 (1987). 189. 1). Brazel, R. Polher, I. Oberbaumer and K. Kuhn, EJB 172, 35 (1988). 190. S. I,. Hostikka and K. Tryggvason, JBC 263, 19488 (1988). 191. J. C. Myers. P. S. Howard, A. M. Jelen, A. S. Dion, and E. J. Macarak, JBC 262, 9231 (1987). 192. R. Soininen, M. Huotari, M. Hostikka, D. J. Prockop and K. Tryggvason,JBC 263, 17217 (1988). 193. E. Poschl, R. Polher and K. Kuhn, E M B O J . 7, 2687 (1988). 194. N. Turner, P. J. Mason, R. Brown, M. Fox, S. Povey, A. Rees and C. D. Pusey, J. Clin. Invest. 89, 592 (1992). 195, K. E. Morrison, M. Mariyama, T. L. Yang-Feng and S. T. Reeders, Am. J. Hum. Genet. 49, 545 (1991). I,%. R . J. Butkowski, J. P. M. h g e v e l d , J. Weislander, J. Hamilton and B. G . Hudson, JBC 262, 7874 (1987). 197. J. Saus, J. Weislander, J. P. M. Langeveld, S. Quinones and B. G. Hudson, JBC 263, 1S374 (1988). 198. S. L. Hootikka, R. L. Eddy, M. 6 . Byers, M. Hoyhtya, T. B. Shows and K. Tryggvason. PNAS 87, 1606 (1990). 199. J. Zhou, J. M. Hertz, A. Leinonen and K. Tryggvason,JBC 267, 12475 (1992). 200. J. Zhou, D. F. Barker, S. L. Hostikka, M. C. Gregory, C. L. Atkin and K. Tryggvason, Genomics 9, 10 (1991). 201. D. Vetrie, E. Boye, F. Flinter, M. Bobrow and A. Harris, Genomics 14, 624 (1992).
COLLAGEN GENES AND THEIR MUTATIONS
77
202. D. F. Barker, S. L. Hostikka, J. Zhou, L. T. Chow, A. R. Oliphant, S. C. Gerkin, M. H. Skolnick, C. L. Atkin and K. Tryggvason, Science 248, 1224 (1990). 203. J. C . Myers, T. A. Jones, E. R. Pohjolaineu, A. S. Kadri, A. D. Goddard, D. Sheer, E. Solomon and T. Pihlajaniemi, Am. J. Hum. Gnet. 46, 1024 (1990). 204. B. Kuebelmann, G . Deschenes, G. Gros, M. C. Hors, J. P. Grunfeld, K. Tryggvason, M. C. Gubler and C. Antignac, Am. J . Hum. Genet. 51, 135 (1992). 205. J. Zhou, J. M. Hertz and K. Tryggvason, Am. J . Hum. Genet. 50, 1291 (1992). 206. H. J. Smeets, J. J. Melenhorst, H. H. Lemmink, C. H. Schroder, M. R. Nelen, J. Zhou, S. L. Hostikka, K. Tryggvason, H. H. Ropers, M. C. Jansweijer, L. A. Monniens, H. G. Brunner and B. A. van Oost, Kidney Int. 42, 83 (1992). 207. H. Bentz, N. P. Morris, L. W. Murray, L. Y. Sakai, D. Hollister and R. E. Burgeson, PNAS 80, 3168 (1983). 208. R. E. Burgeson, N. P. Morris, L. W. Murray, K. G. Duncan, D. R. KeeneandL. Y. Sakai, Ann. N.Y. Acad. Sci. 460, 47 (1985). 209. M. G. Parente, L. C. Chung, J. Ryynanen, D. Woodley, K. C. Wynn, E. Bauer, M.-L. Chu and J. Uitto, PNAS 88, 6931 (1991). 210. T. Tanaka, K. Takahashi, F. Furukawa and S. Imamura, BBRC 183, 958 (1992). 211. D. R. Keene, L. Y. Sakai, G . P. Lunstrum, N. P. Morris and R. E. Burgeson, J. Cell Biol. 104, 611 (1987). 212. J. Uitto, E. A. Bauer and A. N. Moshell, J. Invest. Dermatol. 98, 392 (1992). 213. D. S. Greenspan, M. G. Byers, R. L. Eddy, G. G. HoffmanandT. B. Shows, Cytogenet. Cell Genet. 62, 35 (1993). 214. J.-D. Fine, E. A. Bauer, R. A. Briggaman, R. Pearson and V. P. Sybert, J. Am. Acad. D e m t o l . 24, 119 (1991). 215. P. A. Coulombe, M. E. Hutton, A. Letai, A. Hebert, A. Paller and E. Fuchs, Cell 66, 1301 (1991). 216. A. Hovanian, P. Duquesny, C. Blanchet-Bardon. R. G. Knowlton, S. Amselem, M. Lathrop 11, L. Dubertret, J. Uitto and M. Goossens, Clin. Res. 40, 188A (1992). 217. L. al-Imara, A. J. Richards, R. A. Eady, I. M. Leigh, M. Farrall and F. M. Pope, J . Med. Genet. 29, 381 (1992). 218. L. Bruckner-Tuderman, I. Rantala and T. Reunala, J. Invest. Dermatol. 98, 141 (1992). 219. E. H. Epstein, Jr., Science 256, 799 (1992). 220. M. Ryynanen, J. Ryynanen, S. Sollberg, R. V. Iozzo, R. G. Knowlton and J. Uitto, J. Clin. Invest. 89, 974 (1992). 221. L. T. Smith and V. P. Sybert, J . Invest. D e m t o l . 94, 261 (1990). 222. M. K. Gordon, D. R. Gerecke, B. Dublet, M. van der Rest and B. R. Olsen, JBC 264, 19772 (1989). 223. P. Bruckner, M. Mendler, S. Huber and K. H. Winterhalter, JBC 263, 16911 (1988). 224. D. R. Eyre, S. Apron, J. J. Wu, L. H. Ericsson and K. A. Walsh, FEBS Lett. 220, 337 (1987). 225. M. van der Rest and R. Mayne, JBC 263, 1615 (1988). 226. T. Yada, M. Arai, S. Suzuki and K. Kimata, JBC 267, 9391 (1992). 227. S. Ayad, A. Marriott, V. H. Brierley and M. E. Grant, BJ 278, 441 (1991). 228. D. McCormick, M. van der Rest, J. Goodship, G Lozano, Y. Ninomiya and G. R. Olsen, PNAS 84, 4044 (1987). 229. S . Huber, K. H. Winterhalter and L. Vaughan, JBC 263, 752 (1988). 230. Y. Muragaki, T. Kimura, Y. Ninomiya and B R. Olsen, EJB 192, 703 (1990). 231. R. Har-el, Y. D. Sharma, A. Aguilera, N. Ueyama, J. J. Wu, D. R. Eyre, L. Juricic, S. Chandrasekaran, M. Li and H. D. Nah, JBC 267, 10070 (1992). 232. M. Perala, M. Hanninen, J. Hastbacka, K. Elima and E. Vuorio, FEBS Lett. 319, l(1993).
78
WILLIAM G . COLE
233. H. Yoshioka, H . Zhang, F. Ramierz, hi.-G. Mattei, M. Moradi-Ameli, M. van d e r Rest and M. K. Gordon, Genomics 13, 884 (1992). 234. J. M . Fitcli, A. Mentzer, R. Mayne and T. F. Linsenmayer, Deu. B i d . 128, 396 (1988). 235. N. B. Slepecky, J. E. Savage and T. J. Yoo, Aefa Oto-bryngol. 112, 611 (1992). 2.36. J. J. Fitch, A. Mentzer, R. Mayne and T. F. Linsenmayer. Deuelopment 105, 85 (1989). 2.37 K. K. Svoboda, I. Nishimura, Y. Ninomiya and B. R. Olsen, PNAS 85, 7496 (1988). 238. R. E. Swiderski and M. Solursh, Demlopment 115, 169 (1992). 2.39. R. E. Swiderski and M. Solursh, Deu. Dyn. 194, 118 (1992). 240. K. Nakata, K. Yamamura, J. Miyazaki, B. R. Olsen, Y. Muragaki, Y. Yamada and T. Kirnura, Prof. Orthop. Res. Soc. 38, 2.51 (1992). 241. G. J , Gibson, B. W. Beaumont and M. H. Flint, J. Cell Biol. 99, 208 (1984). 242. T. Kirsch and K. von d e r Mark, EJB 196, 575 (1991). 243. T. F. Linsenmaver, E . Gibney and T. M. Schmid, Deu. B i d . 113, 467 (1986). 244. A. R. Poole and I. Pidoux, J . Cell Bid. 109, 2547 (1989). 245. T. M. Schmid and T. F. Linsenmayer, Dea B i d . 138, 53 (1990). 246. G . J. Gibson, C . H. Bearman and M. H. Flint, Collagen Reht. Res. 6, 163 (1986). 247. A. P. Kwan, C. E. Cummings, J. A. Chapman and M. E. Grant. 1. Cell B i d . 114, 597 (1991). 248. S. Apte, M. G. Mattei and B. R. Olsen, FEBS Lett. 282, 393 (1991). 249. J. T. Thomas, C . J. Cresswell. B. Rash, H. Nicolai, T. Jones, E. Solomon, M. E. Grant and R. P. Boot-Handford, B/ 280, 617 (1991). 250. S, Apte and B. R. Olsen, Proc. Orthop. Res. Soc. 39, 117 (1993). 251. W. A. Sweetman, B. Rash, 8 . Sykes, P. Beighton, J. T. Hecht, B. Zbel, J. T. Thomas, R. Boot-Hanford, M . E. Grant and G . A. Wallis, A m . 1.Hum. Genet. 51, 841 (1992). 252. R. bf. Dharmavaram. M. Peng, R. R. Strawbridge and S. A. Jiminez, BBRC 187, 420 i1992). 253. 0. Jacenko, P. Luvalle, K. Solum and B. R. Olsen, ibfatrix in press (1993). 2%. C. IIuerre, C. Junien, D. Weil, h4.-L. Chu, M. M. Morabito, N. Van Cong, J. C. Myers, C. Foubert. M . 4 . Gross, D. J. Prockop, A. Boue, J.-C. Kaplan, A. d e la Chapelle and F. Hamirez, PNAS 79, 6627 (1982). 255. E. Retief, M . I. Parker and A. E. Retief, Hum. Genet. 69, 304 (1985). 256. E. Solomon, L. R. Hoiorns, N. Spurr, M. Kurkinen. D. Barlow, B. L. M. Hogan and R. Ihlgleish. PNAS 82, 3330 (1985). 257. E. Solomon, F Hall and M. Kurkinen, Ann. Hum. Genet. 51, 125 (1987). 258. M. Mariyama, K . Zheng, T. L. Yang-Fend and S. T. Reeders, Genomics 13, 809 (1992). 259. D . S. Greenspan, $1. 6. Byers, R. L. Eddy, W. Cheng, S. Jani-Sait and T. B. Shows, Genomics 12, 836 (1992). 260. C. Huerre-Jeanpierre, I. Henry, M. G. Mattei. D. \.Veil, K. H. Grzeschik, M. L. Chu, M. Bernard, F. Ramirez and C. Junien, Cytogenet. Cell Genet. 40, 657 (1985). 261. B. S. Emanuel. L. A. Cannizzaro, J. M. Seyer and J. C. Myers, PNAS 82, 3385 (1985). 262. C . A. Francomano, G . R. Cutting, M . K. McCormick, M. L. Chu, R. Timpl, H. K. Hong and S. E. Antonarakis, Hum. Genet. 87, 162 (1991). 263. D. Weil, M. G . Mattei, E. Passage, N. Van Cong, D. Pribula-Conway, K. Mann, R. Deutzmann, R. Timpl and M. L. Chu, Cytogenet. Cell Genet. 46, 713 (1987). 26.i. I). Weil, M. 6. Mattei, E. Passage, V. C. N'Guyen, D. Pribula-Conway, K. Mann, R. Deutzmann, R. Timpl and M. L. Chu. Am. J. Hum. Genet. 42, 435 (1988). 265. A. M. Christiano, L. C. Chung-Honet, A. Hovnanian and J. Uitto, Genomics 14, 827 (1992).
COLLAGEN GENES AND THEIR MUTATIONS
79
266. Y. Muragaki, M. G. Mattei, N. Yamaguchi, B. R. Olsen and Y. Ninomiya, EJB 197, 615 (1991). 267. Y. Muragaki, 0. Jacenko, S. Apte, M. G . Mattei, Y. Ninomiya and B. R. Olsen, JBC 266, 7721 (1991). 268. T. Kimura, M. G. Mattei, J. W. Stevens, M. B. Goldring, Y. Ninomiya and B. R. Olsen, EJB 179, 71 (1989). 269. I. Henry, A. Bernheim, M. Bernard, M. van der Rest, T. Kimura, C. Jeanpierre, F. Barichard, R. Berger, B. R. Olsen and F. Ramirez, Genomics 3, 87 (1988). 270. I. M. Hanson, P. Gorman, V. C. Lui, K. S. Cheab, E. Solomon and J. Trowsdale, Cytogenet. Cell Genet. 51, 1010 (1989). 271. T. Kirnura, K. S. Cheah, S. D. Chan, V. C. Lui, M. G. Mattei, M. van der Rest, K. Ono, E. Solomon, Y. Ninomiya and B. R. Olsen, JBC 264, 13910 (1989). 272. L. Tikka, P. Tania, H. Pirkko, D. J. Prockop and K. Tryggvason, PNAS 85, 7491 (1988). 273. T. B. Shows, L. Tikka, M. G. Byers, R. L. Eddy, L. L. Haley, W. M. Henry, D. J. Prockop and K. Tryggvason, Genomics 5, 128 (1989). 274. L. Pajunen, M. Tamminen, E. Solomon and T. Pihlajaniemi, Cytogenet. Cell Genet. 52, 190 (1989). 275. K. Huebner, L. A. Cannizzaro, E. W. Jabs, S. Kivirikko, H. Manzone, T. Pihlajaniemi and J. C. Myers, Genomics 14, 220 (1992). 276. T. C. Pan, R. Z. Zhang, M. G. Mattei, R. Timpl and M. L. Chu, PNAS 89,6565 (1992). 277. G. Tromp, H. Kuivaniemi, A. Stacey, H. Shikata, C. T. Baldwin, R. Jaenisch and D. J. Prockop, BJ 253, 919 (1988). 278. D. J. McGookey, A. C. M. Smith, G. Waldstein and P. H. Byers, Am. j . Hum. Genet. 45, A206 (1989). 279. H. Kuivaniemi, S. Kontusaari, G . Tromp, M. Zhao, C. Sabol and D. J. Prockop, JBC 265, 12067 (1990). 280. S. Kontusaari, G. Tromp, H. Kuivaniemi, R. L. Ladda and D. J. Prockop, Am. J. Hum. Genet. 47, 112 (1990). 281. B. Lee, E. Vitale, A. Superti-Furga, B. Steinmann and F. Ramirez, JBC 266,5256 (1991). 282. S. Thakker-Varia, D. Anderson, H. Kuivaniemi, G. Tromp, D. J. Prockop and C. A. Stolle, Matrix 10, 249 (1990). 283. T. Wu, G. Tromp, H. Kuivaniemi and D. J. Prockop, in “Miami Short Reports, Vol. 1. Advances in Gene Technology: The Molecular Biology of Human Genetic Disease. Proceedings of the Miami Bio/Technology Winter Symposium” (F. Ahrnad, ed.), p. 39. (1991). 284. J. Earley, G . Tromp, H. Kuivaniemi, Z. Gatalica and D. J. Prockop, Znt. Conf. Mol. Biol. Puthol. Mutrix, 4th AIII-14 (1992). 285. S. Kontusaari, G. Tromp, H. Kuivaniemi, A. M. Romanic and D. J. Prockop, J. Clin. Znoest. 86, 1465 (1990). 286. G . Tromp, H. Kuivanierni, C. Stolle, F. M. PopeandD. J. Prokop,JBC 264, 19313(1989). 287. A. J. Richards, P. N. Ward, P. Narcisi, A. C. Nicholls, J. Lloyd and F. M. Pope, Hum. Genet. 89, 414 (1992). 288. A. J. Richards, J. C. Lloyd, P. N. Ward, A. De Paepe, P. Narcisi and F. M. Pope, J. Med. Genet. 28, 458 (1991). 289. P. H. Johnson, A. J. Richards, F. M. Pope and D. A. Hopkinson, J. Inherited Metub. Dis. 15, 426 (1992). 290. S . Kontusaari, G. Tromp, H. Kuivaniemi, C. Stolle, F. M. Pope and D. J. Prockop, Am. J. Hum. Genet. 51, 497 (1992). 291. A. Renieri, M. Seri, J. C. Myers, T. Pihlajanierni, A. Sessa, G . Rizzoni and M. De Marchi, Hum. Genet. 89, 120 (1992).
80
WILLIAM G . COLE
292. C. Antignac, J. Zhou, M. Sanak, P. Cochat, B. Roussel, C. Deschenes, F. Gros, B. Knebelmann. hl.-C. Hors-Cayla, li. Tryggvason and M . C. Gubler, Kidney Znt. 42, 1178 (1992). 293. A. Renieri, M . Seri, J. C. hlyers, T. Pihlajaniemi, L. Massella, G. Rizzoni and M . De Marchi, Hum. Mol. Genet 1, 127 (1992).
Signal-Transducing G Proteins: Basic and Clinical Implications’ C. W. EMALA,* W. F. SCHWINDINGER,~ G. S. WAND+ AND M. A. L E V I N E ~ . ~ *The Departments of Anesthesiology and ?Medicine The Johns Hopkins Unioersity School of Medicine Baltimore, Maryland 21205 I. Guanine Nucleotide Binding Proteins
........................
11. Structure of a Subunits of G Proteins ........................... 111. Function of a Subunits of G Proteins ............
IV. Structure of Subunits of G Proteins ........................... V. Function of $y Dimers of G Proteins . . . . . . . . . . . . .
......................... A. B. C. D. E. F. G.
Altered G-Protein Function Genetic Studies of G,a ..................................... Methods of Study ...... Albright Hereditary Osteo ................... Deficient Expression or Function of G,a as the Basis for Albright Hereditary Osteodystrophy . . .......................... Sporadic Endocrine Neoplas McCune-Aibright Syndrome ... Altered Expression of G Proteins ............................
.............
IX. Glossary.. ...................................................
81 82 86 88 90 92 93 94 94 95 97 100 100 101
105 106 107
1. Guanine Nucleotide Binding Proteins Guanine nucleotide binding proteins (GTP-binding proteins) are a superfamily of proteins that regulate diverse cellular functions. Members of this superfamily sort transmembrane signals, direct the fidelity of protein synthesis, guide vesicular transport through the cytoplasm, and control growth 1 2
A glossary for this chapter appears on p. 106. To whom correspondence should be addressed.
Progress in Nucleic Acid Research
and Molecular Biology, Vol. 47
81
Copyright 8 1994 by Academic Press, Inc. All rights of reproduction in any form reserved.
82
C. W. EMALA E T AL.
and clifferentiation of cells. GTP-binding proteins include a group of small (i.e., 21-28 kDa) proteins that regulate intracellular hnctions (e.g., ~21‘“s and EF-Tu), as well as a group of larger proteins (i.e., 39-52 kDa) that regulate transmembrane signal transduction. The GTP-binding proteins utilize a common mechanism, the binding and hydrolysis of GTP as a “molecular switch” to regulate their activity. This GTPase cycle is initiated by the release of GDP and the binding of GTP. The binding of GTP causes a conformational change that activates the GTPbinding protein and increases its a f h i t y for effector proteins. The GTPbinding protein remains active until bound GTP is hydrolyzed to GDP by an intrinsic GTPase activity of the protein. The signal-transducing GTP-binding proteins, termed G proteins, couple receptors to diverse intracellular second messengers, including enzymes and ion channels. The G proteins share a heterotrimeric structure composed of an a chain and a Py dimer. The a chain is most unique; it binds and hydrolyzes GTP, and facilitates discrimination between different receptor and effector molecules. At least 17 different cx chains interact with a smaller pool offour P (1-7) and at least six y (8-13) subunits. The f3y dimer is tightly associated with a GDP-bound a chain and facilitates interaction of the G protein with a receptor molecule. In addition to their role regulating a-chain function, the Py subunits appear capable of transmitting intracellular messages in some cells and may anchor the af3y complex to the cell membrane.
II. Structure of a Subunits of G Proteins The G proteins share a heterotrimeric structure consisting of an a subunit and two smaller, tightly coupled subunits, py (Fig. 1). The a subunits bind guanine nucleotides, possess intrinsic GTPase activity, and couple receptor with effector molecules; some are substrates for ADP-ribosylation by bacterial toxins. The a subunits demonstrate the greatest diversity, are unique to each G protein, and are thought to confer functional specificity, allowing discrimination among multiple receptors and effectors. The 17 different a chains so far identified range in size from 350 to 395 amino acids, have an overall 40% amino-acid homology, and have 60-90% homology within subfamilies (12).The a chains have been subdivided into four subfamilies based on their amino-acid sequence homology: (1)Gsa and Go,,; (2) G,a(1-3), G,a, GLa, transducins 1 and 2, and gustducin; (3) Gqa, G,,a, G14a, G,,5cx; and (4)Giza, Gl,a (Fig. 2) (12).Expression of some a subunits appears to be highly tissue-specific. For example, one form of transducin ( T a l ) is specific to the rods whereas a second form (Ta2) is expressed only in cones of the
SIGNAL-TRANSDUCING G PROTEINS
83
FIG. 1. A schematic representation of the predicted three-dimensional conformation of a G protein. The putative regions that interact with the receptor and effector are shown. The regions G1 through G5 are regions believed important for GDP-GTP exchange, GTP-induced conformational changes, and GTP hydrolysis. [Reprinted with permission from Ref. 80; 0 The Endocrine Society.]
retina (14, 15);Golfis expressed primarily in olfactory neuroepithelium (16); and gustducin is expressed only in taste buds of the tongue (17). Other a subunits, such as Gsa, the G p s , and G,, have a ubiquitous distribution (18). Receptor activation of G proteins facilitates exchange of bound GDP for GTP by the a subunit, and causes dissociation of the a subunit from the Py dimer (Fig. 3). The free a-GTP chain interacts with specific signal effector enzymes or ion channels to regulate their activity. The interaction of the a subunit with its effector is terminated with hydrolysis of GTP to GDP by an intrinsic GTPase. The GDP-liganded a chain reassociates with the Py dimer and the heterotrimeric G protein is ready for another cycle of receptor activation. The interaction of additional proteins that regulate the rate of GDP dissociation and GTP hydrolysis adds another level of control to G-protein activity. Guanine-nucleotide-releasingproteins (GNRPs) catalyze the release of bound GDP from the GTP-binding protein, allowing GTP to bind and activate the GTP-binding protein. Examples of GNRPs include ribosomes that enhance the release of GDP from EF-Tu during protein synthesis, and
84
C. W. EMALA ET AL.
GS
Gi
Gq
\
A
G12
io
50
1
60
io
6
!h
,
loo
'--I
Amino acid identity ('YO)
FIG. 2. Amino-acid homology of the four subfamilies of G-protein
Q
subunits.
hormone receptors that facilitate the release of GDP from a subunits of G proteins. GTPase-activatingproteins (GAPS)increase the rate of GTP hydrolysis by small GTP-binding proteins such as p21rm (19). The (Y subunit of G proteins is hypothesized to contain its own GAP region, explaining the greater kcat-c:TPof the CL chain (3-5 min-1) compared to p21ras (0.02 min-I), and also may account for its larger size. Other proteins may regulate the GTPase of at least some G proteins. For example, the y subunit of cGMP phosphodiesterase, the effector protein of transducin, functions as a GAP for transducin (20). The a subunits of many G proteins undergo posttranslational modifications. The N-myristoylation of an amino-terminal glycine in Cia, Goa, Gz a , and Gta is important for attachment of the a chain to the membrane, probably via enhanced aff;nityof the modified CY chain for the Py dimer. The function of additional modificationsof the N-terminal region of transducin by heterologous fatty acids is unclear at present (21). Modifications of G proteins that alter their function include phosphorylation of a subunits. Cia@)subunits are substrates for phosphorylation by
85
SIGNAL-TRANSDUCING G PROTEINS Hormone Receptor
1
xptor
\
FIG. 3. Schematic representation of the GDP-GTP cycle of G-protein (Y subunits. Following release of GDP, GTP binds and releases Pr. The activated (Y subunit with GTP bound then activates a second messenger until GTP is hydrolyzed to GDP, allowing p-y to again return the heterotrimer to its basal state. Additionally, liberated P-y subunits may interact with second messengers; in this example, Pr subunits can stimulate or inhibit adenylate cyclase depending on the type of adenylate cyclase present. The effects of toxin treatment or several mutations are schematically shown to block GTPase activity in G,u or the activation of G p .
protein kinase C. The basal level of phosphorylation of Gia(2)is increased in hepatocyte membranes from rats with induced diabetes, and G p can be phosphorylated on a serine by protein kinase C in platelets (22-24). Some (Y chains can be modified by bacterial toxins. The A, chain of choleragen covalently attaches an ADP-ribose to arginine 201 of the (Y subunit of G, or Golf, causing a loss of GTPase activity. The activated (Y subunit results in constitutive activation of adenylate cyclase. The resulting high levels of CAMPimpair luminal transport of salt and water, causing secretory diarrhea. Pertussis toxin, an islet-activating protein (IAP), ADP-ribosylates the cx subunit of Gi, Go, or transducin, which uncouples them from receptor activation. X-ray crystal structures of p21ra and EF-Tu have identified critical noncontiguous amino-acid sequences that form a guanine-nucleotide-binding pocket and function in the hydrolysis of GTP (25-30). Although the threedimensional conformation of G-protein (Y chains has not been described, comparison of regions of amino-acid homology between ras and a conserved (Y chain has facilitated predictions of functional domains (Fig. 1). Five regions of the polypeptide chain, designated G1 to G5, have been identified as functional domains important for GDP-GTP exchange, GTPinduced conformational changes, and GTP hydrolysis. The G1 region has the
86
C. W. EMALA ET AL.
amino-acid sequence motif GlyXXXXGlyLys(Ser/Thr). In the G1 of p21ras, amide groups of several amino acids and the €-amino group of lysine 16 form hydrogen bonds with the a and p phosphates of GTP or GDP. The G2 region, which corresponds to amino-acid residues 32-40 in p21ra8, changes conformation with the binding of GTP. The binding of the GTP analog Gpp(NH)pand a magnesium ion in the G2 region of p2lraSallows interaction of the p and y phosphates of GTP with threonine 35. The presence of Mg2+ is essential for GTP hydrolysis, and the conserved threonine residue is present in each putative G2 sequence. The G 3 region corresponding to amino-acid residues 53-62 in p21rus contains the sequence motif conserved in all GTPases, AspXXGly. A conserved aspartate binds the catalytic Mg2+ while a conserved glycine binds to the y-phosphate of GTP. Dramatic conformational change occurs in amino acids 60-63 when GDP is exchanged for GTP. The G4 region consists of the characteristic sequence motif [(Am/ Thr)(Lys/Glu)XAsp] and contains residues responsible for binding to the purine ring of guanine nucleosides and confers guanine specificity. The G5 region has not been unambiguously identified by the amino-acid sequence in all GTPase subfamilies. In p21ras, residues 144-146 of this region interact indirectly with the guanine nucleotide. The corresponding region of G-protein a chains consists of the amino-acid sequence motif Thr(Cys/Gln)Ala(ThrNalfAspThr, which may also indirectly interact with the guanine nucleotide. Several regions of a chains are important for interaction of a chains with eEector molecules (Fig. 1; see also Fig. 11). Residues 236-356 of the a chain of C,a comprise the shortest linear chimeric construct that results in activation of adenylate cyclase. Scanning mutagenesis assays have been used to identify four separate regions (Cl-CIV) in which amino-acid substitutions prevent activation of adenylate cyclase (31).Three noncontiguous amino-acid clusters appear to form a surface within Gsa that may bind and stimulate adenylate cyclase. This surface includes a region corresponding to a domain in p21ru.y that undergoes a conformational change with the binding of GTP.
111. Function of a Subunits of G Proteins The a chains of C proteins have been identified by biochemical purification or molecular cloning. In many instances, molecular cloning has revealed the existence of more than one protein that might subserve the role of a specific G protein first identified by function. The initial description of an inhibitory Gi protein has led to the cloning of three distinct genes encoding three closely related Gi proteins. Further diversity derives from alternate
SIGNAL-TRANSDUCING G PROTEINS
87
splicing of gene products (e.g., four species of Gsa and two to four forms of Go are generated by alternative splicing) (32-34). G proteins couple cellsurface receptors to intracellular enzymes or channels. More than 100 distinct receptors have been shown by pharmacologic or molecular biological means to be coupled to effector molecules through G proteins. The reader is referred to a recent comprehensive review for the growing list of G-proteincoupled receptor-effector systems (13). The G-protein-coupled receptors share a common topographical organization (Fig. 4). The receptors' extracellular N-terminal domain has sites for N-linked glycosylation. The receptor structure contains seven hydrophobic segments, which are predicted to span the plasma membrane. Each receptor has a cytoplasmic C-terminal domain that has sites for phosphorylation on serines and threonines. The ligand-binding sites, at least for rhodopsin and catecholamines, have been identified within the plane of the plasma membrane and include important contacts on almost all transmembrane segments. Threonine and serine residues in the third cytoplasmic loop and the carboxyl-terminal tail are substrates for phosphorylation by protein kinase A, protein kinase C, and 6-adrenergic receptor kinase (PARK). Phosphorylation of the receptor leads to desensitization of the hormone response. Homo-
?-"'
FIG. 4. A schematic representation of the P-adrenergic receptor, which is a representative member of G-protein-coupled receptors predicted to contain seven transmembrane hydrophobic regions. BARK, P-Adrenergic receptor kinase; PKA, protein kinase A.
88
c. w.
EMALA
Er
AL.
logous desensitization of the p-adrenergic receptor requires the binding of the protein p-arrestin following phosphorylation. The cytoplasmic loop between transmembrane domains V and VI contains amino acids essential for G-protein coupling. G proteins regulate the activity of several enzymes and ion channels, including (1) cGMP-specific phosphodiesterase, which is coupled to rhodopsin 11, transducin ( G , )in the visual system, (2) hormone-sensitive adenylate cyclase, which is coupled to receptors that increase or decrease activity through two classes of G proteins, G , and G,,lf or G , and G,, respectively, (3) phospholipase C , which is coupled through members of the G, family, and (4)at least six sodium, potassium, and calcium-ion channels that are coupled through a subunits, including G , , GI, Go, and Gk (35-38). Receptor activation in different tissues can elicit a variety of cell responses, indicating that some receptors may couple with more than one G protein. Thus some receptors (e.g., muscarinic) can couple to homologous G proteins (e.g., GI, G,,, or G,,) that inhibit adenylate cyclase or activate phospholipase C. By contrast, expression of cloned parathyroid receptors (39) and calcitonin receptors (40,41) leads to stimirlution of adenylate cyclase and activation of phospholipase C , suggesting that a single receptor can couple to two diuergent G proteins (e.g.. G, and a G protein linked to phospholipase C). Recently, similar coupling abilities have been demonstrated for the thyrotropin receptor (42).
IV. Structure of p Subunits of G Proteins Although early attempts to understand G-protein function had focused primarily on 01 chains, a growing interest in the role of the Py dimers has emerged. Four different p subunits (1-7) and six y subunits (8-13) have thus far been identified, and it is likely that additional forms exist. Little is known about the function, tissue distribution, specificity of Py dimerization, or specificity of coupling of p-y dimers to a subunits; however the PI and Pz polypeptides are immunologically (43, 44) and structurally (1-3, 45, 46) distinct and are encoded by separate genes (47).Recent immunohistochemical evidence indicates that the p3 subunit is present in cones whereas the PI subunit is present in rods of the retina (Fig. 5) (48, 49). This cell-specific distribution allows intriguing speculation concerning specificities of function and coupling of the p subunits. Each p subunit consists of 340 amino acids and migrates in SDS-PAGE with an apparent mass of 35-36 kDa. Eight repetitive segments of 40 amino acids (termed WD40) occur in the p chains, and comprise a motif of unclear significance that is found in several other apparently unrelated proteins (12).
SIGNAL-TRANSDUCING G PROTEINS
89
FIG. 5. (A) Immunoperoxidase staining of a cross-section of monkey retina with a rabbit polyclonal antibody against G-protein PI subunit. Large black arrow indicates a stained amacrine cell body, small black arrow indicates a stained ganglion cell body, and white arrow indicates a cone photoreceptor, which is not stained. (B) Monkey retinal section stained with a rabbit polyclonal antibody against G-protein p3. Arrow indicates a stained bipolar cell. RPE, Retinal pigment epithelium; PRL, photoreceptor layer; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; OFL, optic fiber layer. [Reprinted with modifications from Peng et al., Proc. Natl. Acad. Sci.
U.S.A. 89, I0882 (1992).]
The six y subunits each consist of 70 amino acids; they migrate with apparent masses of 6-10 kDa (8-13). The “CAAX” (CysAlaAlaX) carboxylterminus residues are the sites of posttranslational modification (50-53). A terminal cysteine is isoprenylated, followed by the proteolysis of three amino acids distal to the cysteine, and carboxylation of the isoprenylated cysteine occurs. The modified cysteine residue is then thought to anchor the G-protein heterotrimer to the membrane. There is discrimination in the specificity of coupling of p and y subunits (Fig. 6) (54, 55). Limited tryptic proteolysis and measurement of Stokes radii of p and y subunits translated in vitro offer insight into the specificity of Py dimerization. p1 dimerizes with y1 or y2, p2 dimerizes with y2 but not yl, and p3 dimerizes with neither y1 nor y2 in vitro. The specificity of p and y interactions offers another level of regulation of G-protein-mediated signaltransduction pathways. Moreover, Py dimers appear to differ in their ability to couple a subunits to receptors or modulate effectors. The f3y dimers have opposing effects on adenylate cyclase depending on the type of adenylate cyclase present. Py dimers inhibited type-I adenylate cyclase but stimulated type-I1 adenylate cyclase, and these effects were accentuated by the addition of G,a subunits (56).
C . W. EMALA ET AL.
FIG. 6. Limited tryptic proteolysis provides a means to investigate the conformation of the
f3 subunit in the presence or absence of y. Tryptic digests of in citro translated Py dimers vields fraginents of 26-27 kDa, which are not obtained when f3 monomers are digested. Lane 1. no y subunit; lane 2, no y subunit; lane 3, yz added; lane 4, y I added. Samples were incubated in the absence (lane 1) or in the presence (lanes 2. 3, 1)of 20 pmol of trypsin. Arrowhead indicates po.iition of the 26- or 27-kDa tryptic fragments. Suhunits y I and y2 diinerize with p,, y2 dimerizchs with p2, but neither y subunit dinierizes with P3. [Reprinted with modifications from Schmidt et n l . . I . H i d . Cheni. 267, 13807 (1992).]
The (3, and Pz subunits have a widespread tissue distribution but the abundance of each protein varies (53, with highest concentrations in rat brain, lung, kidney, liver, spleen, and human placenta. There are lesser amounts in rat erythrocytes and cardiac and skeletal muscle. Conversely, tissue expression of fl3 and p4 appears to be more variable. Northern blot hybridization identified p3 niRNA in retina, rhabdomyosarcoma, pheochromocytoma, neuroblastoma, and dermal fibroblasts (Fig. 7) (5). Distribution of the inRNA encoding the p4 subunit vanes significantly, being highest in the brain, eye, lung, heart, and testis (7). Identification of a p4 protein has not yet been reported.
V. Function of fly Dimers of G Proteins The functions of the py dimers appear diverse and include (1)binding to an inactive a-GDP subunit to reassociate the heterotrimer into its inactive
SIGNAL-TRANSDUCING G PROTEINS
91
FIG. 7. (A) Blot hybridization analysis of bovine (lanes 1-3) and human (lanes 4 and 5) P-subunit mRNAs. Each lane contained 10 pg of total retinal RNA. The hybridization probe was the radiolabeled bovine subunit cDNA derived from clone BTdl (lanes 1-3) and cDNAs derived from human retina clones encoding the PI, pz, or p3 subunit or the 45-base oligonucleotide derived from the 3’ untranslated region of p3. (B) Blot hybridization analysis of p1 and p3subunit mRNA in human cell lines. Poly(A)+RNA was isolated from human cell lines and hybridized first with the radiolabeled cDNA from the human p3 subunit clone p22 (lanes 1-5). After exposure to X-ray film, the filter was strip-washed off the bound probe and rehybridized with a radiolabeled cDNA from the human p1 subunit clone (lane 6-10). Lanes 1 and 2, rhabdomyosarcoma; lane 3, pheochromocytoma; lane 4, neuroblastoma; and lane 5, dermal fibroblast. RNA size markers are indicated at left. [Reprinted with modificationsfrom Levine et al., Proc. Natl. Acad. Sci. U.S.A. 87, 2329 (1990).]
92
C. W. EMALA ET AL.
state, (2)anchoring the heterotriiner to the membrane via an isoprenylated y subunit (58), and (3) transducing the intracellular message in some cells, which may include (a) transduction of the message of the mating pheromone receptor in yeast (59-61), (b) regulation of cardiac potassium channels (62), ( c ) activation of retinal and cardiac phospholipase A, (63, 64),(d) differing direct effects on the inodulation of various isoforms of adenylate cyclase (Fig. 3) 136, 65, 66), (e) assisting in the translocation of P-adrenergic receptor kiiiast to the membrane to facilitate P-adrenergic phosphorylation and down-regulation (67), and (f) stimulation of phospholipase C in cultured granulocytes (HL-60) (68).
VI. The fi3 Subunit Our studies i n a variety of tissues suggest that the P3 mRNA is widely distributed, but attempts to identify the P3 protein in membrane preparations by immunoblot analysis have been unsuccessful. An affinity-purified polyclonal P:, antibody has been used to localize the P3 to the cones of the retina b y immunohistochemical staining (48), but immunoblotting with this antibody has not identified the protein in tissues that contain the mRNA. It and pz proteins and the is uncertain if the ubiquitous expression of limited identification of P3 reflect a true absence of P3 protein in tissues. Conversely, the quantity of P3 present in membranes may be too low to be detected by immunoblot, or the P3 protein may be present in greater abundance in a soluble rather than membrane fraction of the cell. Recent immunohistochemical studies in our laboratory suggest that in some tissues the distribution of P3 is limited to only certain cell types within tissues (Fig. 5). If distribution of P3 is limited to few cells in tissues, detection of the PJ protein by immunoblot analysis may not be possible. The P:, protein is specifically localized to photoreceptor cone cells of the retina, and PI is uniquely localized in the rod photoreceptor cells, as determined by iinmunocytochemistry utilizing specific antisera (48).The PI antibody specifically stained rods and the P2 antibody weakly but specifically stained the outer plexiform layer and discrete laminae of the inner plexiform layer. The Po antibody specifically stained the entire cone cell, including the outer segment, axon, and synaptic terminal. Double-labeling immunofluorescence confirmed reactivity of the P3 antibody with the three types of cones; red, blue,and green. These findings in the monkey retina were confirmed in the retinas of human, cattle, rabbit, rat, and ground squirrel. The specific localization of PI and P3 subunits to rods and cones, respectively, and the presence of distinct transducin subunits and distinct cGMP phosphodiesterases in rods and cones raise an intriguing possibility that P
SIGNAL-TRANSDUCING G PROTEINS
93
subunits may be segregated and specific to an a subunit. This awaits the determination of any specificity of binding of p subunits to transducin subunits. Furthermore, attempts to form dimers in vitro between p3 and y1 or y, have been unsuccessful, suggesting that another y subunit couples in vivo to p3 which would presumably be present in the cones of the retina (Fig. 6). A growing complexity emerges with respect to the tissue distribution and specificity of coupling of different subunits of the heterotrimer, which affords the cell a complex array of second-messenger signaling pathways. Thus the cell may modulate its response to external stimuli not only by the type of receptors and second-messenger pathways it contains, but also by the availability and perhaps competition for G-protein subunits between different signaling pathways.
VII. Clinical Implications of Altered G-Protein Function There is growing evidence that altered function or expression of G proteins may pIay a role in several clinical disorders. These include covalent modifications of a chains by toxins of the bacteria Vibrio cholerm and Bordetella pertussis, genetic mutations in genes encoding a chains that result in increased (e.g., McCune- Albright syndrome and neoplasias) or decreased (e.g., Albright hereditary osteodystrophy) function. Moreover, expression of a chains of G proteins is influenced by hypo- or hyperthyroidism (69), glucocorticoid treatment (70), insulin deficiency (24), ethanol (71-75), and heart failure (76-79). A more comprehensive description of altered signal transduction in these conditions appears in two recent reviews (80, 81). Our laboratory has focused on analysis of genetic defects in G,a as a basis for altered regulation of hormone-sensitive adenylate cyclase and clinical disease. The adenylate cyclase system consists of at least three distinct components: specific receptors, adenylate cyclase molecules, and G proteins. Activity of adenylate cyclase is regulated by G proteins that couple signals produced by the interaction of hormones, neurotransmitters, and other ligands with specific receptors at the cell surface. At least two G proteins, one stirnulatory (e.g., G,, G,,,) and the other inhibitory (e.g., G,, GJ, regulate catalytic activity of adenylate cyclase. Stimulation of adenylate cyclase enhances the formation of CAMP. Subsequent actions of CAMP-dependent protein kinases lead ultimately to the physiological expression of the agonist. Stimulatory receptors (RJ include those for P-adrenergic agonists, PTH, TSH: ACTH, glucagon, and other peptides, whereas inhibitory control is exerted by agents such as a,-adrenergic and muscarinic agonists that bind to inhibitory receptors (Ri) (82).
94
C. W. EMALA ET AL.
A. Genetic Studies of G p The G,a protein is encoded by a single gene, GNASl, that is located in the human chromosome 2 0 q 1 3 . 1 4 13.2 (83). The GNASl gene spans approximately 20 kb and contains 13 exons and 12 introns (84). The nascent G,a mRNA is alternatively spliced to yield four products, by including or excluding exon 3, and by utilizing alternative splice-acceptor sites in intron 3 to include or exclude a single serine residue (32). These four transcripts encode a chains that migrate as 45- or 52-kDa proteins, and contain 380 or 381, and 394 or 395 amino acids, respectively. An alternate exon 1 has been identified (termed 1’) located 2.5 kb 5’ of the previously described exon l(85). Mutations in GNASl are associated with several human disorders. Inherited mutations in GNASl that result in decreased expression or function of the G,a protein have been identified in individuals with Albright hereditary osteodystrophy (AHO) (86). Sporadic mutations in GNASl that inactivate intrinsic GTPase activity of G,a and thereby lead to constitutive activation of adenvlate cyclase have been identified in a subset of sporadic human pituitary (87) and thyroid adenomas (88). Similar activating mutations of GNASl have been identified in tissues from individuals with McCune- Albright syndrome (MAS). The mosaic distribution of the abnormal GNASl allele may account for the unusual distribution of bone lesions, cutaneous hyperpigmentation. and endocrine neoplasia in these patients (89, 90).
B. Methods of Study Mutational analysis of the GNASl gene has been greatly facilitated by the advent of the polymerase chain reaction (PCR) and development of methods for rapid screening of amplified DNA fragments for the presence of mutations. We have used denaturing gradient gel electrophoresis (DGGE) to analyze amplified segments of the GNASl gene from patients with A H 0 and MAS (Fig. 8). Pairs of specific oligonucleotide primers were synthesized for each of the 13 exons of G p . These oligonucleotides corresponded to intron sequences that flank each of the exons. To optimize analysis of each amplified melting domain, the MELTMAP 87 program (91)was used to design primer pairs and one oligonucleotide from each primer pair was synthesized with a 5’ G-C-rich clamp. PCR fragments were amplified from DNA prepared from peripheral leukocytes from patients and from normal controls. These fragments contained one or two exons, splice-donor and -acceptor sites, and flanking intron sequence. The fragments were then analyzed by DGGE (Fig. 8). This technique employs a polyacrylamide gel with a concentration gradient of the denaturants (urea and formaniide) that increases toward the bottom of the gel. The double-stranded DNA fragments migrate through the gel until they become partially denatured, at which point their migration is
95
SIGNAL-TRANSDUCING G PROTEINS Exon
Allele A
-
I ' L
Genomic DNA
Allele B
1
PCR
I I
t
c
Electrophoresis
-
!IA-
a NDGE
-A I
DGGE
FIG.8. Analysis of genomic DNA for point mutations. Genomic DNA was amplified by polymerase chain reaction using primer pairs in which one oligonucleotide had a 40-base G.C extension at the 5' end ( G C clamp). PCR products are then subjected to electrophoresis at 60°C using polyacrylamide gels that contain a linearly increasing gradient of formamide and urea. Homologous alleles result in a single band (denoted A or B), whereas heterologous (A and B) alleles yield two homoduplexes and two more slowly migrating heteroduplex bands. DGGE, Denaturing gradient gel electrophoresis.
greatly retarded. A single base-pair mismatch can sufficiently alter the melting point of a DNA fragment and thereby alter migration through the gel. The sensitivity of this technique is improved when the mutation is present in only one allele of the gene. Under these circumstances, the PCR product is resolved into four distinct bands on DGGE, representing two homodupIex and two heteroduplex fragments that are formed during the PCR. Mutations identified by PCR and DGGE can then be sequenced.
C. Albright Hereditary Osteodystrophy In 1942, Albright et al. (92)described a group of patients with clinical and biochemical features of hypoparathyroidism (i.e, hypocalcemia and hyper-
96
C . W. EMALA ET AL.
phosphateinia) who lacked the normal phosphaturic response to infusion of parathyroid extract. They proposed that biochemical hypoparathyroidisin in these patients was not caused by a deficiency of parathyroid hormone (PTH) but 1,). a resistance of the target tissues, bone and kidney, to the biological actions of PTH. Thus, this condition was termed pseudohypoparathyroidism (PHP). These patients also had a distinctive constellation of developmental and skeletal defects, including round facies, short stature, brachydactyly, obesity, heterotopic ossifications, and, in some patients, mental retardation (Fig. 9). Subsequently, other subjects were identified who had these same physical defects but who lacked evidence of hormone resistance; this disorder was termed pseudopseudohypoparathyroidism (pseudoPHP) (93). This constellation of skeletal and developmental abnormalities, with or without hormone resistance, is now termed Albright hereditary osteodystrophy.
FIG.9. A sul>ject with pseudohypoparath~roidism type la demonstrating the physical stigmata of Allxight hereditary osteodystrophy.
SIGNAL-TRANSDUCINGG PROTEINS
97
There is considerable variability in the clinical presentation of AHO, even in affected members of the same family. Round facies, short stature, and brachydactyly may be obvious in some subjects and subtle in others. There is heterotopic ossification in approximately half the patients; some may have profound mental retardation or normal intelligence. Hormone resistance is also variable; hormone resistance does not occur in all target tissues, nor does it occur in all patients with AHO.
D. Deficient Expression or Function of G p as the Basis for Al bright Hereditary Osteodystrophy PHP was the first recognized human disease to be ascribed to diminished responsiveness to a hormone by otherwise normal target organs. Characterization of the molecular basis for PTH resistance in PHP commenced when it was shown (94) that the actions of PTH on its target organs, bone and kidney, are mediated by cyclic 3',5'-adenosine monophosphate (CAMP), and that FTH infusion in man leads to increased urinary excretion of nephrogenous cAMP (95). Patients with PHP type 1 1 have a markedly blunted urinary cAMP response to exogenous PTH. This observation first suggested that PTH resistance in PHP type 1 is the result of a defect in the hormonereceptor adenylate cyclase complex that produces CAMP. Patients with A H 0 have reduction of approximately 50% in G,a activity, as determined by functional assays of membranes from a variety of tissues, including red blood cells, lymphocytes, and fibroblasts (96). In most cases, these functional deficiencies are accompanied by decreased levels of G,a protein (Fig. 10)(97)and mRNA (98). In other cases, levels of G p protein or mRNA may be normal despite a functional deficiency of G,a. Multiple distinct mutations that account for G,a have been identified in the GNASl gene, including missense mutations in the coding sequence, mutations in sequences necessary for correct splicing, and small deletions (Fig. 11) (86, 99, 100). Thus, the autosomal dominant inheritance of A H 0 and G p deficiency is explained by transmission of heterozygous mutations in the GNASl gene. The inheritance of A H 0 has generated considerable debate. The reported fema1e:male ratio of 2:1 among affected individuals had suggested that A H 0 is an X-linked disorder. However, examples of male-to-male transmission have been documented, and it is currently believed that the mode of inheritance is autosomal dominant with sex modification (98). This is consistent with the recent association of A H 0 with inherited defects in the gene for G,a (GNASl),located on chromosome 20 (101). 1 In contrast to individuals with PHP type 2, a much rarer condition in which the urinary cAMP response to PTH is normal but the phosphaturic response is deficient (137).
98
C. W. EMALA ET AL.
i
A A
125
A
0 0
25
50
75
100
125
G,a BIOACTIVITY (% Normal)
FIG. 10. Biological and immunological activity of erythrocyte G,a protein in normal (A) and A H 0 (0)patients.
Patients with PHP type l a have deficient expression of G,a and show resistance not only to PTH but to other hormones and neurotransmitters that activate adenylate cyclase. Many patients have biochemical hypothyroidism with low serum levels of T4, an elevated serum level of TSH, and a normalsized thyroid gland. Subjects demonstrate an exaggerated release of pituitary thyrotropin to TRH administration, but fail to show appropriate thyroid release of T3 (102). These observations are consistent with resistance of follicular cells to TSH (103). Many subjects with PHP type l a have hypogonadism, oligomenorrhea, or amenorrhea with elevated levels of plasma gonadotropins; exaggerated responses to GnRH (gonadotropin releasing hormone) are common in many patients. Several clinical conundrums remain unanswered despite advances in our knowledge of the molecular basis for G,a deficiency. Patients with PHP type l a do not show abnormal responses to all hormones that stimulate adenylate cyclase. For example, PHP type l a patients have normal physiologic responses to ACTH and AVP. Some of this variability may be explained by deficiencies in the level at which the response is tested. PHP type l a patients dre considered to have impaired responses to glucagon and isoproterenol when plasma cAMP levels are analyzed, but normal responses if the physiologic effects (e.g., blood glucose) are measured. Thus, apparently normal hormone response of some tissues may indicate that less cAMP is required to produce a physiological effect. Conversely, it remains unknown whether G,a deficiency impairs adenylate cyclase activity in all tissues to an
4-bp deletion
+
5'
I
I
EXON
2
3
Gsa Gene
+I I +I
*T+C
A+G
*T+GI
*G+A
*C+T
A+G
4-bp deletion 1-bp deletion
Gsa
Protein
NH2
I II I
I I I I
I
I
COOH
FIG. 11. G p gene and protein in AHO. The upper diagram depicts the human G,a gene, which spans over 20,000 bp and contains 13 exons and 12 introns. Ten distinct mutations have been identified in affected members of ten unrelated families. The mutation in exon 1 eliminates the initiator methionine codon and prevents synthesis of a normal C,a protein (86). The 4-bp deletions in exon 7 (134)and exon 8 (100),and the 1-bp deletion in exon 10 all shift the normal reading frame and prevent normal mRNA andlor protein synthesis. Mutations in intron 3 and at the donor splice junction between exon 10 and intron 10 cause splicing abnormalities that prevent normal mRNA synthesis (99). The four mutations indicated with an asterisk represent missense mutations (100,135, 136); the resultant amino-acid substitutions are indicated in the schematic diagram of the G,a protein at the bottom of the figure. Some of these mutations may prevent normal protein synthesis by altering protein secondary structure, but the Arg -+ His substitution in exon 13 appears to encode an altered protein that cannot couple normally to receptors (135).
100
C. W. EMALA ET AL.
equivalent degree. Perhaps even more perplexing is the existence of pseudoPHP. Patients with pseudoPHP, compared to their relatives with PHP type la, have similar degrees of G,a deficiency and have mutations in GNASl. Surprisingly, in these subjects G p deficiency is not associated with hormone resistance. Even more perplexing is the observation that individuals with PHP and individuals with pseudoPHP occur in a single family, but PHP type l a and pseudoPHP do not occur in the same generation. Moreover, there are no examples of affected males having progeny with PHP, or of affected females having offspring with pseudoPHP. We have no explanation for these observations.
E. Sporadic Endocrine Neoplasia Somatic mutations in G,a have been identified in a subset of pituitary tumors secreting human growth hormone (88)and autonomously functioning human thyroid tumors (104, 105). These point mutations result in specific amino-acid replacements, including Arg201-+ Cys, Arg201-+ His, and Gln227 -+ Arg, that reduce the intrinsic GTPase activity of G p , thereby activating G,CLaxid enabling it to stimulate adenylate cyclase constitutively. These observations have led to the concept that activating mutations of the G,a gene convert it into a putative oncogene termed g s p (106).Analogous mutations in the cognate Arg-201 residue have been found in the Gia(2) chain in tumors of human ovary and adrenal cortex (gip 2) (104).
F . M cCune- At bright Sy ndrome McCune-Albright Syndrome is characterized by the clinical triad of cutaneous hyperpigmentation, polyostotic fibrous dysplasia, and endocrine dysfunction. The pigmented cutaneous lesions, termed ct&-nti-Zuit spots, have irregular borders that have been described to resemble the “coast of Maine.” The lesions typically display a segmental distribution that follows the developmental lines of Blaschko (106). Based on the peculiar distribution of the cutaneous lesions, it was suggested that MAS results from a postzygotic somatic cell mutation in an unknown gene that leads to a mosaic distribution of affected cells (107, 108). An analogous pattern of variable involvement of hormonally responsive cells occurs in subjects with MAS. The metabolic abnormalities are characterized by excessive function of the responsive cells, and are associated with endocrine syndromes including precocious puberty, hyperthyroidism, hypercortisolism, growth hormone excess, and hyperprolactinemia. The bone lesions of MAS (polyostotic fibrous dysplasia) bear considerable resemblance to those of hyperparathyroidism. These diverse metabolic abnorinalities share in common the involvement of cells that respond to extracellular signals through activation of the hormone-sensitive adenylate cyclase system.
SIGNAL-TRANSDUCINC G PROTEINS
101
However, these metabolic disturbances are not accompanied by elevated plasma concentrations of the relevant trophic or stimulatory hormones. Thus, MAS patients with precocious puberty demonstrate ovarian enlargement with development and involution of ovarian cysts, but have prepubertal levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and a prepubertal response of LH to luteinizing-hormone-releasing hormone (LHRH) (109). Patients with hyperthyroidism demonstrate thyroid enlargement with thyroid cysts and have suppressed levels of TSH (107). The few patients with cortisol excess have been found to have adrenal hyperplasia and undetectable levels of ACTH (110). Finally, excessive secretion of GH by subjects with MAS is indistinguishable biochemically from that which occurs in patients who have autonomous GH-secreting pituitary tumors (111). These observations have led to the speculation that MAS is caused by a lesion that results in constitutive activation of adenylate cyclase. This speculation has recently been confirmed by the description of mutations in the GNASl gene encoding in patients with MAS (89, 90). These mutations occur in the codon for Arg-201 in exon 8, and result in substitution of His or Cys at that position. These mutations are identical to those present in many human endocrine tumors, and result in inhibition of the GTPase activity of G p , thereby causing constitutive activation of adenylate cyclase. Expression of the GNASl Arg-201 mutation is greatest in cells from affected tissues and is absent or present in low copy number in apparently normal tissues (89, 90). Differential levels of mutant Gsa alleles have been demonstrated in ovarian tumors (go), cufd-au-laitlesions (89), fibrous dysplasia (112), and in nonendocrine tissue (112; W. F. Schwindinger, unpublished). These findings suggest that the molecular basis of MAS is a heterozygous somatic mutation in GNAS1 that occurs early in development and that results in mosaicism. The mosaic distribution of cells bearing the mutant GNASl allele readily explains the observed clinical variability and noninheritance of MAS.
G. Altered Expression of G Proteins Expression and/or function of G proteins is altered by many drugs, hormones, and metabolic states. We have shown that levels of Gp(2) and Gp(3) proteins and mRNA are greater in cardiac ventricles from hypothyroid animals than from euthyroid animals (69). Immunoreactive p1 and pz polypeptides were also increased in the hypothyroid state and corresponded with comparable increases in the relative levels of p1 and p2mRNAs. There were no differences seen between the amounts of Gia(2), Gia(3), p1and pz in the euthyroid state and the hyperthyroid state. In addition, steady-state levels of G p protein and mRNA were not altered by thyroid hormone status. Interestingly, these perturbations in G-protein expression were not associated with alterations in adenylate cyclase activity.
102
C. W. EMALA ET AL.
Glucocorticoids can also regulate expression of G proteins. Dexamethasone increases expression of G,a in the rat pituitary GH, cell line (70).Administration of corticosterone for 7 days increased G,a levels in the frontal cortex of rats (113). Levels of GSa fall in adipocytes following adrenalectomy and return to normal with glucocorticoid replacement (114). Moreover, glucocorticoids increase adenylate cyclase activity in astrocytoma cells and increase adenylate cyclase activity and G,a expression in vascular smooth muscle (115, 116). Induction of insulin deficiency in rats by treatment with streptozotocin leads to tissue-specific changes in the expression of selected G proteins (24). Insulin deficiency is associated with decreased levels of mRNA and protein for Gia(2), Gia(3), and G,a in hepatocytes whereas levels of Gp(3) are increased in the adipocyte. In these experimental models of diabetes mellitus, reduced expression of G, results in decreased inhibition of adenylate cyclase and increased cAMP production. In addition to hormones, many drugs influence G-protein expression. For example, chronic lithium treatment decreases levels of mRNA and protein for Gp(1) and Gia(2)without affecting levels of other G-protein subunits, including G,a, G,a, and p subunits (117).Both cocaine and morphine alter expression of G proteins in specific regions of the brain. We have focused on the effects of ethanol on expression of G proteins in the pituitary, central nervous system, and peripheral blood lymphocytes. The effects of ethanol on a cell are not the result of nonspecific perturbations in membrane lipid structure, but require interaction of ethanol with specific lipid-protein domains or with hydrophobic regions of particular proteins. A primary action of ethanol is to promote the interaction of G,a and adenylate cyclase. The result may be increased or decreased adenylate cyclase activity, depending on whether the ethanol exposure is acute or chronic. Acute ethanol exposure augments adenylate cyclase activity in many systems (118-122). By contrast, chronic ethanol exposure generally reduces adenylate cyclase activity in both striatal tissue and cerebral cortex of mice and rats (118131). Because the primary site of action of ethanol appears to be G,, such an adaptation could be similar to changes that occur during heterologous desensitization (75). This appears to be the case, and is further supported by observations in cultured cells (74).For example, in neuroblastoma N1E-115 cells, ethanol acutely augments cAMP production in response to prostaglandin E, (PGE,) (74). However, when cells are incubated in ethanol for 7 days, the response to PGE and adenosine analogs was significantly decreased. A similar change was observed in NG108-15 cells (75). Ethanol acutely enhanced cAMP stimulation in response to adenosine analogs. However, after
SIGNAL-TRANSDUCING G PROTEINS
103
chronic ethanol exposure, a decreased response to the adenosine was observed. What could account for the ability of ethanol to effect a process that resembles heterologous desensitization (i.e., the response to agonists that interact with PGE and adenosine receptors is reduced after chronic ethanol exposure)? In NG 108-15 cells, ethanol-induced reduction in adenylate cyclase activity is coincident with diminished synthesis of G p ; levels of both G p protein and mRNA are reduced (75). In addition to an ethanol-induced reduction in G p , the activity of G p extracted from ethanol-exposed cells is lower than that fiom control cells, as estimated from reconstitution assays in S49 cyc-cells (75). However, the effect of ethanol on adenylate cyclase activity may vary in other cell types. For example, exposure of N1E-115 cells to ethanol for 48 hours leads to a large increase in Gia that is associated with decreased CAMP response to PGE and N6-2-phenylisopropyladenosine(PIA), but not to cholera toxin (74, 132). However, if N1E-115 cells are incubated for longer periods with ethanol, a 60%decrease in G p is also observed. In the third cell line, N18TG2, ethanol exposure had no significant effect on agonist-stimulated CAMP production or on the quantity of either G protein. These studies emphasize that different cell types can respond differently to chronic ethanol treatment. We have investigated the effects of chronic ethanol exposure on G-protein expression in the anterior pituitary in the Long-Sleep (LS) and ShortSleep (SS) lines of mice. Using a biological indicator that is dependent on the activation of adenylate cyclase, proopiomelanocortin (POMC) biosynthesis, we found that acute ethanol stimulates POMC production in both lines of mice (LS and SS) (133). However, whereas chronic ethanol exposure can sustain POMC production in the SS mice, hormonal tolerance develops in LS mice. In this setting, the loss of ethanol's ability to elevate POMC mRNA levels in the LS line is defined as hormonal tolerance. Development of tolerance was coincident with reduced ability of GTP-yS to stimulate adenylate cyclase activity and reduced levels of Gsa protein. In the anterior pituitary, regulation of POMC gene transcription and biosynthesis of POMCderived peptides are under the regulation of the hormone-sensitive adenylate cyclase signal-transduction system. We therefore asked whether the decrease in POMC production (e.g., tolerance) in LS mice is associated with a reduction in anterior pituitary adenylate cyclase activity. In fact, coincident with deGelopment of tolerance in the LS line, there was a reduction in anterior pituitary adenylate cyclase activity. In principle, the ethanol-induced decrease in pituitary adenylate cyclase activity observed in LS mice could have been caused by (1)decreased expression or activity of the stimulatory protein, G p , or adenylate cyclase, or (2) increased expression or activity of the inhibitory protein, Gia.
C. W. EMALA ET AL.
104
Therefore, we examined expression of G proteins in the anterior pituitary before and after the development of tolerance. Decreased adenylate cyclase activity was accoiiipanied by a decrease in the level of the stimulatory G protein G,a, whereas levels of the inhibitory G protein G p , were unchanged (71). In the SS line, which did not develop hormonal tolerance, ethanol did not induce a significant change in adenylate cyclase activity or in the expression of either G protein. It is our hypothesis that ethanol (directly or indirectly) regulates expression of G,a in the LS but not SS mice, and therefore regulates activity of adenylate cyclase. According to this model, chronic ethanol exposure will produce hormonal tolerance in the POMC system. Differential regulation of G proteins could be a critical molecular event in the pathogenesis of tolerance. These observations underscore that the threshold for tolerance may be in part genetically determined. We next examined whether the ethanol-induced decrease in expression of G,a was restricted to the anterior pituitary or represented a phenomenon that was generalized throughout the central nervous system. Therefore, we examined the effects of ethanol on cerebellum and pons, in both I S and SS mice (72). Ethanol treatment of SS mice produced a fourfold increase in levels of G , a ( l )and G,a(i?)in both cerebellum and pons compared to control mice. Moreover, ethanol produced a twofold increase in levels of 41- and 40kDa proteins, corresponding to G i a ( l )and Gia(2),which were identified by pertussis toxin-dependent ADP ribosylation. By contrast, ethanol did not alter expression of G p , whether assessed by iminunoblot analysis, cholera toxin-dependent ADP ribosylation, or by the ability of detergent-extracted G,a to reconstitute a functional adenylate cyclase in membranes from S49 cyc muiine Iyniphoma cells, a cell line that genetically lacks G p . Similarly, ethanol treatment did not alter levels of G,a or G& in either cerebellar or pons membranes. After ethanol treatment, plasma membranes prepared from cerebellum and pons had significantly reduced adenylate cyclase activity when assayed in the presence of GTP, GTPyS, NaF, forskolin, and ligands for three distinct receptors coupled to the stimulation of adenylate cyclase. Pretreatment of plasma membranes with pertussis toxin, which reduces the biological activity of G p (and G,a), reversed the ethanolinduced inhibition of adenylate cyclase activity. We speculate that enhanced expression of C i a (1) arid Gp(2) iinpairs signal transduction in the CNS, and may impair signal-transduction potency of neurotransmitters that activate adenylate cyclase. Unlike the effect of ethanol in anterior pituitary, ethanol treatment produced similar effects oil CNS G-protein expression in both the LS and SS strains of mice. Our data are consistent with two mechanisms by which ethanol exposure can reduce signal transduction through the adenylate cyclase system; either ~~
SIGNAL-TRANSDUCING G PROTEINS
105
mechanism can induce hormonal tolerance. In the pituitary, chronic ethanol exposure reduces expression and decreases adenylate cyclase activity. In the pons and cerebellum, ethanol enhances expression of G,a(l)and Gia(2)and enhances inhibition of adenylate cyclase. In these tissues, ethanol did not alter expression. Neither G s a nor Gi protein levels were affected b;- ethanol in the line that did not develop hormonal tolerance (e.g., SS). Blood ethanol levels and rates of ethanol clearance were equivalent between lines. It is apparent that genetic factors can influence the threshold for the acquisition of hormonal tolerance to ethanol. What evidence is there that expression and function of the proteincoupled adenylate cyclase system is altered in human subjects with alcoholism? Lymphocytes and platelets isolated from alcoholics show reduced accumulation of intracellular CAMP when incubated in the presence of several hormones (75, 128-130). To further elucidate the basis for this effect, we have investigated adenylate cyclase activity in peripheral lymphocytes from abstinent alcoholic men (n = 22), actively drinking alcoholic men (n = 41), and nonalcoholic (control) men ( n = 16) (73). Lymphocyte membranes from abstinent alcoholics contained threefold greater levels of Gia(2)protein than did membranes from control subjects. By contrast, levels of G , a protein were similar in both groups. Lymphocytes from abstinent alcoholics had threefold greater levels of G,a(2)mRNA ( p < 0.001) and threefold greater levels of Gsa mRNA ( p < 0.03) than lymphocytes from control subjects. Lymphocytes from actively drinking alcoholics had levels of Gsa protein, G p ( 2 ) protein, and Gia(2)mRNA that were similar to those from control subjects. However, lymphocytes from actively drinking subjects contained 1.8-fold greater levels of G,a mRNA than those from control subjects. The enhanced Gia(2)in lymphocytes from abstinent alcoholics was associated with decreased basal, PGE,, GTPyS-, and forskolin-stimulated adenylate cyclase activity compared to both controls and actively drinking alcoholics. These results indicate that lymphocyte adenylate cyclase activity is reduced during abstinence from alcohol, and increased expression of the inhibitory G protein, Gia(2),may account for this change. It is possible that such regulation of G proteins can contribute to the development of tolerance.
VIII. Summary The pivotal role that G proteins play in transmembrane signal transduction is highlighted by the rapidly expanding list of receptors and effector molecules that are coupled through G proteins. G proteins are poised to allow discrimination and diversification of cellular signals into the cytosolic
106
C . W. EMALA ET AL.
milieu. The utilization of an evolutionarily conserved "GTPase clock by G proteins, offers insight into the fundamental role these proteins play in biology. Knowledge of the implication of altered expression or function of G proteins in human disease is now emerging. It is not surprising that deficiency or expression of altered forms of these important proteins can lead to global or restricted metabolic disturbances, depending upon the distribution and role of the G protein. Human disorders, including heart failure, alcoholism, endocrine abnormalities, and neoplasia, are now recognized as due in part to altered expression or function of G proteins.
IX. Glossary ras EF-TU Tol GNRP GAP IAP S DS-PAGE
PTH TS H ACTH
GNAs1 DGGE G-C PHI3 gsP giP 2 LH FS H LHRH PGE PIA s49 cycI, s
ss
POMC
21-kDa protein products of ras oncogenes (a small GTPase ) bacterial elongation factor (a small GTPase) transducin; a G-protein a subunit of the retina guanine-nucleotide-releasingprotein GTPase-activating protein islet-activating protein sodium dodecyl sulfatepolyacrylamide gel electrophoresis parathyroid hormone thyroid-stimulating hormone adrenocorticotropic hormone the gene encoding the G-protein a subunit, Gsol denaturing gradient gel electrophoresis guanine. cytosine pseudohypoparathyroidism G, protein; a G,a protein with putative oncogene potential Gi protein-2; a Gia(2)protein with putative oncogene potential luteninizing hormone follicle-stimulating hormone luteinizing-hormone-releasing hormone prostaglandin E NG-2-phen ylisoprop yladenosine a murine lymphoma cell line lacking G,a Long-Sleep strain of mice Short-Sleep strain of mice proopiomelanocortin
SIGNAL-TRANSDUCING G PROTEINS
107
REFERENCES 1. K. Sugimoto, T. Nukada, T.Tanabe, H. Takahashi, M. Noda, N. Minamino, K. Kandawa, H. Matsuo, T. Hirose, S. Inayama and S. Numa, FEBS Lett 191, 235 (1985). 2. H. K. W. Fong, J. B. Hurley, R. S. Hopkins, R. Miake-Lye, M. S. Johnson, R. F. Doolittle and M. I. Simon, PNAS 83, 2162 (1986). 3. B. Gao, A. G. Gilman and J. D. Robishaw, PNAS 84, 6122 (1987). 4 . T.Evans, A. Fawzi, E. D. Fraser, M. L. Brown and J. K. Northup, JBC 262, 176 (1987). 5. M. A. Levine, P. M. Smallwood, P. T. Moen, Jr., L. J. Helman and T. G. Ahn, PNAS 87, 2329 (1990). 6. B. K. Fung, B. S. Lieberman and R. H. Lee, JBC 267, 24782 (1992). 7. E. von Weizsacker, M. P. Strathmann and M. I. Simon, BBRC 183, 350 (1992). 8. N. Gautam, J. Northup, H. Tamir and M. I. Simon, PNAS 87, 7973 (1990). 9. J. D. Robishaw, V. K. Kalman, C. R. Moomaw and C. A. Slaughter,JBC 264,15758 (1989). 10. J. J. Cali, E. A. Balcueva, I. Rybalkin and J. D. Robishaw, JBC 267, 24023 (1992): 11. K. J. Fisher and N. N. Aronson, MCBioZ 12, 1585 (1992). 12. M. I. Simon, M. P. Strathmann and N. Gautam, Science 252, 802 (1991). 13. L. Birnbaumer, Annu. Reu. Pharmncol. Toxicol. 30, 675 (1990). 14. C. L. Lerea, D. E . Somers, J. B. Hurley, I. B. Klock and A. H. Bunt Milam, Science 234, 77 (1986). 15. C. L. Lerea, A. H. Bunt Milam and J. B. Hurley, Neuron 3, 367 (1989). 16. D. T. Jones and R. R. Reed, Science 244, 790 (1989). 17. S. K. McLaughlin, P. J. McKinnon and R. F. Margolskee, Nature 357, 563 (1992). 18. L. Birnbaumer, J. Abramowitz and A. M. Brown, BBA 1031, 163 (1990). 19. H. R. Bourne, D. A. Sanders and F. McCormick, Nature 348, 125 (1990). 20. V. Y. Arshavsky and M. D. Bownds, Nature 357, 416 (1992). 21. K. Kokame, Y. Fukada, T. Yoshizawa, T. Takao and Y. Shimonishi, Nature 359,749 (1992). 22. N. J. Pyne, G. J. Murphy, G. Milligan and M. D. Houslay, FEBS Lett. 243, 77 (1989). 23. M. Bushfield, G . J. Murphy, B. E. Lavan, P. J. Parker, V. J. Hruby, G. Milligan and M. D. Houslay, BJ 268, 449 (1990). 24. M. Bushfield, S. L. Grimths, G. J. Murphy, N. J. Pyne, J. T. Knower, G. Milligan, P. J. Parker, S. Mollner and M. D. Houslay, BJ 271, 365 (1990). 25. S. B. Masters, R. M. Stroud and H. R. Bourne. Protein Eng. 1, 47 (1986). 26. E. F. Pai, U. Krengel, G. A. Petsko, R. S. Goody, W. Kabschand A. Wittinghofer, E M B O J. 9, 2351 (1990). 27. H. R. Bourne, D. A. Sanders and F. McCormick, Nature 349, 117 (1991). 28. S. R. Holbrook and S.-H. Kim, PNAS 86, 1751 (1989). 29. A. M. de Vos, L. Tong, M. V. Milburn, P. M. Matias, J. Jancarik, S. Noguchi, S. Nishimura, K. Miura, E . Ohtsuka and S. H. Kim, Science 239, 888 (1988). 30. C. H. Berlot and H. R. Bourne, Cell 68, 911 (1992). 31. J. B. Hurley, BBRC 92, 505 (1980). 32. P. Bray, A. Carter, V. Guo, C. Puckett, J. Kamholz, A. Spiegel and M. Nirenberg, PNAS 84, 5115 (1987). 33. M. Strathmann, T. M. Wilkie and M. I. Simon, PNAS 87, 6477 (1990). 34. J. J. Murtagh, R. Eddy, T. B. Shows, J. Moss and M. Vaughan, MCBiol11, 1146 (1991). 35. A. M. Brown and L. Birnbaumer, Am. J. Physiol. 254, H401 (1988). 36. D.A. Brown, Annu. Reu. Physiol. 52, 215 (1990). 37. A. Yatani, R. Mattera, J. Codina, R. Graf, K. Okabe, E. Padrell, R. Iyengar, A. M. Brown and L. Birnbaumer, Nature 336, 680 (1988).
108
C. W. EMALA ET AL.
38. A. Yatani. H. Hamin, J. Codina, hl. R. bfazzoni, L. Birnbaumer and A. M . Brown, Science 241, 828 (1988). 39. A. B. Abou Samra, H. Juppner, T. Force, hi. W. Freeman, X. F. Kong, E. Schipani, P. Vrena, J. Richards, J. V. Bonventre, J. T. Potts. Jr., H. M. Kronenberg and G. 17. Segre, PYAS 89, 27.32 (1992). 40. 0. Chabre, B. R. Conklin, H. Y. Lin. H. F. Lodish, E. Wilson and H. E. Ives. Mol. Endocrinol. 6, 551 (1992). 41. T. Force. J. 1’.Bonventre, bl. R. Flanner); A. H. Gorn, M. YaminandS. R. Goldring, Am. J. Physiol. 262, FlllO (1992). 4 2 . J. Van Sandr, E. Raspe, J. Prrret, C . Lejeune, C. Maenhaut. 6. Vassart and J. E. I h m o n t , 3101. Cell. Endocriid. 74, R1 (1990). 4.3. I). J. Roof, hi. L. Applebury and P. C. Sternweis, JBC 260, 16242 (1985). 44. S. M . Mumby. R. A. Kahn, D. R. Manning and A. G. Gilman, PNAS 83, 265 (1986). 4.5. H. K. \V. Fong. T. T. Ainatruda. 8. iV. Birren and M. I. Simon, PNAS 84, 3792 (1987). 46. J. Codina, 11. Stengrl, S. L. Woo arid L. Birnbaumer, FEBS I ~ t 207, t 187 (1986). 47. T. T. t\matruda. N. Gautam. H. I;. Fong. J. K. Northup and M. I. Simon, JBC 263, Sjo8 (1988). 48. Y. l V . Peng. J. I>. Kohishaw. M. A. Levine and K. \V. Yau. PNAS 89, 10882 (1992). 19. R. H . Lee, €3. S. Lieberman, H. K. Yarnane, D. Bok and B. K. Fung, JBC 267, 24776 (1992). 50. B. K. Fung. H . K . Yainane. I. hi. Ota and S. Clarke, FEBS Lett. 260, 313 (1990). .5l. P. S. Backlund, W. F. Simonds and A. M. Spiegel, JBC 265, 15572 (1990). .52. Y Fukada. T. Takao, H. Ohguro, T. Yoshi7;lwa. T. Akino and 1’. Shimonishi, Nature 346, 658 (1990). 5.3. R. K. Lai, D. Perez-Sala, F. J. Canada and R. R. Rando, PNAS 87, 7673 (1990). 54. C. J, Schmidt and E. J. Neer, JBC 266, 4538 (1991). ,55. C . 1. Schmidt. T. C. Thomas, M. A. Levine and E. J. Neer, JBC 267, 13807 (1992). 56. \2: J. Tang and A. G . Gilman, Science 254. 1500 (1991). 5 ; . K. I). Hinsch, I. Tychowiecka, H. Gausepohl. R. Frank, W.Rosenthal and G. Schultz, R B A 1013, 60 (1989). 58. A . hl. Spiegrl. P. S. Backlund. J r . , 1. E. Butr).nski, T. L. Jones and W. F. Simonds, TIBS 16, 338 (1991). 59. hl. Whitrwa!; L. ffougan. D. Digmard, D. Y. Thomas, L. Bell, C. S a r i . F. J. Grant, P. Ohara and V, L. hlxkay. Cell 56, 467 (1989). 6%). Y. Kaziro, II. Itoh, T. Ko;ozllsa, M . Nakafuku and T. Satoh, ARB 60, 349 (1991). 61. I;. J. Blumer and J. Thorner, Annu. Rec. Physiol. 53, 37 (1991). 62. 1). E. Logothetis. Y. Kurachi, J. Galper, E. J. Neer and D. E. Clapham, Nature 325, 321 1.1987). 63. J. .4xelrod, H. hi. Burch and C. L. Jelsema. Trends iVeuroSci. 11, 117 (1988). 6 J D. Kim, D 1. Lewis. L. Graziadei, E. J. Neer, D. Bar-Sagi and D. E. Clapham, Nutctrcz 337, 557 (1989). Schratler. K. R. Reed and H. R. Bourne, Nature 6.5. A. D. Federnian, B. R. Conklin. K 356, 159 (1992). 66. T. Katada. I(. Kusakabe, hf. Oinunia ;ind X1. Ui, JBC 262, 11897 (1987). 67. J. A . Pitcher, J. Inglese. J. B. HigRins, J. L. Arrim, J. P. Casey, C. Kim, J. L. Benovic, M . Irl Kwatra, 51. G. Caron and R. J. Letkoitz, Science 257, 1264 (1992). 68. kf. Chnps, <:. Hou, D. Sidiropoilos, J. B. Stock, K. H. Jakolis and P. Gierschik. EJB 206, 821 (1992). \\I.
SIGNAL-TRANSDUCING G PROTEINS
109
69. M. A. Levine, A. M. Feldman, J. D. Robishaw, P. W. Ladenson, T. G. Ahn, J. F. Moroney and P. M. Smallwood, JBC 265, 3553 (1990). 70. F. Chang and H. R. Bourne, Endocrinology 121, 1711 (1987). 71. G. S. Wand and M. A. Levine, Alcohol Clin. Exp. Res. 15, 705 (1991). 72. G. S. Wand, A. M. Diehl, M. A. Levine, D. Wolfgang and S. Samy, JBC 268,2595 (1993). 73. C. Wdtman, M. A. Levine, B. McCaul, D. Svikis and G. S. Wand, Alcohol Clin. Exp. Res. 17, 315 (1993). 74. M. E. Charness, L. A. Querimit and M. Henteleff, BBRC 155, 138 (1988). 75. D. Mochly-Rosen, F. Chang, L. Cheever, M. Kim, I. Diamond and A. S . Gordon, Nature 333, 848 (1988). 76. H. K. Hammond, L. A. Ransnas, F. C. White, C. M. Bloor and P. A. Insel, Circulation 78(Suppl. 11) (1988). 77. J. P. Longabaugh, D. E . Vatner, S. F. Vatner and C. J. Homcy,]. Clin. Invest. 81, 420 (1988). 78. A. M. Feldman, R. G. Tena, P. D. Kessler, H. F. Weisman, S. P. Schulman, R. S . Blumenthal, D. G. Jackson and C. Van Dop, Circulation 81, 1341 (1990). 79. Y. K. Katoh, I. Komuro, F. Takaku, H. Yarnaguchi and Y. Yazaki, Circ. Res. 67,235 (1990). 80. A. M. Spiegel, A. Shenker and L. S. Weinstein, Endocr. Reu. 13, 536 (1992). 81. G. Milligan and M. Wakelam (eds.), “G Proteins: Signal Transduction and Disease.” Academic Press, San Diego, 1992. 82. A. G. Gilman, Cell 36, 577 (1984). 83. M. A. Levine, W. S . Modi and S . J. O’Brien, Genomics 11, 478 (1991). 84. T. Kozasa, H. Itoh, T. Tsukamoto and Y. Kaziro, PNAS 85, 2081 (1988). 85. Y. Ishikawa, C. Bianchi, B. Nadal-Ginard and C. J. Homcy, JBC 265, 8458 (1990). 86. J. L. Patten, D. R. Johns, D. Valle, C. Eil, P. A. Gruppuso, G. Steele, P. M. Smallwood and M. A. Levine, N . Engl. J. Med. 322, 1412 (1990). 87. L. Vallar, A. Spada and G. Giannattasio, Nature 330, 566 (1987). 88. C. A. Landis, S. B. Masters, A. Spada, A. M. Pace, H. R. Bourne and L. Vallar, Nature 340, 692 (1989). 89. W. F. Schwindinger, C. A. Francomano and M. A. Levine, PNAS 89, 5152 (1992). 90. L. S. Weinstein, A. Shenker, P. V. Gejman, M. J. Merino, E. Friedman and A. M Spiegel, N . Engl. J. Med. 325, 1688 (1991). 91. L. S. Lerman and K. Silverstein, in “Methods in Enzymology” (R. Wu, ed.), Vol. 155, p. 482. Academic Press, Orlando, Florida, 1987. 92. F. Albright, C. H. Burnett and P. H. Smith, Endocrinology 30, 922 (1942). 93. F. Albright, A. P. Forbes and P. H. Henneman, Trans. Assoc. Am. Physicians 65, 337 (1952). 94. L. R. Chase and 6. D. Aurbach, Science 159, 545 (1968). 95. L. R. Chase, G. L. Melson and G. D. Aurbach, J. Clin. Inuest. 48, 1832 (1969). 96. M. A. Levine, T.G. Ahn, S. F. Klupt, K. D. Kaufman, P. M. Smallwood, H. R. Bourne, K. A. Sullivan and C. Van Dop, PNAS 85, 617 (1988). 97. J. L. Patten and M. A. Levine, J . Chn. Endocrinol. Metab. 71, 1208 (1990). 98. C. Van Dop, H. R. Bourne and R. M. Neer, f. Clin. Endocrinol. Metab. 59, 8% (1984). 99. L. S. Weinstein, P. V. Gejrnan, E. Friedman, T. Kadowaki, R. M. Collins, E. S. Gershon and A. M. Spiegel, PNAS 87, 8287 (1990). 100. A. Miric, J. D. Vechio and M. A. Levine, 1. Clin. Endocrinol. Metab. 76, 1560 (1993). 101. C. Blatt, P. Eversole-Cire, V. H. Cohn, S. Zollman, R. E. K. Fournier, L. T. Mohandas, M. Nesbitt, T. Lugo, D. T. Jones, R. R. Reed, L. P. Weiner, R. S. Sparkes and M. I. Simon, PNAS 85, 7642 (1988).
110
C. W. EMALA ET AL.
102. St. A. Le\.int., H. tV. Downs, Jr.. A. hl. Moses. N. A. Breslau, S. J. Marx, R. D. Lasker, R. E. Rizzoli, 6. D. Aurbarh and A. M . Spiegel. Am. J. Med. 74, 545 (1983). 103. E. Mallet, P. Carayon, S. Amr, P. Brunelle, T. Ducastelle, J. P. Basuyau and C. Hellouin cte hienibus, I . Clin Endocrinol. Metub. 54, 1028 (1982). 1M. J. Lyons. C . A. Landis, H. GrifEth, L. Vallar, K. Grunewald, €1. Feichtinger , Q.Y. Yuh, 0. H . Clark, E. Kawasaki, H. H. Bourne and F. McCormick, Science 249, 655 (1990). 10.5. H . C. Suarez, J. '4. du Villard, B. Caillou, $1. Schlumberger, C. Parmentier and R. hlonier. Oncogene 6, 677 (1991). 106'. R . Happle. Clin. Cunet. 29, 321 (1986) 107. P. P. Feuillan, T. Shawker, S. R. Rose, J. Jones, R. K. Jervanram and B. C. Nisu1a.J. Clin. Endocrinol. Mrtab. 71, 1596 (lW). 10h. R. Happle, J . Am. Acad. Dannutol. 16, 899 (1987). 109. C . hi. Foster, J. L. Ross, T. Shawker. 0. H. Pescovitz, D. L. Loriaux, G. B. Cutler and F. Cornite. J. C l i n . Endocrinol. Metrib. 58, 1161 (1984). 110. N. hlauras and R. hl. Bliuard, Acta Endocrinol. Suppl. 256, 207 (1986). I l l . I.. Cuttler. J. A. Jackson, M . S. Uz-Zafar, L. Levitsky, R. C . Mellinger and L. A.Frohnian, 1. Clin.Endocrinol. Afetab. 68, 1148 (1989). 112. A . Shenker. D. E. Sweet, A. hf. Spiegel and L. S . Weinstein,]. Bone Miner. Res. 7, S115 (alistr.) (1992). 113. N. Saito, X. Guitart, h l . Hayward, J. Tallman, R. Duinon and E. Nestler, PNAS 86, 3906 (1989,. 114. hi. Ros, J. E. Northup and C. C . Mallmi, B] 257, 737 (1989). 115. A. Balmforth, K. Yasunari. P. Vaughen and S. Ball, J. Yetirochem. 52, 1613 (1989). 116. E. Yasunari, hi. Kohno, A. Balmforth. K. Mrirakawa, K. Yokokawa, N. Jurihara and T. Takeda, flypertension 13, 575 (1989). 117. S F. Colin, H. Chang, S. Mollner, T. Pfeuffer, R. R. Reed, R. S. Duinan and E. J. Nestler, PK.4S 88, 10634 (1991). ZIX. S. Stenstroni and E. Richelson, J . Phannueol. Exp. Ther. 221, 334 (1992). 119. T. Saito. J. hf. Lee and B. Tabakoff. I . Xeurocheni. 44, 1037 (1985). 120. C. S. Rabe, P. R. Giri, P. L. Hoffman and B. Tabakoff. Biochem. Pharnmol. 40, 565 ( 1990). 121. R. A . Rabin and P. B. Xlolinoff, J . Phaniiucol. Exp. Ther. 227, 551 (1983). 122. C . T. Chung, L. Tamarkin. P. L. Hoffnian and B. Tabakoff, J. Phannucol. E x p Ther. 249, 16 (19891. 123. 11. C . Bode and P. €3. hiolinoff, J. Phonnucol. Exp. Ther. 246, 1040 (1988). 124. L. E. Nagy. I. Diamond, K. Collier, L. Lopez, B. Ullnian and A. S. Gordon. Mol. Phonnucol. 36, 744 11989). 12.5. T. Saito. J. hl. Lee. P. L. Hoffman and B. Tabakoff, J. Seurochein. 48, 1817 (1987). 126. R. A. Rahin, 1. Phartimol. E x p . Ther. 252, 1021 (1990). 127. S. Hynie, F. Linefelt and B. B. Fredholni, Acta Pharmucol. Toxicol. 47, 58 (1980). 128. L. E. Nan. I. Diamond and .4. Gordon, PNAS 85, 6973 (1988). 129. I . Diarnond, B. N'rubel. \V. Estrin and A. Gordon, PNAS 84, 1413 (1987). 1.30. 8. Tattakoff, P. L. Hoffman, J. hl. Lee. T. Saito, B. Willard and F. DeLeon-Jones, N. Engl. 1. Med. 318, 134 (1988). 1.32. A . S. Gordon, E. Collier and I. Diamond, PXAS 83, 2105 (1986). 132. M. E . Charness, L. A. Querimit and I. Diamond, J B C 261, 3164 (1986). 133. C;. S. \Vand, Endocrinology 124, 518 (1989). 1 3 4 . I, S . Weinstein, P. V. Gejnran, P. de hfazancourt. N. American and A. M. Spiegel, Genoinics 13, 1.319 (1992).
SIGNAL-TRANSDUCINGG PROTEINS
111
135. W. F. Schwindinger, A. Miric and M. A. Levine, Program Abstr. 74th Annual Meet. Endocr. SOC.abstr. 35 (1992). 136. A. Miric and M. A. Levine, in “G Proteins: Signal Transduction and Disease” (G. Milligan and M. Wakelam, eds.), p. 29. Academic Press, San Diego, 1992. 137. M. K. Drezner, F. A. Neelon and H . E. Lebovitz, N . Engl. J . Med. 280, 1056 (1973).
This Page Intentionally Left Blank
The tis Genes, Primary Response Genes Induced by Growth Factors and Tumor Promoters in 3T3 Cells HARVEYR. HERSCHMAN,~ DEANA. KUJUBU,~ BRADLEYS. FLETCHER, QIUFU MA, BRIANc. vARNUM,3 REBECCAS . GILBERTAND SRINIVASA T. REDDY Department of Biological Chemistry and Laboratory of Structural Biology and Molecular Medicine UCLA School of Medicine Los Angeles, Calgornia 90024
I. Phorbol-induced Primary Response Genes Can Be Cloned from Swiss 3T3 Cells ................................. ............ 11. The tis21 Gene Encodes a Protein with Similarity to a Presumptive Anti-oncogene ............................. ............ 111. The tisll Gene Is a Member of a Multigene Family . . . . . . . . . . . . . . . IV. The tislO Gene Encodes a Functional Prostaglandin Synthase/Cyclooxygenase . . . . V. Both Prostaglandin Synthesis a .................. Induced in Swiss 3T3 Cells VI. The Structures of the tisl0lpgs-2 and pgs-l Genes Are Similar VII. tisl0lpgs-2 Satisfies the Criteria for the “Second Pool” of Prostaglandin Synthase ............................ VIII. tisl0lpgs-2 Is Induced in Macrophages .......................... IX. Can the Proteins Encoded by the tislO/pgs-2 and pgs-l Genes Form Functional Heterodimers? What Would Be the Consequences of This Interaction for Pharmacologic Intervention? X. Similarities in the Expression and Regulation Prostaglandin Synthase and Nitric-Oxide Synthase . . . . XI. Conclusions and Future Directions .............................. References ........... ..................
115
119 121 I24 126 137 139 139
142 142 143 144
To whom correspondence should be addressed. Present address: Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104. 3 Present address: Department of Pharmacology, AMGEN Center, Thousand Oaks, CA 91320. 1
2
Progress in Nuclei? Acid Research and Molccular Biology, Vol. 47
113
Copynght 0 1994 by Academic Press, Inc. A11 rights of reproduction in any form reserved.
114
HARVEY R. HERSCHMAN ET AL.
A wide variety of cellular responses to extracellular ligands share a common generic pathway.. (1) A hydrophilic ligand (a growth factor, hormone, neurotransmitter, morphogen, or antigen) binds to a transmembrane receptor present on the responding cell. (2) An intracellular signal is generated by the bound receptor, as a consequence of this ligand-receptor interaction. (3) Signal-transduction mechanisms within the cytoplasm activate intracellular protein kinases. (4) Latent transcription factors are activated by phosphorylation and/or dephosphorylation, initiating the transcription of previously quiescent genes. (5) The new transcripts are translated into proteins whose functions alter the biological properties of the cell. If the hydrophylic ligand is a growth factor, the elicited response is a commitment to leave the resting (Go)state and reenter the cell cycle. If the ligand is a hormone, the endocrine function of the cell may change. Should the ligand be a neurotransmitter, a memory trace may be laid down. For morphogens, cells alter their developmental fates as a result of induced gene expression. Antigen stimulation provokes clonal cell expansion and immunoglobulin synthesis. Stimulation of cell division in response to growth factors is. therefore, a special case of a generalized biological mechanism by which extracellular ligands elicit cellular responses as a consequence of ligand-induced gene expression. Numerous questions come to mind: How do ligands, binding to cellsurface receptors, generate intracellular signals? What are the signal transduction pathways within cells that activate latent transcription factors? What transcription factors are activated? What populations of genes are transcribed by the transcription factors activated in response to specific ligands? Are overlapping populations of quiescent genes transcriptionally activated in distinct biological responses elicited by different ligands, such as growth factors and neurotransmitters? What are the roles of the newly induced gene products in modulating subsequent changes in cellular phenotypes? Do distinct mitogens activate transcription of similar constellations of genes? To address these problems in the context of the mitogenic response, we isolated cDNAs for a group of genes induced in Swiss 3T3 cells by the mitogen and tumor promoter tetradecanoyl phorbol acetate (TPA, or, simply, phorbol).d We reasoned that we could study the nature of signal transduction leading to gene expression by working backward from the regulatory regions of these genes, identifying cis-acting sequences necessary for their induc-
’ .Abbreviations:TPA, tetradecdnoyl phorbol acetate (phorbol);tis,TPA-induced sequence: PGS, prostaglandin synthase; EGF, epidermal growth factor; FGF, fibroblast growth factor; P I X F . platelet-derived growth factor; CM-CSF, granolocyte-macrophage colony-stimulating factor: NGF. n e n e growth factor; PLA,, phospholipase A,; DEX, dexamethasone; COX, cycloox)-gendse; LPS. lipopolysaccharide; IFN, interferon: NO, nitric oxide; NOS, nitric-oxide synthase.
THE
tk
115
GENES
tion, transcription factors required for their induced expression, and receptor-mediated signaling mechanisms necessary to activate these transcription factors. Conversely, we could study questions of (1) convergence of alternative stimuli induced by different ligands, and (2) specificity of gene expression in response to different ligands by considering the combinatorial expression of these genes in response to distinct inducers. Finally, we could investigate the roles of the products of these ligand-induced genes in alternative biological responses by sequencing their cDNAs and characterizing their encoded proteins. We emphasize our own studies in this review, and do not attempt to be comprehensive in our citations of the literature. There are several review articles (I, 2) that contain more extensive commentary on primary response genes identified in other contexts.
1. Phorbol-induced Primary Response Genes Can Be Cloned from Swiss 3T3 Cells Primary response genes are genes whose transcription can be induced, in response to extracellular stimulation, by activation of preexisting transcription factors. No new proteins need to be synthesized for induced transcription of primary response genes; the components of the transcriptional machinery, present in the cells in an inactive state in unstimulated cells, are activated as a result of ligand- and receptor-stimulated signal-transduction pathways (3).We chose phorbol as the mitogen for these studies because it is a potent mitogen for 3T3 cells (4), it is also a tumor promoter, and its immediate mechanism of cellular activation (stimulation of protein kinase C) is known. We chose Swiss 3T3 cells for study because of their long history as a major paradigm for studies of growth factor-induced mitogenesis ( I ) . Moreover, we had previously isolated phorbol-nonproliferative mutants of 3T3 cells (4) and thought that phorbol-induced expression of some of these primary response genes might be altered in these mutants. To isolate phorbol-induced primary response genes, Swiss 3T3 cells were exposed to phorbol in the presence of cycloheximide for 3 hours. A lambda phage cDNA library was prepared from poly(A)+-selected RNA isolated from these cells. Duplicate filter lifts of plaques from this library were screened with [32P]cDNA prepared from poly(A)+ RNA isolated from cells treated with phorbol cycloheximide, and with [32P]cDNAfrom cells treated with cycloheximide alone. Phage clones that reacted with the former but not the latter probe were further characterized on secondary screenings. Northern analyses with these phage inserts were used to verify phorbol induction and to identify redundant clones in the population. Using these criteria, we identified overlapping partial cDNAs for seven distinct primary
+
116
HARVEY R. H E R S C H M A N ET A L .
response genes whose message levels are induced by phorbol treatment of Swiss 3T3 cells (5). We refer to these genes as “TPA-induced sequences,” or tis genes. Expression patterns of the seven primary response t i s genes (tisl, tis7, tis8, tisl0, t i s l l , tis21, and tis28) share several common features. (1) The basal levels of message for all of these genes are low, often undetectable by northern analysis of total RNA. (2) Induction is rapid; maximal levels of mKNA accumulation peak between 0.5 and 3 hours after phorbol addition. (3)The induction is transient; message levels return to baseline values, even in the continued presence of phorbol (5).
A. The tis Genes Are Induced by Several Mitogens in 3T3 Cells We could address some of the questions posed above without determining the sequences encoded by the tis genes. Although the tis-gene cDNAs were cloned in response to phorbol treatment, their expression could also be induced by polypeptide growth factors-such as epidermal growth factor (ECF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF)-as well as by mitogenic stimulation in response to elevated serum concentration (5). Indeed, cDNAs for several of these same genes were cloned by others investigating serum-induced gene expression in 3T3 cells (6-8). We have previously reviewed the relationship between seruminduced and phorbol-induced primary response genes (1). The data suggest that these structurally diverse mitogens stimulate intracellular signaltransduction pathways that converge on common activation mechanisms for the t i s genes. Alternatively, the regulatory regions of the tis genes may all be rich in modular elements, acting in cis, that regulate transcription in response to dternative transcription factors activated by distinct signaltransduction pathways.
B. tis Genes Are Induced by a Variety of Ligands, in Many Distinct Cell Types We could also address, without any sequence information about the tis gene products, the issues of specificity and selectivity of primary response gene expression following ligand-induced alterations in distinct cell populations. Many of the tis genes, isolated as phorbol-induced cDNAs following mitogenic stimulation of Swiss 3T3 cells, are also induced in response to celltype-specific stimuli such as nerve growth factor (NGF), to stimulated diflerentiation of PC12 pheochromocytoma cells (S), and to granulocytemacrophage colony-stimulation factor (GM-CSF) treatment of myeloid cells (10). Indeed, cDNAs for several of the tis genes have also been cloned as NCF-induced cDNAs from PC12 cells (11-13) and cytokine-induced cDNAs
THE
tiS
GENES
117
from lymphoid cells (14). Many of the tis genes could also be induced in cultured astrocytes, in response to growth factors, neurotransmitters, and agents that elicit morphological differentiation (15-1 7; reviewed in 18, 19). It is apparent from these data that a widely divergent group of stimuli, acting on a broad spectrum of cells to elicit a great many distinct cellular responses, can induce the expression of a number of common primary response genes. These conclusions are underscored by the extraordinary number of stimulatory inputs that can induce the expression of several of the primary response genes in cells of the nervous system (reviewed in 19).
C. Distinct Subsets of tis Genes Are Inducible in Alternative Cell-Type Responses If the same genes can be induced in a variety of cell types, in response to a wide range of ligands, questions arise as to how specificity in ligandinduced biological responses occurs. How can different cells mount distinct biological responses, if the same set of primary response genes is expressed? How can two different agents elicit distinct biological responses in the same cell, if the same primary response genes are induced by these agents? Although many tis genes can be induced in a multiplicity of systems, cell-typespecific expression is also observed. For example, the PC12 pheochromocytoma cell cannot express the tis1O gene, in response to any signal; the tis10 gene is “restricted with regard to this cell line (9). On the other hand, the tisl gene cannot be induced by any agent in the murine 32D myeloid cell line or in normal neutrophils (10). Similarly, the tis8 gene cannot be expressed in IC21 macrophage cells (20).Differential patterns of cell-type restriction for primary response gene expression no doubt contribute to cellular specificity of biological responses (21). We have also demonstrated that, in the same cell, distinct ligands induce different ratios of the tis gene products. For example, depolarization and NGF induce differing relative expression of the tis8 and tisl genes in PC12 cells (22, 23). Posttranslational modifications of the FOS protein are also different in PC12 cells followingfos induction by depolarization versus NGF activation (24-26). The combination of (1)qualitative cell-type-specific restriction of primary response genes, resulting from developmental programs, (2) quantitatively distinct patterns of induction of the primary response genes by alternative ligands, and (3) cell- and ligand-specific posttranslational modifications is likely to provide a large part of the diversity needed to account for the ability of cells to mount a wide range of biological responses mediated by the primary response genes. Additional diversity in cellular responses to ligand stimulation is provided by the developmental history of the responding cell, modulating the allowable repertoire of secondary response genes express-
118
HARVEY R. HERSCHMAN ET AL.
able in response to newly induced primary response gene-encoded transcription factors.
D. tis Genes Are Expected to Encode Proteins with Different Types of Functions What sorts of functions might be carried out by the products of the first genes to be transcribed in a mitogenic response? We might expect that transcription factors, necessary to activate “secondary response genes” in a gene expression cascade leading to initiation of DNA synthesis, might be one class of primary response gene activated by mitogen-induced signal transduction. In fact, as previously known, before most of the searches for mitogeninduced primary response genes began, serum and other mitogens can induce transcriptional activation of the c-fos gene (27-30). The AP-1 transcription factors are composed of heterodimer products of the members of thefos and jun gene families (31, 32). Both c j b s and c-jun are primary response genes; their transcripts are rapidly and transiently elevated in response to a wide variety of ligands in a number of cell types (reviewed in 1). When cells within the tissues of an intact organism are stimulated to divide, they also activate signaling mechanisms that allow communication with neighboring cells, informing surrounding cells that the responding cell is undergoing a cellular response, with potential consequences for its neighbors. It is likely that mitogen-stimulated cells may, therefore, produce cytokine-like molecules that are secreted and interact in a paracrine fashion with neighboring cells. Some of this speculation is hindsight; two of the first primary response genes identified by differential screening, kc and j e (27), encode molecules that appear to be cytokine-signaling molecules (33-35). We also expect to identify primary response gene products whose cellular functions we cannot recognize from the sequence of the transcripts and/or proteins. Our ability to clone classes of genes based on physiological differences, such as quiescence versus mitogenic activation, exceeds our current understanding of the physiological processes, and the gene products mediating them, that are required for ligand-induced cellular phenotypic changes. In this regard, the situation is not unlike that encountered by workers cloning retroviral oncogenes and their cellular homologues: even today the exact roles of the products of the c-src, c-myc, c-mJ and c-ras genes remain obscure.
E. Some tis Genes Encode Ligand-Inducible Transcription Factors Hybridization studies demonstrated that the tis28 cDNA is a partial cDNA clone derived from the c-fos message (5). The FOS protein is one partner in the heterodinieric AP-1 transcription factor (31, 32). Sequencing
THE
tis
GENES
119
studies of the egr-llz~-268/tis8 cDNA, isolated as a serum-inducible (7, 3638) or phorbol-inducible (39) primary response gene, suggested that the protein product of this gene might be a transcription factor. The specific cisacting DNA consensus binding element for this transcription factor, GCG(G/T)GGGGCG, has been identified (40-42). Subsequent studies (reviewed in 1 ) have demonstrated that this gene is, indeed, a transcription factor whose levels in cells are regulated by ligand induction of message transcription. The rat cognate of this gene, NGFI-A, induced by nerve growth factor and other ligands in PC12 cells (9),has also been cloned as an NGF-inducible primary response gene (11). Sequencing studies of the NlOlnur77ltisl cDNA, also isolated as a serum-inducible (43, 44) or, phorbol-inducible (45)primary response gene, suggested that this gene is a member of the steroid hormone receptorltranscription factor supergene family (45). The rat cognate of this gene, NGFI-B, was also identified in PC12 cells following induction by NGF (9,46) and other ligands (9). Subsequent studies demonstrate that this protein is, indeed, a DNA-binding protein likely to serve as a transcription factor (47, 48). Whether a ligand analogous to the steroid hormone is required for transcriptional activation of NlOlnur77/tisl INGFI-B has not yet been resolved. A number of laboratories have characterized (1) the DNA sequences acting in cis that are required for c-fosltis28, c-jun, egr-lltis8, and NlOlnur77/tisl induction, (2) the transcription factors necessary to induce their expression in response to ligands, and (3) the protein kinase reactions leading to transcription factor activation and gene expression. The primary response genes encoding these transcription factors and the activities of their encoded proteins are being investigated in many laboratories. These primary response genes and their transcription factor products are the subject of many recent research papers and review articles. We do not discuss these genes or their products any further in this review.
II. The iis27 Gene Encodes a Protein with Similarity fo a Presumptive Anti-oncogene The phorbol-ester induced expression of tis21 mRNA is very rapid, peaking within the first hour. Moreover, the tis21 gene is responsive to polypeptide growth factors, such as E G F and PDGF, and to forskolin, as well as to phorbol (Fig. 1).Thus this gene can be induced by agents that activate tyrosine-kinase-signaling pathways, protein-kinase-A-mediated pathways, and protein-kinase-C-mediated pathways. Promoter-construct experiments suggest that the first 460 nucleotides 5' of the transcription start site of the
120
HARVEY R. HERSCHMAN ET AL.
Flc;. 1. The tis21 gene is rapidly and transiently induced by a variety of ligands. Total RNA was prepared froin density-arrested Swiss 3T3 cells treated with epidermal growth factor (EGF; 10 nglml), forskolin (FOR: 40 nglrnl), phorbol (TPA; 50 ng/ml), or 20%fetal bovine serum (SER) for 1. 2. 4,and 8 hours. RNA was subjected to electrophoresis and transferred to nitrocellulose; 10 ~g of total RN.4 was loaded in each lane. The blot was hybridized with cDNA probes for tis21 and chol?. choh is a cDNA for a constitutive message, used to normalize for differences in loading of RNA. These data are reproduced from 49.
tis21 gene have the cis-acting elements necessary for induction by all ofthese agents (49). Thc tis21 gene can be expressed in a wide range of cells in response to phorbol ester stimulation (5, 49). The rat hoinologue of tis21 has been cloned as an NGF-inducible gene, pc3, from PC12 cells (SO). A putative signal sequence in the pc3-encoded protein has led to the suggestion that this inolecule may be secreted from cells. Antibody prepared to recombinant tis21 protein can identify a 17-kDa protein that is rapidly synthesized in response to mitogen stimulation in Swiss 3T3 cells (49). Pulse-chase experiments suggest that this protein has an extremely short half-life, 15 minutes or less ( 5 0 ~ )However, . pulse-chase experiments using our antibody to tis21 suggest that the tis21-encoded protein is not secreted from cells after induction, either by phorbol-treated Swiss 3T3 cells or by NGF-treated PC12 cells (SOU). The protein encoded by the human btgl gene shows 59% identity and 7S% conserved sequence similarity with rat PC3 protein (51).The exon/intron structure of the tis21 gene (42) and the btgl gene (51) demonstrate remarkable similarity, strengthening the suggestion that these two genes are niembers of a gene family. btgl is not the human homologue of pc3/tis21, however. A human gene more closely related that btgl to tis21lpc3 has been identified, but not characterized (51). btgl was cloned and characterized because of its proximity to a breakpoint [t(8;12)]translocation that occurs in a human B cell chronic lyinphocytic leukemia. The btgl gene is not involved in the translocation, but lies only 10 kb downstream from the breakpoint (.'2). Overexpression of btgl in NIH 3T3 cells decreases growth rates and
THE
tiS
121
GENES
reduces cloning ability, leading to the suggestion that it is an “antiproliferative gene” whose loss of function may contribute to uncontrolled growth (51). The similarities in both the exonlintron structure of the btgl and tis21lpc3 genes and the sequences of their encoded products suggest that continued characterization of the tis21 gene and its product should provide additional information on cell growth and differentiation.
111. The fisJ7 Gene Is a Member of a Multigene Family The predicted open-reading-frame of the tisll gene product is not related to any known protein. However, within the protein are two copies of a repeated amino-acid sequence, YKTELCX&X,CX,H, separated by 12 amino acids (53-55). The tisll protein was also cloned as a primary response gene from both NIH 3T3 and BALBIc 3T3 cells, as Nup475 (56) and l T P , respectively (57).Antisera to recombinant Nup475 protein detected a transient elevation in nuclear staining following mitogen stimulation (56). NuclePro)-rich ar localization, the (Cys + His) motif, and presence of (Ser domains led to the suggestion that the protein encoded by the tislllnup4751 ttp gene may be a rapidly inducible transcription factor (55-57) Many of the primary response genes that encode mitogen-inducible transcription factors are members of gene families. The c-fos gene is a mbmber of a family that includes at least four genes (c-fos,fru-1, fru-2, and fosB; reviewed in 1). Similarly, the c-jun gene is a member of a gene family that includes at least two other genes, junB and junD (1). The egrlltis8 gene belongs to a family of transcription factors with related DNA-binding domains (1).We used both hybridization with degenerate oligonucleotides and polymerase-chain-reaction procedures to identi&, from both cDNA libraries and from genomic DNA, two additional murine genes (tisIIb and tislld) that encode proteins related to the tisII-encoded protein (55). The YKTELCX,CX,CX,H repeats and the spacing between them are completely conserved in the proteins encoded by t i s l l , tisllb, and tislld. The conserved repeats are found within a 67-amino-acid region of all three proteins that shares very strong additional sequence conservation (Fig. 2). The regions of sequence similarity shared by the murine tisll, tisllb, and tislld proteins are shown in schematic form in Fig. 3. It seems likely that the regions of major sequence conservation among the tisll proteins may be DNA-binding domains present in a family of related transcription factors. However, data demonstrating this hypothesis have not been published at this time. The rat homologue of tisllb, cmgl, was cloned as an EGF-inducible
+
122
HARVEY R. HERSCHMAN ET AL.
- M D L S A I Y E S L Q S - - - - - - - - - - q T a S A q F D - - - -
-n
D ~ S O D
tfJ~ H G S E V C K G N K M L R H S A R N L H A L
ii llb lld
M L D K K A V G T P V A A A P S S S F T P G F L
11 llb lld
- - G T S L G G - L W N I N S D S I P S G V T - - - - a R L T G R S N Y S ~ D R I A V [ T u AA h F P R R H ~S Q L P A H P V P S P G S C S P K F P G A P N G G G - - - S D C G P A G G
11 1lb lld b::
lld 11 llb lld itb lld
-
_- _- -_ -_ -_
- G Q P H - [ G o -
-- -- -- _- -_
-
- - -
-,-
i
S G G G G A S
1-
- - 7 R f l I p m L S A D R P R L O S F S F A G F P S
G D L R A F G A R D A L H L G F A R E P R P K L H H S L S F S G F P S
G R R S S P P P P G F S G ~ S L S P S S S P P P G D L P L P A A I A A H - - - y f q I m L f i A g D L g m H H - - Q P G L E S a L L L D S P T S R T P P P S S S S S
-
k#$
S P S A FL S A A b G g V F R R b P N 0 R : P C P SR M R SG TL PT GP G S T I D G N N P F F S ~ E L S D C S S A A N T P S G A P
A
ALf)A A A A A L L Y R ;
W G P L G G L A R S P S A H S L G S D P D D Y A S S G S S L G G PQT G@A
F L F F P H E D L[EI- - S
~ F DiPLfjM p a D ~ s LD H E O Y P C A S C S S S G A N N A F A F G P E L S S
FIG. 2. The TIS11, TISllb, and TISlld proteins share regions of sequence identity and similarity. The predicted amino-acid sequences of the TIS11, TISllb, and TISlld proteins are aligned to identify maximal sequence similarity. Identical amino acids and conservative substitutions are boxed. The 67-amino-acid “core” region. conserved in all three proteins, is within the area enclosed in heavy lines. These data are reproduced from 55,
gene in rat colonic epithelial cells (58).The rat cmgl- and murine tisllbencoded proteins differ by only one serine-to-threonine substitution, a remarkable level of sequence conservation. In comparison, the murine tis21and rat pc4-encoded proteins differ at 13 amino-acid residues. The murine proteins encoded by nur77Jtisl and rat n&-B have much greater extents of amino-acid differences, and differ in size. Similarly, the egr-1 ltis8- and ngfIA-encoded proteins differ in size and amino-acid sequence.
~
123
THE t i S GENES
1 TISfI I
,
I ,
, I
,I *.
I
M
3 (
, I
I I
.,
w r ; I
. ,
: : j zI
I
.,
M
,.
~. , ,I ,I
. m
s'
v
d TISIIB
:<*,
,., ,,
b
\
I
I % \ % <
, , < . *
::::
,
.
I
t
mffl
]
TISIID
FIG.3. The TIS11, TISllb, and TISlld proteins share regions of sequence identity and similarity. The regions of strong sequence similarity in these three proteins are indicated in hatched boxes.
The tisll gene is not detectably transcribed in unstimulated 3T3 cells, but is rapidly and transiently expressed following phorbol or growth factor treatment. In contrast, the basal levels of tisllb and tislld are quite significant. Moreover, treatment with phorbol or other mitogens does not dramatically elevate the levels of these two messages in Swiss 3T3 cells (Fig. 4). Induction of tisll mRNA accumulation by phorbol or growth factors is dramatically enhanced by cycloheximide. In contrast, cycloheximide has relatively little effect on t i s l l b and tislld message levels in Swiss 3T3 cells (55). These data suggest that, in 3T3 cells, the t i s l l b and tislld genes are subjected to much less transcriptional modulation than the tisll gene. The differences in their message levels in induced and uninduced cells would not have been sufficient to permit identification of the tisllb and tislld cDNAs in our original differential hybridization screen for phorbol-induced se-
FIG. 4. Phorbol induces tisll mRNA accumulation to a much greater extent than does tisllb or tislld. Density-arrested 3T3 cells were treated with phorbol (50 ng/ml) for the times (in minutes) shown. Total RNA was isolated, and 10 pg was subjected to electrophoresis, transfer, blotting, and hybridization. Each probe was hybridized to a separate filter. These data are reproduced from 55.
124
HARVEY R. HEASCHMAN ET AL.
quences; the cloning of these two cDNAs depended on sequence homologies. The fact that cnzglltisllh is inducible in rat epithelial cells and is relatively constitutive in swiss 3T3 cells raises the exciting possibility that the regulation of members of this gene family may be ceil-type specific.
IV. The tisl0 Gene Encodes a Functional Prostaglandin Synthase/Cyclooxygenase The t i s f 0 gene is the most highly restricted of the tis primary response genes. In our original analysis of primary response gene expression in various cell culture lines, we found tisl0 message induced only in fibroblast cell lines (59). Subsequently, we observed that this gene could be induced in murine in yeloid cell lines and in human neutrophils by granulocytemacrophage colony-stimulating factor, as well as by phorbol esters (10). The tissue- and cell-type restriction of the tislO gene, in contrast to the relatively widespread expression of many of the other tis genes, suggested a potential cell-type-specific function for the TISlO protein. The t i s l 0 message predicts an open-reading-frame of 604 amino acids (59).Analysis of the predicted amino-acid sequence demonstrates extensive sequence identity with the previously cloned human, murine, and ovine cDNAs for prostaglandin synthaselcyclooxygenase (EC 1.14.99.1). The murine tislO-encoded and prostaglandin synthase proteins are over 60%identiCdl, and have over 80% sequence similarity when conservative amino-acid replacements are considered (59). We now refer to the prostaglandin synthase gene as pgs-1 and to the tislO gene as tisl01pgs-2. The chicken form of the tisl0tpgs-2 cDNA was cloned from a cDNA library prepared from a chicken embryo fibroblast cell line expressing a temperature-sensitive v-src gene (60). Because of the evolutionary distance between chicken and those species (human, mouse, sheep) from which the pgs-l cDNAs had previously been cloned, these workers could not be certain whether their cDNA represented the chicken homologue of pgs-1 or a product of a distinct gene. Induction of tisl01pgs-2 mRNA accumulation, following activation of a temperature-sensitive v-src gene, was also demonstrated in 3T3 cells (61).However at the time this experiment was reported, the sequence similarities between tisl01pgs-2 and pgs-1 were not known. cDNAs for the murine form of the tisl0lpgs-2 gene were subsequently cloned by several other groups (62, 63). The cDNA for the human homologue of the tisl01pgs-2 gene has subsequently also been cloned, using sequence data from the murine protein (64).
12s
THE tis GENES
Although there are extensive sequence similarities between the PGS-1 and TISlO/PGS-2 proteins, it is clear that these enzymes are encoded by distinct genes. The PGS-1 proteins from humans, mice, and sheep all share a 17-amino-acid sequence located near the amino-terminal end of the molecule that is not present in the murine TISlOJPGS-2 molecule. In contrast, there is an 18-amino-acid sequence, present near the carboxy-terminal end of the TISlOIPGS-2 protein, that is not present in the PGS-1 proteins. These relationships are illustrated diagrammatically in Fig. 5 . It appears that the tislO/pgs-2 gene encodes a second form of prostaglandin synthase/cyclooxygenase.Expression of the tisl0Jpgs-2 coding sequences in COS-1 cells demonstrated that this gene encodes a functional prostaglandin synthase; both the cyclooxygenase and hydroperoxidase activities of the enzyme complex were expressed in the transfected cells (65). A second form of prostaglandin synthase activity was also demonstrated biochemically in rat ovarian granulosa cells (66). Partial amino-acid sequencing demonstrated that this molecule, inducible by pituitary glycoprotein hormones in these cells, is the rat homologue of TISlO/PGS-2 (67). Many of the important features of the PGS-1 molecule are conserved in the TIS10/PGS-2 protein, as would be expected for related proteins that carry out such a complicated enzymatic function. The two regions thought to be the axial and distal binding sites for heme are conserved completely between these two proteins. The histidine residue thought to be involved in the distal heme-binding position is conserved in a KALGH sequence found in the three PGS-1 proteins. PGS-1 is enzymatically inactivated by aspirin as a result of acetylation at serine 503;this site is conserved in TISlO/PGS-S. Many laboratories are currently attempting to identify nonsteroidal antiinflammatory compounds that can differentially inhibit the enzymatic activity of these two prostaglandin synthases.
Leader sequence ( 17 amino acids)
t
0
PGS /COX
u TISlO *
TISlO peptida (l8 omino acids)
FIG.5. The PGS-1 and TISlO/PGS-2 proteins share regions of sequence identity and similarity. The unshaded areas indicate regions of sequence similarity or identity. The shaded area in the N-terminal region of PGS-1 indicates a 17-amino-acidhydrophobic sequence present in PGS-1 but absent in TISlO/PGS-2. The shaded area in the C-terminal region ofTISlO/PGS-2 indicates the 18-amino-acid insertion present in TISlO/PGS-2 but missing from PGS-1.
126
HARVEY R. HERSCHMAN E T AL.
V. Both Prostaglandin Synthesis and TlSl O/PGS-2 Synthesis Are Induced in Swiss 3T3 Cells Other workers have reported that mitogen treatment of 3T3 cells induces prostaglandin synthesis and secretion, and have suggested that this response is dependent on the synthesis of new protein(s) (68-70). We have confirmed these observations; phorbol-induced prostaglandin synthesis is inhibited by cycloheximide in Swiss 3T3 cells (Fig. 6). We prepared an antipeptide antiserum to a region of the 18-amino-acid sequence unique to TISlOIPGS-2 (Fig. 5). This antiserum can detect TISLOIPGS-2 in microsomal membranes of COS-1 transfected cells, but does not react with PGS-1 protein (71). Immunofluorescent staining is detectable with the antipetide antiserum in Swiss 3T3 cells treated for 6 hours with phorbol (Fig. 7). In contrast, no staining is present in untreated cells. Incubation with immunizing peptide can block the immunofluorescent staining, demonstrating the specificity of the antiserum. Cycloheximide treatment can completely prevent the appearance of phorbol-induced TISlO/PGS-2 immunoreactivity, suggesting that the phorbol-induced synthesis and secretion of prostaglandin E, is de-
TIME (hours 1
CHX
FIG.6. Cycloheximide inhibits phorbol-induced prostaglandin E, synthesis and secretion in Swiss 3T3 cella. Left panel: Density-arrested 3T3 cells were treated with phorbol(50 ngiinl) for the hours shown. Media were c d e c t e d and prostaglandin concentrations were determined by radioimmunoassay. Right panel: Cells were either exposed to cycloheximide (10bg/ml) for 30 minutes or were left untreated, then exposed to phorbol(50 ng/ml) for 4 hours. Media were collected and prostaglandin concentrations were determined. Data points are the averages and standard deviations of three dishes. CONT, Control; CHX, cycloheximide; TPA, phorbol. These data are reproduced from 88.
THE
GENES
127
FIG.7. Antibody to the unique carboxy-terminal region of TISlOIPGS-2 can detect induced TISlO/PGS-Z protein synthesis by irnmunofluorescence in phorbol-treated Swiss 3T3 cells. Indirect imrnunofluorescence of untreated Swiss 3T3 cells (upper left), cells treated with phorbol(50 ng/ml) for 6 hours (upper right), cells treated with phorbol(50 ng/ml) but incubated with 1 p M TISlO/PGS-2-specific peptide 30 minutes prior to and during incubation with primary antibody (lower left), and cells treated with phorbol (50 ng/ml) and cycloheximide (10 $ml) for 6 hours (lower right). These data are reproduced from 71.
pendent on the production of the inducible TISlO/PGS-2 form of prdstaglandin synthase. Western blot analysis confirmed that no detectable TISlO/PGS-2 antigen is present in quiescent, untreated Swiss 3T3 cells (Fig. 8). TISlO/PGS-B antigen accumulates in 3T3 cells following phorbol treatment, peaking at 6-8 hours after mitogen stimulation. Antigen levels then decline, eventually returning to baseline values, even in the continued presence of phorbol. Accumulation and disappearance of the TISlO/PGS-2 protein (Fig. 8) are mediated by a combination of phorbol-induced synthesis of the protein and cellular degradation. A procedure employing metabolic labeling and subsequent immunoprecipitation was used to measure these two parameters.
128
HARVEY R. HERSCHMAN ET AL.
FIG.8. Phorhol induces the transient accuinulation of TISIOIPGS-2 protein in Swiss 3T3 cells. Swiss 3T3 cells were treated with phorhl (50 ng/ml). At the hours indicated, extracts
were prepared and subjected to electrophoresis and western iminunoblot analysis, using antiI,ody to the TISlO’PGS-2 carboxy-terminal peptide. Antibody-antigen complexes were identified with a chemilriininescence assay; 75 pg of protein was loaded in each lane. These data are reproduced from T I .
Quiescent, untreated Swiss 3T3 cells synthesize only minimally detectable levels ofTISlO/PGS-Z protein (Fig. 9). In the first hour following stimulation with phorbol there is relatively little increase in incorporation of [35S]methionine or [ZSIcysteine into TISlO/PGS-2 protein. However, subsequent periods of pulse-labeling suggest a peak of synthesis in the third to the fifth hours d t e r mitogen stimulation. To measure TISLOIPGS-2 protein degradation, cells were induced by exposure to phorbol, and proteins were labeled with radioactive cysteine and methionine. The inducer and the metabolic labels were removed from the medium, and cells were analyzed-by imniunoprccipitation, electrophoresis, and autoradiography-at successive intervals for the remaining metabolically labeled TISlOIPGS-2 protein (Fig. 9). Thc half-life of the TISlO/PGS-S protein in Swiss 3T3 cells, determined from this experiment, is 4 hours. A doublet is observed in the immunoprecipitation experiments shown in Fig. 9. Previous studies using antiserum to the sheep seminal vesicle prostaglandin synthase, PGS-1, have also precipitated doublet bands (72). It is likely that those polyclonal antisera to PGS-1 precipitate both PGS-1 and ‘TISlO/PGS-2, thus making the previous data difficult to interpret. Immunizing peptide can block the precipitation of both forms of the TISlOIPGS-2 doublet reacting with the antipeptide antiserum (71),suggesting that both imniunprecipitated TIS1O/PGS-2 proteins share the common carboxyterminal epitope. The doublet formation may result from differential glymsylation of a common protein, as suggested for the PGS-1 molecule (73). However, alternative splicing of the human pgs-l message to produce a message that would encode a PGS-1 protein with a 37-aminoacid deletion has also been reported (74), and is also a possibility to explain the doublet band observed here.
THE
tk
GENES
129
FIG.9. Phorbol induces the synthesis of TISlO/PGS-2 protein in Swiss 3T3 cells. Top panel: Swiss 3T3 cells were incubated in serum-free, methionine/cysteine-free medium for 30 minutes prior to stimulation with 50 ng/ml phorbol. The cells were labeled with [35S]methionine and [35S]cysteine for sequential 1-hour intervals. The numbers above the lanes indicate the time periods (in hours) following phorbol addition when the cells were metabolically pulse labeled. Cells were lysed and the supernatants were subjected to immunoprecipitation, using antibody to the TISlO/PGS-2 carboxy-terminal peptide. Immunoprecipitates were subjected to electrophoresis and autoradiography. Bottom panel: degradation of the TISlO/PGS-2 protein. Swiss 3T3 cells were treated with phorbol(50 ng/ml) and subjected to metabolic labeling for 6 hours with [35S]methionine and [35S]cysteine. Medium with inducer and radioactive amino acids was then removed and replaced with methionine- and cysteine-supplemented medium. Cells were harvested at the hours indicated following the transfer to nonradioactive, methionine/cysteine-rich medium. Lysates were prepared and subjected to immunoprecipitation with the antipeptide antiserum. These data are reproduced from 71.
130
HARVEY R. HERSCHMAN ET AL.
The regulation of PGS activity is not governed solely by synthesis and degradation. PGS-1 rapidly autoinactivates during catalysis of the enzymatic reaction, producing antigenically detectable but enzymatically inactive protein (75, 76). Although autoinactivation studies have not yet been reported for the TISlO/PGS-2 protein, the similarities between these two PGS enzymes suggest that it is a safe assumption that autoinactivation is a property ofTISlO/PGS-2 as well. The ability of cells to convert free arachidonic acid to PGH, is likely to be a complex mix of the level of constitutive PGS-1 enzyme, synthesis of the tisl0lpgs-2 message and protein following ligand stimulation, covalent inactivation of the enzymes, and the degradation of both the PGS-1 and TISlO/PGS-2 proteins.
A. Expression of tis7O/pgs-2 in Swiss 3T3 Cells Can Be Induced by a Variety of Ligands Although the tis genes were isolated in response to phorbol stimulation, they are, in general, inducible in 3T3 cells by a variety of mitogens (5, 20, 59). Moreover, prostaglandin synthesis can be induced in 3T3 cells by a variety of stiinulatory agents, including phorbol, serum, and a number of polypeptide mitogens. Once tisIOIpgs-2 was identified as an inducible gene for prostaglandin synthaselcyclooxygenase,we investigated further the induction of this gene by alternative agents in S wiss 3T3 cells. We also compared induction of tisl0lpgs-2 to that of pgs-1, because induction of the pgs-1-encoded enzyme in BALBlc 3T3 cells had previously been suggested to occur in response to platelet-derived growth factor (77). Swiss 3T3 cells treated with EGF, forskolin, serum, or phorbol all rapidly and transiently express tislolpgs-2 message (Fig. 10). The tisl0Ipgs-2 gene responds to signals presumably mediated by protein tyrosine kinase (EGF receptor), protein kinase A (forskolin), and protein kinase C (phorbol) signaltransduction pathways. In contrast, none of these agents significantly altered the level of pgs-1 message; the expression of the pgs-1 gene appears to be rigidly constitutive in Swiss 3T3 cells. However, induction of pgs-1 message accumulation has been reported in human lung fibroblasts (74) and human endothelial cells (78, 79).
B. Glucocorticoids Inhibit Induction of tis 7O/pgs-2 in Swiss 3T3 Cells Eicosanoid production in response to ligand Stimulation has been demonstrated in a number of cell types, including fibroblasts (80),endothelial cells ( S l ) , neutrophils (8.21, macrophages (83-85),monocytes (86),and muscle cells (87). In each of these cases, glucocorticoids can attenuate the production of eicosanoids. Conventional explanations for induct'ion of prostaglandin
THE
ti.9 GENES
131
FIG. 10. The tislO/pgs-2 gene is rapidly and transiently induced by a variety of ligands. Total RNA was prepared from density-arrested Swiss 3T3 cells treated with EGF (10 ng/ml), forskolin (FOR; 40 ng/ml), phorbol (TPA; 50 ng/ml), or 20% fetal bovine serum (SER) for 1, 2, 4, and 8 hours. RNA (10 pg/ml) was subjected to electrophoresis and transferred to nitrocellulose. Two separate electrophoretic analyses and blots were performed for the experiments shown here. One blot was hybridized with a cDNA probe for t i s l O / p g s d . The second blot, prepared from the same RNAs, was hybridized with cDNA probes for pgs-l (COY) and chob. These data are reproduced from 59.
synthesis and its inhibition by glucocorticoids have previously centered around the activation of phospholipase A, (PLA,), and possible regulation of PGS-1 enzyme levels. Our demonstration that there exists a second, ligandregulated form of prostaglandin synthase and that PGS-1 levels are not modulated by extracellular ligands in Swiss 3T3 cells led us to reexamine this question. We had previously demonstrated that cycloheximide could block both phorbol-induced prostaglandin accumulation and phorbol-induced synthesis of TISlOIPGS-2 protein in Swiss 3T3 cells (Figs. 6 and 7). We then examined the effect of dexamethasone on these same two phorbol-mediated events (88). Dexamethasone completely blocks both PGE, induction (Fig. 11)and the accumulation of detectable TISlO/PGS-2 (Fig. 12) in phorbol-treated Swiss 3T3 cells. As shown in Fig. 12, dexamethasone also blocks seruminduced TISlO/PGS-2 accumulation, suggesting that glucocorticoids may block induced expression of the tislO/pgs-2 gene in response to all ligands. We thought it likely that the dexamethasone inhibition of phorbolinduced TISlOIPGS-2 accumulation was occurring at the level of mRNA accumulation, because this is the most common mechanism of glucocorticoid regulation. We challenged 3T3 cells with phorbol following incubation with dexamethasone, and characterized the production of both tislO/pgs-2 and
132
HARVEY H. HERSCHMAN ET AL.
CONT TPA TPA t
DEX FIG. 11. Ikxamethasone inhibits phorl)ol-induced prostaglandin E, synthesis and secretion i n Swiss 3T3 cells. Cells were either exposed to 2 phf dexainethsone (DEX) for 4 hours or were left untreated. then exposed to phorbol (TP.4;50 ng/ml) for 4 hours. Media were collected md prostaglandin E, cu,ncentrations were determined by radioimmunoassay. Data points are the averages and standard deviations of three dishes. These data are reproduced from (88.
pgs-1 message (Fig. 13). Dexamethasone alone had no effect on tislOlpgs-2 mRNA levels. However, incubation with this hormone blocked the phorboliriduccd accumulation of tislOlpgs-2 message. In contrast, dexaniethasone had no effect on the constitutively expressed levels of pgs-1 message. Dexainethasone also inhibited the forskolin-induced accumulation of tis10lpgs-2 message (88),reinforcing our suggestion that glucocorticoids block all ligandinduced tisl0lpgs-2 mRNA accumulation in Swiss 3T3 cells. Cortisol and aldosterone, at concentrations higher than those observed to he inhibitory for dexamethasone, also blocked phorbol-induced tislolpgs-2 message accumulation. In contrast, progesterone and testosterone, steroids without glucocorticoid activity, had no effect on induction of tisl Olpgs-2 message (88). Dexamethasone at concentrations as low as 2 nM can inhibit phorbolinduced tislO/pgs-2 message accumulation (Fig. 14). In contrast, concentrations of dexamethasone 1W times higher do not inhibit the phorbol-induced accumulation of tis8/egrl message. Thus, glucocorticoid inhibition of tislOl pgs-2 gene expression in response to mitogens is not a common feature of all priman response genes. It will be of great interest to determine which subset of primary response genes are subject to this additional level of hormonal regulation.
FIG. 12. Dexamethasone inhibits phorbol- and serum-induced synthesis of TISlOIPGS-2 protein. Control Swiss 3T3 cells (upper left), cells treated with phorbol (TPA; 50 ng/ml) for 6 hours (upper middle), cells treated with 20% serum for 6 hours (upper right), cell5 treated with dexaniethasone (2 + M ) for 10 hours (lower left), cells treated with dexaniethasone for 4 hours followed by phorbol for 6 hours (lower middle), and cells treated with dexamethasone for 4 hours followed by serum for 6 hours (lower right) were fixed and subjected to indirect immunofluorescent analysis. These data are reproduced from 71.
134
HARVEY R. HERSCHMAN ET AL.
FIG. 13. Dexamethasone inhibits phorhl-induced accumulation of tislO/pgs-2 rnHNA. Swiss 3T3 cells were treated with phorbol (TPA;50 ng/rnl) or dexamethasone (DEX)(2 K M )for the times (in hours) indicated. DEX4, TPA2 cells were preirrcuhated with DEX for 4 hours prior to exposure to phorbol for 2 hours. DEX TPAP cells were incubated for 2 hours with phorbol and DES,with no preincuhation. Total RNA was isolated, subjected to electrophoresis, and transferred to nitrocellulose; 10 p,g of RNA was loaded in each lane. The blot was hybridized with c D N A probes for tislO/pg.s-2, pgs-l (pgs/cox) and chob. These data are reproduced from 88.
C. Expression of #is7O/pgs-2 in Swiss 3T3 Cells Is Regulated at the Transcriptional Level The je primary response gene (27) encodes murine homologue of macrophage chemotactic-protein-1 (MCP-1). This protein is thought to play a role in wound healing, atherosclerosis, and inflammatory responses (89). Glucocorticoids block mitogen induction of jeltncp-1. However, the mode of glucocorticoid inhibition of jelmcp-1 induction appears to be cell-type specific; the hormone blocks rnitogen-induced transcription of the jelrncp-1 gene in BALB/c 3T3 cells (W), but mediates the stability ofjelmcp-1 message in vascular smooth muscle cells (91). These observations, as well as many studies on the steroid regulation of other inducible genes, suggest that the mechanisms by which glucocorticoids inhibit gene expression can vary with respect to cell type, ligand, and gene. We carried out nuclear transcription experiments to determine whether steroid inhibition of tisIOIpgs-2 induction occurs at the transcriptional or posttranscriptional level. Little or no transcription could be detected for the tis8/egr-l, tis21, or tisl01pgs-2 genes in nuclei from unstimulated cells (Fig. 15). Nuclei isolated from cells treated for 15 or 30 minutes with phorbol incorporated substantial isotope into transcripts for each of these three genes. These observations suggest that increased transcription is a major
THE
tiS
GENES
135
FIG. 14. Dexamethasone (DEX) does not inhibit phorbol-induced accumulation of tis8/egr-l mRNA. Total RNA was prepared from Swiss 3T3 cells preincubated for 4 hours with either vehicle (ethanol) or DEX at the concentrations shown, then treated with phorbol (50 ng/ml) for 2 hours. RNA was also prepared from DEX-treated, phorbol-treated, and untreated cells. The RNA preparations were subjected to northern analysis. Each lane contains 10 bg of RNA. Blots were hybridized with tislO/pgs-2 and tis8/egr-I radioactive cDNA probes. These data are reproduced from 88.
mechanism by which phorbol increases the message levels of the tis8iegr-1, tis21, and tislO1pgs-2 primary response genes. Incubation of cells with dexamethasone prior to phorbol treatment 'dramatically suppressed nuclear incorporation of radioactive RNA precursors into transcripts of the tisl0ipgs-2 gene, without appearing to have a substantial effect on the synthesis of transcripts from the tis8legr-1 or tis21 genes. These data suggest that, in cells previously incubated with glucocorticoids, transcriptiona1 inhibition contributes heavily to the observed attenuation of phorbol-induced tisl01pgs-2 mRNA accumulation. It is possible that processing of messenger precursors andior the stability of tisf0Jpgs-2 message are also modulated by glucocorticoids, as reported for other genes. While characterizing the structure of the tisl01pgs-2 gene, we also cloned several kilobases of DNA 5' to the start-site of transcription. We have fused these 5' regions of the tislO1pgs-2 to the luciferase gene, to analyze promoter structure and function by transient transfection analyses. A luciferase reporter-construct containing the first 371 bp 5' of the start-site of the tislO1pgs-2 transcript can respond to phorbol, serum (Fig. 16), forskolin, and platelet-derived growth factor (B. S. Fletcher and H . R. Henchman, unpublished). Cotransfection of this reporter-construct, along with a con-
136
HARVEY R. HERSCHMAN ET AL.
Frc:. 15. Dexamethasone (DEX) inhibits phorhl-induced transcription of the tislO/pgs-2 gene. Swiss 3T3 cells were incubated with dexamethasone (2 F M ) for 4 hours, then treated with phorbol iT; SO ngiml) for 15 or 30 minutes. Control (CON) cells were treated either with DEX done for 4 hours, or with phorhol for 15 and 30 minutes. Nuclei were prepared and allowed to incorporate radioactive nucleotides into RNA. RNA was isolated and hybridized to filters containing pGEhl plasmid DNAs with inserts or with pGEM DNA (as a nonspecific control). tis8,egr-f , fis21, tislOlpgs-2, and chob. After washing, the filters were subjected to autoradiography.
PXt
TISIO,
TISIO,
c .m
:4000
e
CI,
=L
\
.c 5
3000
~
S
FIG. 16,The first 370 nucleotides of the tisl0ipgs-2 promoter contain cis-acting response elements for p h o r h l and serum. NIH 3T3 cells were transfected with an empty expression vector, with fislo,, (a plasmid in which the first 963 nucleotides ofthe tislolpgs-2 promoter arc fused to a luciferase reporter), or with tisZ0, (a plasmid in which the first 371 nucleotides ofthe tisl0ipgs-2 promoter are fused to luciferase). Control cells (C), phorbol-treated cells (T; SO ng/ml), and serriin-treated cells (S) were assayed for luciferase activity. Error bars indicate standard deviations. These data are reproduced from 65.
THE
137
tis GENES
struct expressing pp6@", also results in elevated luciferase activity (B. S. Fletcher, W. Xie and H. R. Herschman, unpublished). We conclude that the first 371 nucleotides of the tislO1pgs-2 regulatory region contain cis-acting response elements for phorbol, serum, forskolin, PDGF, and ppG@rc. However, induction of luciferase activity by these agents cannot be blocked with dexamethasone, using either the construct containing 371 nucleotides (tisl0,) of the tislOlpgs-2 regulatory region or a construct containing approximately 1 kb (tisl0,) of promoter region (B. S. Fletcher, D. A. Kujubu and H. R. Herschman, unpublished). Dexamethasone blocks induction of the tislO1pgs-2 gene by a number of inducers, including phorbol, serum, and forskolin (71, 88). We anticipate that there must be a specific DNA site at which dexamethasone-mediated events are able to block tisl01pgs-2 gene transcription induced by a variety of agents. This site must be either greater than 1kb upstream from the start-site of transcription, or must lie within the transcribed region of the gene. Regulation of gene transcription by DNA encoding a sequence within the 3' untranslated region of the message has recently been reported for the primary responseje gene (92). One of our current major objectives is to identify the site and nature of glucocorticoid inhibition of the tisl01pgs-2 gene.
VI. The Structures of the tis7O/pgs-2 and pgs-7 Genes Are Similar Although pgs-1 and tisl Olpgs-2 share extensive sequence similarity, the enzyme encoded by the former has a hydrophobic region present in its amino-terminal end; this region is not present in the enzyme from the latter (Fig. 5). TISlOIPGS-2 has an 18-aminoacid sequence near its carboxy terminus that is not present in the PGS-1 protein of mouse, man, or sheep (59). We used a combination of polymerase-chain-reaction analysis and direct sequencing to identify, from genomic clones, the exonlintron borders of the tislO1pgs-2 gene and to analyze the sizes of the introns. The murine tisl01pgs-2 gene contains 10 exons and 9 introns (Fig. 17). The pgs-1 gene has one additional exon (and, therefore, one additional intron), encoding the hydrophobic leader sequence found near the amino terminus. The initial and final exons of the two genes are different in size, encoding distinct 5' untranslated sequences and amino-terminal portions of the protein, as well as distinct untranslated 3' sequences. The eight internal exons of the tislO1pgs-2 gene (exons 2-9) are all identical in size to the corresponding human pgs-1 exons, with the exception of tislO1pgs-2 exon 3. This exon encodes an additional proline present in the TISlOIPGS-2 protein, but absent in murine, ovine, and human PGS-1. The pgs-1 gene maps to
138
HARVEY R. HERSCHMAN E T AL.
murine chromosome 2. The tislO/pgs-2 gene is located on murine chromosome 1 (93). Although the exodintron structures of the tisl0Ipgs-2 and pgs-1 genes are quite similar, their overall sizes are substantially different (Fig. 17). The pgs-1 gene is over 22 kb long (94). The structure of the murine pgs-1 gene has recently been shown to be nearly identical to the human pgs-1 gene, both in exodintron structure and in size (95). In contrast, the murine tislOipgs-2 gene is only 8 kb long; many of the introns are substantially smaller in the inducible tisl01pgs-2 prostaglandin-synthase gene. It is of some interest to note that all the primary response genes characterized to date are quite small. Many of these genes have only one or two introns. The c - f i ~ .c-jun, egrlltis8, egr-2/krodO, nur771tis1, tis21, and j e genes are all
9
io
II
E X O I NUMBER
cox
L 52 8 247
H
9
to
287
410
EXOI IUYBER
I
tis 10
J
1 2
---
I1
3 4 5 I I ,
I II
6 7 0 I ,
I
II I1
I
I
9
to
I
I
8 8
I
I
ff I
*cox
(>22 kb)
H
2 kb Frc. 17. The tblO/pgs-2 and pgs-1 genes have similar structures. The exons of the mnrine tislO/pgs-2 gene and the human pgs-l gene are compared in the upper panel. The numbers in the boxes indicate the nuinber of nucleotides in that exon. The arrows below the genes indicate the protein-coding regions of the transcripts. Arrows above the genes indicate the transcription start sites. Using the same scale, the lower panel illustrates the exon-intron structure of the human pgs-1 gene and the inurine tisloipgs-2 gene. The numbers identify exons. The broken line in the tislO/pgs-2 gene indicates an uncharacterized region 5' of the coding portion of the first exon for this gene. The solid a r e a of the exons identify the protein-coding sequences. These data are reproduced from 65.
THE t i S GENES
139
less than 6 kb long (1).It appears that the requirements for rapid transcriptional responses lead to the production of small genes.
VII. tisIO/pgs-2 Satisfies the Criteria for the "Second Pool" of Prostaglandin Synthase Prior to the discovery of tislOlpgs-2, ligand-regulated synthesis and secretion of prostaglandins in fibroblasts, monocytes, macrophages, smooth muscle cells, and epithelial cells were thought to be due to activation of phospholipase A, to release arachidonic acid and, in some cells, to elevation of prostaglandin synthaselcyclooxygenase (PGS-1) activity. Glucocorticoid inhibition was thought to be due exclusively to the inhibition of PLA,, preventing the release of free arachidonic acid; substrate for eicosanoid synthesis was thought to be limiting and PGS-1 was generally thought to be present in excess. However, several groups demonstrated that cycloheximide or glucocorticoids can inhibit the induction of both cyclooxygenase activity and immunoprecipitable enzyme. Needleman and colleagues (96), as well as others, proposed that some cells may have two pools of PGSICOX enzyme, one PGS pool that is expressed constitutively and a second PGS pool that is regulated by ligand-induced signal-transduction pathways and whose induction is inhibited by glucocorticoids. The tislO1pgs-2 gene satisfies all criteria for the proposed mitogeninducible, glucocorticoid-inhibitable second pgslcox gene. tisl01pgs-2 is inducible by a variety of ligands (59)and is rapidly and transiently transcribed (Fig. 15). The product has both hydroperoxidase and cyclooxygenase activities (69, appears to be the rate-limiting enzyme for prostaglandin synthesis and secretion in some cells (88), and is inhibited by glucocorticoid hormones (88). It appears that the induction of the tislO1pgs-2 gene will be the ratelimiting step in the induced production of prostanoids, in at least some biological systems. Moreover, limitation of the TISlOIPGS-2 protein, due to the inhibition of its mRNA accumulation, is likely to play a major role in glucocorticoid inhibition of eicosanoid production. These recent observations have led to major reevaluations in current ideas on the regulation of prostanoid synthesis.
VIII. tisIO/pgs-2 Is Induced in Macrophages We observed that tislO1pgs-2 mRNA can be induced by phorbol or GMCSF in murine monocytes and in human neutrophils (lo), despite its relatively restricted expression in a wide variety of cell lines (59). These data
140
HARVEY R. HEHSCHMAN ET AL.
suggest (1)that the production of prostaglandins, as a consequence of niacrophage activation, might be due to induction of the tisl01pgs-2 gene, and (2) that glucocorticoid inhibition of prostaglandin production in activated macrophages might result from inhibition of tislOlpgs-2 gene expression. However, at the time we made this observation we had not determined that the tislO/pgs-Z cDNA shared sequence similarity with the pgs-l cDNA. Farber (97) cloned a partial cDNA for tislU/pgs-2 during differential screening to identify cytokine-induced genes in the murine macrophage RAW 264.7 cell line. Russell and colleagues (98) identified a p71/73 protein synthesized in the activation response of bone-marrow-derived tumor macrophage and RAM,‘ 264.7 cells. Microsequencing studies and immunoblots with our antipeptide antiserum directed uniquely to the TISlOIPGS-2 protein (71)demonstrated that the ~ 7 1 1 7 3protein induced by lipopolysaccharide (LPS) activation of RAW 264.7 cells is the TISlOIPGS-2 protein (99). Induction of tislO/pgs-2 mRNA andlor protein accumulation has now been demonstrated in activated BAN’ 264.7 macrophage-like cells (99), bone-marrow-derived macrophages (98, 99), and murine and rat alveolar macrophages (100, 101). We have examined several murine macrophage lines to establish model systems to study the contributions of PLA,, TISlOIPGS-2, and PGS-1 expression in the production of prostaglandins by activated macrophage. The inurine RAW 264.7 and JT74.Al cells express substantial tislO/pgs-2 message following LPS treatment (Fig. 18). In contrast, murine P388D, cells do not express any tisl Ulpgs-2 mRNA following LPS activation. The smaller transcript seen in the RAW 264.7 cells is a tislOlpgs-2 transcript that terminates at an alternative polyadenylation site (62).Because P388D, cells can be
FIG. 18. Lipopolysaccharide induces tislO/pgs-2 induction in some rnurine macrop1l;lge cell lines. R.4\V 2647, J774A.1, and P38811, murine macrophage cells were treated with LPS (5 ngirnl) for the times (in hours) shown. Total RNA was isolated, subjected to electrophoresis, and transferred to nitrocellulose; 10 pg of total RNA was loaded in each lane. The blot was hybridized with cDNA probes for tislO/pgs-2 and chob. The two upper bands are alternatively polyidrnylated forms of the tisfoipgs-2 message. The lowest band is the choh message.
THE
tiS
GENES
141
activated to produce prostaglandins, comparisons among these three cell lines should prove a fertile source of information regarding the alternative mechanisms of regulation for prostanoid synthesis. Interferon gamma (IFN-y) is a potent activator of murine macrophages. IFN-7 can induce tislO1pgs-2 mRNA accumiilation in RAW 264.7 cells (97). In our hands, IFN-y did not stimulate substantial tislO1pgs-2 mRNA accumulation in these cells, even up to 24 hours after stimulation (unpublished). However, we find that IFN-7 can augment the activity of LPS in inducing tisIO1pgs-2 message; approximately one-tenth as much LPS is required to induce maximal tislO/pgs-2 message accumulation in the presence of IFN-y (Fig. 19). Synergistic interactions between IFN-y and other cytokines and macrophage effectors are often observed (102-104). These macrophage cell lines should provide a resource in which to study the roles of endotoxin, cytokines, and glucocorticoids in the regulation of macrophage prostaglandin synthesis. It is likely that regulatory mechanisms controlling macrophage eicosanoid synthesis may be cell-type specific, and
FIG. 19. Interferon gamma (IFN-y) shifts the dose-response curve of LPS induction of tislO/pgs-2 message to the left for RAW 264.7 murine macrophage cells. RAW 264.7 cells were treated for 4 hours with LPS at the concentrations (ng/ml) shown in the figure in the absence (-IFN) or presence (+IFN) of murine IFN-y (50 ng/ml). Total RNA was isolated, subjected to electrophoresis, and transferred to nitrocellulose; 10 pg of total RNA was loaded in each lane. The blot was hybridized with cDNA probes for tiSlO/pgs-2 and chob.
142
HARVEY R. HERSCHMAN ET AL.
involve alterations in the expression of the phospholipase A, gene(s), the pgs-1 gene, and the tislOJpgs-2 gene.
IX. Can the Proteins Encoded by the tisIO/pgs-2 and pgs- 7 Genes Form Functional Heterodimers? What Would Be the Consequences of This Interaction for Pharmacologic Intervention? There is currently great interest in the pharmaceutical industry in identifying drugs that can distinguish between the two forms of prostaglandin synthase, PGS-1 and TISlOJPGS-2. The appeal and utility of a drug that could differentially inhibit the prostaglandin synthase induced in the inflammatory response is clear. However, the PGS-1 molecule is thought to be functional as a dimer (105,106). We (and others) have now demonstrated that many cells (Swiss 3T3 cells, epithelial cells, ovarian granulosa cells, macrophage cell lines, alveolar macrophages, and peritoneal macrophages) express both a constitutive pgs-1 gene and an inducible tisl0Jpgs-2 gene. The two proteins produced from these genes are both found in the microsomal fractions of crude subcellular analyses of transfected COS-1 cells (65). If the two proteins from pgs-1 and tkl0Jpgs-2 must form homodimers to produce an active enzyme, the question arises of potential PGS-l:TISlO/PGS-2 heterodimerization in cells to produce an additional form of the enzyme. If the two gene products can heterodimerize, the enzymatic and pharmacologic properties of the overall prostaglandin synthase activity in an activated cell are likely to change as the levels of TISlOIPGS-2 monomers, and therefore the constitution of active homodimers and heterodimers, change during the induction response. Extensive studies on the intracellular localization and interactions of the two pgs gene products will be required to answer this important basic and practical question.
X. Similarities in the Expression and Regulation of Inducible Forms of Prostaglandin Synthase and Nitric-Oxide Synthase Nitric oxide (NO) is a major secretory product of many mammalian cells. NO appears to be a paracrine mediator of cellular interactions, regulating critical functions in homeostasis and host defense (107, 108). NO production has been observed in endothelial cells (109, ] l o ) ,macrophages ( I l l ) , hepatocytes (112), bone marrow cells (113), and mesangial cells (114). N O functions
THE
tk GENES
143
as a vasodilator (]lo),a neurotransmitter ( ] I S ) , and a macrophage immune defense molecule (116). NO is synthesized by nitric-oxide synthase (NOS) from L-arginine. cDNAs for constitutive calciumlcalmodulin-activated NOS proteins have been cloned from brain (115) and endothelial cells (117-119). A second, inducible form of NOS, termed mac-NOS, was recently cloned from activated RAW 264.7 macrophage cells (120-122). The enzymatic activity of mac-NOS is not dependent on calciumlcalmodulin. Like the PGS isoforms, some cells may express both constitutive and inducible forms of NOS. Because (1) both prostaglandins and NO act as paracrine effectors, (2) both tislOlpgs-2 and mac-nos are induced by LPS in macrophages, and (3) induction of mac-nos and tklO1pgs-2 is blocked by glucocorticoids in macrophages (88, 123), we investigated whether the inducible form of nos is also expressed in 3T3 cells. We find that mac-nos is a primary response gene, induced by phorbol in both Swiss and BALBlc 3T3 cells (124). The time course of appearance of these two messages is similar following induction. Overlapping, but not identical, groups of ligands can induce both tisl Olpgs-2 and mac-nos expression in 3T3 cells. We think it likely that similar cellular and molecular mechanisms of regulation may exist for these two genes, each of which plays a key role in the production of paracrine mediators of cellular function.
XI. Conclusions and Future Directions In the past 7 years, our knowledge of ligand-induced signal-transduction pathways, and primary response gene expression in has undergone profound expansion. New families of transcription factors (egrl ltis8-related genes, members of the c-fos family, and members of the c-jun family) induced by growth factors, tumor promoters, and hormones have been identified and characterized. We hope, by studying the tisll family of genes in mammalian cells as well as by studying their homologues in organisms more amenable to genetic manipulation, such as flies and yeast, to determine whether this group of genes also falls into this functional group. The roles of some of the primary response genes, such as tis21lpc3 (49, 50) and tis7lpc4 (12, 45), remain obscure, despite the description of their encoded proteins and gene structure. Once again, studies on lower organisms may help to provide clues as to the function of such genes. Otherwise, our understanding of the roles of these primary response genes in effecting phenotypic alterations in cell behavior in response to extracellular signals is likely to remain enigmatic until our knowledge of cellular physiology increases as a result of basic studies andlor until these genes are implicated in
144
HARVEY R. HERSCHMAN ET AL.
a cellular pathway as a result of some pathophysiology related to their function. The identification of new cytokines (JE, KC) and enzymes (TIS101PGS-2, niac-NOS) that regulate the synthesis of paracrine effectors (tisl01pgs-2, tnuc-nos)has led many laboratories, including our own, into new fields. It is of some interest to note that the four groups that cloned the cDNA for the inducible form of prostaglandin synthase did not have major research programs geared to the study of inflammation or immune responses, but were instead concerned with questions either of regulation of cell division by growth factors and mitogens or of the effect of viral transformation on the regulation of cellular proliferation (59, 60, 62, 63). One of our major goals in the near future will be to try to identify the relative roles of the two forms of PGS in cellular and organismal processes such as mitogenesis, reproduction, and inflammation. We plan to use both antisense approaches and the development of murine strains with homozygously disrupted tislOlpgs-8 and pgs-1 genes to study these issues. We will also concentrate on determining the nature of the DNA genomic elements acting in cis and the trans-acting regulatory factors that govern induction of this gene by agents such as forskolin (protein kinase A), phorbol esters (protein kinase C), PDGF (ligandmediated receptor tyrosine kinase activity), and v-src (intracellular tyrosine kinase). Emphasis will also be placed on elucidating the molecular mechanism by which glucocorticoid inhibition of tislOlpgs-2 induction is achieved. Finally, the similarities and differences in the regulatory mechanisms controlling the expression of the inducible nitric-oxide synthase and prostaglandin synthase genes will be the subject of continued interest and investigation.
This work was supported by National Institutes of Health Grant M24797 (HRH) and by DOE contract 1)E FC03 87ER60615 between the Regents of the University ofCalifornia and the Department of Energy. D. A. Kujulm was sueported by NIH physician-scientist award L’SPHS 1K11 01815. R. S. Gilbert is a postdoctoral fellow supported by USPHS Training Grant C,MO-8042.
REFERENCES I . H. R . Herschntan, ARB 60, 281 (1991). 2. I,. F. Lau and D. Nathans, “Hormonal Control and Regulation of Gene Transcription,” 11. 165. 1991. 3 . li. R. Yamamoto and B. M. .4lberts, ARB 45, 721 (1976).
THE tis GENES
145
4. E. Butler-Gralla and H. R. Henchman, J. Cell. Physiol. 107, 59 (1981).
5. R. W. Lim, B. C. Varnum and H. R. Henchman, Oncogene 1, 263 (1987). 6 . L. F. Lau and D. Nathans, EMBOJ. 4, 3145 (1985). 7 . V. P. Sukhatme, K. Sreedharan, F. G. Toback, R. Tauh, R. G. Hoover and C. H. TsaiMorris, Oncogene Res. 1, 343 (1987). 8. J. M. Almendral, D. Sommer, H. Macdonald-Bravo, J. Bbrckhardt, J. Perera and R. Bravo, MCBiol8, 2140 (1988). 9. D. A. Kujuhu, R. W. Lim, B. C. Varnum.and H. A. Henchman, Oncogene 1,257 (1987). 10. B. C. Varnum, R. W. Lim, D. A. Kujubu, S. Luner, S. E. Kaufman, J. S. Greenherger, J. C. Gasson and H. R. Herschman, MCBiol 9, 3580 (1989). 1 1 . J. Milbrandt, Science 238, 797 (1987). 12. F. Tirone and E. M. Shooter, PNAS 86, 2088 (1989). 13. K. Cho, W. C. Skarnes, B. M. Minsk, S. Palmieri, L. Jackson-Grushyand J. A. Wagner, MCBiol9, 135 (1988). 14. S. G. Irving, C. H. June, P. F. Zipfel, U. Siehenlist and K. Kelly, MCBiol 9, 1034 (1989). 15. A. T. Arenander, R. W. Lim, B. C. Varnum, R. Cole, J. de Vellis and H. R. Herschman, J. Neurosci. Res. 23, 247 (1989). 16. A. T. Arenander, R. W. Lim, B. C. Varnum, R. Cole, J. de Vellis and H. R. Henchman, J. Neurosci. Res. 23, 257 (1989). 17. A. T. Arenander, J. de Vellis and H. R. Herschman, J. Neurosci. Res. 24, 107 (1989). 18. H. R. Henchman, “Regulation of Gene Expression in the Nervous System: Neurology and Neurohiology,” Vol. 59, p. 93. 1990. 19. A. T. Arenander and H. R. Henchman, in “Neurotrophic Factors” 0. Fallon and S. Loughlin, eds.), p. 89. Academic Press, New York, 1992. 20. H. R. Henchman, Cell activation in “Genetic Approaches/Advances in Regulation of Cell .. Growth” 0. J. Mond, J. C. Canhier, and A. Weiss, eds.), Vol. 2, p. 83. Raven, New York, 1991. 21. H. R. Herschman, TIBS 14, 455 (1989). 22. J. G. Akin, D. A. Kujubu, S. RafEoni, D. D. Eveleth, H. R. Henchman and R. A. Bradshaw, JBC 266, 5401 (1991). 23. D. P. Bartel, M. Sheng, L. F. Lau and M. E. Greenherg, Genes Deu. 3, 304 (1989). 24. J. I. Morgan and T. Curran, Nature 322, 552 (1986). 25. T. Curran and J. I. Morgan, PNAS 83, 8521 (1986). 26. T. G. Hazel, R. Misra, I. J. Davis, M. E. Greenherg and L. F. Lau. MCBiol 11, 3239 (1991). 27. B. H. Cochran, J. Zullo, I. M. Verma and C. D. Stiles, Science 226, 1080 (1984). 28. W. Kruijer, J. A. Cooper, T. Hunter and I. M. Verma, Nature 312, 711 (1984). 29. R. Miiller, R. Bravo, J. Burckhardt and T. Curran, Nature 312, 716 (1984). 30. M. E. Greenherg, L. A. Greene and E. B. Ziff, JBC 260, 14101 (1985). 31. P. K. Vogt and T. J. Bos, Ado. Cancer Res. 55, 1 (1990). 32. S. J. Busch and P. Sassone-Corsi, Trends Genet. 6, 36 (1990). 33. P. Oquendo, J. Alberta, D. Wen, J. L. Graycar, R. Derynck and C. D. Stiles, JBC 264, 4133 (1989). 34. B. J. Rollins, E. D. Morrison and C. D. Stiles, PNAS 85, 3738 (1988). 35. R. S. Kawahara and T. F. Deuel, JBC 264, 679 (1989). 36. V. P. Sukhatme, X. M. Cao, L. C. Chang, C. H. Tsai-Morris, D. Stamenkovich, P. C. P. Ferreira, D. R. Cohen, S. A. Edwards, T. B. Shows, T. Curran, M. M. Le Beau and E. D. Adamson, Cell 53, 37 (1988). 37. P. Lemaire, 0. Revelant, R. Bravo and P. Charnay, PNAS 85, 4691 (1988). 38. B. A. Christy, L. F. Lau and D. Nathans, PNAS 85, 7857 (1988).
146
HARVEY R. HERSCHMAN ET AL.
39. 1%.C. \h-num, R. M'. Lim, V. P. Sukhatme and H. R. Herschman, Oncogene 4, 119
11989). 40. X.Can, R. A. Koski, A. Gashler, M:McKiernan, C. F. Morris, R. GatFney, R. V. Hay and \I P. Sukhatme, MCBiol 10, 1931 (1990). 4 1 . P. Lemaire, C. Vesque, J. Schmitt, H. Stunnenberg, R. Frank and P. Charnay, MCBiol 10, 3456 (1990). 42. B. Christy and D. Nathans, PNAS 86, 8737 (1989). 43. T. (;, Hazel, D. Nathans and L. F. Lau, PNAS 85, 8444 (1988). 44. R. P. Ryseck, H. Macdonald-Bravo. M. G . Matt&, S. Ruppert and R. Bravo. EMBO]. 8, 3327 (1989). 15. B. C. Varnum, R. W'. Lim and H. R. Herschman, Oncogene 4, 126'3 (1989). 46. J. Milbrandt, Neuron 1, 183 (1988). 47. T. E. Wilson, T. J. Fahrner, M. Johnston and J. Milbrandt, Science 252, 1296 (1991). 48, R. E. Paulsen, C. A. Weaver. T. J. Fahrner and J. Milbrandt, JBC 267, 16491 (1992). 49. 13. S. Fletcher, R. W. Lim, B. C. Varnum, D. A. Kujubu, R. K. Koski and H. R. Herschman, JBC 266, 14511 (1991). .%. A. Bradburv, R. Possenti, E. M. Shooter and F. Tirone, PNAS 88, 3353 (1991). =a. B. C. Varnurn, R. K. Koski and H. Henchman, J . Cell Physiol., in press (1994). 51. J. P. Rouault, R. Rimokh, C. Tessa, G . Paranhos, M. Ffrench, L. Duret, M. Garoccio, D. Germain. J. Samarut and J. P. Magaud, EMBO I. 11, 1663 (1992). .52. K. Rimokh. J. P. Rouault, K. Wahbi, $1. Gadoox, M. Lafage, E. Archimbaud, C. Charrin, 0. Gentilhomme, D. Germain, J. Samarut and J. P. Magaud, Genes Chrom. Cancer 3,24 (1991). 53. 8. C. Varnum, R. \\'. Lim, V. P. Sukhatme and H. R. Herschman, Oncogene 4, 119 (1989). 54 Q. M a , B. %num and H. R. Herschman, Oncogene 6, 1277 (1991). 55. B. C. Varnurn, Q.Ma, T. Chi, B. Fletcher and H. R. Herschman, MCBiol11, 1754 (1991). 56. R. N. DuBois, M. W. McLane, K. Ryder, L. F. Lau and D. Nathans, JBC 265, 19186 11990). 5 7 . N'. S. Lai, I>. J. Stumpo and P. J. Blackshear. JBC 265, 16556 (1990). ,S8.hl. Gomperts, J. C. Pascall and K. D. Brown, Oncogene 5, 1081 (1990). 39. I). A. Kujuhn, B Fletcher, B. C. Varnum, R. W. Lim and H. R. Henchman, JBC 266, 12866 (1991). 60.M'. Xie, J. 6. Chipman, I>. L. Robertson, R. L. Erikson and D. L. Simmons, PNAS 88, 1692 (19911. 61. S. A . Qureshi, C . I<. Joseph, M. Rim, A. Marony and D. A. Foster, Oncogene 6, 995 (1991). 62. $1. K. O'Banion, V. D. Winn and D. A. Young, PNAS 89, 4888 (1992). 63. R. P. Ryseck, C. Raynoschek, H. Macdonald-Bravo and I<. Dorfman, Cell Growth 0tj'f.r. 3, 443 (1992). 64. T. Hla and K. Neilson, PNAS 89, 738.1 (1992). 65. B. S. Fletcher, D. A. Kujubu, D. $1. Perrin arid H. R. Herschnian,JBC 267, 4438 (1992). 66. If'. Y. L. Wong and J. S. Richards, Mol. Endocn'nol. 5, 1269 (1991). 67. J. Sirois and J. S. Richards, JBC 267, 6382 (1992). 68. A. H. Lin, M. J. Bienkowski and R. R. Gorman, JBC 264, 17379 (1989). 69. M. J. Pash and M. Barly, FASEB J. 2, 2613 (1988). 70. S. C. L. Hong, R. Polsky-Cynkin and L. Levine, ]BC 251, 776 (1976). 71. D. A. Kujubu, S. T. Reddy, B. S. Fletcher and H. R. Herschman, JBC 268,5425 (1993). 72. J. W. Han, H. Sadowski, D. A. Young and J. G. Macara. PNAS 87, 3373 (1990). 73. A. Raz, A. Wyche, N. Siegal and P. Needleman, ]BC 263, 3022 (1988). 74. A. Dim, A. M. Reginato and S. A. Jimenez, JBC 267, 10816 (1992).
THE
75. 76. 77. 78.
tis
GENES
147
W. L. Smith and W. E. M. Lands, Bchem 11, 3276 (1972). R. W. Egan, J. Paxton and F. L. Kuehl, Jr., JBC 251, 7329 (1976). A. H. Lin, M. J. Bienkowski and R. R. Gorman, JBC 264, 17379 (1989). K. K. Wu, R. Sanduja, A. L. Tsai, B. Ferhanoglu and D. S. Loose-Mitchell, PNAS 88, 2384 (1991). 79. J. A. Maier, T. Hla and T. Maciag, JBC 265, 10805 (1990). 80. A. Raz, A. Wyche and P. Needleman, PNAS 86, 1657 (1986). 81. E. M. Doerfler, L. R. Danner, H. J. Shelhamer and E. J. Parrillo, J. Clin, Inoest. 83,970 (1989). 82. G . D. Bottoms, M. A. Johnson, C. H. Lamar, J. F. Fessler and J. J. Turek, Circ. Shock 15, 155 (1985). 83. A. A. Aderem, S. D. Cohen, D. S. Wright and A. Z. Cohn, J . E r p . Med. 164, 165 (1986). 84. J. I. Kurland and R. Bockman, J. E r p . Med. 147, 952 (1978). 85. W. R. Fuller, R. C. Kelsey, J. P. Cole, T. C. Dolleryand J. MacDermot, Clin. Sci. 67,653 (1984). 86. T. Hla and K. Neilson, PNAS 89, 11586 (1992). 87. J. J. Pash and M. J. Bailey, FASEB J. 2, 2613 (1988). 88. D. A. Kujubu and H. R. Herschman, JBC 267, 7991 (1992). 89. B. J. Rollins, P. Stier, T. Ernst and G . G. Wong, MCBiol 9, 4687 (1989). 90. R. S. Kawahara, Z. W. Deng and T. F. Deuel, JBC 266, 13261 (1991). 91. M. Poon, J. Megyesi, R. Green, H. Zhang, B. Rollins, R. Sahstein and M. Taubman,JBC 266, 22375 (1991). 92. R. R. Freter, J. C. Irminger, J. A. Porter, S. D. Jones and C. D. Stiles, MCBiol 12, 5288 (1992). 93. X. W. Ping, C. Warden, B. S. Fletcher, D. A. Kujubu and H. R. Herschman, Genomics 15, 458 (1993). 94. C. Yokoyama and T. Tanabe, BBRC 165, 888 (1989). 95. S. A. Kraemer, E. A. Meade and D. L. DeWitt, ABB 293, 391 (1992). 96. J. Fi, J. L. Masferrer, K. Seibert, A. Raz and P. Needleman, JBC 265, 16737 (1990). 97. J. M. Farber, MCBiol 12, 1535 (1992). 98. R. J. MacKay, J. L. Pace, M. A. Jarpe and S. W. Russell, J. Zmmunol. 142, 1639 (1989). 99. T. A. Phillips, D. A. Kujubu, R. J. Mackay, H. R. Herschman, S. W. Russell and J. L. Pace, J. Leukocyte Biol. in press (1993). 100. S. H. Lee, E. Soyoola, P. Chanmugam, S. Hart, W. Sun, H. Xhong, S. Liou, D. Simmons and D. Hwang, JBC 267, 25934 (1992). 101. M. G . O’Sullivan, E. M. Huggins, Jr., E. A. Meade, D. L. DeWitt and C. E. McCall, BBRC 187, 1123 (1992). 102. T. A. Hamilton and D. 0. Adams, Zmmunol. Today 8, 151 (1987). 103. D. Boraschi, S. Censini, M. Bartalini and A. Tagliabue, J. Zmmunol. 135, 502 (1985). 104. R. B. Lorsbach, W. J. Murphy, C. J. Lowenstein, S. H. Snyder and S. W. Russell, JBC 268, 1908 (1993). 105. G. J. Roth, C. J. Siok and J. Ozols, JBC 255, 1301 (1980). 106. F. J. Van der Ouderaa, M. Buytenhek, D. H. Nugteren and D. A. Van Dorp, BBA 487, 315 (1977). 107. C. J. Lowenstein and S. H. Snyder, Cell 70, 705 (1992). 108. C. Nathan, FASEB J. 6, 3051 (1992). 109. L. J. Ignarro, G. M. Buga, K. S. Sood, K. E. Byrnes and G. Chandhuri, PNAS 84,9265 (1987). 110. R. M. J. Palmer, A. G. Ferrige and S. Moncada, Nature 327, 524 (1987). 111. J. Hibbs, Jr., R. Taintor, Z. Vavin and E. Rachlen, BBRC 157, 87 (1988).
148
HARVEY H. HERSCHMAN ET AL.
112. R. D. Curran, T. R. Billiar, D. J. Stuehr, K. Hofinann and R. L. Simmons, J. Exp. Med. 170, 1769 (1989). 11.3. C:. J. Punjabi, D. L. Laskin, D. E. Heck and J. D. Laskin, J . Itntnunol. 149, 2179 (1992). 113. J. Pfeilschilier and H. Schwarzenbach, FEBS Lett. 273, 185 (1990). 11.5. I). S. Bredt, P. M. Hwang, C. E. Glatt, C. Lowenstein. R. H. Heed and S . H. Snyder, .Vatitre 351, 714 (1991). 716. I). J. Stuehr. H. J. Cho. N. S. Kwon and C. F. Nathan, PNAS 88, 7773 (1991). 117. S. P. Janssens, A. Shirnouchi, T. Quertermous, I>. B. Bloch and K. D. Bloch, JBC 267, 14519 (1992). 116. S. Lamas, P. A. Marsden, C. I;. Li, P. Tempst and T. hiichel, PNAS 89, 6348 (1992). 119. if'. C. Sessa, J. K. Harrison, C. 51. Barber, D. Zeng, M. E. Dureiux, D. D. D'Angleo, K. H. Lynch and M . J. Peach, / B C 267, 15274 (1992). 120. C. J. Lowenstein, C. S. Glatt, D. S. Bredt and S. H. Snyder, PNAS 89, 6711 (1992). 121. C, H. Lyons, G. J. Orloff and J. M. Cunningham, JBC 267, 6370 (1992).. 122. (2. Vv'. Xie, H. J. Cho, J. Calaycay, R. A. Mumford, K. M. Swiderek, T.D. Lee, A. Ding, T. Trow and C. Nathan, Science 256, 2% (1992). 123. 51. Di Rosa. M . hdomski, R. Carnuccio and S. Moncada, BBRC 172, 1246 (1990). 124. R. S. Gilbert and H. R. Henchman, J . Cell. Physiol. 157, 128 (1993).
Nuclear Pre-mRNA Processing in Higher Plants
’ KENNETH R.
LUEHRSEN, SHARIFTAHAAND VIRGINIA WALBOT
’
Department of Biological Sciences Stanford Unioersity Stanford, California 94305
I. Biochemistry of Splicing and Intron Recognition . . . . . . . . . . . . . . . . . .
............................ ts ofMaize . . . . . . . . . . . . . . . . . . ................. icing . . . . . . . . . . . . . . . . . . . .............
VI. Perspective . References. ..................................................
150 158 174 183 185 188 190
The nuclear genes of eukaryotes include both protein-coding and noncoding segments. Protein-coding segments are exons, and introns are noncoding regions that separate exons. Introns are included in the primary transcript (pre-mRNA), but are excised in the nucleus before the mature mRNA is translated into protein. Since the discovery of introns in 1977, several theories have been proposed to explain their prevalence. One proposal is that introns were present in primordial genes, and acted as “hotspots” of recombination for the rapid exchange of exons and the generation of new enzymatic activities (1, 2). An alternative view is that introns were acquired much later (3, 4 ) possibly through the action of transposableelement (TE)1 insertions (5). Evidence has accumulated to support both views, which are not mutually exclusive. 1 Abbreviations: AS, alternative splice site; BMS, Black Mexican Sweet; bp, base pair; CaMV, cauliflower mosaic virus; CAT, chloramphenicol acetyltransferase; cDNA, complementary DNA; CS, change-of-state; GUS, f3-glucuronidase; kb, kilobase pair; m,G, 2,2,7trimethylguanosine; nt, nucleotide; PTB, polypyrimidine-tract binding protein; RNAP, RNA polymerase; PCR, polymerase chain reaction; snRNA, small nuclear RNA; snRNP, small nuclear ribonucleoprotein; TE, transposable element; TIR, terminal inverted repeat; UTR, untranslated region. Gene symbols: A, anthocyaninless; Ac, activator; Adh, alcohol dehydrogenase; Bz, bronze; Ds, dissociator; dSpm, defective Spm; Gpc, glyceraldehyde-3-phosphatedehydrogenase, cytosolic; hsp, heat-shock protein; Lc, leaf color; Mu, mutator element; Nos, nopdine synthase; rbcS, ribulose-1.5-bisphosphate carboxylase, small subunit; P, pericarp; Sh, shrunken; Spm, suppressor-mutator; tnp, transposase protein; Wx, waxy
Progress in Nudeic Acid Research and Mokcular Bialopy, Val. 47
149
Copyright 0 1994 by Academic Press, Inc. All rights of reproduction in any form reserved
150
KENNETH R. LUEHHSEN E T AL.
There are five classes of introns: (1)Some tRNAs contain an intron in the anticodon loop; these are excised by specific endonuclease and ligase activities. (2) Trans-splicing of pre-mRNAs occurs in some lower eukaryotes (i.e., trypanosomes and Caenorhabditis elegans) and results in the addition of a leader exon to the 5’ end of some mRNAs. (3)Group I introns are found in the genes of lower eukaryotes, in the mitochondria1 genes of plants and animals, and in the chloroplast genes of higher plants; these introns fold into a complex secondary structure and autocatalytically self-splice in the absence of protein. (4)Group I1 introns have a distribution similar to group-I selfsplicing introns, although some have an associated “maturase” protein. Group-I and group-I1 introns are distinguished by different secondary structures and the requirement of a guanine nucleotide cofactor for group-I intron splicing. (5) Nuclear pre-mRNA introns are present in some genes of all eukaryotes; these introns are spliced in large ribonucleoprotein particles called spliceosomes (6). Self-splicing group-I1 and nuclear pre-mRNA introns are processed by a similar mechanism, suggesting that the latter evolved from the former (7, 8). The focus of this review is on nuclear pre-mRNA splicing in plants (with emphasis on maize); several recent reviews have discussed the other intron types (9-12). We first discuss the salient points of nuclear intron splicing in yeast and animals. We review the literature on small nuclear RNAs and plant intron splicing, and present a working model for plant intron recognition. We then evaluate the alternative RNA processing events for several transposable-element-induced mutations of maize as a test of the intronrecognition model.
1. Biochemistry of Splicing and lntron Recognition A. Cis Requirements Although the enzymology of pre-mRNA splicing is still being studied, several reaction intermediates have been well-characterized, allowing a detailed hypothesis of the mechanism (see Figs. 1 and 2). Intron removal is the ~~
~
~~
-7
FIG. 1. Outline of the nuclear pre-mRNA splicing process in yeast, mammals, and plants. (-4) A generalized structure for yeast and mammalian introns. After transcription, the U1 snRNP is the first to bind the intron (dotted line). The U2 snRNP binds near the branchpoint (BP), followed hy U4/U6-U5 tri-snRNP addition to assemble the functional spliceosome. The first cleavage releases the 5‘ exon and the lariat-exon 2 intermediate. The second cleavage reaction results in the ligation of exons 1 and 2 and the release of the lariat intron. (B) A typical plant gene is composed of (A + T)-rich introns adjacent to (G C)-rich exons. The question mark indicates that the reaction mechanism for plant splicing has not been determined. polyT, Polythvniidine tract; polyY, polypyrimidine tract; BP, branchpoint.
+
A Yeast
BP
B
A+Trich
polyT 777
An
5'
\L
......
BP
3
152
KENNETH H. LUEHHSEN E r AL.
u’5 F I G 2. Base-pairing interactions between SIIRNASand the pre-mRNA during splicing. The Iuse-pairing interactions of the pre-mRNA and snRNAs are shown; the hybrids probably do not form coincidentall!; hut appeaF and disappear in an as yet undetermined temporal order. ‘The base-pairing interactions between the snRNAs are not shown. Lower-case letters are intron sequences (dotted line). BP. Branchpoitit; 0. m,G cap structure. Redrawn from 29.
result of two trans-esterification reactions. In the first, the 5’ end of the intron is cleaved by a nucleophilic attack by the 2’ OH from a branchpoint nucleotide (usually an A) near the 3’ end of the intron. The resulting reaction products are the upstream exon (with a 3’ OH) and the intron-downstream exon; the intron has a “lariat” structure and a 2‘-5’ linkage (branch structure) at the branchpoint nucleotide. In the second trans-esterification, the first nucleotide of exon 2 is the target of a nucleophilic attack by the last nucleotide of exon 1, and the resulting cleavage-ligation reaction produces the ligated exons and the excised intron (lariat form). The mature inRNA is transported to the cytoplasm, but the excised intron is degraded in the nucleus. Introns must be recognized and excised with great fidelity, because nucleotide additions or deletions in an open-reading-frame usually results in the translation of a nonfunctional polypeptide. What are the cis-acting sequence features that distinguish introns from exons? Although introns can be
SPLICING IN HIGHER PLANTS
153
several kilobases in length, they contain three or four short (<30 nucleotides) highly conserved sequence motifs as diagrammed in Fig. 1. Almost all introns have the dinucleotides G-U and A-G at the 5'-donor and 3'-acceptor ends, respectively, and these dinucleotides are part of longer, less conserved 5' and 3' splice junction sequences (Table I). Another conserved sequence is the branchpoint, which is the invariant UACUAAC in yeast and the variable UNCURAC in mammals; no conserved branchpoint sequence has been identified in plants (13, 14). Finally, mammalian introns have a 20to 30-nt polypyrimidine tract found just distal to the branchpoint region. Although yeast and plant (15) introns do not have a well-defined polypyrmidine tract, they usually have a 15- to 20-nt U-rich region immediately upstream of the 3' acceptor; the U tract is involved in 3'-acceptor choice in yeast (16) and possibly in plants (16a, 16b). In addition to the conserved motifs found at each splice junction, plant introns are more (A + U)-rich than the surrounding exons, and this feature is functionally important for plant splicing. Although mammalian introns do not have a base-content bias, the introns from some lower eukaryotes (such as Tetrahymena and C . elegans) are (A + U)-rich (17); it is not known if this feature is essential for splicing in these organisms. The important features of nuclear pre-mRNA splicing in yeast and mammals, ascertained using both in viva and in vitro splicing assays ( 1 1 , 18),are outlined in Fig. 1. The conserved motifs in pre-mRNAs are necessary for specific base-pairing interactions with small nuclear RNA (snRNAs) in the spliceosome (12);the snRNAs are thus involved in intron recognition and are also probably involved in catalysis. The snRNAs that base-pair with the conserved intron elements are complexed with proteins to form four different ribonucleoprotein particles (snRNPs). The splicing process is initiated when U1 snRNP associates with the 5' splice junction, and six conserved nucleotides (Table I) at the 5' end of U 1 snRNA base-pair with the intron 5' splice junction (19). Mutation of the pre-mRNA 5' splice junction can severely diminish splicing or activate cryptic splice sites upstream or downstream of the native site, illustrating the importance of this base-pairing interaction in 5' splice site choice (20, 21). Recent evidence from Schizosaccharomyces pombe shows that two nucleotides of U 1 base-pair with the conserved A-G at the 3' splice junction (22);this interaction probably serves to position the 5' and 3' splice junctions in close proximity to one another (see Fig. 2). In the next stage of assembly, U2 snRNP binds to the branchpoint region with concomitant base-pairing of U2 RNA with the branchpoint sequence (23-25). U2 snRNP binding in mammalian introns is facilitated by the prior association of the polypyrimidine-tract binding-protein (PTB) with the
TABLE I PLANTCONSENSUS SPLICEJUNCTION SEVUENCES~~ Expected match to consensus (%) Consensus splice-junction sequence
-2 to t 6
-1 to +6
5.2 4.6 5.2 17.9 8.9
8.4 7.3 8.5 40.6 14.4
5' sequence
All plants (%). Monocot (72); Ilicot (%): Yeast (96): Vertebrate (%)
-2
-1
A
G 81 80 82 50 77
I
-7 U 40 50
62 63 61 44 (T) 62 U
+1 G
+2 U 100
+3 A
100 100 100 100
100 100 100 100 A
70 68 70 97 60 U
-6 U 44
-5 U
so
67
-4 G 48 42
-3 C 81 60
100
c
c
+4 A 52 45 56 89 74 U
+5 G 54 60 49 100 84
-2
-1
A 100 100
G 100 100
c
+6 U 53 50
54 94 50 A , . . 5' U1 sequence
3' sequence Monocot (a): Dicot (8):
-8 U 43 47
64
+1 G
+2
64
42 44
58
U -
UThe plant data are derived from the compilation of 346 monocot and 528 dicot introns reported in 14. T h e yeast and vertebrate data are derived from 17. T h e vertical bar represents the intron-exon junction
SPLICING IN HIGHER PLANTS
155
neighboring polypyrimidine tract (26).Finally, the U4/6-U5 tri-snRNP associates with the 3’ splice junction, resulting in the functional spliceosome. A conserved single-stranded loop of U5 snRNA base-pairs with the exon dinucleotides immediately proximal and distal to the intron in yeast (27, 28), and possibly mediates a proofreading function (12). Using the known basepairing interactions of U1, U2, and U5 with the pre-mRNA, a composite secondary structure can be drawn that resembles the Holliday structure used to model DNA recombination [Fig. 2 (29)]. U1 base-pairs to the conserved 5‘ G-U and 3’ A-G dinucleotides found at the ends of all introns, U2 base-pairs to the branchpoint region, and U5 binds the up- and downstream exons. In addition to snRNA base-pairing to the pre-mRNA, there is also evidence that both U2 and U4 base-pair with U6 sometime during the process of splicing (30-33). Less is known about the subsequent enzymology of the splicing reactions (12). But because nuclear pre-mRNA introns share many features with group-I1 self-splicing introns (7, 8), RNA catalysis has been proposed. Recently, it was suggested that U6 snRNA acts as a ribozyme and may be the catalytic site for the trans-esterification reactions (32, 34). This hypothesis is supported by the observation that U6 is similar in sequence to self-splicing viral RNAs. In addition, the U6 genes of several fungi have intron insertions in this same region ( 3 4 , suggesting that the introns may have arisen by a reverse splicing mechanism. The same region of U6 proposed to be involved in RNA catalysis also base-pairs with U4 snRNA, suggesting that U4 acts as an antisense repressor (35) until U6 is needed to mediate cleavage and ligation. Because plants, yeast, and animals all contain the same snRNAs, it is reasonable to assume that plant introns are spliced by a mechanism similar to that of other kingdoms. A more detailed discussion of plant snRNAs is presented in Section 1,B.
9. snRNAs In mammals, there are 14 separate snRNAs, designated U1 through U14 (36, 37). They were named sequentially in the order of their discovery, and are termed U-RNAs because of their high uridine content. The snRNAs are involved in pre-mRNA splicing (Ul, U2, U4, U5, and U6), rRNA maturation (U3, U8, U13, and U14), mRNA polyadenylation (Ull), and histone 3’-end formation (U7). Each snRNA is encoded by a multigene family, although there is little sequence or length heterogeneity within each family (37).The snRNAs involved in splicing range in size from -100 to 200 nt in mammalian cells, and are present in about -106 copies per cell (summarized in Table 11). U1, U2, U4, and U5 are transcribed by RNA polymerase (RNAP) 11, whereas U6 is transcribed by RNAP I11 (reviewed in 9, 38). U1, U2, U4, and U5 have a 2,2,7-trimethylguanosine(m,G) cap; the cap is added posttranscrip-
____ Mammalian
pldllt
Cior1ed Transcri1)etl
mRNA U1
1)Y RNA pol I1
m )Go cap? Yw
Length (nt)
wRNP
4.s5OClatt.d protein
Funcbtlon
U1 Last, pairs to 5’ and 3’
I fi5
splice junctions
U2
U4
RNA pol 11
HNA pol I 1
Yes
Y1.s
189
139
u2
U 4 U 6 and
A’. B‘J
Core
“t+ snRNP”
U2 base pairs with branchpoint conSellSuS
Comment First step in recognition; ycast Cll is
- L en g t h (nt)”
G e n o m e copy
15H-I85
Pea (>6)
Yeast U2 is 1175 nt
208-260
Potato
(25-40).
Arubidupsis (10- 15). maize (25-40)
RNA pol 11
Yes
117
U5 and “tri- Core pliis snRNP” several unique
Proofreading?
Affects 5‘ and 3‘ spliet. site choice
125-137
U6
RNA pol 111
No”
107
U4iU6 and “tris nR N P
Catalytic center
N u Sm binding site; Ufi added to mature U4 snRNPs in nucleus; homology with selfsplicing viral RNAs; fungal introns
101-104
Potato (lo),Ara-
bidopsis (7). maize (1). pea (3). wheat (3) Beanv (2). pea (3)
160-176
Antisense regulator of Ufi
gene\) Pea (6). soy” bean (21, hean- (I), tomato (9). wheat (6)
S69 n t
U5
Core
( n u m b e r of
Potato (>20)
Arabidupsis (I), tomato (l), maize (1). bean‘ (I), wheat (I), potato (1)
~2,2,7-Trimethylguanosine. *Monocots and dicots. .-The core proteins are named B, B’, D,. D,, D,, E, F. and 6; they range in size from 9 to 29 kDa. The F protein probably rccognizcs the Stn binding site dThe U1 snRNP A1 and 70-kDa proteins have nnclear localization sequences. ePhaseolus uulguris. fThe U2 snRNP A’ and B proteins have nuclear localization sequences.
nVicia faba. hU6 RNA is capped with m7guanosine.
SPLICING IN HIGHER PLANTS
157
tionally in the cytoplasm and is partially necessary for nuclear localization. U6 RNA has the standard m7G cap and does not leave the nucleus following transcription. The snRNAs have extensive secondary structure, a feature that is highly conserved among phyla (37). Splicing snRNAs are each complexed with several proteins and form snRNPs, which together form the spliceosome particle. Less is known about the structure and function of plant snRNAs. Plants contain U1, U2, U4, U5, and U6 snRNAs that are homologous to the known mammalian snRNAs and are presumably involved in pre-mRNA splicing (39, 40). Each plant snRNA can be folded into the same secondary structure as its yeast and animal counterpart (41), strongly implying a similar function in plants and animals. Like mammals, plant U1, U2, U4, and US are transcribed by RNAP 11, whereas U6 is transcribed by RNAP I11 (9). Plant U l , U2, U4, and U5 contain the m3G cap (41), indicative of posttranscriptional modification in the cytoplasm and subsequent import into the nucleus. Like mamm4ian U6, plant U6 does not have the m3G cap structure (42). Plant snRNAs are present in only -104 copies per cell versus the typical 106 per cell typical of mammalian cells. Heterogeneity of both length and sequence distinguishes plant snRNAs from those of both yeast and mammals (Table 11) (40). Unlike the snRNA gene families in mammals, which contain tandem repeats, plant snRNAs are encoded by multigene families at unlinked loci (43-45). Within tandem repeats, individual genes are homogenized by gene conversion. In contrast, unlinked plant snRNAs are free to diverge within the constraint of selection pressure to retain function. The sequence variations in plant snRNAs (41)are not in regions reported to be involved in intermolecular RNA-RNA basepairing interactions; this evidence suggests that the snRNA-pre-mRNA interactions described in yeast and mammals (12) are probably retained in plants. In the regions of intramolecular base-pairing, snRNA sequence variants always have a compensatory change in the complement, making it likely that plant snRNAs retain the conserved secondary structure (41). However, there are base changes in plant snRNAs that occur in regions associated with protein binding (41). This observation opens up the possibility that these variants might bind tissue- or intron-specific snRNP proteins, but there is no experimental evidence to support this conjecture. Curiously, the expression of pea U1, U2, U4, and US snRNAs is developmentally regulated, while a single size class of U6 is constitutively expressed (46). Members of the U1, U2, U4, and U5 families are differentially expressed in seed, seedlings, and mature leaves. U1 and U4 variants appear and disappear during seed development, as the seed progresses through maturation and reaches a transcriptionally inactive state. Another shift in U1 and U4 populations occurs as the seedling develops into a mature plant. An
158
KENNETH R. LUEHRSEN ET AL.
identical pattern of U1 and U4 expression is seen in mature seeds and mature leaves, both of which are transcriptionally quiescent, suggesting that a subset of U1 and U4 variants is correlated with transcriptional activity of the cell, but not with tissue type. It is possible that some snRNA variants facilitate efficient splicing in cells that are rapidly transcribing many introncontaining genes. snRNAs are complexed with proteins to form functional particles called snRNPs (47). In mammals, there are eight proteins (named B, B’, D,, D,, D,, E. F, and G in 47) that constitute the core proteins bound to all snRNPs; there are many additional proteins unique to each snRNP. One distinguishing feature of U1, U2, U4, and U 5 is the Sm binding site, a 9- or 10-base U-rich region where the core snRNP proteins bind. U 6 does not have the Sm binding site, but this snRNA binds U4 through a long region of complementarity. By biochemical fractionation, four distinct snRNPs have been isolated: U1, U2, U4/6, and U5. In oioo, U4/6 and U 5 exist as a “tri-snRNP.” The functional spliceosome is made by a stepwise addition of these snRNPs and additional proteins to the pre-mRNA (reviewed in 11, 18, 48). In mammals, snHNAs are localized in discrete regions of the nucleus (49, 50), suggesting a nonrandom placement of the RNA processing machinery. The characterization of plant snRNP proteins is just beginning. The U5 snRNP has been purified from broad bean ( V i c i ~ f ~and, b ~ based ) on immunological cross-reactivity, several snRNP proteins are shared among plants and mammals (51).This suggests that the protein components of the splicing machineries have been conserved among plants and animals. Recently, a cDNA for the U2B” gene has been cloned from potato (52, 53). Comparing potato and mammalian U 2 B , there is 70% similarity in amino-acid sequence (including conservative changes), again suggesting that the mammalian and plant splicing apparatus share more similarities than differences (52). One important difference between plant and animal introns is the requirement that plant introns be (A + U)-rich to be efficiently spliced (see Fig. 1 and Section 11, D). It remains to be seen if there are proteins involved in splicing in plants that are not found in yeast and mammals. As will be discussed, plant introns contain (A + U)-rich sequences that facilitate efficient splicing, and these motifs might interact with a novel binding protein.
II. Plant Splicing A. Methods Used to Assay Plant Splicing Analysis of splicing in yeast and mammals has utilized both in vivo and in oitro assays. Each approach has strengths and limitations. In vivo splicing assays involve a natural milieu in which the pre-mRNA is appropriately
SPLICING IN HIGHER PLANTS
159
presented to the splicing machinery (i.e., coated with nuclear proteins), whereas in vitro assays, in which splicing reactions occur at -1% the rate found in vivo, permit the temporal detection of splicing intermediates. All of the plant splicing studies have been done in vivo, through the use of either transgenic plants or transfected tissue culture cells. I n viuo splicing studies using test introns inserted into an autonomously replicating vector, resulting in amplified levels of transcript, have been described (54).To date, there is no in vitro assay available for plants, precluding the identification of reaction intermediates (Fig. 1B). Many plant splicing studies involve measuring a reporter gene whose activity depends on intron splicing (55-57). Often, these assays require that splicing yield the correct reading frame, but reporter gene expression does not assess the diversity of RNA products. Alternatively, transcript-RNA structure and quantity are assessed (56, 58). Although northern blots are useful in sizing and quantifying message levels, less abundant alternatively spliced mRNAs might be overlooked. In addition, because many plant introns are small (
160
KENNETH H. LUEHHSEN
n AL.
B. Structure of Plant lntrons 1. CONSERVED Moms
A consensus 5’ splice junction sequence for both monocot and dicot introns has been proposed (14) and is shown in Table I. Plants, yeast, and vertebrates have the identical 5’ splice junction consensus sequence, AGIGUAAGV (the vertical bar indicates the position of cleavage). The G-U at positions + I and t-2 is nearly invariant with only a few exceptions (see Table 111). Positions -2 through +6 of the plant 5’ splice junction consensus are coniplementary to eight nucleotides near the 5’ end of plant U 1 snRNA, suggesting that the pre-mRNA and U 1 anneal during splicing. McCullough et nl. (21) made a series of mutations in the 5‘ splice junction of pea rhcS iritroii 1 and tested the effects on splicing in tho. As expected, mutating the canonical G-V to A-U or G-A inactivated the native splice site and simultaneously activated up- and downstream cryptic 5’ splice sites. Point mutations made at positions + 3 (A to C) and +5 (G to C) in the 5’ splice junction of a synthetic intron showed that cryptic 5’ splice sites were activated (61).These findings indicate that U 1 base-pairing to the 5’ splice junction is probably an important determinant in selecting the correct 5’ splice site. The percent match at each position of the 5’ splice junction consensus is, however. lower in plants than in either yeast or vertebrates. Considering the TABLE 111 PLANT IYTRONS WITH uNCSG.AI, SPLICE JUNCTION SEQUENCES
Gene and intron
Plant
Comment
Ref.
GC replaces G T at 5’ splice junction
126
Rice
r\DPglucose pyrophosphorylase intrm
CA replaces GT at 3’ splice junction; CC replaces AG at 3’ splice junction
127
Cucumber
Hydroxypyruvate reductase intron 6
GC replaces GT at 5’ splice junction
3
hl ai zt’
d S I m type-11 deletion variant
GC replaces GT at 5’ splice junction
128
Sfaize
M d 3 R gene-A intron 3
GC replaces GT at 5’ splice junction
1.
hlaize
fcx-frI9
CG replaces AG at 3’ splice junction of an alteriiatively spliced n1RNz4
129
-7
Hershberger and V. Walbot (unpublished)
SPLICING IN HIGHER PLANTS
161
overall conservation of 5’ splice junction sequences, the product of the percent match (Table I) at positions -2 through + 6 (or -1 through +6) predicts that only 5.2% (8.4%)of plant introns will be an exact match to the consensus; this contrasts with the 17.9%(40.6%)and 8.9% (14.4%)values calculated for yeast and vertebrates, respectively. In particular, the G at position + 5 is 100%and 84%conserved in yeast and vertebrates, respectively, and is essential for efficient splicing in yeast (62).A consensus G is found at position + 5 of plant introns, but occurs in only 54%of all introns. Mutating the G at +5 to an A or a C had little effect on splicing efficiency in dicots, indicating that this nucleotide is not as important to 5’ splice-site function as it is in yeast and vertebrates (21).The A at + 4 is also well conserved; it is present in only 52% of plant intron 5’ splice junctions, in contrast to the 89%and 74% of yeast and vertebrate junctions, respectively. The relaxed sequence motif of plant 5’ splice junctions suggests that additional intron features may specify intron recognition. The lack of precise complementarity between U 1 and a typical 5’ intron sequence acquires added significance when the life history of plants is considered. Laboratory yeast and mammalian cells are maintained at a relatively fixed temperature, whereas plants experience diurnal fluctuations of 1020°C, or more. Considering the range of temperatures at which splicing occurs in plants, it is highly unlikely that base-pairing across an imperfectly conserved motif is sufficient for correct 5‘ splice choice. The disparity in base content between introns and exons (discussed in Section 11,B,2)might be an additional signal. It is also possible that 5’ and 3’ splice junctions interact during splicing and must be “matched for efficient processing (63). All but two plant 3’ splice junctions reported so far (see Table 111) have the canonical 3’ acceptor A-G at the end of the intron; the A-G is part of a weakly conserved, longer consensus shown in Table I. Unlike animal introns, plant introns do not have a well-defined polypyrimidine tract 20 to 50 nt upstream of the acceptor A-G (13, 15). Instead, there is a very strong bias for U nucleotides proximal to the 3‘ A-G acceptor; 10 or more of the 13 nt proximal to the 3’ A-G acceptor are U (15).A U-rich tract in yeast maximizes splicing at the proximal A-G (16), and recent experiments suggest that 3’ acceptor usage may be enhanced by a proximal U-rich tract in plants in conjunction with an adjacent (G + C)-rich exon sequence (I&, 16b). Introns from yeast and mammals have a conserved branchpoint sequence, 20 to 50 nt upstream of the 3’ acceptor. In yeast introns, the branchpoint occurs at the highly conserved motif UACUAAC (A is the branch nucleotide), while in mammalian introns there is a more relaxed consensus sequence, UNCURAC. U2 base-pairs with the branchpoint sequence during splicing (23-25). Surveys comparing plant introns detected no similar or
2
u 0
P
3
a
2
-
5 0
4.5
4.4
4.3
4.2
4.1
4.0
3.9
3.8
3.7
3.8
3.5
3.4
3.3
3.2
3.1
3.0
2.9
2.8
2.7
2.8
2.5
2.4
2.3
2.2
2.1
2.0
1.9
1 .B
1.3
0 1
N 0
i
A
0
o i
0
:
w
3
2:
z P i
0 i
SPLICING I N HIGHER PLANTS
163
other conserved “branchpoint” sequence (13,14).The structural similarity of plant, yeast, and animal nuclear introns and the presence of U2 snRNA in plants make it likely that the biochemistry of splicing is similar among phyla, but there is no direct evidence of lariat formation in plants. Thus, if U2 basepairs with a plant branchpoint sequence, only a few base pairs might be involved, with mismatches possibly accommodated through stabilization by snRNP proteins. The branchpoint nucleotide in yeast and mammals is usually an A. Mutating adenosine residues in an artificial intron of 85 nt demonstrated (61, 64)that no adenosine residue is required within -50 nt of the 3‘ acceptor A-G for efficient splicing in either tobacco or maize. If a lariat intermediate is formed during plant splicing, the data show that nucleotides other than A can substitute as a branchpoint acceptor.
2.
INTRON
LENGTHAND BASECONTENT
Plant and animal genes differ greatly in the average length of their introns. Animal introns range in size from 31 nt to over 105 nt (65), but plant introns are grouped in a much narrower size range, from 66 nt to less than 104 nt; a survey illustrating the length difference between plant and vertebrate introns is shown in Fig. 3. Plant internal introns (within coding regions) average only 249 nt versus 1127 nt for vertebrates and 86 nt for fungi (65).Furthermore, for example, 80% of all maize introns are less than 200 nt. Plant introns are thus more like introns from other lower eukaryotes (e.g., Tetrahymena, Caenohrabditis), which are also short (17 , 65). Can plants splice long introns efficiently? The maize Lc gene contains a 3-kb intron and the transposable element Spm contains a 4.4-kb intron, and each is efficiently spliced. The longest plant intron reported is the 7-kb intron from the maize Pericarp gene; it is also efficiently (and alternatively) spliced (66, 67). Results from experiments using synthetic introns indicate that a minimum intron length of 70-73 nt is necessary for efficient splicing in both monocots and dicots (68).This is consistent with the size distribution of natural introns; for example, only 3% of maize introns are less than 73 nt. The minimum size of plant introns is similar to the minimum length of -80 nt required for efficient splicing in mammals. A minimum intron length is probably necessary to allow multi-snRNP binding to a small region of the pre-mRNA. Perhaps the most striking difference between plant and animal introns is the strong bias for high (A U) content in plant introns versus exons (17 , 61,
+
FIG. 3. Graph showing the size distribution of plant (hatched bars) and vertebrate (solid bars) introns. The lengths of 297 vertebrate (125) and 244 plant introns were compiled and grouped into bins according to the log 10 value for length. Note that very few introns fall below 101.8 (-64 nt), the minimum length required for efficient splicing of plant and animal introns.
164
KENNETH R. LUEHRSEN ET AL.
69, 70). A survey ( I 7 )of base-pair content of introns and exons indicates that plant introns are, on average, 15% more (A + U)-rich than exons; this contrasts with humans, where the difference is only 2%. A more recent analysis (14) showed that dicot introns and exons average 71% A + U and 55% A + li, respectively. A similar differential is found in monocot introns and exons, which average 61% A + U and 42% A + U , respectively. Our survey of the base content of maize introns and exons (Fig. 4) shows that introns average 60%A + U, with a bias for U (34%)over A (26%);in contrast, maize exons average only 42% A + U . The disparity in base composition between introns and exons have been proposed to be a feature defining intron borders (21, 61, 64, 69). The genes of other organisms, such as Tetruhytiwnu and Cmnohrubditis, also show a difference in the (A + U)-content of their introns and exons (17), indicating that this base content disparity might be widespread in nature. Several experiments described in Section 11,D show that the (A + U)-richness of plant introns is essential for intron recognition, selection of 5’-donor and 3’-acceptor sites, and efficient splicing.
C. Assays of lntron Splicing in HeteroIogous Systems The similarity of plant and animal introns was first assessed by testing how well the introns are spliced in a foreign host. A summary of the reported experiments is presented in Table IV. The general conclusion is that, whereas plant introns are usually spliced in mammals, mammalian introns are
A
C G exans
U
A
C G introns
U
FIG.4. Base-content survey of maize introns and exons. The 26 maize genes for which the complete gene structure was determined are included in the survey of 184 exons (47,078 total nucleotides) and 152 introns (42.134 total n d e o t i d e s l
165
SPLICING IN HIGHER PLANTS
either not efficiently or not faithfully processed in plant cells. For example, six of nine plant introns tested were spliced either in HeLa cells or in a HeLa in vitro splicing extract. Bean phaseolin intron 1 was poorly spliced in a HeLa splicing extract (71), but the intron is 72 nt and below the minimum length of -80 nt generally required for mammalian introns (72). Soybean leghemoglobin introns 1and 3 were inaccurately spliced in HeLa cells (69), because cryptic 3' acceptors were used; this is possibly a consequence of plant introns not having a polypyrimidine tract. That some plant introns are faithfully and efficiently spliced in HeLa cells and in vitro splicing extracts suggest that the structural similarities of plant and mammal introns reflect similarities in the biochemistry of splicing. In contrast, animal introns are not efficiently spliced in plant cells. Of the 15 animal introns tested in tobacco, 14 failed to splice efficiently or accurately. Only the SV40 small-t antigen was spliced efficiently (73);this intron is 80% A U and hence is similar in base content to plant introns. Taken together, the data suggest that plant introns contain sequence information apart from the conserved splice junctions, and that this information is not present in most animal introns.
+
D. The Role of (A
+ U)-Rich Sequences
Filipowicz and colleagues recognized that, unlike mammalian introns, plant introns are unusually (A U)-rich, although the exons surrounding them are (G C)-rich (69). They proposed that this disparity might be essential for the efficient and accurate splicing of plant introns. This hypothesis was tested (64)by constructing synthetic introns with (A + U)-rich internal sequences surrounded by consensus splice junctions. Several different synthetic introns were constructed using syn7 as a starting intron; syn7 is 85 nt in length and is composed of consensus 5' and 3' splice junctions, a mammalian branchpoint consensus sequence (CUUAC), and an (A U)-rich internal sequence. The entire intron is 75% A U. The synthetic introns were placed in a (G C)-rich (60%) exon environment upstream of an intron-containing leghemoglobin gene, and the gene chimeras were assayed in transgenic tobacco calli and transiently in Nicotiana plumbaginilfolia. Spliced and unspliced transcripts were analyzed by RNase protection to determine splicing efficiencies. When tested in N . plumbaginilfolia, syn7 was efficiently spliced (82%),above the 55% value for the linked leghemoglobin control intron. This experiment indicates that a synthetic polyribonucleotide can function as an intron and suggests that no previously undetected conserved sequence is required for efficient splicing. Curiously, unspliced transcripts were abundant (> 10% of total transcript) in transient assays but were barely detectable in transgenic calli. No splicing intermediates (such as a lariat structure) were detected.
+
+
+
+
+
TABLE IV SP1,IC:INC; OF INTHONS IN f1ETEHOLOGOUS HOSTS
Organism
Plants Pea
Gene
rbcS
Wheat Maize Wheat Pea Oat Bean
rhcS Adhl Amylase Legumin J Phytochrome Phaseolin
Maize Soybean
bronze-1 Leghemoblobin
Soybean
Leghemoglobin
Sorghum Bean
PEPcarboxylase Phaseolin
Soybean Maize
Leghemoglobin .4ctin
Maize
waxy
Intron
Spliced in
Introns 1 and 2 Intron 1 Intron 6 Intron 2 Intron 1 Intron 1 Intron 1
HeLa in oitro
Intron 1 Introns 1 and 3 Intron 2
HeLa in uitro
All Introns 1 through 5 Intron 1 Introns 1 and 2 Introns 9 and 10
__ HeLa in citro HeLa in oitro HeLa in uitro
-
-
Not (or poorly) spliced in
Comment
Ref. 130
50% spliced 30% spliced
Tobacco Tobacco
-
-
__
-
HeLa in oitro
HeLa cells
Intron is 72 nt; splices poorly in monkey cells -
Each splices at alternative 3’ acceptor
131 131 132 132 71 71
71 69
69
HeLa cells and in uitro Tobacco Maize
-
Maize Nicotiuna plumbaginifolio Nicotiana plumbuginifolia
133
Also splices in tobacco
61
Also splices in tobacco Intron 1 only 42% spliced in Nicotiunu plumbaginifolia Introns 9 and 10 are 40% and 42% (A + U), respectively
61 61 61
Bean
Phaseolin
Intron 3
Maize
Adhl
Maize
Adhl
Introns 1 and 2 Introns 3.and 6
-
Tobacco
-
Tobacco
-
Tobacco
Yeast Cryptococcus
Animals Human Human Human
Intron 1 through 7
Growth hormone
Intron 1 through 4 Intron 1 Introns 1 and 2
-
Introns 1 and 2 Introns 1 and 2 Intron 1 Small-t antigen
-
violaceus Tobacco
-
Tobacco
-
Tobacco
a-Globin P-Globin
Drosophila
P element
Mouse
Metallothionein
Human
Metallothionein t antigen
SV40
+
Zylanase
albidus
U)-rich; 50-69 Introns are not (A nt in length; only 46-54% (A + U)
Tobacco
-
Tobacco and sunflower Tobacco Tobacco and
Orychophagmus
Tobacco
Intron inserted in the bacterial neomycin phosbhotransferase gene Introns 1 and 2 are 56% (A + U) and 54 (A + U),respectively Cryptic 3’ acceptor for intron 3; introns 3 and 6 are 66% (A + U) and 62% (A + U), respectively
334a 134a
135
136
Intron 2 is spliced at alternative 3’ acceptor Both introns -70% (A + U), but are 56 and 53 nt in length
-
Intron is 66 nt and 80% (A
71 69
137 138
-
134
+ U)
63 73
168
KENNETH H. LUEHHSEN ET AL.
The syn7 intron was 75% A + U, but was biased toward U (50%)over A (25%).To test whether an A-rich or U-rich sequence was required for efficient splicing, a synthetic intron was constructed that was again 75%A + U, but was biased for A (48%)over U (27%).The splicing efficiencies of the U-rich and A-rich introns were 82% and 9396, respectively, indicating that, in N. pltimbaginifoliu, the relative proportions of A and U did not affect splicing. As a test for whether an (A + U)-rich intron sequence is required for efficient splicing in tobacco, (G + C)-rich synthetic oligonucleotides were used to replace (A + U)-rich sequences in syn7. After replacing up to 19 A and U nucleotides (near the 3' splice junction) with G and C nucleotides, and reducing the overall (A + U)-content to 52%, the synthetic introns were still spliced efficiently (281%). When the overall (A + U)-content of the synthetic intron was decreased to 36% or <32% by further replacement (in the center of the intron) with (G + C)-sequences, the splicing efficiency was drastically reduced to 47% or 58% A U, and were spliced efficiently. These results indicate that the deleterious effects of (G + C)-rich sequences can be overcome by restoring overall AU-richness to the intron. Similarly, we found that inserting (G + C)-rich sequences into maize Alcohol &hydrogenuse-I intron-1 interferes with splicing. We inserted (G C)-rich Adhl cDNA (exon) sequences of 0.6 to 0.9 kb into different restriction sites of Adhl intron 1, increasing the overall (G + C)-content of the intron from 43% to >48% (74). The insertions were not in or near the conserved splice junctions. Each of the insertions was poorly spliced and the most deleterious phenotypes were observed when the cDNA was placed near the 5' splice junction; alternatively spliced products did not accumulate to a detectable degree on northern blots. As a control, we found that the insertion of 0.65 kb of a native intron sequence (from actin intron 3) did not interfere with intron function, showing that Adhl intron 1 can be modified with additional sequences and still function properly. We and others also found that insertions of the (G + C)-rich Mu1 transposable element into Adhl intron 1 and actin intron 3 interfere with splicing and create alternative HNA processing events (75, 76). Taken together, these experiments suggest that recognition of introns requires more than just the conserved splice junction sequences, and that the splicing machinery probably interacts with
+
+
+
+
169
SPLICING IN HIGHER PLANTS
the entire intron in a process that distinguishes (A + U)-rich introns from (G + C)-rich exons. Dicot introns generally splice efficiently in monocots, but there are several examples in which monocot introns are poorly spliced in dicots (Table IV). For example, soybean leghemoglobin intron 1 splices efficiently in the monocot maize and in the dicot N . plumbagin$olia, but both introns 9 and 10 from the maize Waxy gene are poorly spliced in N . plumbagin$olia. With few exceptions, the absolute (A + U)-content of dicot introns is >60%, and experimental results show that synthetic introns <50% in A + U are poorly spliced in N . plumbagin$olia (61).In contrast, monocot introns average 60% A + U, but several introns are less than 40% A + U. The poor splicing of the maize Wx introns in N . plumbagin$olia may reflect their unusually low (A U)-content of less than 42%, which is below the minimum required for splicing in dicots. The syn7 series of synthetic introns described above was also tested in the monocot maize (61), and the results show that (A + U)-rich introns are efficiently spliced. In addition, synthetic introns that contain up to 75% G C and that are poorly spliced in tobacco are efficiently spliced in maize; this confirms that maize cells can splice (G + C)-rich introns. Native maize introns that are (G + C)-rich have 5’ and 3’ splice junction sequences that conform more closely to their respective consensus sequences, indicating that stronger base-pairing interactions with U1-snRNA might afford improved recognition of (A + U)-poor introns (61). Collectively, these findings suggest that intron (A U)-richness is important for monocot splicing, but that there are mechanisms that allow splicing of (G + C)-rich introns. About 80% of maize introns are <200 nt, suggesting that, for short introns, there are minimal internal sequence requirements for recognition and splicing. Are the required (A U)-rich sequence motifs redundant in long introns? We have addressed this question by making internal deletions of two native maize introns while leaving the conserved intron borders intact. Removing as much as 398 bp of the 534-bp Adhl intron 1 (Fig. 5) or 352 bp of the 882-bp actin intron 3 (not shown) did not diminish splicing efficiency or intron enhancement ( 1 6 ~ )Removing . >430 bp ofAdh1 intron 1 did impair intron function, resulting in reduced intron enhancement and lower splicing efficiency, indicating that some internal intron motifs must be retained. The results suggest that there are minimal internal sequence requirements for efficient splicing, but because large deletions in long introns have no phenotype, the functional motifs are probably redundant. Is an (A U)-rich sequence sufficient to specify an intron and its borders? Using a novel approach, we inserted (A + U)-rich fragments of an intron sequence into the (G + C)-rich (-70%) exon sequence of the Bz2 gene (Fig. 6) and determined how the resulting transcripts were processed
+
+
+
+
+
170 Piasmid
KENNETH R. LUEHRSEN ET AL.
lntron Length
% Luclferase
Expression
intron Structure
pAL67
534
l l 1 1
PAL6103
244
I aa
86
pAL6776 pAL67 73
136
104
72
57
158
398
430
93
64
a 83
pAL67 70
290
100
21
21
I 5 6
4n
51
Frc. 5. Transient expression assay of plasmid constructs containing deletion variants of Adhl intron 1. The plasmid pAL.61 contains the luciferase reporter gene downstream of the Adhl intron 1; its construction has been described in detail (56).Internal deletions were made in Adhl intron 1, and the effects on luciferase expression were tested in a transient expression assay using maize tissue culture cells. The filled boxes represent the remaining intron sequence, and the line shows the deleted intron sequence; the number below each area indicates the number of nucleotides in each region.
(K. H. Luehrsen and V. Walbot, submitted). We found that inserting an internal Adhl intron 1 sequence (that lacked both splice junctions) into Bz2 resulted in the Adhl insert being wholly or partially spliced from the transcript. In one construct, the 346-bp middle of Adhl intron 1 was placed 41 bp downstream of the single Bz2 intron. We found, using the Bz2 5’ splice donor, that the Bs2 intron, the intervening 41-nt exon, and the entire Adhl insert were excised as a single intron. The native Bz2 3’ acceptor was skipped in favor of a cryptic 3’-acceptor at the border between the (A + U)rich Adhl intron sequence and the distal Bz2 exon sequence. These observations support the hypothesis that the transition from an (A + U)-rich to a (G + C)-rich sequence determines the intron 3‘ border and that the 41-bp BzZ exon sequence is too short to be recognized within the context of a large (A U)-rich sequence. When this same Adhl intron fragment was inserted in the antisense orientation into Bz2, two introns were created from the (A + U)rich inserted sequence. The more (G + C)-rich portions of the insert remained as exon sequences. The two introns were excised using cryptic sites at both the 5’ and 3’ splice junctions. When the antisense orientation of the pea legumin intron was inserted into the maize zein (intronless) gene and expressed in tobacco (79, the (A + U)-rich intron sequence was spliced from the transcript through the use of cryptic splice sites. Also, usage of a 5‘ donor can be enhanced by its being
+
171
SPLICING IN HIGHER PLANTS
Plasmid
pcn-s
Insert
346bpmkkReof
Adhl-Simn 1 (ma-)
Splicing outcome
___.
FIG. 6. Alternative splicing induced by insertions of (A + U)-richintron sequence into the B z 2 gene. A 346-bp fragment from the center of Adhl intron 1 was inserted downstream of the single Bz2 intron in either the sense (pi/I346sS) or antisense (pc/I346aS) orientations. Aftef transient expression in maize protoplasts, the splicing outcomes were determined by sequencing cDNAs derived from each construct; other alternative processing events were also observed (not shown) ~
adjacent to a (G + C)-rich sequence (21).Taken together, the results suggest that (A +. U)-rich regions of the pre-mRNA are recognized as intron sequences and are spliced from the transcript, using 5'-donor and 3'-acceptor sequences determined by the (A U)/(G C) transition and by a loose match to the consensus motif...
+
+
E. Splice Site Selection and lntron Recognition Model Based on the data discussed in the previous section, we propose the following working hypothesis as a framework for understanding splicing in higher plants. We propose that the first step of splicing is intron recognition. At this step, internal intron motifs are bound by a nuclear factor (a protein? an RNP?) that recognizes (A U)-rich or U-rich motifs in the body of the intron. Short introns (
+
A
1 GUCCGCCUUGUUUCUCCUCUGUCUCUUGAUCUGACUAAUCUUGGUUUAUGAUUCGUUGAGUAAUUUUGGGGAAAGCUUCGUCCACAGUUUUUUUUUCGAU
Hind11 I 101 GAACAGUGCCGCAGUGGCGCUGAUCUUGUAUGCUAUCCUGCAAUCGUGGUGAACUUAUGUCUUUUAUAUCCUUCACUACCAUGAAAAGACUAGUAA~ 201
UCUCGAUGUAACAUCGUCCAGCACUGCUAUUACCGUGUGGUCCAUCCGACAGUCUGGCUGAACACAUCAUACGAUAUUGAGCAAAGAUCUAUCUUCCC~ Egl I I
301
UUCUUUAAUGAAAGACGUCAUUUUCAUCAGUAUGAUCUAAGAAUGUUGCAACUUGCAAGGAGGCGUUUCUUUCUUUGAA~AACUAACUCGUUGAGUGG -
401
C C C U G U U U C U C G G A C G U A A G GC C ~ G C U G C U C C A C A C A U G U C C A U U C G AA ~ A C C G UG U U U A G C A A G G G C G A A A A GU U U G C A U C U U G A U GAUUUAGC
StuI 501 UUGACUAUGCGAUUGCUUUCCUGGACCCGUGCAG
B 1 GUGAGCACCGAGCAGAGCACGGCAGCAAGUGUCUUUUCUUCAAGGUAACGUGCAACAAACUGCCGUGCCUUUCUGCAG FIG. 7. (A) The seqiience of the 5 W n t maize AdhI intron 1. The strings ofthree or more consecutive Us, or >70% U content for strings 4 nt and longer, are tloul,le-iiiiderlined. (B) The 78-nt single intron from maize Bz.2. with the regions rich in U (as defined in A) douhleimderlined.
173
SPLICING IN HIGHER PLANTS
tion would be accurate provided that long stretches of U residues are absent or infrequent in exons. Confirming this expectation, the U-U and A-U dinucleotides are over- and underrepresented in plant introns and exons, respectively (14). As the pre-mRNA is transcribed and released from the DNA template, we propose that the internal intron recognition motifs are bound by a factor that defines the middle of the intron. We propose that this binding serves two roles. First, potential 5’-donor and 3‘-acceptor sites within the intron are blocked. This is important in plants, because the 5’ and 3’ splice site consensus sequences are short and many introns contain “reasonable” border motifs that are, in fact, never used in splicing. We propose that the correct borders are utilized because the splicing machinery is targeted to the edges of the intron by interacting with the internal intron recognition factor (see Fig. 8). The search window to find either a 5’ or a 3’ splice site would encompass the 10 to 50 nt immediately upstream and immediately downstream of the area coated with the intron recognition factor. We propose that the closest sequence with a reasonable match to the 5’ splice site consensus (a G-U plus two or three additional complementary bases within the region that binds to U1 snRNA) is utilized. Similarly, the closest A-G dinucleotide may be sufficient to serve as the 3’ acceptor; as discussed previously, its use might be enhanced by being distal to a U-rich tract. The internal recognition protein would stabilize snRNP interaction with the intron-exon junctions facilitating splice site selection and full spliceosome assembly despite the divergence of nucleotides at the splice sites and the variability in temperature of plant cells. In summary, we propose that the requirement for internal intron recognition is the unique aspect of intron definition in plants. This extra step provides a mechanism for identifying short introns in the context of large exons, for preventing use of cryptic splice-sites that occur within introns, and for favoring the use of the correct splice sites. The model is entirely consistent with the experimental results available now, but it has not yet intron recognition factor 5’ splice junction
3’ sptiyjunction
AU-rich intron
FIG. 8. intron recognition model for plants. A typical plant gene is composed of (A + U)rich introns surrounded by (G C)-rich exons. We propose that a U- or (A + U)-rich binding factor recognizes and coats the intron sequence, leaving the 5’ and 3‘ splice junctions exposed for binding by snRNPs. (G C)-rich exons are proposed to be deficient in the (A + U)-rich motifs that are substrates for the hypothetical binding protein and hence are left uncoated.
+
+
174
KENNETH R. LUEHRSEN ET AL.
been rigorously tested. For example, what are the sequence requirements for an internal intron recognition motif? In a large intron, what spacing of internal recognition motifs is required? How close to the 5’ and 3’ intron edges are the last recognition motifs?
III. Transposable-element-induced Mutants of Maize Transposons are a rich source of genetic variation in maize and other higher plants. Many transposon sequences inserted in transcription units have an impact on RNA processing by providing alternative splice junctions and polyadenylation signals within the transcript (reviewed in 5, 78). A number of transposon-mediated changes in gene expression have been analyzed in great detail, and these case studies provide a good test of the intron recognition model outlined in Section 11. As identical transposable elements have been inserted in different genes, the impact of the context of the insertion can be explored on a limited basis. In addition, once inserted, subsequent changes in the transposon sequence may alter the splicing phenotype. We discuss several examples in which internal deletions of maize transposons have converted an insertion sequence from a poor to a very good intron. These examples can illuminate the key features of intron recognition in maize. One limitation of studying RNA processing utilizing spontaneous transposon insertion events is that every allele analyzed was recovered because it had a novel phenotype. That is, the sample of alleles is biased for changes that caused a major change in gene expression. It is possible that many transposon insertions are entirely cryptic; for example, if a transposon insertion fails to decrease gene expression compared to the wild-type allele, it will not be recognized as a mutant. And, as is described in Section III,D, some null or low-expression alleles caused by transposon insertion can be restored to partial function by changes in the transposon, but these new partialfunction alleles will be recognized. On the other hand, many changes in the transposon may not restore gene expression, and these cases are not recognized by geneticists and hence have not been analyzed at the molecular level. It is important to keep in mind that one particular transposon can have different effects if inserted at different locations in a transcription unit; this demonstrates that the combination of gene context and transposon sequence determines the type of RNA processing observed. A second aspect of transposon behavior is that an element can be inserted in either orientation
175
SPLICING IN HIGHER PLANTS
relative to the reading frame, with each orientation contributing a different sequence to the transcript. A third feature to consider is that transposable element behavior can influence the impact of an insertion element. In the presence of transposase protein, which is encoded by the autonomous element of a particular element family, transposition can occur. In addition, binding of transposase (and other proteins encoded by the regulatory element) can influence transcription (79) and may influence RNA processing as well. For simplicity, therefore, the impact of a transposon insertion on RNA processing events should be measured in a genetic background lacking an active regulatory element and hence lacking these trans-acting factors. A fourth feature is that individual transposon insertions can suffer spontaneous deletions, altering the size and sequence content of the insertion sequence; as the insert changes, its impact on RNA processing can change dramatically. Fifth, different families of transposable elements differ in their structure, sequence, and content of cryptic 5’ and 3’ splice sites. The terminal inverted-repeat sequences of both the AclDs and SpmldSpm element families contain multiple cryptic splice sites (80, 81). For example, the Ds elements contain three cryptic 5‘ splice sites representing all three reading frames, so that some fraction of splicing events that utilize the sequences in the element termini could restore the reading frame and thus allow production of a partially functional protein. Several authors have proposed that elements processed in this manner are in fact evolving into introns (5, 82). In this section, we describe the impact of the same 2.2-kb hfective Spm (dSpm)element on RNA processing events in several maize genes and of the allelic deletion series of the dSpm in two of these genes. The impact of Ds insertions in several genes is also considered. After describing what is known about each insertion case, we use the results to evaluate the intron recognition model.
A. Properties of Ds Ds elements are the defective (transposase-minus) members of the AclDs family. There are three basic classes of Ds elements that differ in base distribution and the structure of the “right” and “left” terminal inverted repeat (TIR) sequences. Standard Ds elements are 3 to 4.5 kb in length with simple, internal deletions compared to the 4.7-kb Ac element; their base composition is -44% G C. Ds2 elements are -1.3 kb and share substantial homology with Ac at the ends, but contain a unique sequence of about 500 bp in the center; these elements are 47% G C. The -400-bp Dsl elements contain only the 11-bp imperfect TIRs of Ac and an additional -20 bp of homology internal to the right TIR; Dsl elements are very (A + U)-
+
+
176
KENNETH R. LUEHHSEN Kr AL.
+
rich, and <29% G C. The impact of a number of Ds insertions was recently reviewed (5) and is only briefly mentioned here.
B. Multiple RNA Processing Fates after Ds Insertions into Exons Ds insertions into maize exons yield three types of changes in RNA processing events: (1) intron creation using sites within the insertion or a combination of an element 5’-donor site and a cryptic 3’-acceptor site in a flanking exon, (2) alternative splicing in which the Ds insertion becomes part of a novel intron, and (3)polyadenylation within the Ds insert. These alternative R N A fates occur in the absence of Ac. Dsl elements are very short for maize transposons (-400 bp), and with a 71% (A + T)-content, Dsl elements are much more similar to introns than to exons. The first report of intron creation by a Dsl element involves a 405-bp Dsl inserted in the leader sequence of the adhl-Ftn335 allele. The 5’ splice sites within the terminus of Dsl were spliced to a 3’ acceptor created as part of the host sequence duplication generated by tranposon insertion (83, 84). Similarly. a Dsl insertion in exon 9 of the wx-ml allele creates an intron; in this case, three 5‘ donors within Dsl and three 3‘ acceptors (two in Dsl and one in the flanking gene) are used (82).With Dsl insertions, intron creation is the only reported change in RNA processing. Intron creation also occurs after insertion of longer Ds elements into exoiis; so far, all of these cases involve Ds in the antiparallel orientation (opposite the direction of transcription of Ac). As with D s l , multiple 5’ sites near the terminus of-the Ds element can be utilized in wr-rn9, which contains a 4.37-kb deletion derivative of Ac, and in wx-B4, which contains a 1.49-kh Ds2 element (80).The 3’ acceptors within the element and in the flanking DNA are utilized (80).Analysis of the structure of wx-m9 highlights the question of exon size in maize. Although most maize introns are small (>ZOO nt), exons can be relatively large (>300 nt) and there are few microexons (<50 nt). When Ds is spliced from the w.x-ni9 transcript, a inicroexon of 12 nt would be created on the 3’ side, provided the downstream intron is still in the transcript. If the kinetics of intron removal could be analyzed in more detail, this would be an interesting case of exon definition to examine. In some cases, Ds insertions result in a combination of altered splicing behavior and polyadenylation within the inserted element. For antiparallel insertions-those in which the Ds 5’ splice sites are in the “correct” orientation to be recognized-polyadenylation within the element has been detected, i.e., the A c deletion in Ds2 in adh-2F11 (85). Based on northern blotting, the Ds2 in exon 4 of adhl-2F11 yields about 10%mRNA polyadenylated in the insert sequence (85). The other RNA is alternatively spliced, providing in-frame mRNA that apparently encodes a partially fimctional
177
SPLICING IN HIGHER PLANTS
product. The 5’ splice junction of intron 3 is spliced to a cryptic site within exon 4, a site not normally used, removing all of intron 3, exon 4 proximal to the Ds2 insert, all of Ds2, and a few distal bases of exon 4. In this allele, no evidence was found for use of splicing sites within the 1.3-kb Ds2 element. In alleles with “parallel” insertions of the larger Ds elements, the 5‘ and 3’ splice sites are in the wrong orientation to yield an intron. Consequently, in these cases polyadenylation within the insert is the major impact of the Ds element on RNA processing (78). For example, with the w x - d and wx-B3 alleles containing Ds and Ac elements, respectively, most of the RNA is polyadenylated within the transposon sequences (78).
C. Properties of 2.2-kb dSpm Elements Spm is an 8.3-kb autonomous tranposable element encoding two overlapping gene products, TNPA and TNPD. The two products result from the alternative splicing of the 4.4-kb first intron of Spm (86)(see Section IV). The dSpm elements are simple deletion derivatives of the autonomous element, typically involving removal of continuous segments of the internal part of Spm. Many such deletions alter the amount or type of gene product produced in the absence of Spm, suggesting that posttranscriptional events rather than excision are affected. Deletions with a recognizable, new phenotype are termed “change of state,” or CS, alleles. The impact on RNA processing of the 18-type of dSpm will be described (Table V). The I8 element is 2.2-kb long, and was first cloned from the wx-m8 TABLE V 18 dSpm INSERTIONS IN MAIZEGENES
RNA processing event“ Reporter allele
Insert location
Size
a1 -ml CS5719
Exon 2
2.2
a2-ml Class I1 state
Exon 1
-
wx-d
Exon 11
bzl -ml3
Exon 2
cs3
css cs64
-
(kb)
Splicing
Probably
2.2 1.3
Inefficient Efficient
2.2 2.2
Not observed Inefficient; spliced at AS1 and AS2 Efficient Efficient Inefficient; AS1 removed by deletion
OEfficient splicing is defined as >SO%
Ref.
-
-
1.8 0.9 2.2
Polyadenylation
Efficient
-
87, 89 81, 93, 94
178
KENNETH R. LUEHRSEN ET AL.
+ C. The same element has been identified in the a2-m1, a l - m l , and bzl-m13 alleles; a2-ml was the first of these mutable alleles to be genetically identified by McClintock. The other alleles probably contain the identical element transposed from a2-ml (88);at the DNA sequence level, the elements are identical, although not all have been fully sequenced.
allele (87j. This dSpm element is 48% G
D. Altered RNA Processing after Insertion of the 2.2-kb dSpm Element and Its DeIetio n Derivatives As was observed for large Ds insertions, the parallel orientation d S p m inserts examined result in polyadenylation within the element sequence. In the wx-rn8 allele, dSpm is inserted in the middle of an exon, and transcripts terminate within the transposon sequence (87, 89). The site utilized is not normally a transcript termination sequence in Spm. Three alleles with antiparallel dSpm insertions have been examined. Again, similar to Ds insertions, 5’ and 3’ splice sites within the dSpm transposon are utilized in a variety of gene contexts. For example, the same 3’ acceptor A-G is utilized in both a2-ml and bzl-m13. The a1 -m1(6078)allele contains an antiparallel dSpm insertion four bases internal to the exon 2lintron 2 boundary (90,91). The dSpm is not spliced from the mRNA in the original allele; instead, most of the transcript is read through. The a1 -ml allele allows molecular examination of a phenomenon McClintock termed ’change of state. CS derivatives of mutable alleles are permanent alterations in the allele; CS alleles contain deletions or internal rearrangements of dSpm that alter interaction with transposase or the impact of the insert on the expression of the host gene. We consider several cases in which a CS derivative has higher expression that the original allele in the absence of S p m ; because transposase is not present, the increase in gene expression must reflect a change in the production of transcript that encodes the host gene product. For example, the 5719 CS derivative of al-ml has an internal deletion within the 2.2-kb dSpm that removed most of the central and (G C)-rich T, and the region, leaving a dSpm of 789 bases. This insert is now 57% A allele is expressed at a much higher level; it is likely that the dSpm is spliced from the transcript. More is known about two a2-ml alleles, which contain an antiparallel dSpm insertion. The dSpm is inserted about 20% into the intronless A2 gene (Fig. 9). The A2 coding region is 70% G C, as are the sequences immediately surrounding the dSpm insertion. With the 2.2-kb dSpm insert present, kernels are almost colorless, indicating that almost no mRNA is produced that encodes the A2 product. That is, the level of splicing
+
+
+
179
SPLICING IN HIGHER PLANTS
00 bp (55% GC)
a2-M original state 353 bp (78% GC)
FIG.9. Structure of the a2-ml allele. The a2-ml original-state allele has a 2.2-kb dSpm element inserted into the intronless A2 gene. The a2-ml class-I1 state is a deletion derivative of the a2-ml original state in which a 900-bp sequence was deleted. The deletion results in the creation of an intron in the class-I1 state allele; a G-C substitutes for the canonical G-U that is used in almost all 5' splice junctions (see Tables I and 111).
of the dSpm insert from the transcript is either very low or the splicing that occurs does not restore a functional open reading frame. In the state-I1 CS allele of a2-mI, however, a well-spliced intron is created. In this allele, there is a deletion in dSpm that removes 900 bp (55% G + C), including a 353-bp block that is very (G + C)-rich (78%). The remaining d S p m sequence is 1341 bp and only 43% G + C. In this CS allele, over 75% of the mRNA is spliced, removing almost all of the dSpm; seven amino-acids are added to the A2 product, and the resulting protein yields almost wild-type coloration. The 5' and 3' splice sites utilized in this case of intron creation are both within the dSpm, and hence existed in the same context in the original, low-function a2-ml allele. However, the dSpm was not spliced to an appreciable extent until the (G C)-rich central sequence was deleted. The relevance of these transposon cases to our model of intron recognition is that intron creation depends on the overall (A + U)-content of a region and the proximity of suitable 5' and 3' splice sites. In the case of a2-ml alleles, the splice sites were always present, but were only used efficiently to
+
KENNETH R. LUEHRSEN ET AL.
180
allow removal of the dSpm as an intron when the (A + U)-content of the insert increased from 52% to 57% and was free of (G + C)-rich (>60%) blocks. It is also instructive that one large intron was created, not a series of smaller ones. The allele bd-in13 has the same 2.2-kb dSpm insertion 38 bp downstream of the single intron of B z l (81) (Fig. 10). Expression of the bzl-m13 allele is suppressed by the products of an autonomous Spm element; hence, excision events appear as spots of wild-type pigmentation on a bronzecolored background (92). In the absence of Spm, the bzl-m13 allele conditions full kernel color. A long series of CS alleles (summarized in part in Table V) exist for the bzl-m13 allele, and these were selected as derivatives in which dSpm was excised later in development and showed a low rate of germinal reversion (92). Like bzl-m13, many of the CS alleles condition full kernel pigmentation in the absence of Spm. Molecular analysis showed that each CS allele had an altered dSpm element present in the same position and orientation as the original bzl-m13 insertion (92-94). Most of the CS alleles had a large deletion of the dSpm sequence, but still contained at least 1 kb of the insertion. How is functional BZ1 enzyme produced when hundreds of base pairs of dSpm sequence are inserted in the middle of the B z l gene? Northern analy-
A
"."""..
.""**"... 5'
V
An 3
FIG. 10. Structure of the bz-nll3 allele. The Ic-nt13 allele has a 2.2-kb dSpm element inserted in the second exon, 38-bp downstream of the single B z l intron. CS3 and CS9 are deletion derivatives (dotted line) of bz-rn13. AS1 and AS2 are alternative 3'-acceptor sites.
181
SPLICING IN HIGHER PLANTS
sis of bzl-m13 and the CS alleles showed that multiple RNA species were present for each variant in the absence of Spm (93). Some transcript from each allele was of the size expected for unspliced RNA, and contained both bzl and dSpm sequences. Two additional transcripts of 2.4 and 1.8 kb were detected for several CS alleles, but only the 1.8-kb transcript was found for CS3 and CS9. Using a dSpm probe, it was further determined that the 2.4kb transcript contained some dSpm sequence, whereas the 1.8-kb transcript did not. The 2.4- and 1.8-kb transcripts each hybridized to a bzl probe 3’ of the insertion site, implying that they did not arise by polyadenylation within the dSpm element. Taken together, the data suggest that the dSpm element is spliced from the 1.8-kb transcript, but that the 2.4-kb transcript still contains some, but not all, of the dSpm sequence. Sequencing of the cDNAs from several of the CS alleles (81,94) showed that the bzl intron is sometimes spliced using a 3’ acceptor (AS1) in the distal terminal inverted repeat of the dSpm element. Using AS1, the bzl intron, the intervening 38 nt, and all of the dSpm element (except the final 2 nt of the distal TIR) are excised, resulting in a 1.8-kb transcript. Removal of 38 nt of exon 2 and addition of 2 nt from the right TIR leave the bzI reading frame intact. The amount of BZ1 enzyme activity observed for each CS allele is proportional to the level of 1.8-kb transcript (spliced at ASl), consistent with the notion that the 1.8-kb mRNA encodes functional BZ1 product. The CS64 allele has a 4-bp deletion that removes AS1, and this allele is null, further indicating that the 1.8-kb transcript encodes functional BZ1. Taken together, the results imply that translation of the 1.8-kb transcript produces a truncated BZ1* protein that still conditions kernel pigmentation. Further, S1 nuclease and cDNA analyses of mRNA from several CS alleles indicated that the bzl intron 5’ donor is sometimes spliced to a second 3‘ acceptor (AS2) in the middle of dSpm, resulting in the 2.4-kb transcript. The dSpm sequence in the 2.4-kb transcript disrupts the bzl reading frame and is not expected to encode functional BZ1 enzyme. No transcripts containing the 38 nt between the bz1 intron and the dSpm element were detected, indicating that the bzl intron 3’ acceptor is always skipped in favor of either AS1 or AS2 in dSpm. Although many CS alleles condition full kernel color in the absence of Spm, in uiuo levels of BZ1 activity vary widely among alleles (93). This suggests that the production of the 1.8-kb transcript (splicing at AS1) differs for each CS allele and that the deletion of dSpm sequence changes the frequency with which AS1 and AS2 are used. Using the splicing model outlined in Section 11, we discuss the alternate use of AS1 and AS2, and why the bzl 3’ acceptor is always skipped. The dSpm element in bzl-m13 is 52% A T overall and is inserted in the very (G C)-rich (70%)b d exon 2. The dSpm element is recognized as
+
+
182
KENNETH R. LUEHRSEN ET AL.
intronlike, owing to the 18% difference in (G + C)-content between it and bzl exon 2. In the original bzl-m13 allele, the bzl 3’ acceptor is never used and 51% of the transcript is spliced at AS1; AS1 is used 5.8-fold more often than AS2 (94).Internal deletions in the dSptn sequence alter the relative use of AS1 and AS2. Although the dSpm element is (A + T)-rich, there is a 331b p region near its 3’ end that is 79% G + C (see Fig. 10);this sequence is between AS2 and AS1. A 1.3-kbdeletion in CS9, including AS2 and all of the (G C)-rich region, improved the splicing efficiency at AS1 from 51% to 95%. The overall (A T)-content of the dSpm in CS9 is increased to 58%. By making the region more (A + U)-rich and intronlike, the CS9 transposon is better recognized and its splicing efficiency is virtually wild-type. Similarly, the CS allele of a%mI illustrated that removal of this region improved splicing of dSptn. Our previous work has shown that the insertion of a (G C)rich sequence into maize introns interferes with splicing (74); that the deletion of the (G + C)-rich segment in CS9 improves splicing is a test of the reverse possibility. The CS3 allele is missing a 437-bp (65% G + C) segment that includes most of the (G + C)-rich region, but it still retains both AS1 and AS2. For the CS3 allele, 91% of the transcript RNA is spliced at ASl, and AS1 is used 47fold more often than AS2. Thus, removing the (G + C)-rich sequence block between AS2 and AS1 greatly favors the use of AS1 over AS2 compared to the bzl-m13 allele. We propose that the transition from an (A + U)- to a (G + C)-rich sequence just downstream of AS2 helps it to be recognized as a 3’ acceptor, and that the CS3 deletion removes this signal. With the removal of the (G + C)-rich segment in CS3, AS3 was masked by being surrounded by an (A + U)-rich segment. If the (G + C)-rich segment of dSptn helps promote the use of AS2 as a 3’ acceptor, why is splicing at AS1 favored over AS2 in bzl-m13? AS1 might be an intrinsically better 3’ acceptor than AS2. Although the critical cis-acting sequences involved in plant 3’-acceptor choice have not been fully determined, plant 3’ acceptors are usually preceded by a U-rich block (14, 15). Ten of sixteen nucleotides preceding the A-G of AS1 are U, whereas only six of 16 nucleotides preceding AS2 are U, suggesting that AS1 might be a superior 3’ acceptor. Alternatively, we suggest that because AS1 is at the far downstream edge of an (A + U)-rich sequence, its use is favored. Even though AS2 is proximal to the 331-nt (G + C)-rich block, the 240-nt block proximal to AS1 is 56% A + U, and is thus intronlike (Fig. 10). When presented with an RNA having (A U)-rich insertions, the maize splicing machinery appears to favor the removal of the entire region; transcripts spliced at AS2 still retain the 240-bp (A + T)-rich region within a (G C)rich millieu and have possibly escaped full processing. We predict that AS2 would be efficiently used if a suitable 5‘ donor was available near the edge of
+
+
+
+
+
SPLICING IN HIGHER PLANTS
183
+
the (G C)-rich block that immediately follows AS2; this would, in effect, create two introns. In the natural alleles, however, no sequence similar to the 5’ donor consensus is present within 50 bp downstream of the beginning of the (G + C)-rich block. If an additional 5’ donor were available, we predict that two introns (using AS2 and AS1) would separate an exon that includes the 331-nt (G C)-rich block of dSpm. Why isn’t the native bzl 3’ acceptor used in the mutants? We propose that the insertion of an (A U)-rich sequence just downstream (38 nt) of the bzl 3’ acceptor internalizes it into a much larger (A + U)-rich region, where it might be “coated with a U-rich binding protein. It was not recognized because it no longer appeared at a discrete border between (A + U)- and (G + C)-rich sequences. The 38 bp that separates the intron and dSpm insertion is probably not long enough to be recognized as an exon; [recall that a 41-nt (G C)-rich exon in Bz2 was skipped in a similar situation (Fig. 6)]. Small exons may be at a particular disadvantage if splice-site choice depends on internal intron recognition. An unusually small exon of 24 nt appears in Gpcl, but the next smallest maize exon is 47 nt, suggesting that exons must be of a minimum size to be distinguished from surrounding introns. The requirement of a minimum exon size probably prevents missplicing to 5’ donors or 3’-acceptor sequences that appear fortuitously in both exons and introns.
+
+
+
IV. Examples of Alternative Splicing In Section 111, the TE-induced alternative splicing of several maize mu,tants is described. Many animal genes undergo tissue- and stage-specific alternative splicing (18,95),but only a few examples of alternative splicing of native plant genes have been described (Table VI). The first reported case of alternative splicing in plants was for the spinach rubisco activase transcript (96). Although rubisco activase exists as a singlecopy gene, two immunlogically similar polypeptides of 41 and 45 kDa are present in spinach leaves. Sequencing the corresponding cDNAs indicated the use of alternative 5’ donors and a common 3’ acceptor for the sixth intron. Splicing at the upstream 5’ donor results in an mRNA encoding the 45-kDa polypeptide. Use of the downstream 5‘ donor added 22 nt to the mRNA, including a stop codon that leads to the truncated 41-kDa polypeptide. In western blots using rubisco activase antibody as a probe, the 45- and 41-kDa proteins were present in equimolar amounts in spinach leaves. Although both of these forms of rubisco activase are present in leaves, no functional difference has been ascribed to the two forms; each activates rubisco in the absence of the other. The mechanism of alternative splicing is
184
KENNETH H. LUEHRSEN ET AL.
EXAMPLES OF
TABLE \'I ALTERNATIVESPLIolNC
IN PLANTS
Ref.
Com inent Maize
S p m intron 1
Either the 4.4-khintron 1 is excised or alternative 3' acceptor in intron 1 a l l w s expression of the t n p D gene
86
Spiixtch
Rubisco activase intron 6
Alternative 5' donor results in a truncated protein; similar splicing seen in Hordeurn, but not in Chlntnydotnona.~ or maize
86, 96-99
Arabidopsis,
RNA polymerase I1
Alternatively spliced intron in 3' UTR
139
P intron 2
Alternative 3' acceptor
67
soybean
hlaize
also undetermined. Alternative splicing of the same rubisco activase intron has been described for Arabidopsis and barley (97), but only the larger polypeptide (upstream 5' donor) is observed in inaize (98) and Chlninydonwnas (99). The maize P gene is a regulator of pigment synthesis in pericarp tissue, and its amino-acid sequence shows homology to rnyb transcription factors (66. 67). The gene encodes two transcripts of 1.8 and 0.945 kb, resulting from alternative splicing of the second intron. The second intron is either 4.9 or 7 kb in length. The 7-kb intron is the longest so far described for plants. For the second intron, the same 5' donor is used with two different 3' acceptors. Each transcript is also alternatively polyadenylated; splicing of the 7-kb intron removes the polyadenylation signal used for the 1.8-kb transcript. Both transcripts are abundant in aim, and genetic analysis of P inutants suggests that the protein product translated from the 1.8-kb transcript is necessary for P function. The protein products from the 1.8-and 0.945-kb transcripts have the same N-terminal region, including the region of hoinology to myb, but differ by the length of the C-terminal end. It has been suggested (67) that the myb-containing product of the 0.945-kb transcript might act as a competitive inhibitor of P function. No mechanism was proposed to account for the use of alternative 3'-acceptor sequences. The transposable element S p m is perhaps the most interesting example of plant alternative splicing (86). The 8.3-kb element has several long open reading frames, two of which (ORF1 and ORF2) occur in the 4.4-kb first
SPLICING IN HIGHER PLANTS
185
intron. Genetic analysis had shown that transposition requires the integrity of intron 1 reading frames, implying that the transposase might result from the translation of unspliced or alternatively spliced mRNAs. Transposition requires the tnpA and tnpD gene products produced by alternative splicing; direct evidence for the contribution of these products was provided by transforming tobacco with various cDNAs (86, 100).The most abundant Spmencoded mRNA is 2.4 kb and encodes the tnpA gene product. Using RTPCR to amplify rare cDNAs, Masson et d.(86)were able to recover alternatively spliced cDNAs that contained the first intron and its reading frames. In these rare cDNAs, the first intron 5‘ donor was spliced to a 3’ acceptor upstream of the intron 1 ORFs, allowing the ORFs to be translated. The tnpD gene product is composed of ORFs 1 and 2 fused by the removal of an intron. The mechanism responsible for 3‘ acceptor choice has not been determined, but ORF2 shows 29% amino-acid identity with the reu-encoded protein of HIV-1. The reu gene product is involved in the regulation of viral splicing, suggesting that the protein product of Spm ORF2 is potentially involved in modulating splicing of the tnpD transcript.
V. Biological Phenomena Associated with Splicing
A. lntron Enhancement Although some plant genes do not have introns (i.e., maize zein genes and most histone genes), most have from one to more than 20 introns scattered throughout the protein-coding exons and the 5’ and 3’ UTRs. For some plant genes and plant reporter-gene chimeras, the inclusion of a spliceable intron in the transcription unit increases gene expression at both the mRNA and protein levels; a similar finding has been seen in mammals (101).This phenomenon has been termed “intron enhancement of gene expression.” Several studies show that introns enhance gene expression in both monocots (55, 56, 102, 103) and dicots (54, 104, 105). Quantitatively normal expression of the maize Adhl gene in stably transformed BMS calli requires one or more introns in the transcription unit (55).The level of enhancement compared to the cDNA is up to 50-fold depending on the intron(s) used and their positions in the transcription unit. In transient assays, Adhl intron 1 enhanced the expression of chimeric gene constructs having the CAT, firefly luciferase, neomycin phosphotransferase, or GUS reporter genes driven by the CaMV 35s and Nos promoters (55, 56). In addition to Adhl intron 1, several other maize introns enhance expression. Adhl introns 2 and 6 (106), Shrunken-] intron 1 (57, 107), the single Bronze-1 intron (55),and actin intron 3 (56) typically enhance expression
186
KENNETH R. LUEHRSEN ET AL.
from 2- to 100-fold when placed upstream of a reporter gene. Intron enhancement has also been described in dicots: the potato ST-LS intron 2 increases reporter gene expression -6-fold in bean (105), and pea rbcS introns increase expression -5-fold in transgenic tobacco (54, 104). Introns can function across species barriers; the maize Adhl intron 1 enhances expression in other monocots such as rice and wheat (108),and the maize Sh1 intron 1 enhances expression in guineagrass and napiergrass (107).The bean catalase intron 1 enhances expression of a linked GUS gene in the monocot rice but not in the dicot tobacco, indicating that the ability of individual introns to enhance expression must be determined empirically (109). Surprisingly, intron enhancement is observed even when an intron is not efficiently spliced. In transient assays using constructs containing Adhl intron 1 or actin intron 3, significant amounts of unspliced RNA accumulated (56),but 2- to 10-fold enhancement levels were seen. The ability of an intron to enhance gene expression appears to depend on its placement within the transcription unit. Inserting Adh1 intron 1 and Sh1 intron 1 upstream of the promoter has little effect on expression (55, 57), suggesting that these introns do not function as transcriptional enhancers. Adhl intron 1 can stimulate CAT expression 110-fold when placed in the 5' untranslated region (UTR) but only 5-fold when placed in the 3' UTR (55). Similarly, Adhl introns 2 and 6 placed in the 5' UTR enhance expression of a CAT-containing chimeric gene from 12- to 20-fold, but have no effect when placed in the 3' UTR (106). The molecular mechanisms responsible for enhancement are not well understood. Although some animal introns contain transcriptional enhancers and thus increase initiation at the proximal promoter (11O-112),most introns do not stimulate transcription, but rather mediate enhancement posttranscriptionally (55, 57, 113). Studies using mammalian cells suggest that entry of the pre-mRNA into the splicing pathway improves the nuclear stability of the transcript, possibly by leading to more efficient capping (114) or polyadenylation (113). Alternatively, the spliceosome might protect the pre-mRNA from nuclease attack, or the transcript could be shunted into a more efficient transport pathway through splicing machinery localized in the nucleus (115).That plant introns mediate greater enhancement when near the 5' end of the transcription unit suggests that early recognition of the intron within the nascent transcript facilitates mRNA accumulation.
B. Effects of Stress on Splicing Splicing in yeast and animals is inhibited by heat stress (reviewed in 116); under these conditions, unspliced pre-mRNA accumulates. To date, there has been little systematic study of splicing during environmental stress of plants. Curiously, unspliced pre-mRNA is routinely detected in normal plant
SPLICING IN HIGHER PLANTS
187
tissue (60). Because plants in the temperate zone experience wide diurnal fluctuations in temperature as well as variations in nutrient availability and exposure to toxic molecules, it is possible that the unspliced transcripts observed reflect stress conditions. The first studies on the effect of heat stress on plant splicing found that splicing is unaffected by elevated temperature. Splicing of the Gmhsp-26A pre-mRNA is unaffected in soybean seedlings kept at 40°C for 2 hours in a sucrose/potassium phosphate buffer (I17). A similar heat stress protocol on petunia leaves showed that the splicing of petunia hsp7O pre-mRNA is unaffected at 42°C (118). In maize seedlings incubated for several hours at 42"C, no accumulation of unspliced Bz2 pre-mRNA was observed (60). In contrast, maize seedlings kept for 10 minutes at 45°C accumulated polyubiquitin pre-mRNAs, indicating that the heat stress inhibited splicing (119). This experiment was carried out by submersing the seedling in 45°C water, rather than in a sucrose solution. Because methods of stress induction often vary, exact comparisons of data from different studies are difficult. The finding that some plant heat-shock genes contain introns suggests that the plant-splicing machinery might remain functional during heat stress. However, severe heat stress can inhibit splicing of at least two heatinduced, intron-containing transcripts. Maize hsp7O transcripts were isolated from tassel spikelets incubated at 24"C, 40"C, and 45°C; unspliced premRNA accumulated only at 45"C, a potentially lethal temperature (120).The splicing efficiency of Arabidopsis hsp81 pre-mRNA at 22"C, 30"C, 35"C, and 40°C has been determined (121).Although spliced mRNA was present at all temperatures, unprocessed pre-mRNAs were detected only at 40°C. It is not surprising that milder heat stress was sufficient to interfere with intron processing in Arabadopsis, as this plant shows optimal growth at cooler temperatures than does maize. Taken together, the above experiments show that heat stress can interfere with splicing, even for intron-containing genes that are induced under the stress condition; however, some splicing continues even at lethal temperatures. It will be interesting to know whether introns from different genes are differentially spliced under the same heatstress conditions. Also, the temperature at which a plant or plant tissue experiences heat stress and splicing failure is probably specific for each species. Splicing failure may be observed only after near-lethal exposure. Studies of the impact of heavy metals on splicing indicate that cadmium and, to a lesser extent, copper block splicing. Using petunia leaf tissue immersed in 50 pM cadmium chloride, the accumulation of both spliced and unspliced hsp7O transcripts has been observed (118). Dosages of 0.5 and 5 mM CdCl, resulted in increased levels of both spliced and unspliced transcript. When the tissues were treated with a solution of 5 mM CuCl,, spliced and unspliced transcripts also accumulated, but at levels only a fraction of
188
KENNETH R. LUEHRSEN ET AL.
that seen after cadmium treatment. Both spliced and unspliced products of soybean Gmhsp-26A are found after a %hour 0.2 mM CuSO, treatment (122). Splicing of a soybean auxin-regulated pre-mRNA is not inhibited following a %hour 1 mM CuCI, treatment (123). As with heat stress, stress induction methods varied among the studies, and these differences might explain the conflicting results. Other heavy metal and chemical stresses have been investigated-including silver nitrate, zinc acetate, zinc chloride, sodium arsenate, and sodium chloride-but no accounts of splicing interference have been reported for the transcripts examined. High temperatures block intron processing in DrosophiZu, and this block is absolute (1%). Splicing failure occurred in all transcripts tested and was relatively complete. Similarly, it appears that both heat shock and heavy metal stress may interfere with intron processing in many plants, even though unspliced transcripts have not always been observed. Unlike Drosophila, however, accumulation of spliced transcripts is never completely blocked in plants, and for stress-inducible transcripts, accumulation of both spliced and unspliced forms increases with the severity of the stress. This pattern is consistent with the expectation of greater flexibility of biochemical processes in plants relative to animals, because temperature plants must acclimate continuously to diverse environmental stresses.
VI. Perspective As has been observed for many other biochemical processes, plant intron splicing conforms to the general principles established by studies of fungi and animals. However, it is also true that, despite the similarity of mechanisms among eukaryotic kingdoms, the regulation of biochemical processes is often distinct, an outcome of the differences in selection pressure. Given the variable environmental conditions experienced by flowering plants, it might be predicted that plant intron splice sites would have been precisely conserved, and even enlarged, so that complementarity to the relevant snRNAs would optimize the probability of correct splice site selection over a broad temperature range. This is the case in yeasts. The short fungal introns contain these highly conserved motifs and a U-rich domain preceding the 3’ border; together these “required” features constitute up to 50%of the intron sequence. In contrast, higher plant intron splice site consensus regions and the postulated branchpoint region show less conservation than do mammalian introns, all of which are spliced at a constant temperature. Given the lower nucleotide sequence conservation of plant splice sites and the variety of conditions under which plant introns are spliced, how are plant introns accurately defined and metabolized?
189
SPLICING IN HIGHER PLANTS
We propose that dispersed internal intron motifs (probably U-rich in monocots and (A U)-rich in dicots) serve to demark a region containing a potential intron. Thus, it is proposed that the initial step in pre-mRNA splicing in plants is intron recognition. We further propose that the nuclear factor that binds the internal intron motifs masks potential splice sites within the body of the intron and may direct or stabilize the interaction of the relevant snRNPs with splice sites at the proximal and distal edges of the intron. We interpret the pattern of (G C)-rich exons flanking (A U)-rich (or U-rich) introns observed for plant transcripts as reflecting the selection for internal intron binding motifs within introns and selection against such motifs in exons. As most plant introns are short, i.e., 80% of maize introns are less than 200 nt, only one or a few internal intron recognition motifs may be required to specify most introns. Longer introns are postulated to contain multiple motifs. Two lines of evidence support this conjecture. First, the internal regions of long introns can be deleted without affecting splicing efficiency. Second, these “superfluous” intron middles can create introns when inserted in (G C)-rich exon sequences, indicating that they contain the information required to specify an intron. We consider it likely that internal intron recognition in plants reflects a specialization of an RNA-binding factor involved in nuclear-RNA processing in fungi and animals. A factor that plays a general RNA-binding role in these groups could readily have been selected for a more critical and specific role in flowering plants. Alternatively, mammals and fungi may have lost a splicing factor common to plants and lower eukaryotes with (A U)-rich introns. Intron recognition in plants appears to be an imperfect process given that the steady-state levels of unspliced transcript in plants are much (10- to 100fold) higher than in other kingdoms. The apparent relaxation of conservation of splice site sequences in plants may reflect the greater role played by the hypothesized internal intron recognition motifs in intron definition in plants. Such relaxation may, however, alter the kinetics and/or fidelity of splicing, resulting in unspliced or alternatively spliced products that accumulate in plant cells despite their lack of biological function. An equally plausible explanation is that variable conditions preclude efficient splicing of all introns under all conditions, resulting in the continuous production of some unspliced mRNAs under any growth regime. Explicit tests of the intron recognition hypothesis and further exploration of the structure of the plant splicing components should allow refined insight into the requirements for intron processing in flowering plants. A combination of studies utilizing engineered introns and the allelic series derived from transposable-element insertions provide the starting material for in vivo studies. Further information, including confirmation of lariat formation, awaits development of an in vitro splicing assay using plant extracts. Of
+
+
+
+
+
190
KENNETH R. LUEHRSEN ET AL.
particular interest will be discoveries that highlight the unique features of plant splicing and that link this fundamental molecular process to the constraints of angiosperm life history. ACKNOWLEDGMENTS We thank Chris KO for comments on this manuscript and all the members of the Walbot laboratory for helpful discussions. Our research on maize intron splicing is supported by grants from the NlH and U S D A .
REFERENCES 1 . W. Gilbert, Science 228, 823 (1985).
2. 3. 4. 5. 6. 7. 8.
9.
W. Gilbert, Nature 271, 501 (1978). T. Cavalier-Smith, Mature 315, 283 (1985). J. R. Manhart and J. D . Palmer, Nature 345, 268 (1990). M. Purugganan and S. Wessler, Genetica 86, 295 (1992). E. Brody and J. Abelson, Science 288, 963 (1985). A. Jacquier, TZBS, 15, 351 (1990). P. A. Sharp, Science 254, 663 (1991). 6. J. Goodall, T. Kiss and W. Filipowicz, in "Nuclear RNA Splicing and Small Nuclear RNAs and Their Genes in Higher Plants" (B. J. Miillin, ed.), p. 255. Oxford University
Press, Oxford, 1991. 10. T. Blumenthal and J. Thomas, Trends Genet. 4, 305 (1988). 11. S. U'.Ruby and J. Abelson, Trends Genet. 7 , 79 (1991). 12. C. Guthrie, Science 253, 157 (1991). 13. J. W. S. Brown, NARes 14, 9549 (1986). 14. 0. White, C. Soderlund. P. Shanmugan and C. fields, Plant Mol. Biol. 19, 1057 (1992). 15. B. A. Hanley and M. A. Schuler, NARes 16, 7159 (1988). 16. B. Patterson and C. Guthrie, Cell 64, 181 (1991). 16a. K. R. Luehrsen and V. Walbot, Plont Mol. Biol.; in press (1994). 16b. H. Lou, A. J. McCullough and M. A. Shuler, MCBiol 13, 4485 (1993). 17. C. Csank, F. M. Taylor and D. W. Martindale, NARes 18, 5133 (1990). 18. M. R. Green, Annu. Rev. CeU BioZ. 7, 559 (1991). 19. M . Rosbash and B. Seraphin, TZBS 16, 187190 (1991). 20. K. K. Nelson and M. R. Green, Genes Dew. 2, 319 (1988). 21. A. J. McCullough, H. Lou and M. A. Schuler, MCBiol 13, 1323 (1993). 22. C. I. Reich, R. W. VanHoy, G. L. Porter and J. A. Wise, Cell 69, 1159 (1992). 23. Y. Zhuang, A. M. Goldstein and A. M. Weiner, PNAS 86, 2752 (1989). 24. J. Wu and J. Manley, Genes Dec. 3, 1553 (1989). 2.5. R. A. Parker, P. G. Siciliano and C. Guthrie, Cell 49, 220 (1987). 26. M . A. Garcia-Blanm, S . F. Jamison and P. A. Sharp, Genes Dew. 3, 1874 (1989). 27. A. Newman and C. Norman, Cell 65, 115 (1991). 28. A. J. Newman and C. Norman, Cell 68, 743 (1992). 29. J. A. Steitz, Science 257, 888 (1992). 30. J. Wu and J. L. Manley, Nature 352, 818 (1991). 31. B. Datta and A. M. Weiner, Nature 352, 821 (1991).
SPLICING IN HIGHER PLANTS
191
P. Fabrizio and J. Abelson, Science 250, 404 (1990). H. D. Madhani and C. Guthrie, Cel 71, 803 (1992). T. Tani and Y. Oshima, Genes Dev. 5, 1022 (1991). H. D. Madhani, R. Bordonn6 and C. Guthrie, Genes Dev. 4, 2264 (1990). J. Andersen and G . W. Zieve, BioEssays 13, 57 (1991). C. Guthrie and B. Patterson, ARGen 22, 387 (1988). H. D. Parry, D. Scherly and I. W. Mattaj, TlBS 14, 15 (1989). S. V. van Santen and R. A. Spritz, PNAS 84, 9094 (1987). 40. D. B. Egeland, A. P., Sturtevant and M. A. Schuler, Plant Cell 1, 633 (1989). 41. B. A. Hanley and M. A. Schuler, NARes 19, 1861 (1991). 42. T. Kiss, M. A n d and F. Solymosy, NARes 15, 543 (1987). 43. P. Vankan and W. Filipowicz, EMBO J . 7, 791 (1988). 44. R. Waugh, G. Clark and J. W. S. Brown, Gene 107, 197 (1991). 45. Y. Q. Hu, J. W. Brown, R. Waugh and P. C. Turner, BBA 1129, 90 (1991). 46. B. A. Hanley and M. A. Schuler, NARes 19, 6319 (1991). 47. R. Luhrmann, B. Kastner and M. Bach, BBA 1087, 265 (1990). 48. R. B. Meagher, M. D. McLean and J. Arnold, Genetics 120, 809 (1988). 49. S. Huang and D. L. Spector, PNAS 89, 305 (1992). 50. D. L. Spector, X.-D. Fu and T. Maniatis, EMBOJ. 10, 3467 (1991). 51. Z. Palfi, M. Bach, F. Solymosy and R. Luhrmann, NARes 4, 1445 (1989). 52. G. G . Simpson, P. Vaux, G. Clark, R. Waugh, and J. D. Beggs and J. W. S. Brown, NARes 19, 5213 (1991). 53. C. G . Simpson, R. Sinibaldi and J. W. S. Brown, PlantJ. 2, 835 (1992). 54. A. J. McCullough, H. Lou and M. A. Schuler, NARes 19, 3001 (1991). 55. J. Callis, M. Fromm and V. Walbot, Genes Dev. 1, 1183 (1987). 56. K. R. Luehrsen and V. Walbot, MGG 225, 81 (1991). 57. C. Maas, J . Laufs, S. Grant, C. Korfhage and W. Werr, Plant Mol. Biol. 16, 199 (1991). 58. G. J. Goodall, K. Wiebauer and W. Filipowicz, in “Methods in Enzymology” (J. E. Dahlberg and J. N. Abelson, eds.), Vol. 181, p. 148. Academic Press, San Diego, 1990. 59. J. Nash, Ph.D. thesis. Stanford University, Stanford, California, 1992. 60. J. Nash and V. Walbot, Plant Physiol. 100, 464 (1992). 61. G. J. Goodall and W. Filipowicz, EMBO J. 10, 2635 (1991). 62. R. Parker and C. Guthrie, Cell 41, 107 (1985). 63. E. Waigmann and A. Barta, NARes 20, 75 (1992). 64. G. J. Goodall and W. Filipowicz, Cell 58, 473 (1989). 65. J. D. Hawkins, NARes 16, 9893 (1988). 66. P. Athma, E. Grotewald and T. Peterson, Genetics 131, 199 (1992). 67. E. Grotewald, P. Athma and T. Peterson, PNAS 88, 4587 (1991). 68. G. J. Goodall and W. Filipowicz, Plant Mol. Biol. 14, 727 (1990). 69. K. Wiebauer, J. J. Herrero and W. Filipowicz, MCBiol8, 2042 (1988). 70. R. M. Sinibaldi and I. J. Mettler, This Series 42, 229 (1992). 71. S. V. van Santen and R. A. Spritz, Gene 56, 253 (1987). 72. B. Wieringa, E. Hofer and C. Weissmann, Cell 37, 915 (1984). 73. A. G. Hunt, B. D. Mogen, N. M. Chu and N.-H. Chua, Plant Mol. Biol. 16,375 (1991). 74. K. R. Luehrsen and V. Walbot, NARes 20, 5181 (1992). 75. K. R. Luehrsen and V. Walbot, Plant Cell 2, 1225 (1990). 76. D. F. Ortiz and J. N. Strommer, MCBiol 10, 2090 (1990). 77. C. G. Simpson and J. W. S. Brown, Plant Mol. Biol. 21, 205 (1993). 78. C. F. Weil and S. R. Wessler, Annu. Rev. Plant Physiol. Plant Mol. Biol. 41, 527 (1990). 79. H. Cuypers, S . Dash, P., Peterson, H. Saedler and A. Gierl, EMBOJ. 7, 2953 (1988). 32. 33. 34. 35. 36. 37. 38. 39.
192
KENNETH R. LUEHHSEN ET AL.
80. S. R. Wessler. 6. Baran atid M . Varagona, Science 237, 916 (1987). 81, Ii.-Y.Kim, J. it: Schiefelbein, \’. Raboy, D. B. Furtek and 0. E. Nelson, Jr., PNAS 84,
,5863 \I9871 8.2. S . R. Wessler, MCBiol 11, 6192 (19911. 8.3. \V. I). Sutton. M! L. Gerlach, D. Schwartz and W. J. Peacock, Science 223, 1265 (1984). 84. E. S. Dennis, hl. hl. Sachs, W. Gerlach, L. Beach and W. J. Peacock, NARes 16, 3815
(1988). 8.5. R. Simon and P. Starlinger, MGG 209, 198 (1987). 86. P Misson, 6. Rutherford, J. A. Banks and N. Fedoroff, Cell 58, 755 (1989). NT. .\. Gierl. Z. Schwarz-Somrner and H. Saedler, EMBO J . 4, 579 (1985). 88. 2. Schwarsr-Sommer, A. Cierl, H. Cuypers, P. ‘4. Peterson and H. Saedler, EMBO J. 4,
591 (19851. 89. 2. Schwari-Sommrr, A. Gierl, R. 8 . Klosgen, U. Wienand, P. A. Peterson and H. Saedler, EMBO J . 3, 1021 (1984). 90. E. Tacke. Z. Schwarz-Sommer, P. A. Peterson and H. Saedler. Maydica 31, 83 (1986). 91. 2. Schwarz-Sonirner, N. Shepherd, E. Tacke, A. Gierl, W. Rohde, L. Leclercq, M. Mattes. R. Berridtgen. P. A. Peterson and H. Saedler, EMBOJ. 6, 287 (1981). 92. J. W.Schiefelbein, V. Raboy, N. l’Fedoroff . and 0. E. Nelson, PNAS 82, 4783 (1985). 93. \.. Rabo?; H.-Y. Kim. J. W. Schiefelbein and 0. E. Nelson, Genetics 122, 695 (1989). 94. R . J. Okagaki. T. D. Sullivan, J. W.Schiefelbein and 0. E. Nelson, Plant Cell 4, 1453 j 1992). 93. S. E. Leff, $1. G. Rosenfeld and R. 1.1. E \ m s , AAB 55, 1091 (1986). 9 6 J. 51. Wreneke, J. hf. Chatfield and \V. L. Ogren, Plant Cell 1, 815 (1989). 9;. S. J. Rutidle and R. E. Zielinski, JBC 266, 4677 (1991). 98. M . E. Salvucci. J. 51. Werneke, W.L. Ogren and A. R. Portis, P h n t Physiol. 84, 381 (1987). 99. K. H. Knesler and W. Ogren, Plant Physiol. 94, 1837 (1990). 100. A . Pereira and H. Saedler, EMBO J , 8 , 1315 (1989). 101. A. R. Buchnian and P. Berg. MCBiol8, 4395 (1988). Z0.2. D. hlcElro): \V. Zhang. J. Cao and R. Wu, Plant Cell 2, 163 (1990). 103. J. H . Oard, 11. Paige and J. Dvorak, Plant Cell Rep. 8, 156 (1989). 104. C. l>rati, hf. Favrrau. D. Bond-Nutter, J. Bedbrook and P. Dunsmuir, Plant Cell 1, 201 i 1989). 10a5. P. Leon, F. Planckaert and V. Lt’albot, Plant Pltysiol. 95, 968 (1991). 106. I>. biascarenhas. I. J. Xlettler, D. A. Pierce and H. W. Lowe, Plant Mol. B i d . 15, 913 (1990). 107. V i’asil, M . Clancy, R. J. Fed, I. K. Vasil and L. C. Hannah, Plant Physiol. 91, 1575 (1989). 108. I>. I. Last. K. I. S. Brettefl, D. A. Chamberlain, A. M. Chaudhury, P. J. Larkin, E. L. Marsh, W.J. Peacock and E. S. Dennis, Theor. Appl. Genet. 81, 581 (1991). 109. A. Tanaka. S. blita, S. Ohta, J. Kynzuka, K. Shirnarnotoand K. Nakaniura, NARes 18, 6767 (1991). 110. S. 11. Gillies. S. L. Morrison, V. T. Oi and S. Tonegawa, Cell 33, 717 (1983). I J I . S. Hayashi. E. Goto, T. S . Okada and H. Kondoh, Genes Dec. 1, 818 (1987). 11.2. W’.Horton, T. Miyashita, K. Kohno. J. R. Hassel and Y. Yamada, PNAS 84, 8864 (1987). 11.3. M . T. F. Huang and C. M. Gorman. XARes 18, 937 (1990). 114. K. lnoue, M. Ohno. H . Sakamoto and Y. Shimura, Genes Dea 3, 1472 (1989). 115. I>. L. Spector. PN.4S 87, 147 (1990). Z16. H. J. Yost, R. B. Peterson and S. Lindquist, Trends Genet. 6, 223 (1990). 117. E. Czarnecka, L. Edelman, R. SchiifH and J. I,. Key, Plant Mol. Biol. 3, 45 (1984).
SPLICING IN HIGHER PLANTS
193
J. Winter, R. Wright, N. Duck, C. Gasser, R. Fraleyand D. Shah, MGG211,315(1988). A. H. Christensen, R. A. Sharrock and P. H. Quail, Plant Mol. Biol. 18, 675 (1992). N. Hopf, N. Plesofsky-Vig and R. Brambl, Plant Mol. B i d . 19, 623 (1992). T. Takahashi, S. Naito and Y. Komeda, Plant Physiol. 99, 383 (1992). E. Czarnecka, R. T. Nagao, J. L. Key and W. B. Gurley, MCBiol 8, 1113 (1988). 6 . Hagen, N. Uhrhammer and T. J. Guilfoyle, JBC 263, 6442 (1988). H. J. Yost and S. Lindquist, Science 242, 1544 (1988). M. W. Smith, J. Mol. Euol. 27, 45 (1988). P. Katinakis and D. P. S. Verma, PNAS 82, 4157 (1985). A. M. Weiner, Cell 72, 161 (1993). A. Menssen, S. Hohmann, W. Martin, P. S. Schnable, P. A. Peterson, H. Saedlerand A. Gierl, EMBO J. 9, 3051 (1990). 129. S. R. Wessler, Maydica 36, 317 (1991). 130. K. Hartmuth and A. Barta, NARes 14, 7513 (1986). 131. B. Kieth and N.-H. Chua, EMBO J. 10, 2419 (1986). 132. J. W. S. Brown, G. Feix and D. Frendewey, EMBO J. 5, 2749 (1986). 133. D. Tagu, C. Cretin, C. Bergounioux, L. Lepiniec and P. Gadal, Plant Cell Rep. 9, 688 (1991). 134. J. Paszkowski, A. Peterhans, R. Bilang and W. Filipowicz, Plant Mol. B i d . 19, 825 (1992). 134a. H. Lou, A. J. McCullough and M. A. Schnler, Plant J. 3, 393 (1993). 135. J.-F. Lalibertk, 0. Nicolas, S. Durand and R. Morosoli, Plant Mol. B i d . 18, 447 (1992). 136. A. Barta, K. Sommergruber, D. Thompson, K. Hartmuth and M. A. Matzke, Plant Mol. Biol. 6, 347 (1986). 137. J. M. Martinez-Zapater, R. Finkelstein and C. R. Somerville, Plant Mol. Biol. 11, 601 (1988). 138. V. Pautot, R. Brzezinski and M. Tepfer, Gene 77, 133 (1989). 139. M. A. Dietrich, J. P. Prenger and T. J. Guilfoyle, Plant Mol. Biol. 15, 207 (1990). 118. 119. 120. 121. 122. 123. 124. 125. 126. 127. 128.
This Page Intentionally Left Blank
New Concepts in ProteinDNA Recognition: Sequence-directed DNA Bending and Flexibility’ RODNEYE. HARRINGTON* AND ILGAWINICOV*J *Departments of Biochemistry and +Microbiology University of Nevada Reno Reno, Nevada 89557
I. DNA Sequence Dependence in Protein-Nucleic Acid Binding Specificity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A. Sequence-dependent Bending in DNA . . . . . . . . . . . . . . . . . . . . . . . B. Sequence-dependent Flexibility or Kinking in DNA C. Evidence for Sequence-dependent Flexibility in DNA . . . . . . . . . . 11. A Short Taxonomy of DNA-bending Proteins and Their Recognition Sequences ................................................... A. Prokaryotic Helix-Turn-Helix Proteins ................. B. Eukaryotic Helix-Turn-Helix C. Zinc-finger Proteins: The ”C,H,” Classes D. The “C,” Class of Zinc-binding Proteins . . . . . . . . . . . . . . . . . . . . . . .................. E. Leucine-zipper Proteins . . . . F. Minor-groove-binding Proteins: The TFIID Transcription Factor Complex . . . . . . , . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G. The NF-KB Protein and Its Binding to DNA H. Other DNA-binding Proteins with Putative F1 Their Recognition Sites . Sequences . . . . . .
196 199 200 202
213 214 221 227
233 236 240 243
245 248
111. Models of Sequence-directed Structure-Function Relationships in
Selected Regulatory Systems
References
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..
253 259 261 263
One of the most interesting and fruitful recent developments in molecular biology is the continuing coalescence of genetic control with the older field of DNA molecular biOphysics and structure. It has been known for some time that many biological processes at the molecular level, including 1
A glossary of abbreviations and polynucleotide notation appears on p. 261.
Progress in Nucleic Acid Research and Molecular Biology, Vol. 41
195
Copyright 6 1994 by Academic Press, Inc. All rights of reproduction in any form reserved.
1%
RODNEY E. HARRINGTON AND ILGA WINICOV
the regulation of genes, occur concurrently with the binding of regulatory proteins to specific sites on the genomic DNA. These regulatory nucleoprotein complexes are usually characterized by unusual binding &nity as well as site specificity. Many cases are known in which the same protein can regulate different trans-actional events by binding to different DNA recognition sites, or in which differential regulation can occur from the competitive binding of two or more proteins to the same site. Recent crystallographic, spectroscopic, and biochemical studies provide some structural rationale for the extraordinary binding specificity of many of these regulatory complexes, and a number of consensus structural “motifs” for the DNA-binding domains of proteins have been described (reviewed in 1-3). However, how the DNA contributes to the binding specificity i s not so apparent. For some time, it has been recognized that the well-known DNA structural “families” may exhibit some sequence dependence, but no instances of specific DNA families binding with high specificity to regulatory proteins have so far been demonstrated. Rather, the DNA in regulatory nucleoprotein complexes seems to be invariably in the B-form, the softest and most labile of the various structural families known. Thus, sequenceregulated, highly localized DNA structures must be implicated in proteinDNA recognition. Such sequence dependence in DNA structure has been recognized for some time, and has been related in certain ways to protein binding (reviewed in 4-6). In this writing. we attempt to knit together available structural information on the DNA-binding domains of a representative set of regulatory proteins with what is presently known about sequence-directed DNA structures. Because the discovery and identification of new transcription and regulatory factors are currently proceeding at such an explosive pace, we make no pretense that this discussion can be a comprehensive and current review of these systems. Rather, we focus on unusual D N A structures with known sequence dependencies, such as bends, and the relatively new concept of sequence-directed structural softness or flexibility, and correlate these with protein structural motifs wherever possible. We show that analyses of consensiis binding sequences in DNA can provide important clues both for identifying possible roles of localized DNA structures (or microstructures) in protein-DNA interactions and for interpreting these roles in structure-function terms.
I. DNA Sequence Dependence in Protein-Nucleic Acid Binding Specificity The perception of DNA structure-fhnction relationships by molecular biologists has undergone considerable modification in recent years. The
STRUCTURAL FLEXIBILITY IN
DNA-PROTEININTERACTIONS
197
earlier depiction of DNA as a homogeneous, stiff, nearly rodlike macromolecule has had to acquiesce to the notion that many of its important biological functions are based not on its overall global conformation but rather on highly localized structural features directed by relatively short sequences of bases. A number of factors have played roles in this remarkable shift of paradigms, but two of the most important have been the discovery of axial bending in DNA and the observation that regulatory proteins generally bind to specific sequences of bases with extraordinary affinity. An important consequence is that most biological processes are modulated at the molecular level by the interactions of regulatory proteins with themselves or other proteins and with their characteristic operator DNA. A corollary is that the trajectory of the DNA is precisely defined, particularly in large, multisubunit nucleoprotein complexes. Because both of these factors are highly site specific, they can confer a corresponding level of site specificity to the processes they control, which include transcriptional regulation, the action of hormone receptors, and certain types of site-specific recombination, including the precise insertion of viral DNA into host genomes. Thus, our advancing knowledge of biological control processes at the molecular level has mandated an equivalent understanding of localized, sequence-directed DNA structures. The mechanisms by which certain proteins recognize specific regions of DNA are not fully understood and are generally complex. In spite of this, the broad classification of energetic factors leading to both binding specificity and affinity into direct and indirect readout components, as originally suggested by Drew and Travers (7), provides a useful basis for conceptualizing the role of localized, sequence-directed DNA structures in specific proteinDNA binding. Direct readout was first proposed in the early 1980s (8, s), based on modeling studies of the Cro protein crystal structure fitted to uniform, Watson-Crick DNA. A small number of amino-acid residues, usually about three, aligned along one side of a “recognition” a-helix [or occasionally a p-ribbon (lo)]in the DNA-binding domain of the protein, form specific hydrogen bonds with a “recognition matrix” of complementary nitrogen or phosphate sites in the DNA. In most cases, access is through the major groove because in B-family DNA the major groove width is adequate to accommodate the protein-recognition element, and the potential hydrogen-bonding sites are relatively exposed. However, new classes of minor-groove-binding proteins have recently been characterized. Additional contacts of the protein-recognition element with the DNA backbone, usually with phosphates, ensure correct placement of the element within the DNArecognition matrix. Although direct readout provides a mechanism for high binding specificity, this can be further amplified by cooperative proteinprotein interactions and by involving additional protein-recognition ele-
198
RODNEY E . HARRINGTON AND ILGA WINICOV
ments in the binding process. A special case of the latter is the interaction of dimeric proteins with palindromic DNA-recognition matrices. The structural fit between the protein and DNA binding partners that facilitates these highly specific interactions is termed indirect readout. Until fairly recently, it was thought that this could be understood as a complementary assembly of localized static protein and nucleic acid structures, and the “goodness of fit” between the two would be determined by the specific structures and hence by their sequences. It has been known for over a decade that B-form DNA exhibits sequence-dependent structural variability (11, 12) that leads also to corresponding variability in conformation or molecular shape (13, 14). When spaced in a sequence at helical periodicity, localized structural dislocations can lead to longer range structural features such as fixed bends. It is likely that sequence-dependent DNA structure including such coherent additivity effects leading to planar curvature is an important ingredient of indirect readout. In addition to enhancing protein-DNA interactions by improving the geometrical fit, DNA bending appears to facilitate or modulate looping between regulatory elements acting in cis at a distance (15) and in the architecture of multisubunit regulatory complexes (16).The first of these may include the interactions of enhancers with promoter regions, a number of protein-mediated intrapromoter associations, and effects of chromatin structure on transcriptional regulation ( I 7). It is becoming increasingly clear, however, that a picture of indirect readout based only on static structures is a serious oversimplification. Evidence is accumulating that there is also a dynamic aspect in which proteinDNA binding is affected by conformational deformations of both the protein and the DNA. These result from structural adjustments involving localized changes in helical twist angles and in the direction of the helical axis at the dinucleotide level. The structural accommodations between a specific binding protein and its DNA-binding site are determined by a complicated interplay of intermolecular and intramolecular electrostatic, hydrophobic, and van der Waals forces. These interactions are nonspecific in themselves, but are strongly dependent on the conformational features of both the DNA and the correctly folded DNA-binding domain of the protein. Both the protein and DNA partners seek regions of the other that maximize these interactions. The nucleoprotein complex will therefore reflect not only the greatest possible accommodation between static structures of the binding partners, but its formation may entail some level of structural distortion in one or both partners as well. Virtually all specific nucleoprotein complexes must utilize conformational lability in both the protein and DNA components to improve direct recogni-
STRUCTURAL FLEXIBILITY IN
DNA-PROTEININTERACTIONS
199
tion (18).The structural and conformational factors involved in indirect readout are highly sequence dependent because maximum accommodations between the binding partners will occur only at a juxtaposition of critical sequences in both partners. However, there may also be some synergism between direct and indirect readout effects: the nucleoprotein conformation that corresponds to maximum structural accommodation by the binding partners will usually also be the conformation that optimizes the formation of specific hydrogen-bonding contacts. It is in the context of all these effects that the extraordinary sequence specificity of interactions between binding proteins and their relatively short cognate DNA-recognition regions can be understood. It now seems likely that each specific nucleoprotein complex utilizes a characteristic and possibly unique combination of direct and indirect readout mechanisms. Furthermore, an extraordinary level of complexity in nucleoprotein binding as well as a complex interplay of multiple chemical and physical mechanisms are probably necessary to achieve the required level of site specificity and to reduce errors to a genetically acceptable level in truns-actional events having high site-specificity requirements.
A. Sequence-dependent Bending in DNA Curvature in B-form DNA regions has been studied for almost a decade and is now believed to be an intrinsic property of certain DNA sequences (reviewed in 16, 19-23). The earliest curvature elements to be identified were the phased A, tracts found in DNA fragments obtained from kinetoplast minicircles of the African trypanosome. Their anomalously slow migration in polyacrylamide gels was assumed to derive from planar, or nearly planar, axial curvature (22). Subsequent studies on these systems using a variety of experimental methods, including gel mobility retardation (23)and measurement of cyclization .probabilities (24-27), variants of methods pioneered by Shore and colleagues (28,29), clearly established that DNA with helical-phased regions containing tracts of A, with n 2 5 were indeed curved. Two models have been proposed to account for this curvature. In the wedge model, each A, tract is curved because the axial deflections of successive A-A dinucleotides combine coherently to produce a planar curve (3033). In the junction model, axial deflections arise from the structural discontinuities occurring at the junction between the A, tracts, presumed to be in a modified B-form structure (34), with adjacent B-form DNA (35).In both models, the A, tracts are in nearly perfect helical register, which assures that the curvatures of individual bending elements add coherently to produce a larger overall bend. Experiments to date do not confirm one model over the
200
RODNEY E. HAHRINGTON AND ILGA WINICOV
other, and it now seems possible that both are simply variants of the same model (21). Hegions of putative A, curving DNA in important biological systems have recently been identified (reviewed in 5 , 6, 36). More recently, evidence has appeared suggesting that sequence-directed curving in DNA may be a more general phenomenon, involving a number of sequence elements in addition to A,, regions (13, 14). A set of first-order predictive rules that provide a semiquantitative description of general sequence-directed fixed bending has recently been proposed (13).Although a number of moderately curved sequences that contain no A, tracts have been identified ( I d ) , curvature from phased A,, elements is still much larger than from other reported curvature motifs (13, 14). it now seems probable that sequence-dependent DNA structures, including coherent effects leading to curvature, serve to orient or steer the DNA in large, multisubunit nucleoprotein complexes (16).Fixed DNA bending may also be important in looping between regulatory elements acting in cis at a distance (15).
6. Sequence-dependent Flexibility or Kinking in DNA Although much more difficult to demonstrate experimentally, sequencedirected DNA flexibility very likely plays a functional role similar to that of static axial bending. The distinction between flexible and fixed or static bending in DNA is based on relative deformability of the helical axis trajectory in a direction perpendicular to the axis. All DNA is flexible to some extent, as manifested by its finite persistence-length in solution (37, 38; reviewed in 36). Just as the helical axis changes direction in certain sequence elements ( I S ) , the local bending or torsional modulus may also vary significantly among sequence motifs. Steric considerations indicate that flexibility in the double helix will generally occur preferentially by roll toward either the major or the minor groove (39). This involves less configurational readjustment of the backbone than a flexure due entirely to tilt. Such anisotropic flexibility, if it occurred in a completely directional fashion (as might be the case in the interaction of a DNA sequence element with a protein), would have configurational consequences similar to those of fixed or static bending. Thus, larger flexibility effects might derive from the coherent contributions of multiple flexibility elements located in a helically phased array just as with fixed bending motifs. Both static bending and flexibility at specific sequence elements can promote the necessary DNA trajectories to effect a tight fit between DNA and proteins in nucleoprotein complexes. Conformational lability from flexible sequence elements may fine-tune this process and may, i n addition, offer structural explanations for instances in which more than one protein can bind specifically to the same
STRUCTURAL FLEXIBILITY IN
DNA-PROTEININTERACTIONS
201
DNA sequence. From information presently available, localized DNA flexibility may be a more ubiquitous feature of DNA-protein interactions than previously believed (40). The first explicit distinction between flexibility and fixed bending was made in studies of the electrooptical properties of DNA containing putative static bending elements (41, 42). Bending was characterized in terms of the decay of electrical birefringence, a quantity highly sensitive to the effective length or end-to-end distance of a rodlike macromolecule; bending in a DNA fragment, whether static or due to anisotropic flexibility, results in an effective shortening of the molecule. The distinction between static bending and flexibility was based on the measured persistence-length, and particularly on its electrostatic component as deduced from its experimental dependence on ionic strength. Although persistence-length is a measure of chain stiffness, it is a statistical quantity averaged over the entire fragment, so these experiments could therefore not distinguish isotropic from anisotropic chain flexibility effects. In general, measurements of properties that are averaged over the entire chain are not very useful for this type of distinction; they usually cannot distinguish unambiguously between anisotropic flexibility and static bending. This includes most traditional polymer characterization methods, and most enzymatic and biochemical methods as well. Rather, methods are required that can extend the dynamical lifetime of a bent, flexible chain or sequence element. Of these, binding the sequence to a DNA-bending protein is perhaps the least ambiguous, and studies on the free sequence provide suitable controls to differentiate static from flexible bending effects. At present, the most plausible microstructure associated with increased DNA flexibility is the stereochemical kink. This concept was first proposed (43)in an attempt to explain the energetics of DNA wrapping on the nucleosome, and was amplified somewhat in later studies (44).When a structural dislocation leading to an abrupt and discontinuous change in direction of the helical axis is reduced to a single dinucleotide, or to a small set of contiguous nucleotides, the DNA is usually said to kink. Kinks have been proposed to occur from relatively massive structural alterations in the DNA due to pyrimidine dimers or psoralen crosslinks (45),from drug-binding interactions (46),from single-strand bubbles (47), and from protein binding to DNA (3, 31, 40, 48-51; reviewed in 3). Simple stereochemical kinks are evidently possible that primarily involve roll into the major or minor groove (43, 44), avoiding a change in local tilt (31,40,50,51).Such kinks represent a dislocation in the helical axis where the stacking interactions between two neighboring base pairs is essentially lost (50, 51). It has been calculated that a roll of 15 to 20"between the base planes corresponds roughly to a loss of 50% of
202
RODNEY E. HARRINGTON AND ILGA WINICOV
stacking energy (31, SO); this value therefore sets a lower limit to the kink angle. At larger angles, the kink is expected to behave essentially as a free hinge (43, 44). At ordinary temperatures, an appreciable steady-state concentration of kinkable sequence elements may exist in a kinked state due to thermal fluctuations ("DNA breathing"). Schellman (39) has analyzed the effect of such kinking on DNA chain flexibility and has suggested that as many as 2% of all bases could exist in a kinked conformation (44) at any given time in order to account for observed persistence-length values. Using a different analysis, Manning (52)has estimated 1%.Both these values are somewhat less than the upper limit of 5% deduced from proton-exchange rates (53-55). Although the latter may be up to 107 too large (56, 57), even the most conservative estimates of DNA breathing rates (reviewed in 57, 58) suggest that, at ordinary temperatures, an appreciable fraction of DNA bases may be energetically in a kinkable state. Because the sequence elements CA and TA are the lowest in stacking energy among dinucleotides (59, 6O), the equilibrium concentration of these that are energetically in kinkable states at ordinary temperatures may be greater than the above estimates suggest. Indirect evidence is available in support of this view from NMR investigations (61), from studies of nucleosome positioning (62), and from an analysis of sequence versus molecularsize dependencies of gel mobility retardation effects (63).Direct evidence for kinking at (CA)*(TG)dinucleotide elements has been provided by a recent high-resolution cocrystal structure of the complex between the CAP protein of the Escherichia coli lac operon and its operator DNA (3,48).In this work, two sharp kinks of about 40" each are observed at the two (CA)-(TG)elements symmetrically arranged about the pseudodyad of the specific binding consensus sequence. H e l i d phasing is such that this leads to a somewhat outof-plane overall bend of about 90".This is in essential agreement with a bending angle of about 100"deduced from studies using gel electrophoresis methods (64,65),but unlike the gel studies, the cocrystal structure demonstrates clearly that the locus of bending is focused primarily in (CA).(TG) h n k sites. Lower resolution crystallographic studies on the complex of the h phage Cro protein with the 0,3 operator site also show pronounced DNA bending in the complex (66).
C. Evidence for Sequence-dependent Flexibility in DNA 1. INDIRECT EVIDENCEFROM
ANOMALOUS
GEL MIGRATION
The first experimental evidence for sequence-dependent flexibility in free DNA was based on the unusual electrophoretic behavior of certain DNA
STRUCTURAL FLEXIBILITY IN
DNA-PROTEININTERACTIONS
203
fragments having fixed axial curvature but no A,, tracts (40).Each of these fragments was constructed by end-to-end ligation of a curved 21-bp “precursor” sequence. Because the number of helical repeats in each of these precursors was almost exactly two, the curvature in each was propagated coherently into plan